
<html lang="en"     class="pb-page"  data-request-id="5dab3908-2c48-4f83-b3a4-59d9a5682d0e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.1c00793;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2021.64.issue-14"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity" /></meta><meta name="dc.Creator" content="Rocío  Recio" /></meta><meta name="dc.Creator" content="Patricia  Lerena" /></meta><meta name="dc.Creator" content="Esther  Pozo" /></meta><meta name="dc.Creator" content="José Manuel  Calderón-Montaño" /></meta><meta name="dc.Creator" content="Estefanía  Burgos-Morón" /></meta><meta name="dc.Creator" content="Miguel  López-Lázaro" /></meta><meta name="dc.Creator" content="Victoria  Valdivia" /></meta><meta name="dc.Creator" content="Manuel  Pernia Leal" /></meta><meta name="dc.Creator" content="Bernard  Mouillac" /></meta><meta name="dc.Creator" content="Juan Ángel  Organero" /></meta><meta name="dc.Creator" content="Noureddine  Khiar" /></meta><meta name="dc.Creator" content="Inmaculada  Fernández" /></meta><meta name="dc.Description" content="NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carb..." /></meta><meta name="Description" content="NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carb..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 8, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00793" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00793" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00793" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00793" /></link>
        
    
    

<title>Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00793" /></meta><meta property="og:title" content="Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0014.jpeg" /></meta><meta property="og:description" content="NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carbohydrate-based NK1R antagonists and their evaluation as anticancer agents against a wide range of cancer cells. All of the prepared compounds, derived from either d-galactose or l-arabinose, have shown high affinity and NK1R antagonistic activity with a broad-spectrum anticancer activity and an important selectivity, comparable to Cisplatin. This strategy has allowed us to identify the galactosyl derivative 14α, as an interesting hit exhibiting significant NK1R antagonist effect (kinact 0.209 ± 0.103 μM) and high binding affinity for NK1R (IC50 = 50.4 nM, Ki = 22.4 nM by measuring the displacement of [125I] SP from NK1R). Interestingly, this galactosyl derivative has shown marked selective cytotoxic activity against 12 different types of cancer cell lines." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00793"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00793">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00793&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00793&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00793&amp;href=/doi/10.1021/acs.jmedchem.1c00793" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 10350-10370</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00789" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00800" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rocío Recio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rocío Recio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roc%C3%ADo++Recio">Rocío Recio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patricia Lerena</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patricia Lerena</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Lerena">Patricia Lerena</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5048-9524" title="Orcid link">https://orcid.org/0000-0002-5048-9524</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Esther Pozo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Esther Pozo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Esther++Pozo">Esther Pozo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">José Manuel Calderón-Montaño</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">José Manuel Calderón-Montaño</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Manuel++Calder%C3%B3n-Monta%C3%B1o">José Manuel Calderón-Montaño</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Estefanía Burgos-Morón</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Estefanía Burgos-Morón</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Estefan%C3%ADa++Burgos-Mor%C3%B3n">Estefanía Burgos-Morón</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Miguel López-Lázaro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miguel López-Lázaro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miguel++L%C3%B3pez-L%C3%A1zaro">Miguel López-Lázaro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victoria Valdivia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victoria Valdivia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victoria++Valdivia">Victoria Valdivia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manuel Pernia Leal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manuel Pernia Leal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manuel++Pernia+Leal">Manuel Pernia Leal</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8160-0574" title="Orcid link">https://orcid.org/0000-0001-8160-0574</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernard Mouillac</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernard Mouillac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Génomique Fonctionnelle (IGF), INSERM, Université de Montpellier, CNRS, F-34094 Montpellier, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernard++Mouillac">Bernard Mouillac</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juan Ángel Organero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juan Ángel Organero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Física, Facultad de Ciencias Ambientales y Bioquímicas and INAMOL, Universidad de Castilla-La Mancha, Avenida Carlos III, s/n, 45071 Toledo, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juan+%C3%81ngel++Organero">Juan Ángel Organero</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Noureddine Khiar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noureddine Khiar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Investigaciones Químicas (IIQ), CSIC-Universidad de Sevilla, Avenida Américo Vespucio, 49, Isla de la Cartuja, 41092 Sevilla, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#98f3f0f1f9ead8f1f1e9b6fbebf1fbb6fdeb"><span class="__cf_email__" data-cfemail="d2b9babbb3a092bbbba3fcb1a1bbb1fcb7a1">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noureddine++Khiar">Noureddine Khiar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-4211-7138" title="Orcid link">https://orcid.org/0000-0003-4211-7138</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Inmaculada Fernández</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Inmaculada Fernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#b8d1d6d5d9dedef8cdcb96ddcb"><span class="__cf_email__" data-cfemail="a8c1c6c5c9cecee8dddb86cddb">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Inmaculada++Fern%C3%A1ndez">Inmaculada Fernández</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3468-387X" title="Orcid link">https://orcid.org/0000-0002-3468-387X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00793&amp;href=/doi/10.1021%2Facs.jmedchem.1c00793" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 10350–10370</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 8, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 May 2021</li><li><span class="item_label"><b>Published</b> online</span>8 July 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00793" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00793</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10350%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRoc%25C3%25ADo%2BRecio%252C%2BPatricia%2BLerena%252C%2BEsther%2BPozo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D14%26contentID%3Dacs.jmedchem.1c00793%26title%3DCarbohydrate-Based%2BNK1R%2BAntagonists%2Bwith%2BBroad-Spectrum%2BAnticancer%2BActivity%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10370%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00793"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">342</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00793" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rocío&quot;,&quot;last_name&quot;:&quot;Recio&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Lerena&quot;},{&quot;first_name&quot;:&quot;Esther&quot;,&quot;last_name&quot;:&quot;Pozo&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Manuel Calderón-Montaño&quot;},{&quot;first_name&quot;:&quot;Estefanía&quot;,&quot;last_name&quot;:&quot;Burgos-Morón&quot;},{&quot;first_name&quot;:&quot;Miguel&quot;,&quot;last_name&quot;:&quot;López-Lázaro&quot;},{&quot;first_name&quot;:&quot;Victoria&quot;,&quot;last_name&quot;:&quot;Valdivia&quot;},{&quot;first_name&quot;:&quot;Manuel&quot;,&quot;last_name&quot;:&quot;Pernia Leal&quot;},{&quot;first_name&quot;:&quot;Bernard&quot;,&quot;last_name&quot;:&quot;Mouillac&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Ángel Organero&quot;},{&quot;first_name&quot;:&quot;Noureddine&quot;,&quot;last_name&quot;:&quot;Khiar&quot;},{&quot;first_name&quot;:&quot;Inmaculada&quot;,&quot;last_name&quot;:&quot;Fernández&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;10350-10370&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00793&quot;},&quot;abstract&quot;:&quot;NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carbohydrate-based NK1R antagonists and their evaluation as anticancer agents against a wide range of cancer cells. All of the prepared compounds, derived from either d-galactose or l-arabinose, have shown high affinity and NK1R antagonistic activity with a broad-spectrum anticancer activity and an important selectivity, comparable to Cisplatin. This strategy has allowed us to identify the galactosyl derivative 14α, as an interesting hit exhibiting significant NK1R antagonist effect (kinact 0.209 ± 0.103 μM) and high binding affinity for NK1R (IC50 = 50.4 nM, Ki = 22.4 nM by measuring the displacement of [125I] SP from NK1R). Interestingly, this galactosyl derivative has shown marked selective cytotoxic activity against 12 different types of cancer cell lines.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00793&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00793" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00793&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00793" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00793&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00793" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00793&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00793&amp;href=/doi/10.1021/acs.jmedchem.1c00793" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00793" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00793" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00793%26sid%3Dliteratum%253Aachs%26pmid%3D34236855%26genre%3Darticle%26aulast%3DRecio%26date%3D2021%26atitle%3DCarbohydrate-Based%2BNK1R%2BAntagonists%2Bwith%2BBroad-Spectrum%2BAnticancer%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D14%26spage%3D10350%26epage%3D10370%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (9)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290925" title="Carbohydrates">Carbohydrates</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">NK1R antagonists, investigated for the treatment of several pathologies, have shown encouraging results in the treatment of several cancers. In the present study, we report on the synthesis of carbohydrate-based NK1R antagonists and their evaluation as anticancer agents against a wide range of cancer cells. All of the prepared compounds, derived from either <span class="smallcaps smallerCapital">d</span>-galactose or <span class="smallcaps smallerCapital">l</span>-arabinose, have shown high affinity and NK1R antagonistic activity with a broad-spectrum anticancer activity and an important selectivity, comparable to Cisplatin. This strategy has allowed us to identify the galactosyl derivative <b>14α</b>, as an interesting hit exhibiting significant NK1R antagonist effect (<i>k</i><sub>inact</sub> 0.209 ± 0.103 μM) and high binding affinity for NK1R (IC<sub>50</sub> = 50.4 nM, <i>K</i><sub>i</sub> = 22.4 nM by measuring the displacement of [<sup>125</sup>I] SP from NK1R). Interestingly, this galactosyl derivative has shown marked selective cytotoxic activity against 12 different types of cancer cell lines.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The NK1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> belongs to the superfamily of G-protein coupled receptors, which constitute ∼35% of the therapeutic targets of all of the pharmaceutical products on the market.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The preferred endogenous agonist of NK1R is the undecapeptide substance P (SP), which acts as a neurotransmitter and neuromodulator.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> NK1R is present in the central and peripheral nervous systems, smooth muscle, endothelial cells, and also on cells that participate in immune response.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Over the past four decades, intensive research has linked the SP-NK1R system to broad pathophysiological processes including nausea,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> analgesia,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> inflammation,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and depression.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, NK1R is overexpressed in several cancers,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> including melanoma,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> astrocytoma,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> pancreatic ductal carcinomas,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> bone marrow,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and gastric cancer,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> highlighting the potential therapeutic value of NK1R antagonists. This potential has recently been accentuated following several studies demonstrating the beneficial effect of NK1R antagonists on the health of patients infected with the SARS-CoV-2 virus, responsible for the current COVID19 pandemic.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This perspective has boosted the search not only in academia but also in industry, with almost all important pharmaceutical companies investing in this field of selective and potent NK1R antagonists.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A turning point in this race was the discovery of the first nonpeptide NK1R antagonist CP-96,345,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> which has been instrumental in the development of a number of antagonists with improved pharmacological properties; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a> Structural optimizations around the central skeleton ultimately led to the development of Aprepitant,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> which became the first oral drug approved to enter the clinic, specifically targeting NK1R for the treatment of chemotherapy-induced nausea and vomiting.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> During the last 5 years, two other molecules, namely, Netupitant and Rolapitant, have been approved for clinical use for the same indication.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> It is worth mentioning that the discovery of effective NK1R antagonists is challenging due to the complexity of the NK1 transmembrane receptor, the crystal structure of which has only recently been determined.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In a project directed toward the asymmetric synthesis of new NK1R antagonists, we have recently reported the asymmetric synthesis of 5-arylsulfinyl-2-amino-4<i>H</i>-pyrans and their application as antitumoral compounds.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In the present work, we report on the stereoselective synthesis of carbohydrate-based NK1R antagonists (CarbNK1RAnt) and the determination of their selective cytotoxic activities against different types of cancer cell lines.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Generalized nonpeptide NK1R antagonist pharmacophore consisting of two aromatic rings held together by various scaffolds, which contains at least one hydrogen-bond acceptor. Possible arrangement of the aromatic rings: parallel face-to-face (a), perpendicular “T” (b), and edge-on “L” (c). (B) Structures and color visualization of differences and similarities of some pioneering NK1R antagonists, (C) marketed NK1 antagonists, and (D) new NK1R antagonists derived from carbohydrates described in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Preliminary structure–activity relationship studies carried out on a large number of NK1R antagonists developed after the discovery of CP-96,345 allowed the proposition of a pharmacophore model, which consists of a heterocyclic scaffold substituted with at least two aromatic rings in a cis orientation; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In most cases, the fixed orientation between the two aromatic groups aforementioned can be a parallel face-to-face (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A(a)),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> a perpendicular T (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A(b)), or an edge-on L arrangement (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A(c)).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The scaffolds used have evolved from the quinuclidine in CP-96,345, to a simpler piperidine in CP-99,994, Casopitant and Ralopitant; a morpholine ring in Aprepitant; a pyridine ring in Netupitant; or a simple acyclic chain in L-733,060; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B,C. The use of a heterocyclic saturated scaffold with two substituted carbons implies that the molecule is chiral with at least two stereogenic centers. Indeed, both Aprepitant and Ralopitant have three chiral centers, and of the eight possible diastereoisomers, only one has the desired activity. Accessing the desired compound as a single enantiomer is challenging, time consuming, and highly expensive. As an illustrative example, the Merck process developed for the synthesis of Aprepitant consists of a catalytic asymmetric (transfer) hydrogenation process coupled with a successful crystallization-induced diastereoselective transformation and a diastereoselective imine hydrogenation for the creation of three stereocenters.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> A simple and economical alternative to access heterocyclic compounds with multiple chiral centers in close proximity is to use compounds belonging to the chiral pool. A family of compounds well suited for this comprises the carbohydrates, stereochemically rich compounds with hydroxyl groups in virtually all arrangements, allowing the easy tuning of their steric, electronic, and three-dimensional (3D) structures. Moreover, as abundant and renewable biomolecules, they are accessible on a large scale at low cost. Indeed, some monosaccharides are even less expensive than the most common solvents used in synthetic laboratories. As part of a large program aimed at the utilization of carbohydrates in the asymmetric synthesis of synthetically and pharmacologically relevant molecules as well as in the synthesis of biomaterials,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> we decided to develop new NK1R antagonists using sugars as raw materials. As functional groups, we planned to incorporate at the anomeric position the 3,5-bis(trifluoromethyl)benzyl fragment, present in many NK1R antagonists including all currently marketed ones. As a second aromatic fragment, we opted for a <i>p</i>-fluorophenyl function, present in Aprepitant, Fosaprepitant, and other selective NK1R antagonists, as <i>O</i>-benzyl ether at the C-2 position of the carbohydrate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). When both aromatic groups are at the α-face of the pyranose ring, an intramolecular π–π stacking interaction can be established, which, as stated before, has been proposed to play a significant role in other active analogues profiled in structure–activity relationship studies.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure and retrosynthetic route of carbohydrate-based NK1R antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> Synthesis of <span class="smallcaps smallerCapital">d</span>-Galactose-Derived NK1R Antagonists (GalNKR1Ant)</h4><div class="NLM_p">Considering the planned sugar-based 1,2-cis substituted NK1R antagonist analogues, the choice of the starting carbohydrate as well as the sequence followed for implementing the substituents is crucial. From a synthetic point of view, it is a question of using the right sugar and a synthetic sequence that allows the selective functionalization of the C2-OH and to introduce the aglycon group in the carbohydrate α-face. Taking these considerations into account, among all of the hexopyranoses, <span class="smallcaps smallerCapital">d</span>-galactose is the sugar of choice due to the different reactivity of its five hydroxyl groups, mainly due to the cis arrangement of C3-OH and C4-OH. Moreover, the α position of the aglyconic group requires the use of a nonparticipating group at C2 during the glycosylation step. Therefore, using commercially available <span class="smallcaps smallerCapital">d</span>-galactose pentaacetate <b>1</b>(α,β), we first introduced the <i>p</i>-fluorophenyl group at position 2 of the pyranose ring as the corresponding <i>O</i>-benzyl ether, before introducing the (<i>R</i>)-1-[3,5-bis(trifluoromethyl) phenyl]ethan-1-ol at the anomeric position; <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>p</i>-Fluorobenzyl <span class="smallcaps smallerCapital">d</span>-Galactose Derivative <b>7β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PhSH, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 90%; (b) MeONa, MeOH, 0 °C, quant; (c) 2,2-dimethoxypropane (2,2-DMP), 10-camforsulfonic acid (CSA), rt, 85%; (d) <i>tert</i>-butyldiphenylsilyl chloride (TBDPSCI), imidazole, dimethylformamide (DMF), rt, 96%; (e) NaH, TBAI, (<b>6</b>), tetrahydrofuran (THF), rt, 90%.</p></p></figure><div class="NLM_p">Condensation of thiophenol with <span class="smallcaps smallerCapital">d</span>-galactose pentaacetate <b>1(α,β)</b> in the presence of boron etherate trifluoride afforded the corresponding thioglycoside <b>2β</b> in high chemical yield (90%, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), as a single anomer. A Zemplen deacetylation, followed by acid-catalyzed acetalation with 2,2-dimethoxypropane (DMP), afforded the 3,4-acetal <b>4β</b> in 85% yield. A regioselective silylation of the primary alcohol with <i>tert</i>-butyldiphenylsilyl chloride in DMF at rt afforded the mono hydroxylated derivative <b>5β</b> in high yield (96%). Finally, the installation of the <i>p</i>-fluorophenyl fragment was carried out in THF, using NaH as the base and <i>p</i>-fluorobenzyl chloride <b>6</b>. Thus, in only five high-yielding steps, the fully <i>O</i>-protected derivative <b>7β</b> was obtained on a multigram scale (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">The introduction of the (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol fragment in the anomeric position was accomplished as indicated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, following two different approaches. The first one, based on the use of the well-established trichloroacetimidate glycosylation reaction, consisted of treating <b>7β</b> with <i>N</i>-bromosuccinimide (NBS) in wet acetone and subsequent base-catalyzed addition of the obtained lactol <b>8(α</b>,<b>β)</b> to trichloroacetonitrile, to give the trichloroacetimidate donor as a 3:1 mixture of both anomers <b>9α</b> and <b>9β</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Lewis-acid-catalyzed glycosylation of the chiral alcohol acceptor, (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol <b>10</b><i><b>R</b></i>, with the mixture of the trichloroacetimidate donors gave the fully protected <i>O</i>-glycosyl derivative <b>11(α,β)</b>, as a 3:1 mixture of both diastereomers, which were easily separated by column chromatography to give the <b>11α</b> and <b>11β</b> anomers, in 60 and 25% chemical yields, respectively. As an alternative route, the alcohol <b>10</b><i><b>R</b></i> was directly <i>O</i>-glycosylated, using thioglycoside <b>7β</b> as the glycosyl donor. For this, the mixture NIS/trimethylsilyl trifluoromethanesulfonate was used as an activator in the presence of MS (4 Å), affording an equimolecular mixture of both anomers, <b>11(α</b>,<b>β</b>), in a high 81% chemical yield.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <b>11α</b> and <b>11β</b> by Glycosylation of <i>p</i>-Fluorobenzyl <span class="smallcaps smallerCapital">d</span>-Galactose Derivative <b>7β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, acetone (99%), darkness, −15 °C, <b>8α</b>:<b>8β</b> = 2:1, 91%; (b) CCl<sub>3</sub>CN, DBU (cat), c-hex:CH<sub>2</sub>Cl<sub>2</sub> 4:1, rt, <b>9α</b>:<b>9β</b> = 3:1, 97%; (c) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol, <b>10</b><i><b>R</b></i>, TMSOTf, diethyl ether, 4 Å MS, 0 °C to rt, column chromatography: <b>11α</b> 60% and <b>11β</b> 25%; (d) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol, <b>10</b><i><b>R</b></i>, NIS, TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å MS, 0 °C to rt, <b>11α</b>:<b>11β</b> = 1:1 (81%).</p></p></figure><div class="NLM_p">Considering the rigid conformations of the new <span class="smallcaps smallerCapital">d</span>-galactoderivatives, as a fused bicyclic compound with a pyranose ring and a cyclic acetal, we were interested in studying the difference in bioactivity between both anomers, despite the fact that in the case of most NK1R antagonist analogues the cis isomer is the most active one. Moreover, in both diastereomers, <b>11α</b> and <b>11β</b>, deprotection of the hydroxylic groups at 3, 4, and 6 positions and modification of the protecting groups, as indicated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, give us the opportunity to modulate the lipophilicity of the carbohydrate derivatives and study, at the same time, the structure–activity relationship. Desilylation of the <i>O</i>-silyl ether in position 6 with TBAF, followed by acid hydrolysis of 3,4-dimethyl acetal and subsequent formation of the 4,6-<i>O</i>-benzylidene acetal, allows us to obtain the corresponding monoalcohols (<b>12</b> and <b>14</b>) or the more hydrophilic trihydroxylated analogues (<b>13</b>), with α or β configurations, starting from <b>11α</b> and <b>11β</b>, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The presence of the phenyl ring in the benzylidene moiety of <b>14α</b> and <b>14β</b> favors their hydrophobic and/or π–π stabilizing interactions with some NK1R amino acids, as we have determined by docking studies (vide infra).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Deprotection and Protection of Hydroxylic Groups at <b>3</b>, <b>4</b>, and <b>6</b> Positions of <span class="smallcaps smallerCapital">d</span>-Galactose Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBAF, THF, rt, 80% <b>12α</b>, and 75% <b>12β</b>; (b) CSA (cat), MeOH, rt, quant <b>13α</b> and <b>13β</b>; (c) benzaldehyde dimethyl acetal, CSA (cat), DMF, 40 °C, 95% <b>14α</b> and <b>14β</b>.</p></p></figure><div class="NLM_p last">Upon regioselective protection of the trihydroxylated epimers <b>13</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), a single benzylidene acetal diastereoisomer was formed. Although expected, we, however, conducted selective NOESY1D experiments to confirm the stereochemical outcome of the process.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> For both <b>14α</b> and <b>14β</b>, the registered NOESY1D spectra with selective excitation of the benzylidene acetal protons (see the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf" class="ext-link">Supporting Information</a>) display three sets of signals, for an aromatic proton, H4, and H6 of the sugar. While the NOE contacts observed with the aromatic proton and H6 may be seen for the two diastereomers, the NOE contact observed with H4 is clearly indicative that the absolute configuration of the benzylidene acetal carbon center is indeed <i>R</i>.</div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Synthesis of <span class="smallcaps smallerCapital">l</span>-Arabinose-Derived NK1R Antagonists (AraNK1Ant)</h4><div class="NLM_p">The pentapyranose <span class="smallcaps smallerCapital">l</span>-arabinose is structurally related to <span class="smallcaps smallerCapital">d</span>-galactose with the sole, and important, difference of lacking the 6-hydroxymethyl group. Consequently, starting from <span class="smallcaps smallerCapital">l</span>-arabinose tetraacetate <b>15α</b>, a synthetic approach similar to that developed for <span class="smallcaps smallerCapital">d</span>-galactose has allowed us to obtain a series of analogues in only five or six steps and in the multigram scale; <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Additionally, the absence of the 6-hydroxymethyl group in the obtained analogues (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) will affect both their lipophilicity and conformational behavior.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Fully Protected <span class="smallcaps smallerCapital">l</span>-Arabinose Derivatives <b>22α</b> and <b>22β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PhSH, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, quant; (b) MeONa, MeOH, 0 °C to rt, quant; (c) 2,2-DMP, CSA, rt, 89%; (d) NaH, TBAI, <b>6</b>, THF, rt, quant; (e) NBS, acetone (99%), darkness, −15 °C, <b>20α</b>:<b>20β</b> = 1:2, 80%; (f) CCl<sub>3</sub>CN, DBU (cat), CH<sub>2</sub>Cl<sub>2</sub>, rt, <b>21α</b>:<b>21β</b> = 1:2, quant; (g) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol (<b>10</b><i><b>R</b></i>), Et<sub>2</sub>O, 4 Å MS, 0 °C to rt, column chromatography: <b>22α</b> 16% and <b>22β</b> 50%; (h) (<i>R</i>)-1-[3,5-bis(trifluoromethyl) phenyl]ethan-1-ol (<b>10</b><i><b>R</b></i>), NIS, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å MS, 0 °C to rt, <b>22α</b>:<b>22β</b> = 1:1 (66%).</p></p></figure><div class="NLM_p">Thus, the 2-<i>O</i>-<i>p</i>-fluorobenzyl derivative <b>19α</b> was obtained as a single diastereomer, starting from per-<i>O</i>-acetylated α-<span class="smallcaps smallerCapital">l</span>-arabinose <b>15α</b>, in only four high-yielding steps, with a 77% overall yield; <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The chiral alcohol <b>10</b><i><b>R</b></i> was introduced in the anomeric position using the trichloroacetimidate method to give a 1:2 mixture of both anomeric <i>O</i>-glycosyl derivatives <b>22α</b> and <b>22β</b>. They were also obtained directly from the phenylthioglycoside <b>19α</b>, as a 1:1 mixture of anomers by activation with trifluoromethylsilyl triflate as the Lewis acid, in the presence of NIS and 4 Å MS, at 0 °C. The two diastereoisomers <b>22α</b> and <b>22β</b> showed a very different separation factor, which, after column chromatography, allowed them to be obtained in the pure form with an overall 66% yield. Finally, acid hydrolysis of the 3,4-dimethyl acetal using CSA in methanol yielded the corresponding dihydroxy derivatives <b>23α</b> and <b>23β</b>, in quantitative yields; <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of the Dihydroxylic <span class="smallcaps smallerCapital">l</span>-Arabinose Derivatives <b>23α</b> and <b>23β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CSA (cat), MeOH, rt, quant.</p></p></figure></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Anticancer Activity</h3><div class="NLM_p">First, we evaluated the cytotoxicity of our carbohydrate derivatives against MRC-5 human nonmalignant lung cells and A549 human lung cancer cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay under the same experimental conditions. Both cell lines were exposed to different concentrations of compounds <b>12α</b>, <b>12β</b>, <b>13α</b>, <b>13β</b>, <b>14α</b>, <b>14β</b>, <b>22α</b>, <b>22β</b>, <b>23α</b>, and <b>23β</b> during 48 h before quantifying the cell viability. Aprepitant was used as a reference control to assess the activity of the new derivatives with a known NK1R antagonist, and Cisplatin, a well-known anticancer standard drug, was used as a positive control to study the possible selective cytotoxicity. The obtained results are collected in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf" class="ext-link">Figures S2 and S3</a>). All of the carbohydrate derivatives showed some selective cytotoxicity against the cancer cell line, i.e., for a given concentration, A549 cancer cells were more sensitive than MRC-5 normal cells. <b>12α</b>, <b>12β</b>, and Aprepitant showed the lowest selective activity, with selectivity index values ∼1.5 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). <b>13α</b>, <b>13β</b>, <b>23α</b>, and <b>23β</b> showed a modest selectivity, with IC<sub>50</sub> values in A549 ∼2-fold lower than in MRC-5. Interestingly, both α and β diastereomers of <b>14</b> and <b>22</b> showed the highest selective cytotoxicity against cancer cells, even higher than that of the anticancer drug Cisplatin. <b>14α</b> and <b>22β</b> were the most selective compounds. A549 cancer cells were over 10 times more sensitive than MRC-5 cells to these derivatives.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of Carbohydrate Derivatives and Cisplatin on Lung Cancer Cells (A549) versus Lung Normal Cells (MRC-5)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (mean ± SEM; μM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">MRC-5 (normal)</th><th class="colsep0 rowsep0" align="center">A549 (cancer)</th><th class="colsep0 rowsep0" align="center">selectivity index<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12α</b></td><td class="colsep0 rowsep0" align="left">27.8 ± 5.7</td><td class="colsep0 rowsep0" align="left">18.7 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12β</b></td><td class="colsep0 rowsep0" align="left">39.7 ± 4.2</td><td class="colsep0 rowsep0" align="left">23.4 ± 3.8</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13α</b></td><td class="colsep0 rowsep0" align="left">92.23 ± 16.7</td><td class="colsep0 rowsep0" align="left">40.9 ± 3.1</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13β</b></td><td class="colsep0 rowsep0" align="left">155.7 ± 29.6</td><td class="colsep0 rowsep0" align="left">67.5 ± 18.2</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14α</b></td><td class="colsep0 rowsep0" align="left"><b>225.8 ± 100.9</b></td><td class="colsep0 rowsep0" align="left"><b>24.2</b> ± <b>7.8</b></td><td class="colsep0 rowsep0" align="left"><b>20.1</b> ± 9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14β</b></td><td class="colsep0 rowsep0" align="left">130.8 ± 10.7</td><td class="colsep0 rowsep0" align="left">29.7 ± 5.1</td><td class="colsep0 rowsep0" align="left">5.8 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22α</b></td><td class="colsep0 rowsep0" align="left">503.7 ± 48.7</td><td class="colsep0 rowsep0" align="left">171.9 ± 47.3</td><td class="colsep0 rowsep0" align="left">3.9 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22β</b></td><td class="colsep0 rowsep0" align="left"><b>>800</b></td><td class="colsep0 rowsep0" align="left"><b>59.5</b> ± <b>11.4</b></td><td class="colsep0 rowsep0" align="left"><b>>10.7</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23α</b></td><td class="colsep0 rowsep0" align="left">50.4 ± 3.3</td><td class="colsep0 rowsep0" align="left">20.8 ± 4.0</td><td class="colsep0 rowsep0" align="left">2.8 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23β</b></td><td class="colsep0 rowsep0" align="left">56.2 ± 2.4</td><td class="colsep0 rowsep0" align="left">31.3 ± 5.6</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Aprepitant</b></td><td class="colsep0 rowsep0" align="left">28.9 ± 6.8</td><td class="colsep0 rowsep0" align="left">18.3 ± 3.4</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Cisplatin</b></td><td class="colsep0 rowsep0" align="left">99.2 ± 37.0</td><td class="colsep0 rowsep0" align="left">13.5 ± 2.7</td><td class="colsep0 rowsep0" align="left">8.6 ± 3.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The selectivity index is the mean of the selectivity indices calculated in each individual experiment. The selectivity index is calculated by dividing the IC<sub>50</sub> value obtained in the nonmalignant cell line (MRC-5) by that in the cancer cell line (A549). The most selective compounds are shown in bold.</p></div></div></div><div class="NLM_p">It should be noted that, in general, the carbohydrate derivatives showed higher selectivity than Aprepitant. <span class="smallcaps smallerCapital">d</span>-Galactosyl derivatives were the most active compounds, with similar activity to Aprepitant and Cisplatin against A549 cancer cells. Deprotection of the hydroxyl groups at 3, 4, and 6 positions increased the selective activity in <b>13α</b> and <b>13β</b>, but it also decreased their cytotoxic activity. The introduction of the 4,6-<i>O</i>-benzylidene acetal in diastereomers <b>14</b> increased the selective activity without compromising the cytotoxicity against cancer cells. Indeed, <b>14α</b> showed similar cytotoxicity as Cisplatin against A549 cancer cells, being less cytotoxic against MRC-5 normal cells. <span class="smallcaps smallerCapital">l</span>-Arabinose derivatives <b>22α</b> and <b>22β</b> also showed high selective anticancer activity; however, they were less cytotoxic than the galactose derivatives <b>14</b> against cancer cells. <b>14α</b> was ∼2.5-times more cytotoxic against A549 than <b>22β</b>, being both the most selective anticancer derivatives. For that reason, <b>14α</b> was selected to delve into its anticancer activity.</div><div class="NLM_p">Next, we used MCF7 breast cancer cells, MCF 10 normal breast epithelial cells, UACC-62 melanoma cells, and VH10 skin nonmalignant cells to explore whether the new carbohydrate derivatives were also selective against other types of cancer. These cells were exposed to several concentrations of the compound <b>14α</b> for 48 h, and cell viability was measured by the MTT assay (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). <b>14α</b> was ∼10 times more cytotoxic against MCF7 breast cancer cells than against MCF 10 normal cells. The IC<sub>50</sub> values (mean ± standard error of mean (SEM); μM) in MCF7 and MCF 10 cells were, respectively, 23.9 ± 5.0 and 291.3 ± 52.6. <b>14α</b> also showed selective cytotoxic activity against melanoma cells. UACC-62 melanoma cells were 4.3 times more sensitive than VH10 skin normal cells to the cytotoxic effect of <b>14α</b>. The IC<sub>50</sub> values (mean ± SEM; μM) in UACC-62 and VH10 were, respectively, 31.9 ± 6.0 and 117.9 ± 12.3. It is worth mentioning that <b>14α</b> showed similar cytotoxicity against the three cancer cell lines, with IC<sub>50</sub> values between 25 and 30 μM.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>14α</b> induces selective cytotoxicity toward breast cancer and melanoma cells. Breast cell lines (A) and skin cell lines (B) were exposed to the NK1R antagonist <b>14α</b> for 48 h. Cell viability was estimated with the MTT assay. Values (percentage of cell viability) derived from two independent experiments performed in duplicate, mean with SEM, and <i>p</i> values (paired <i>t</i>-test) are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As <b>14α</b> displayed cytotoxicity against three cancer cell lines (lung cancer, breast cancer, and melanoma), we decided to assess whether <b>14α</b> was also active against other types of cancer. Thirteen human cancer cells lines and one human nonmalignant cell line were treated with <b>14α</b> for 96 h. We used longer exposure times because some of these cell lines have long cell cycles (24–48 h); this longer exposure time allows the cells to pass several cycles in the presence of <b>14α</b>. Cell viability was estimated with the resazurin assay. HaCaT human skin nonmalignant cells were used to study selectivity; these cells are derived from normal adult tissue and have a division rate similar to that of cancer cells. One key limitation of most anticancer drugs is that, in addition to targeting cancer cells, they also target nonmalignant cells with similar division rates. Indeed, results in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> show that our positive control, Cisplatin, did not spare normal HaCaT cells from its cytotoxicity, with <b>14α</b> being more selective than Cisplatin. Compound <b>14α</b> showed a modest selectivity against HT29 (colorectal cancer) and A64-CLS (submaxillary gland adenoma) cells and a very low selectivity against T24 (bladder cancer) and MDA-MB-231 (triple-negative breast cancer). Interestingly, <b>14α</b> showed a marked selective cytotoxic activity against GAMG (glioblastoma), HNO97 (tongue cancer), MeWo (melanoma), PC-3 (prostate), Sk-Br-3 (HER2-positive breast cancer), An3Ca (endometrial cancer), and Sk-OV-3 (ovarian cancer). These cell lines were at least 3 times more sensitive than the normal cell line to <b>14α</b> treatment. HepG2 (hepatocarcinoma) and KATO III (gastric cancer) were at least 9-fold more vulnerable to <b>14α</b> than HaCaT nonmalignant cells. These data show that <b>14α</b> induces selective anticancer activity against a variety of cancer cell lines and suggest that our <span class="smallcaps smallerCapital">d</span>-galactose derivative has anticancer potential. The key role of NK1R in cell proliferation and the elevated expression of NK1R identified in several cancer types<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> could explain the higher sensitivity of cancer cell lines (A549, MCF7, UACC-62, GAMG, HNO97, MeWO, PC-3, HepG2, KATO III) than normal cell lines (MRC-5, MCF 10, VH10, HaCat) to compound <b>14α</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values of <b>14α</b> and Cisplatin on a Panel of Human Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">14α</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">Cisplatin</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (mean ± SEM; μM)</th><th class="colsep0 rowsep0" align="center">selectivity index (vsHaCaT: mean ± SEM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (mean ± SEM; μM)</th><th class="colsep0 rowsep0" align="center">selectivity index (vsHaCaT; mean ± SEM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HaCaT (human skin normal)</td><td class="colsep0 rowsep0" align="char" char="±">596.6 ± 8.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GAMG (glioblastoma)</td><td class="colsep0 rowsep0" align="char" char="±">183.8 ± 1.9</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.9</td><td class="colsep0 rowsep0" align="left">0.7 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HNO97 (tongue cancer)</td><td class="colsep0 rowsep0" align="char" char="±">175.1 ± 73.9</td><td class="colsep0 rowsep0" align="left">4.1 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.4</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A64-CLS (submaxillary gland adenoma)</td><td class="colsep0 rowsep0" align="char" char="±">236.5 ± 15.7</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 1.2</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MeWo (melanoma; BRAF WT)</td><td class="colsep0 rowsep0" align="char" char="±">112.9 ± 16.1</td><td class="colsep0 rowsep0" align="left">5.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.1</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T24 (bladder cancer)</td><td class="colsep0 rowsep0" align="char" char="±">490.8 ± 249.5</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.5</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3 (prostate cancer)</td><td class="colsep0 rowsep0" align="char" char="±">149.4 ± 44.0</td><td class="colsep0 rowsep0" align="left">4.4 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sk-Br-3 (HER2-positive breast cancer)</td><td class="colsep0 rowsep0" align="char" char="±">192.4 ± 14.8</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 0.9</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231 (triple-negative breast cancer)</td><td class="colsep0 rowsep0" align="char" char="±">332.2 ± 32.8</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">10.2 ± 6.3</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AN3Ca (endometrial adenocarcinoma)</td><td class="colsep0 rowsep0" align="char" char="±">137.9 ± 6.4</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 1.4</td><td class="colsep0 rowsep0" align="left">2.1 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sk-OV-3 (ovarian cancer)</td><td class="colsep0 rowsep0" align="char" char="±">153.1 ± 28.4</td><td class="colsep0 rowsep0" align="left">4.0 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 0.5</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KATO III (gastric cancer)</td><td class="colsep0 rowsep0" align="char" char="±">28.8 ± 11.7</td><td class="colsep0 rowsep0" align="left">24.7 ± 9.8</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2 (hepatocarcinoma)</td><td class="colsep0 rowsep0" align="char" char="±">133.3 ± 95.9</td><td class="colsep0 rowsep0" align="left">9.4 ± 6.8</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT29 (colorectal cancer)</td><td class="colsep0 rowsep0" align="char" char="±">256.0 ± 107.9</td><td class="colsep0 rowsep0" align="left">2.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.8</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated for 96 h, and cell viability was determined by the Resazurin assay.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The selectivity index is the mean of the selectivity indices calculated in each individual experiment. The selectivity index is calculated by dividing the IC<sub>50</sub> value obtained in the nonmalignant cell line (HaCaT) by that in the cancer cell line.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Study of the Mechanisms of Anticancer Activity</h3><div class="NLM_p">Our next aim was to study the possible mechanisms involved in the selective anticancer activity of <b>14α</b>. Because tumor cells rely on glycolysis for survival more than normal cells,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> we evaluated if our compound behaved as a glycolysis inhibitor. Since glycolysis consumes glucose and produces lactate, we measured the concentrations of glucose and lactate in untreated A549 cells and in cells exposed for 8 h to <b>14α</b> and to the known glycolysis inhibitor dichloroacetate. Unlike dichloroacetate, <b>14α</b> did not reduce glucose consumption or lactate production, therefore indicating that <b>14α</b> does not inhibit glycolysis.</div><div class="NLM_p">It is known that cancer cells have higher basal levels of reactive oxygen species (ROS) than normal cells, making them more sensitive to exogenous induction of ROS.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Several studies have shown that Aprepitant and other NK1R antagonists as SR140333 increased mitochondrial ROS production, leading to apoptosis.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Therefore, we decided to study whether the generation of ROS was involved in the selective cytotoxic effect of <b>14α</b>. A549 cancer cells were treated with <b>14α</b> for 48 h in the presence or absence of three antioxidants: <i>N</i>-acetylcysteine (antioxidant activity through the glutathione system), catalase (hydrogen peroxide-degrading enzyme), and Mn(III) tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride (MnTMPyP; superoxide anion scavenger). None of these three antioxidants reduced the cytotoxicity of <b>14α</b> on A549 cells. These results suggest that the anticancer effect of <b>14α</b> is not mediated by ROS production.</div><div class="NLM_p last">Several anticancer drugs (e.g., antimetabolites) inhibit DNA synthesis, block replication fork progression, and generate DNA damage that ultimately leads to cell death. In normal cells, this type of DNA damage is usually repaired by homologous recombination (HR).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, some cancers are HR-deficient and, therefore, they are more sensitive to these drugs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Because data suggest that NK1R blockade decreases the synthesis of DNA through the MAPK pathway,<a onclick="showRef(event, 'cit31a ref37'); return false;" href="javascript:void(0);" class="ref cit31a ref37">(31a,37)</a> we tested whether HR-deficient cells were more sensitive to <b>14α</b>. The HR-deficient VC8 cell line (V79 Chinese hamster lung cells mutated in BRCA2) and the HR-proficient VC8B2 cell line (VC8 cells complemented with human BRCA2) were treated with <b>14α</b> for 24 h. After a recovery period of 48 h, cell viability was estimated with the MTT assay. The HR-deficient VC8 cells were slightly more sensitive to <b>14α</b> than the HR-proficient VC8B2 cells. IC<sub>50</sub> values (mean ± SEM; μM) in VC8 and VC8B2 were, respectively, 36.5 ± 4.9 and 63.7 ± 11.1. These data suggest that the possible generation of DNA damage by <b>14α</b>, which could be repaired by HR, might play a minor role in the cytotoxicity of this compound.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Evaluation of the NK1R Antagonist Effect and Correlation with the Anticancer Effect of Selected Compounds</h3><div class="NLM_p">Finally, tests were carried out to, first, confirm the NK1R antagonist activity of the new carbohydrate derivatives and, then, its correlation with the observed anticancer effect. For this, we have chosen three representative derivatives for their chemical structure and their antitumor activity including the <span class="smallcaps smallerCapital">d</span>-galactosyl derivative <b>14α</b>, which provided the best effect, its trihydroxylated analogue <b>13α</b>, exhibiting a lower anticancer activity, and an arabinose derivative <b>23β</b>, exhibiting an intermediate activity.</div><div class="NLM_p">The antagonist activity of these compounds was determined by their ability to inhibit NK1R using the IPone test. This test quantifies the inositol monophosphate (IP1) accumulated inside the cell by time homogeneous fluorescence (HTRF) technology. The accumulation of IP1 is an indicator of the activation of NK1R, so that the NK1R agonist ligands cause an increase in the levels of IP1 in the absence of SP while, on the contrary, the antagonist ligands produce a decrease of these levels in the presence of the endogenous ligand SP. As a control compound, we used the N-acetyl-<span class="smallcaps smallerCapital">l</span>-typtophan 3,5(bis-trifluorometil)benzyl ester derivative (L732,138), whose NK1R antagonist activity is well-known at the molecular level.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, both <span class="smallcaps smallerCapital">d</span>-galactosyl derivatives, <b>13α</b> and 1<b>4α</b>, as well as the arabinose derivative <b>23β</b>, exhibit significant inhibitory effect on the SP activity and can therefore be considered as NK1R antagonists. Specifically, the <i>k</i><sub>inact</sub> values for the galactosyl derivatives <b>13α</b> and 1<b>4α</b> are 0.651 ± 0.239 and 0.209 ± 0.103 μM, respectively, and 0.494 ± 0.047 μM for the arabinosyl derivative <b>23β</b>; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Interestingly, by comparing the potency of the NK1R inhibitory activity of the three synthetic derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entries 2–4), as well as that known of Aprepitant (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entry 1), with their anticancer activity against the lung cancer cell line A549, determined previously, we note that there is a clear correlation between both activities; <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Concentration–response curves for the agonist and antagonist effects of SP (blue), L732,138 (olive green), α-<span class="smallcaps smallerCapital">d</span>-galactosyl derivatives (<b>13α</b> green; <b>14α</b> pink), and β-<span class="smallcaps smallerCapital">d</span>-arabinosyl derivative <b>23β</b> (black) using the IPone assay. The IP<sub>1</sub> accumulation (pmoles) was measured as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are illustrated from a representative experiment performed at least three times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. NK1R Antagonist Effects and Anticancer Activities of <b>13α</b>, <b>14α</b>, and <b>23β</b> Derivatives and Aprepitant</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="2" align="center">NK1R antagonist activity</th><th class="rowsep1 colsep0" align="center" char="±">anticancer activity (A549)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (mean ± SEM; μM)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub> (mean ± SEM; μM)</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (mean ± SEM; μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"><b>Aprepitant</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.41 × 10<sup>–3</sup> <a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.023 × 10<sup>–2</sup> <a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">18.3 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"><b>13α</b></td><td class="colsep0 rowsep0" align="left">1.100 ± 0.403</td><td class="colsep0 rowsep0" align="left">0.651 ± 0.239</td><td class="colsep0 rowsep0" align="char" char="±">40.9 ± 3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"><b>14α</b></td><td class="colsep0 rowsep0" align="left">0.353 ± 0.173</td><td class="colsep0 rowsep0" align="left">0.209 ± 0.103</td><td class="colsep0 rowsep0" align="char" char="±">24.2 ± 7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left"><b>23β</b></td><td class="colsep0 rowsep0" align="left">0.833 ± 0.079</td><td class="colsep0 rowsep0" align="left">0.494 ± 0.047</td><td class="colsep0 rowsep0" align="char" char="±">31.3 ± 5.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values from ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>.</p></div></div></div><div class="NLM_p">Indeed, Aprepitant (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entry 1) > <b>14α</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entry 3) > <b>23β</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entry 4) > <b>13α</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, entry 2) for both activities. Although the exact mechanism(s) of the antitumoral activity of NK1R antagonists is poorly understood, and is currently the subject of intense research,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> the results described indicate that the anticancer activity obtained with the carbohydrate analogues is mediated, at least in part, by the NK1 receptor.</div><div class="NLM_p last">Next, a binding affinity assay conducted by measuring the displacement of [<sup>125</sup>I]SP from the hNK1R from U-373MG cells<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> reveals that <b>14α</b> has an excellent affinity for NK1R with an IC<sub>50</sub> = 50.4 nM and <i>K</i><sub>i</sub> = 22.4 nM. The improved NK1R antagonist activity of <b>14α</b> over the trihydroxylated analogue <b>13α</b> is likely due to the presence of the benzylidene acetal moiety, which can establish additional stabilizing interactions with the NK1 receptor, as has been confirmed in modeling calculations.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Docking Calculations</h3><div class="NLM_p">To gain knowledge about the interactions involved in the molecular recognition among ligands <b>13α</b>, <b>13β</b>, <b>14α</b>, <b>14β</b>, Aprepitant, and NK1R, we performed docking calculations. The obtained docking scores were −9.5, −9.6, −12.0, −12.4, and −11.2 kcal/mol for <b>13α</b>, <b>13β</b>, <b>14β</b>, <b>14α</b>, and Aprepitant, respectively. The capability of docking calculations has been widely recognized for precise predictions of the optimal ligand binding geometries as well as binding interactions.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Thus, using the obtained docking poses and analyzing the hydrophobicity of the binding site, we characterize the intermolecular interactions between the studied ligands and NK1R.</div><div class="NLM_p">The binding site of NK1R has been previously described,<a onclick="showRef(event, 'cit22b'); return false;" href="javascript:void(0);" class="ref cit22b">(22b)</a> and it consists of a deep concave pocket with a large hydrophobic region that can maximize favorable protein–ligand contacts. For this reason, we used the octanol–water partition coefficient (or log <i>P</i>) of the different fragments of the ligands to obtain information about the interaction patterns of the ligands in the binding site.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Docking results revealed that all of the carbohydrate derivatives show a noticeable spatial overlap of the hydrophobic fragments 3,5-bis(trifluoromethyl)phenyl and 4-fluorophenyl, with root-mean-square deviation (RMSD) values from 0.115 to 0.207 Å for the former and from 0.120 to 0.950 Å for the latter (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The hydrophobicity surface of the binding pocket was performed because according to complementary ligand–protein binding interactions, strong hydrophobic regions of a binding site are usually occupied by hydrophobic fragments of ligands.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Superposition of the docked poses of Aprepitant (yellow), <b>13α</b> (red), <b>13β</b> (dark blue), <b>14α</b> (green), and <b>14β</b> (light blue) complexed with NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>). For clarity, hydrogen atoms have been removed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> reveals that most of the amino acids located at the bottom of the binding site have hydrophobic or amphipathic character (Ile113, Ile116, Ile204, Ala294, Met81, Met295, Met291, Phe110, Phe111, Phe264, Trp261, Tyr196). On the other hand, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A shows a top view of the middle-region binding site, which is dominated by charged/hydrophilic amino acids with large H-bonding donor/acceptor capacities (Gln165, His108, Asn109). On the contrary, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B indicates that hydrophobic amino acids are located at the down view of the middle region (Phe264 and Phe268). In addition to this, a strong hydrogen-bonding acceptor residue, Glu193, is found on the left side of the top view of the binding site outer region, which is accompanied by other amino acids with noticeable H-bonding donor/acceptor capacities (Trp184, Tyr196, Hys197). By contrast, the opposite side of this outer region is mainly surrounded by Ala93, Phe287, Ile283, and Tyr287 residues.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding site residues (dark green), hydrophobicity surface, and docked poses for Aprepitant (yellow), <b>14α</b> (green), <b>13α</b> (red), <b>13β</b> (dark blue), and <b>14β</b> (light blue), complexed with NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>). Top (A) and down (B) views are on the left and right sides, respectively. Brown color represents the most hydrophobic surface area and blue color, the least hydrophobic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The analysis of the ligand–protein interactions of the docked complexes (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) shows that the hydrophobic fluorinated aromatic fragments, 3,5-bis(trifluoromethyl)phenyl (log <i>P</i> = 3.70) and <i>p</i>-fluorophenyl (log <i>P</i> = 2.10), in all of the studied carbohydrate derivatives are stabilized at the bottom side of the binding site through a large number of hydrophobic interactions, π–π stacking interactions with Phe268, His197, and Phe264, π–alkyl interaction with Pro112, and alkyl–alkyl interactions with Met295, Phe264, Met291, Ile113, Ile204, and Trp261 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Besides, two types of electrostatically driven interactions were observed (values in parenthesis reflect the interaction distances range found): (i) weak hydrogen bonds between fluoromethyl fragments and amino groups of Asn89 (2.51–2.65 Å) and Thr201 (2.36–3.22 Å), and (ii) halogen bonding between some fluorine atoms of the 3,5-bis(trifluoromethyl)phenyl fragment and the carbonyl group of Pro112 (3.36–3.48 Å). These latter interactions are present in many protein–ligand complexes.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Two-dimensional view of the interaction type of Aprepitant (A), <b>14α</b> (B), <b>14β</b> (C), <b>13α</b> (D), and <b>13β</b> (E) with surrounding amino acids of NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The nonhydrophobic residues Gln165, Asn109, and His108 are in the central part of the binding pocket, where the O-substituted groups and central moieties of the ligands are placed. Oxygen atoms O-1 and O-2 and the amino group of Gln165 established two hydrogen bonds with lengths of 2.52 and 2.67 Å for <b>14α</b> and 2.49 and 2.91 Å for <b>13α</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), which largely contributes to the stabilization of the central moieties of these ligands in the binding site. Such a hydrogen bond was also found for <b>14β</b> (2.62 Å) and none for <b>13β</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><div class="NLM_p">The calculations revealed that the pyranosyl fragment in <b>14α</b> and <b>14β</b> is a moderate hydrophilic moiety (log <i>P</i> = −0.42), which can make close contacts with the polar amino acids Asn109 and His108 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). On the other hand, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B reveals that the large hydrophobic character of the opposite side of the middle binding region is mainly caused by the presence of Phe268 and Phe264 residues, so a small ligand hydrophobicity would tend to have a weaker binding ability with these residues, but the moderate hydrophilicity of the pyranose fragment in <b>14α</b> and <b>14β</b> will result in low docking score penalties due to its interaction with these residues. In addition to this, the oxygen atom O-6 participates in the formation of a strong hydrogen bond with Tyr287 in <b>14α</b> (2.16 Å) but not in <b>14β</b>, suggesting that the former shows better structural requirements for the docking.</div><div class="NLM_p">Regarding compounds <b>13α</b> and <b>13β</b>, the different spatial orientations of their hydroxylated pyranosyl fragments lead to different intermolecular interactions. The amino group of the Glu165 residue establishes a hydrogen bond (2.82 Å) with the oxygen atom of the pyranose fragment of ligand <b>13α</b>. Moreover, the carbonyl group of Asn109 (2.52 Å) and the basic nitrogen of His108 (2.16 Å) form hydrogen bonds with the hydroxyl group at the 6 position. In the case of <b>13β</b>, the hydroxyl groups at 3 and 4 positions and the oxygen atom of Tyr268 act as a H-bonding donor (2.17 Å) and acceptor (2.00 Å), respectively. The log <i>P</i> value of this pyranosyl fragment (−1.29) is significantly more negative than that obtained for the galactosyl derivative (see above), which suggests that the observed poor docking score in these ligands in part may be related to the extremely low hydrophobicity of the pyranosyl fragment, which is partially surrounded by a hydrophobic environment (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).</div><div class="NLM_p">Concerning Aprepitant, two hydrogen bonds are formed between the amino group of Glu165 and an oxygen (2.29 Å) and nitrogen (2.67 Å) atom, located on opposite sides of the morpholine moiety. This provokes an optimal anchoring of this fragment within the central region of the binding site. Besides, the log <i>P</i> value of this fragment (−0.41) is similar to that of the pyranosyl fragment of galactosyl derivatives, which allows a low scoring penalty due to the interactions with hydrophobic residues of the middle binding region.</div><div class="NLM_p">Finally, together with Aprepitant, the only ligands that have fragments on the binding site outer region are <b>14α</b> and <b>14β</b>. The first one has the triazolone group, while the other two have the phenyl group of the benzylidene acetal fragment. These fragments are docked in different binding regions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Thus, the triazolone group (log <i>P</i> = −0.64) is located in a more polar region of this binding site region and it interacts through strong H-bonds with Glu193 (2.04 Å) and Trp184 (1.67 Å) and establishes π–π staking interactions and π–alkyl interactions with His197 and Ile182, respectively. By contrast, the benzylidene groups (log <i>P</i> = 1.94) of <b>14α</b> and <b>14β</b> are surrounded by apolar residues like Ala93 and Phe267 and they form π–π staking interactions with Tyr287.</div><div class="NLM_p last">The obtained results show that hydrophobic and π–π stacking interactions play an important role in the binding affinity at the bottom of the binding site. By contrast, hydrogen-bond interactions seem to be the key factor for the docking in the middle binding region, for which the Gln165 residue plays an important role; however, a low hydrophobicity value of the ligand moiety docked in this region seems to provide an unfavorable binding factor. Finally, the presence of molecular fragments in the outer binding region is needed to increase the docking score. The different nature of residues in separate locations of the outer region binding site allows either a hydrophilic fragment, through hydrogen-bonding interactions, or a hydrophobic one, through strong hydrophobic interactions, to increase the binding affinity.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, we have reported the synthesis of a family of compounds designed as NK1R antagonists, using carbohydrate as the central scaffold. The use of sugars as starting substrates greatly facilitates the obtaining of final products as single isomers, important both for their biological activity and for their possible translation to the market. In addition, the multiple hydroxyl groups allow the regioselective anchoring of different substituents, which facilitates the modulation of the lipophilic/hydrophilic balance and optimizes the bioavailability of the final products. The products synthesized showed a strong affinity and antagonist activity against NK1R and were furthermore shown to be broad-spectrum anticancer agents with high selectivity, comparable to Cisplatin. Among all of the analogues tested, compound <b>14α</b> derived from galactose and whose aromatic groups in positions 1 and 2 are in the cis disposition was found to be the most active and the most selective, exhibiting a significant NK1R antagonist effect (<i>k</i><sub>inact</sub> 0.209 ± 0.103 μM) and a high binding affinity for NK1R (IC<sub>50</sub> = 50.4 nM, <i>K</i><sub>i</sub> = 22.4 nM by measuring the displacement of [<sup>125</sup>I] SP from NK1R).</div><div class="NLM_p">A clear correlation between antagonist and anticancer activities was observed by comparing the potency of the NK1R inhibitory activity of this galactosyl derivative <b>14α</b> with two other synthetic derivatives (<b>13α</b> and <b>23β</b>) and that of Aprepitant.</div><div class="NLM_p last">Interestingly, this galactosyl derivative has shown marked cytotoxic activity against 12 different types of cancer cell lines. Even more interesting is the selectivity observed, with cancer lines being up to 20 times more sensitive than nonmalignant cell lines to the treatment with <b>14α</b>. Docking studies on selected carbohydrate derivatives have provided new information on the key role of the 4,6-<i>O</i>-benzylidene acetal fragment of <b>14α</b> as the most likely responsible for its higher NK1R affinity. Taken together, these results strongly support the possibility of using carbohydrate-based NK1R antagonists as selective anticancer drugs, with the product <b>14α</b> being an interesting compound toward this end.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87353" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87353" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry: General Procedures</h3><div class="NLM_p">For the reactions that were run under an atmosphere of dry argon, oven-dried glassware and dried solvents were used. Chemicals were obtained from commercial sources and were used without further purification. Thin-layer chromatography (TLC) was carried out on silica gel GF254 (Merck), and compounds were detected by charring with phosphomolybdic acid/EtOH or sulfuric acid/EtOH. For flash chromatography, Merck 230–400 mesh silica gel was used. Chromatographic columns were eluted with a positive pressure of air, and eluents are given as volume-to-volume ratios (v/v). Nuclear magnetic resonance (NMR) spectra were recorded with Bruker Avance 500 MHz spectrometers. Chemical shifts are reported in ppm, and coupling constants are reported in Hz. High-resolution mass spectra (HRMS) were recorded in the Centro de Investigación, Tecnología e Innovación in the University of Seville with a Kratos MS-80RFA 241-MC apparatus. Different ionization methods than chemical ionization (CI) are indicated. Optical rotations were determined with a Perkin-Elmer 341 polarimeter. Melting points were measured with a Stuart SMP3 apparatus in open-ended capillary tubes. A Waters Alliance 2690 HPLC instrument with an ACE Excel C18 (4.6 mm × 100 mm, 2 μm particle size) column was used for analytical high-performance liquid chromatography (HPLC) analyses. The elution conditions were as follows: CH<sub>3</sub>CN/H<sub>2</sub>O, 70% (v/v) CH<sub>3</sub>CN gradient with 0.1% formic acid in 7 min, flow rate 1.0 mL/min, calculation of the relative purity of each compound at 254 nm. For compound <b>22β</b>, 80% (v/v) CH<sub>3</sub>CN gradient with 0.1% formic acid in 7 min was used. The purity of all tested compounds was above 95%.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Phenyl 2,3,4,6-Tetra-<i>O</i>-acetyl-1-thio-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>2β</b>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></h4><div class="NLM_p last">To a solution of 3.90 g of <span class="smallcaps smallerCapital">d</span>-galactose pentaacetate (10.00 mmol) in dry dichloromethane (40 mL) at 0 °C under an argon atmosphere, 4.93 mL of boron trifluoride etherate (40.00 mmol) was added dropwise. After 15 min of stirring at room temperature, 1.07 mL of thiophenol (10.50 mmol) was added. After stirring overnight, the starting material was consumed. The reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (2 × 40 mL), and the combined organic phases were washed with saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 3.96 g of <b>2β</b> (9.00 mmol, 90% yield) as a white solid; <i>R</i><sub>f</sub> = 0.79 (EtOAc/hexane, 1:1); m.p.: 115–116 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.52–7.50 (m, 2H), 7.32–7.31 (m, 3H), 5.42 (d, <i>J</i> = 2.7 Hz, 1H), 5.24 (t, <i>J</i> = 10.0 Hz, 1H), 5.05 (dd, <i>J</i> = 3.3, 9.9 Hz, 1H), 4.72 (d, <i>J</i> =, 10.0 Hz, 1H), 4.19 (dd, <i>J</i> = 6.9, 11.4 Hz, 1H), 4.12 (dd, <i>J</i> = 6.2, 11.3 Hz, 1H), 3.94 (t, <i>J</i> = 6.9 Hz, 1H), 2.12 (s, 3H), 2.10 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 170.5, 170.3, 170.2, 169.6, 132.8, 132.6, 129.1, 128.3, 86.8, 74.6, 72.2, 67.5, 67.4, 61.8, 53.6, 21.0, 20.8(2C), 20.7 ppm. [α]<sub>D</sub><sup>20</sup>: +3.6 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>20</sub>H<sub>25</sub>O<sub>9</sub>S: [M + H] <sup>+</sup> 441.1219, found 441.1200 (−4.4 ppm)</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Phenyl 1-Thio-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>3β</b>)</h4><div class="NLM_p last">To a solution of 3.96 g of <b>2β</b> (9.00 mmol) in methanol, at 0 °C under an argon atmosphere, 36.00 mL of a 1 M sodium methoxide methanolic solution (36.00 mmol) was added dropwise. After stirring for 35 min, the starting material was consumed. The reaction mixture was neutralized with acid resin and filtered to obtain 2.40 g of <b>3β</b> (8.80 mmol, quantitative yield) as a white solid, which was used in the next reaction without further purification; <i>R</i><sub>f</sub> = 0.72 (EtOAc/hexane, 1:1); m.p.: 114–115 °C; <sup>1</sup>H NMR (500 MHz, MeOD): δ 7.56–7.54 (m, 2H), 7.30–7.27 (m, 2H), 7.24–7.21 (m, 1H), 4.59 (d, <i>J</i> = 9.8 Hz, 1H), 3.90 (d, <i>J</i> = 3.0 Hz, 1H), 3.78–3.74 (m, 1H), 3.72–3.69 (m, 1H), 3.61 (t, <i>J</i> = 9.5 Hz, 1H), 3.57 (t, <i>J</i> = 6.1 Hz, 1H), 3.50 (dd, <i>J</i> = 3.3, 9.2 Hz, 1H) ppm; <sup>13</sup>C NMR (125 MHz, MeOD): δ 136.1, 132.2, 129.8, 128.1, 90.4, 80.7, 76.4, 71.1, 70.5, 62.7 ppm. [α]<sub>D</sub><sup>20</sup>: −28.3 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>12</sub>H<sub>16</sub>0<sub>5</sub>NaS: [M + Na] <sup>+</sup> 295.0616, found 295.0605 (3.6 ppm).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Phenyl 3,4-<i>O</i>-Isopropylidene-1-thio-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>4β</b>)</h4><div class="NLM_p last">To a suspension of 2.21 g of <b>3β</b> (8.10 mmol) in 60.00 mL of 2,2-dimethoxypropane (2,2-DMP) at room temperature under an argon atmosphere, 7.00 mg of 10-camphorsulfonic acid (CSA) (0.03 mmol) was added. After stirring for 48 h, the reaction mixture was neutralized with triethylamine and filtered to remove the ammonium salts formed. The solvent was evaporated under reduced pressure, and the residue obtained was dissolved in the minimum possible amount of toluene and evaporated to dryness. This process was repeated twice to obtain the mixed acetal with a small amount of the desired diol. Then, the crude obtained was dissolved in the minimum possible amount of methanol and a catalytic amount of CSA at 0 °C was added. After 5 min of stirring at room temperature, the reaction mixture was neutralized with triethylamine, the ammonium salts were filtered, and the solvent was evaporated under reduced pressure. The residue obtained was dissolved in toluene and evaporated to dryness. This process was repeated twice, and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:2) to obtain 2.16 g of <b>4β</b> (6.90 mmol, 85% yield) as a white solid; <i>R</i><sub>f</sub> = 0.40 (EtOAc/hexane, 1:1); m.p.: 92–93 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.48–7.46 (m, 2H), 7.25–7.18 (m, 3H), 4.45 (d, <i>J</i> = 10.0 Hz, 1H), 4.08–4.03 (m, 2H), 3.91–3.87 (m, 1H), 3.81–3.78 (m, 1H), 3.76–3.72 (m, 1H), 3.58 (bs, 1H), 3.55–3.51 (m, 1H), 3.17 (bs, 1H), 1.35 (s, 3H), 1.26 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 132.5, 131.8, 128.8, 127.5, 110.1, 87.2, 79.3, 76.9, 73.6, 71.2, 62.1, 27.8, 26.1 ppm. [α]<sub>D</sub><sup>20</sup>: +3.7 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>15</sub>H<sub>21</sub>O<sub>5</sub>S: [M + H]<sup>+</sup> 313.1 110, found 313.1 107 (−0.9 ppm).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Phenyl 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-3,4-<i>O</i>-isopropylidene-1-thio-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>5β</b>)</h4><div class="NLM_p last">To a solution of <b>4β</b> (103.10 mg, 0.30 mmol) in dry DMF (2.00 mL) at room temperature under an argon atmosphere, <i>tert</i>-butyldiphenylsilyl chloride (TBDPSCI) (0.11 mL, 0.40 mmol) and imidazole (56.34 mg, 0.80 mmol) were added. After 5 h, the reaction was diluted with ethyl acetate (2.00 mL) and quenched with a saturated NH<sub>4</sub>Cl aqueous solution. The aqueous phase was extracted with <i>n</i>-pentane (3 × 20.00 mL) and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 174.49 mg of the desired compound <b>5β</b> (0.30 mmol, 96% yield) as a white solid; <i>R</i><sub>f</sub> = 0.39 (EtOAc/hexane, 1:3); mp.: 50 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.72–7.71 (m, 4H), 7.55–7.53 (m, 2H), 7.45–7.36 (m, 6H), 7.28–7.27 (m, 3H), 4.45 (d, <i>J</i> = 10.2 Hz, 1H), 4.28 (dd, <i>J</i> = 1.9, 5.4 Hz, 1H), 4.08 (t, <i>J</i> = 6.2 Hz, 1H), 4.00–3.90 (m, 3H), 3.55 (ddd, <i>J</i> = 2.2, 7.1, 10.1 Hz, 1H), 2.43 (d, <i>J</i> = 2.0 Hz, 1H), 1.41 (s, 3H), 1.34 (s, 3H), 1.07 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 135.8, 133.6, 133.5, 132.6, 132.5, 129.9 (2), 129.2, 128.1, 127.9, 127.8, 110.3, 88.5, 79.2, 73.5, 71.8, 63.2, 28.3, 27.0, 26.5, 19.4 ppm. [α]<sub>D</sub><sup>20</sup>: +3.3 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>31</sub>H<sub>38</sub>O<sub>5</sub>NaSSi: [M + Na]<sup>+</sup> 573.2107, found 573.2123 (2.8 ppm).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Phenyl 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-1-thio-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>7β</b>)</h4><div class="NLM_p last">To a solution of 4.00 g of <b>5β</b> (6.07 mmol) in THF (80.00 mL) at room temperature under an argon atmosphere, a solution of 0.73 g of sodium hydride (18.25 mmol) in THF (10.00 mL) was added. After 1 h, 0.90 g of Bu<sub>4</sub>NI (2.43 mmol) was added and the reaction mixture was stirred for 30 min. Then, a solution of 1.10 mL of <i>p</i>-fluorobenzyl chloride <b>6</b> (9.10 mmol) in THF (5.00 mL) was added. After 48 h, the reaction mixture was quenched with a saturated NH<sub>4</sub>Cl aqueous solution. The aqueous phase was extracted with ethyl acetate (3 × 40 mL), and the combined organic phases were washed with a saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:8) to obtain 3.60 g of <b>7β</b> (5.46 mmol, 90% yield) as a yellow oil <i>R</i><sub>f</sub> = 0.81 (EtOAc/hexane, 1:4); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.78–7.75 (m, 4H), 7.58–7.56 (m, 2H), 7.49–7.40 (m, 9H), 7.30–7.24 (m, 2H), 7.10–7.04 (m, 2H), 4.84 (d, <i>J</i> = 11.3 Hz, 1H), 4.69 (d, <i>J</i> = 11.3 Hz, 1H), 4.65 (d, <i>J</i> = 9.7 Hz, 1H), 4.34 (dd, <i>J</i> = 2.0, 5.6 Hz, 1H), 4.29 (t, <i>J</i> = 6.0 Hz, 1H), 4.02–4.00 (m, 2H), 3.92 (td, <i>J</i> = 1.9, 6.5 Hz, 1H), 3.55 (dd, <i>J</i> = 6.4, 9.7 Hz, 1H), 1.44 (s, 3H), 1.40 (s, 3H), 1.12 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.5 (d, <i>J</i><sub>CF</sub> = 244.1 Hz), 135.8(2), 135.5, 135.0, 134.0, 133.9 (d, <i>J</i><sub>CF</sub> = 3.1 Hz), 133.5 (2C), 131.9, 130.1 (d, <i>J</i><sub>CF</sub> = 8.4 HZ), 129.9, 129.8, 129.0, 127.9, 127.8, 127.4, 115.2 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 110.1, 86.6, 79.9, 78.4, 76.9, 73.6, 72.9, 63.2, 28.0, 27.0, 26.7, 26.5, 19.4 ppm. [α]<sub>D</sub><sup>20</sup>: +8.4 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>38</sub>H<sub>43</sub>O<sub>5</sub>FNaSSi: [M + Na]<sup>+</sup> 681.2482, found 681.2479 (−0.5 ppm).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α,β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>8</b>(α,β))</h4><div class="NLM_p last">To a solution of 3.02 g of <b>7β</b> (4.59 mmol) in acetone/water 99:1 (120.00 mL) in the darkness at −15 °C, 1.03 g of <i>N</i>-bromosuccinimide (NBS) (5.78 mmol) was added. After 30 min, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (3 × 40.00 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:8) to obtain 2.37 g of a mixture of both anomers <b>8α</b>:<b>8β</b> in a 2:1 ratio (4.18 mmol, 91% yield) as a yellow syrup; <i>R</i><sub>f</sub> = 0.72 (EtOAc/hexane, 1:4).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>8α</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.71–7.66 (m, 4H), 7.43–7.31 (m, 8H), 7.05–7.00 (m, 2H), 5.15 (dd, <i>J</i> = 3.7, 5.0 Hz, 1H), 4.78–4.73 (m, 1H), 4.67–4.64 (m, 1H), 4.41–4.28 (m, 2H), 3.96–3.80 (m, 2H), 3.55 (dd, <i>J</i> = 7.2, 5.9 Hz, 1H), 2.92 (d, <i>J</i> = 4.1 Hz, 1H), 1.40 (s, 3H), 1.36 (s, 3H), 1.05 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7, (d, <i>J</i><sub>CF</sub> = 245.6 Hz), 135.9, 135.8 (2C), 133.9 (d, <i>J</i><sub>CF</sub> = 3.5 Hz), 133.8 (2C), 133.7, 133.5, 130.0 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 129.9, 129.8, 127.8, 115.5 (d, <i>J</i><sub>CF</sub> = 21.3 Hz), 110.0, 96.3, 91.0, 80.1, 78.0, 76.4, 74.7, 73.3, 73.0, 72.8, 72.2, 68.6, 63.0, 27.8 (2C), 27.0, 26.1, 19.4 ppm. HRMS: calcd for C<sub>32</sub>H<sub>39</sub>O<sub>6</sub>FNaSi: [M + Na]<sup>+</sup> 589.2398, found 589.2398 (0.1 ppm).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>8β</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.71–7.66 (m, 4H), 7.43–7.31 (m, 8H), 7.05–7.00 (m, 2H), 4.78–4.73 (m, 1H), 4.67–4.64 (m, 1H), 4.41–4.28 (m, 2H), 4.23 (t, <i>J</i> = 6.1 Hz, 1H), 3.96–3.80 (m, 2H), 3.37 (t, <i>J</i> = 6.5 Hz, 1H), 2.98 (d, <i>J</i> = 6.4 Hz, 1H), 1.41 (s, 3H), 1.36 (s, 3H), 1.05 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7, (d, <i>J</i><sub>CF</sub> = 245.6 Hz), 135.9, 135.8 (2C), 133.8 (2C), 133.7 (d, <i>J</i><sub>CF</sub> = 3.2 Hz), 133.7, 133.5, 129.9 (d, <i>J</i><sub>CF</sub> = 8.5 Hz), 129.9, 129.8, 127.8, 115.3 (d, <i>J</i><sub>CF</sub> = 21.1 Hz), 109.5, 96.3, 91.0, 80.1, 78.0, 76.4, 74.7, 73.3, 72.8, 72.5, 72.2, 68.6, 62.8, 27.8 (2C), 27.0, 26.1, 19.4 ppm. HRMS: calcd for C<sub>32</sub>H<sub>39</sub>O<sub>6</sub>FNaSi: [M + Na]<sup>+</sup> 589.2398, found 589.2398 (0.1 ppm).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-<i>p</i>-fluorobenzyl-3,4-<i>O</i>-isopropylidene-α,β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside, (<b>11α</b>) and (<b>11β</b>)</h4><div id="sec4_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Method A</h5><div class="NLM_p last">To a solution of 2.12 g of <b>8(α,β)</b> (3.74 mmol) in 50 mL of cyclohexane/dichloromethane 4:1 at room temperature under an argon atmosphere, a catalytic amount of DBU (0.23 mL, 1.50 mmol) and 0.96 mL of a 98% 2,2,2-trichloroacetonitrile solution was added dropwise. After stirring overnight, the reaction mixture was quenched with water, and the organic phase was washed with a saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to obtain 2.58 g of trichloroacetimidate <i>tert</i>-butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-6-<i>O</i>-α,β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside, <b>9(α,β)</b> (3.63 mmol, 97% yield), as a mixture of both anomers α:β in a 1:1 ratio, as a yellow syrup, which was used directly in the next reaction without further purification; <i>R</i><sub>f</sub> = 0.69 (EtOAc/hexane, 1:6).</div></div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranosyl Trichloroacetimidate (<b>9α</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.58 (s, 1H), 7.71–7.64 (m, 4H), 7.43–7.31 (m, 8H), 7.03–7.00 (m, 2H), 6.38 (d, <i>J</i> = 3.4 Hz, 1H), 4.82–4.65 (m, 2H), 4.45–4.34 (m, 2H), 4.07 (td, <i>J</i> = 1.9, 6.8 Hz, 1H), 3.98–3.85 (m, 2H), 3.71 (dd, <i>J</i> = 3.5, 6.9 Hz, 1H), 1.40 (s, 3H), 1.36 (s, 3H), 1.04 (s, 9H) ppm. HRMS: calc. for C<sub>34</sub>H<sub>39</sub>O<sub>9</sub>FNCl<sub>3</sub>NaSi: [M + Na]<sup>+</sup> 732.1488, found 732.1471 (−2.3 ppm).</div></div><div id="s0059" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">d</span>-galactopyranosyl Trichloroacetimidate (9β)</h4><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.65 (s, 1H), 7.71–7.64 (m, 4H), 7.43–7.31 (m, 8H), 7.03–7.00 (m, 2H), 5.71 (d, <i>J</i> = 8.3 Hz, 1H), 4.82–4.65 (m, 2H), 4.45–4.34 (m, 2H), 4.27 (t, <i>J</i> = 6.2 Hz, 1H), 3.98–3.85 (m, 2H), 3.64 (dd, <i>J</i> = 6.9, 8.2 Hz, 1H), 1.39 (s, 3H), 1.36 (s, 3H), 1.05 (s, 9H) ppm. HRMS: calc. for C<sub>34</sub>H<sub>39</sub>O<sub>9</sub>FNCl<sub>3</sub>NaSi: [M + Na]<sup>+</sup> 732.1488, found 732.1471 (−2.3 ppm).</div><div class="NLM_p">To a solution of 0.16 g of the obtained tricloroacetimidate <b>9(α,β)</b> (0.22 mmol) and 0.17 g of (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol (0.66 mmol) with 200.00 mg of a molecular sieve (4 Å) in 7.00 mL of ether at 0 °C under an argon atmosphere, 2.80 mL of trimethylsilyl trifluoromethanesulfonate (0.02 mmol) was added dropwise. After stirring for 1 h at room temperature, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The resulting suspension was filtered through a pad of Celite. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to obtain 0.15 mg (0.19 mmol, 85% yield) of a mixture of both anomers <b>11α:11β</b> in a 3:1 ratio, as a yellow syrup. After purification by flash chromatography (EtOAc/hexane, 1:15), 104.00 mg of <b>11α</b> (0.13 mmol, 60% yield) and 44 mg of <b>11β</b> (0.06 mmol, 25% yield) were obtained.</div><div id="sec4_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Method B</h5><div class="NLM_p last">To a solution of 0.20 g of thioglycoside <b>7β</b> (0.30 mmol) and 0.23 g of (1<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol (0.91 mmol) with 200.00 mg of a molecular sieve (4 Å) in 8.00 mL of dichloromethane at 0 °C under an argon atmosphere, 3.90 mL of trimethylsilyl trifluoromethanesulfonate (0.02 mmol) and 0.30 g of NIS (1.50 mmol) were added. After stirring for 1 h at room temperature, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The resulting suspension was filtered through a pad of Celite. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to obtain 193.0 mg (0.24 mmol, 81% yield) of the mixture of both anomers <b>11α</b>:<b>11β</b> in a 1:1 ratio, as a yellow syrup; <i>R</i><sub>f</sub> = 0.81 (EtOAc/hexane, 1:6). After purification by flash chromatography (EtOAc/hexane, 1:15), 97.00 mg of <b>11α</b> (0.12 mmol, 40% yield) and 97.00 mg of <b>11β</b> (0.12 mmol, 40% yield) were obtained.</div></div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-<i>p</i>-fluorobenzyl-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>11α</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.86 (bs, 2H), 7.82 (bs, 1H), 7.73–7.70 (m, 4H), 7.46–7.37 (m, 6H), 7.21–7.18 (m, 2H), 6.97–6.92 (m, 2H), 4.91 (q, <i>J</i> = 6.6 Hz, 1H), 4.61 (d, <i>J</i> = 3.1 Hz, 2H), 4.58 (d, <i>J</i> = 3.6 Hz, 1H), 4.42 (dd, <i>J</i> = 5.5, 7.8 Hz, 1H), 4.29 (dd, <i>J</i> = 2.5, 5.5 Hz, 1H), 4.18 (td, <i>J</i> = 2.4, 6.4 Hz, 1H), 3.98–3.89 (m, 2H), 3.42 (dd, <i>J</i> = 3.7, 7.8 Hz, 1H), 1.49 (d, <i>J</i> = 6.6 Hz, 3H), 1.33 (s, 3H), 1.32 (s, 3H), 1.10 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 162.5 (d, <i>J</i><sub>CF</sub> = 244.8 Hz), 145.9, 135.8(2C), 133.9 (d, <i>J</i><sub>CF</sub> = 3.2 Hz), 133.7, 133.6, 132.1 (q, <i>J</i><sub>CF</sub> = 33.5 Hz), 130.0, 129.7 (d, <i>J</i><sub>CF</sub> = 8.3 Hz), 127.9 (2C), 126.9 (q, <i>J</i><sub>CF</sub> = 2.4 Hz), 123.5 (q, <i>J</i><sub>CF</sub> = 272.9 Hz), 121.9 (sept, <i>J</i><sub>CF</sub> = 4.0 Hz), 115.3 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 109.4, 95.0, 76.3, 76.1, 73.5, 72.6, 71.5, 68.9, 63.4, 28.3, 27.0, 26.6, 24.5, 22.8, 19.5 ppm. [α]<sub>D</sub><sup>20</sup>: +87.8 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>42</sub>H<sub>45</sub>O<sub>6</sub>F<sub>7</sub>SiNa: [M + Na]<sup>+</sup> 829.2771, found 829.2811 (4.1 ppm).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 6-<i>O</i>-<i>tert</i>-Butyldiphenylsilyl-2-<i>O</i>-<i>p</i>-fluorobenzyl-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>11β</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.85 (bs, 1H), 7.79–7.74 (m, 3H), 7.66–7.61 (m, 4H), 7.43–7.32 (m, 7H), 7.05–7.00 (m, 2H), 4.97 (q, <i>J</i> = 6.5 Hz, 1H), 4.82 (s, 2H), 4.46 (d, <i>J</i> = 8.0 Hz, 1H), 4.25 (dd, <i>J</i> = 1.7, 5.5 Hz, 1H), 4.17 (dd, <i>J</i> = 5.8, 6.7 Hz, 1H), 3.87 (dd, <i>J</i> = 6.0, 8.5 Hz, 1H), 3.77–3.71 (m, 2H), 3.42 (t, <i>J</i> = 7.5 Hz, 1H), 1.50 (d, <i>J</i> = 6.5 Hz, 3H), 1.36 (s, 3H), 1.33 (s, 3H), 1.02 (s, 9H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6 (d, <i>J</i><sub>CF</sub> = 245.2 Hz), 148.4, 146.3, 135.8, 135.7, 134.1 (d, <i>J</i><sub>CF</sub> = 3.1 Hz), 133.6, 133.4, 131.9 (q, <i>J</i><sub>CF</sub> = 33.1 Hz), 131.5, 129.9 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 129.9, 127.9, 127.8, 125.8 (q, <i>J</i><sub>CF</sub> = 2.2 Hz), 123.5 (q, <i>J</i><sub>CF</sub> = 272.3 Hz), 121.4 (sept, <i>J</i><sub>CF</sub> = 3.8 Hz), 115.3 (d, <i>J</i><sub>CF</sub> = 21.5 Hz), 110.1, 100.8, 79.7, 79.3, 75.0, 73.6, 73.4, 73.1, 62.6, 28.0, 26.9, 26.4, 25.8, 22.3, 19.3 ppm. [α]<sub>D</sub><sup>20</sup>: +21.2 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>42</sub>H<sub>45</sub>O<sub>6</sub>F<sub>7</sub>SiNa: [M + Na]<sup>+</sup> 829.2771, found 829.2809 (4.5 ppm).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>12α</b>)</h4><div class="NLM_p last">To a solution of 0.70 g of <b>11α</b> (0.87 mmol) in THF (20 mL) at room temperature under an argon atmosphere, 4.34 mL (4.34 mmol) of 1 M tetrabutylammonium fluoride solution was added dropwise. After stirring for 1 h, the reaction mixture was diluted with ether and quenched with saturated NaCl aqueous solution. The aqueous phase was extracted with ethyl acetate (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 0.40 g of <b>12α</b> (0.70 mmol, 80% yield) as a yellow syrup; <i>R</i><sub>f</sub> = 0.13 (EtOAc/hexane, 1:4); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.91 (bs, 2H), 7.83 (bs, 1H), 7.20–7.17 (m, 2H), 6.96–6.92 (m, 2H), 4.92 (q, <i>J</i> = 6.7 Hz, 1H), 4.64 (d, <i>J</i> = 3.6 Hz, 1H), 4.62 (d, <i>J</i> = 12.5 Hz, 1H), 4.58 (d, <i>J</i> = 12.4 Hz, 1H), 4.47 (dd, <i>J</i> = 5.6, 7.9 Hz, 1H), 4.30 (dd, <i>J</i> = 2.7, 5.6 Hz, 1H), 4.19–4.16 (m, 1H), 3.97 (dd, <i>J</i> = 6.0, 11.8 Hz, 1H), 3.87 (dd, <i>J</i> = 3.9, 11.8 Hz, 1H), 3.42 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 2.25 (dd, <i>J</i> = 3.2, 9.3 Hz, 1H), 1.52 (d, <i>J</i> = 6.7 Hz, 3H), 1.35 (s, 3H), 1.33 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6 (d, <i>J</i><sub>CF</sub> = 245.6 Hz), 145.7, 133.7 (d, <i>J</i><sub>CF</sub> = 3.4 Hz), 132.1 (q, <i>J</i><sub>CF</sub> = 33.3 Hz), 129.7 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.9 (q, <i>J</i><sub>CF</sub> = 3.3 Hz), 123.5 (q, <i>J</i><sub>CF</sub> = 272.8 Hz), 122.0 (sept, <i>J</i><sub>CF</sub> = 3.6 Hz), 115.3 (d, <i>J</i><sub>CF</sub> = 21.7 Hz), 109.7, 95.3, 76.3, 75.7, 74.7, 73.1, 71.5, 68.1, 62.9, 28.2, 26.6, 24.5 ppm. [α]<sub>D</sub><sup>20</sup>: +105.5 (<i>c</i>1, chloroform). HRMS (EI): calcd for C<sub>26</sub>H<sub>27</sub>F<sub>7</sub>O<sub>6</sub>: [M]<sup>+</sup> 568.1792, found 568.1790 (0.5 ppm).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>12β</b>)</h4><div class="NLM_p last">To a solution of 0.70 g of <b>11β</b> (0.87 mmol) in THF (20 mL) at room temperature under an argon atmosphere, 4.34 mL (4.34 mmol) of 1 M tetrabutylammonium fluoride solution was added dropwise. After stirring for 1 h, the reaction mixture was diluted with ether and quenched with saturated NaCl aqueous solution. The aqueous phase was extracted with ethyl acetate (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 0.37 g of <b>12β</b> (0.65 mmol, 75% yield) as a yellow syrup; <i>R</i><sub>f</sub> = 0.07 (EtOAc/hexane, 1:4); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.75 (bs, 2H), 7.70 (bs, 1H), 7.29–7.26 (m, 2H), 6.95–6.92 (m, 2H), 4.88 (q, <i>J</i> = 6.5 Hz, 1H), 4.72 (bs, 2H), 4.39 (d, <i>J</i> = 7.9 Hz, 1H), 4.09 (dd, <i>J</i> = 5.8, 6.7 Hz, 1H), 4.02–4.00 (m, 1H), 3.71–3.66 (m, 1H), 3.63–3.58, (m, 2H), 3.34 (dd, <i>J</i> = 7.0, 7.8 Hz, 1H), 1.59 (bs, 1H), 1.44 (d, <i>J</i> = 6.5 Hz, 3H), 1.28 (s, 3H), 1.22 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7 (d, <i>J</i><sub>CF</sub> = 245.7 Hz), 146.6, 134.1 (d, <i>J</i><sub>CF</sub> = 3.4 Hz), 131.8 (q, <i>J</i><sub>CF</sub> = 33.3 Hz), 130.0 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.6 (q, <i>J</i><sub>CF</sub> = 2.9 Hz), 123.5 (q, <i>J</i><sub>CF</sub> = 273.0 Hz), 121.6 (sept, <i>J</i><sub>CF</sub> = 3.6 Hz), 115.3 (d, <i>J</i><sub>CF</sub> = 21.3 Hz), 110.5, 101.6, 79.7, 79.4, 76.4, 74.0, 73.6, 73.1, 62.4, 27.9, 26.5, 22.9 ppm. [α]<sub>D</sub><sup>20</sup>: +28.5 (<i>c</i>1, chloroform). HRMS (EI): calcd for C<sub>26</sub>H<sub>27</sub>F<sub>7</sub>O<sub>6</sub>: [M]<sup>+</sup> 568.1792, found 568.1789 (0.5 ppm).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-α-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>13α</b>)</h4><div class="NLM_p last">To a solution of 0.50 g of <b>12α</b> (0.88 mmol) in methanol (20.00 mL) at room temperature, a catalytic amount of CSA was added. After stirring overnight, the solvent was evaporated under reduced pressure. The residue obtained was purified by flash chromatography (EtOAc) to obtain 0.46 g of <b>13α</b> (0.87 mmol, 99% yield) as a white solid; <i>R</i><sub>f</sub> = 0.51 (EtOAc); m.p.: 147–149 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.89 (bs, 2H), 7.84 (bs, 1H), 7.17–7.14 (m, 2H), 6.98–6.94 (m, 2H), 4.92 (q, <i>J</i> = 6.5 Hz, 1H), 4.79 (d, <i>J</i> = 3.5 Hz, 1H), 4.53 (d, <i>J</i> = 11.9 Hz, 1H), 4.34 (d, <i>J</i> = 11.8 Hz, 1H), 4.16–4.10 (m, 2H), 4.02–3.88 (m, 3H), 3.69 (dd, <i>J</i> = 3.5, 9.8 Hz, 1H), 2.79 (bs, 1H), 2.34 (d, <i>J</i> = 2.6 Hz, 1H), 2.30 (dd, <i>J</i> = 3.6, 7.1 Hz, 1H), 3.07 (d, <i>J</i> = 6.7 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.8 (d, <i>J</i><sub>CF</sub> = 246.9 Hz), 145.8, 133.4 (d, <i>J</i><sub>CF</sub> = 3.0 Hz), 132.2 (q, <i>J</i><sub>CF</sub> = 33.4 Hz), 129.9 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.9 (q, <i>J</i><sub>CF</sub> = 3.8 Hz), 123.4 (q, <i>J</i><sub>CF</sub> = 271.8 Hz), 122.0 (sept, <i>J</i><sub>CF</sub> = 3.8 Hz), 115.7 (d, <i>J</i><sub>CF</sub> = 21.3 Hz), 95.1, 75.9, 73.4, 72.2, 70.9, 69.9, 69.1, 63.5, 24.5 ppm. [α]<sub>D</sub><sup>20</sup>: +121.5 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>23</sub>H<sub>23</sub>O<sub>6</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 551.1281, found 551.1264 (−3.0 ppm).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>13β</b>)</h4><div class="NLM_p last">To a solution of 0.50 g of <b>12β</b> (0.88 mmol) in methanol (200.00 mL) at room temperature, a catalytic amount of CSA was added. After stirring overnight, the solvent was evaporated under reduced pressure. The residue obtained was purified by flash chromatography (EtOAc) to obtain 0.45 g of <b>13β</b> (0.85 mmol, 97% yield) as a white solid; <i>R</i><sub>f</sub> = 0.47 (EtOAc); m.p.: 143–145 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.85 (bs, 2H), 7.80 (bs, 1H), 7.38–7.35 (m, 2H), 7.08–7.05 (m, 2H), 4.99 (q, <i>J</i> = 6.4 Hz, 1H), 4.97 (d, <i>J</i> = 11.5 Hz, 1H), 4.74 (d, <i>J</i> = 11.5 Hz, 1H), 4.56 (d, <i>J</i> = 7.3 Hz, 1H), 3.98 (dd, <i>J</i> = 3.6, 5.9 Hz, 1H), 3.79 (dd, <i>J</i> = 3.9, 12.6 Hz, 1H), 3.71 (dd, <i>J</i> = 3.4, 8.0 Hz, 2H), 3.63–3.56 (m, 2H), 3.44–3.42 (m, 1H), 1.57 (d, <i>J</i> = 6.5 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.8 (d, <i>J</i><sub>CF</sub> = 246.5 Hz), 146.5, 134.2 (d, <i>J</i><sub>CF</sub> = 3.6 Hz), 131.7 (q, <i>J</i><sub>CF</sub> = 33.4 Hz), 129.9 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.6 (q, <i>J</i><sub>CF</sub> = 3.0 Hz), 123.4 (q, <i>J</i><sub>CF</sub> = 272.7 Hz), 121.6 (sept, <i>J</i><sub>CF</sub> = 3.7 Hz), 115.7 (d, <i>J</i><sub>CF</sub> = 21.2 Hz), 102.7, 79.2, 76.8, 74.3, 73.4, 69.5, 62.7, 22.9 ppm. [α]<sub>D</sub><sup>20</sup>: +25.3 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>23</sub>H<sub>23</sub>F<sub>7</sub>O<sub>6</sub>: [M + Na]<sup>+</sup> 551.1281, found 551.1262 (−3.0 ppm).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} (<i>R</i>)-(4,6-<i>O</i>-Benzylidene)-2-<i>O</i>-<i>p</i>-fluorobenzyl-α-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>14α</b>)</h4><div class="NLM_p last">To a solution of 100.00 mg of <b>13α</b> (0.19 mmol) in DMF (15.00 mL) and 0.32 mL of dimethoxymethyl benzene (0.21 mmol) under an argon atmosphere, a catalytic amount of CSA was added. After stirring for 1 h in vacuo at 40 °C, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 100.00 mg of <b>14α</b> (0.18 mmol, 95% yield) as a white solid; <i>R</i><sub>f</sub> = 0.48 (EtOAc); m.p.: 158–159 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (bs, 2H), 7.84 (bs, 1H), 7.47–7.43 (m, 2H), 7.38–7.35 (m, 3H), 7.16–7.13 (m, 2H), 6.95–6.90 (m, 2H), 5.57 (s, 1H), 4.92 (q, <i>J</i> = 6.6 Hz, 1H), 4.81 (d, <i>J</i> = 3.5 Hz, 1H), 4.52 (d, <i>J</i> = 3.0 Hz, 2H), 4.35–4.34 (m, 1H), 4.32 (dd, <i>J</i> = 1.4, 12.6 Hz, 1H), 4.25 (dd, <i>J</i> = 3.7, 10.0 Hz, 1H), 4.15–4.12 (m, 1H), 3.84 (bs, 1H), 3.75 (dd, <i>J</i> = 3.6, 10.0 Hz, 1H), 1.53 (d, <i>J</i> = 6.6 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6 (d, <i>J</i><sub>CF</sub> = 246.1 Hz), 145.6, 137.6, 133.7 (d, <i>J</i><sub>CF</sub> = 3.0 Hz), 132.1 (q, <i>J</i><sub>CF</sub> = 33.6 Hz), 129.7 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 129.5, 128.5, 127.0 (d, <i>J</i><sub>CF</sub> = 2.7 Hz), 126.4, 123.4 (q, <i>J</i><sub>CF</sub> = 272.1 Hz), 122.0 (sept, <i>J</i><sub>CF</sub> = 4.0 Hz), 115.4 (d, <i>J</i><sub>CF</sub> = 21.8 Hz), 101.5, 96.0, 76.3, 76.1, 73.3, 72.7, 69.5, 68.8, 63.3, 24.4 ppm. [α]<sub>D</sub><sup>20</sup>: +94.6 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>30</sub>H<sub>27</sub>O<sub>6</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 639.1594, found 639.1565 (−4.5 ppm).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} (<i>R</i>)-(4,6-<i>O</i>-Benzylidene)-2-<i>O</i>-<i>p</i>-fluorobenzyl-β-<span class="smallcaps smallerCapital">d</span>-galactopyranoside (<b>14β</b>)</h4><div class="NLM_p last">To a solution of 100.00 mg of <b>13β</b> (0.19 mmol) in DMF (15.00 mL) and 0.32 mL of dimethoxymethyl benzene (0.21 mmol) under an argon atmosphere, a catalytic amount of CSA was added. After stirring for 1 h in vacuo at 40 °C, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:4) to obtain 100.00 mg of <b>14β</b> (0.18 mmol, 95% yield) as a white solid; <i>R</i><sub>f</sub> = 0.45 (EtOAc); m.p: 131 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (bs, 2H), 7.80 (bs, 1H), 7.49–7.47 (m, 2H), 7.39–7.36 (m, 5H), 7.05–7.01 (m, 2H), 5.52 (s, 1H), 5.03 (q, <i>J</i> = 6.6 Hz, 1H), 4.93 (d, <i>J</i> = 11.3 Hz, 1H), 4.79 (d, <i>J</i> = 11.2 Hz, 1H), 4.57 (d, <i>J</i> = 7.6 Hz, 1H), 4.19 (dd, <i>J</i> = 1.0, 3.9 Hz, 1H), 4.08 (dd, <i>J</i> = 1.4, 12.5 Hz, 1H), 3.98 (dd, <i>J</i> = 1.9, 12.5 Hz, 1H), 3.74 (td, <i>J</i> = 3.8, 8.9 Hz, 1H), 3.67–3.64 (m, 1H), 3.36–3.35 (m, 1H), 2.45 (d, <i>J</i> = 8.4 Hz, 1H), 1.56 (d, <i>J</i> = 6.6 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 162.6 (d, <i>J</i><sub>CF</sub> = 245.6 Hz), 146.6, 137.7, 134.5 (d, <i>J</i><sub>CF</sub> = 2.8 Hz), 131.6 (q, <i>J</i><sub>CF</sub> = 33.4 Hz), 129.7 (d, <i>J</i><sub>CF</sub> = 8.1 Hz), 129.5, 128.4, 126.7, 126.6 (d, <i>J</i><sub>CF</sub> = 2.8 Hz), 123.6 (q, <i>J</i><sub>CF</sub> = 272.7 Hz), 121.4 (sept, <i>J</i><sub>CF</sub> = 4.0 Hz), 115.4 (d, <i>J</i><sub>CF</sub> = 21.5 Hz), 102.0, 101.6, 79.8, 76.2, 75.6, 74.6, 73.0, 69.0, 66.8, 22.8 ppm. [α]<sub>D</sub><sup>20</sup>: −2.9 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>30</sub>H<sub>27</sub>O<sub>6</sub>NaF<sub>7</sub>: [M + Na]<sup>+</sup> 639.1594, found 639.1563 (−4.3 ppm).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Phenyl 2,3,4-Tri-<i>O</i>-acetyl-1-thio-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>16α</b>)</h4><div class="NLM_p last">To a solution of 5.24 g of β-<span class="smallcaps smallerCapital">l</span>-arabinose tetraacetate (16.50 mmol) in dry dichloromethane (40 mL) at 0 °C under an argon atmosphere, 8.15 mL of boron trifluoride etherate (65.90 mmol) was added dropwise. After 15 min stirring at room temperature, 1.77 mL of thiophenol (17.30 mmol) was added. After stirring overnight, the starting material was consumed. The reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (2 × 40 mL), and the combined organic phases were washed with saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:7) to obtain 6.00 g of <b>16α</b> (16.30 mmol, quantitative yield) as an orange oil; <i>R</i><sub>f</sub> = 0.43 (EtOAc/hexane, 1:2); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.51–7.50 (m, 2H), 7.33–7.29 (m, 3H), 5.30–5.27 (m, 1H), 5.25 (t, <i>J</i> = 8.0 Hz, 1H), 5.11 (dd, <i>J</i> = 3.4, 8.5 Hz, 1H), 4.82 (d, <i>J</i> = 7.7 Hz, 1H), 4.17 (dd, <i>J</i> = 4.3, 12.6 Hz, 1H), 3.68 (dd, <i>J</i> = 2.1, 12.7 Hz, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 170.4, 170.1, 169.6, 133.5, 132.5, 129.2, 128.2, 87.0, 70.7, 68.8, 67.7, 65.4, 21.1, 21.0, 20.9 ppm. [α]<sub>D</sub><sup>20</sup>: +2.5 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>17</sub>H<sub>20</sub>O<sub>7</sub>NaS: [M + Na] <sup>+</sup> 391.0822, found 391.0818 (−1.03 ppm).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Phenyl 1-Thio-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>17α</b>)</h4><div class="NLM_p last">To a solution of 6.00 g of <b>16α</b> (16.30 mmol) in methanol at 0 °C under an argon atmosphere, 10.00 mL of a 1 M sodium methoxide methanolic solution (10.00 mmol) was added dropwise. After stirring for 35 min, the starting material was consumed. The reaction mixture was neutralized with acid resin and filtered to obtain 3.91 g of <b>17α</b> (16.20 mmol, quantitative yield) as a yellow solid, which was used in the next reaction without further purification; <i>R</i><sub>f</sub> = 0.36 (EtOAc); m.p.: 114–115 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.56–7.54 (m, 2H), 7.33–7.28 (m, 3H), 4.48 (d, <i>J</i> = 8.9 Hz, 1H), 4.11 (dd, <i>J</i> = 2.0, 12.8 Hz, 1H), 3.98 (bs, 1H), 3.71–3.59 (m, 3H), 2.46 (bs, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 132.8, 132.5, 129.3, 128.3, 89.4, 74.4, 70.4, 70.0, 68.8 ppm. [α]<sub>D</sub><sup>20</sup>: −54 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>11</sub>H<sub>14</sub>0<sub>4</sub>NaS: [M + Na] <sup>+</sup> 265.0505, found 265.0508 (1.1 ppm).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Phenyl 3,4-<i>O</i>-Isopropylidene-1-thio-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>18α</b>)</h4><div class="NLM_p last">To a suspension of 3.91 g of <b>17α</b> (16.20 mmol) in 120.00 mL of 2,2-dimethoxypropane (2,2-DMP) at room temperature under an argon atmosphere, 7.00 mg of 10-camforsulfonic acid (CSA) (0.03 mmol) was added. After stirring for 30 min, the reaction mixture was neutralized with triethylamine and filtered to remove the ammonium salts formed. The solvent was evaporated under reduced pressure, and the residue obtained was dissolved in the minimum possible amount of toluene and evaporated to dryness. This process was repeated twice to obtain the mixed acetal with a small amount of the desired diol. Then, the crude obtained was dissolved in the minimum possible amount of methanol and a catalytic amount of CSA at 0 °C was added. After 5 min of stirring at room temperature, the reaction mixture was neutralized with triethylamine, the ammonium salts were filtered, and the solvent was evaporated under reduced pressure. The residue obtained was dissolved in toluene and evaporated to dryness. This process was repeated twice, and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:3) to obtain 4.08 g of <b>18α</b> (14.41 mmol, 89% yield) as a white solid; <i>R</i><sub>f</sub> = 0.60 (EtOAc/hexane, 1:1); m.p.: 92–93 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.56–7.53 (m, 2H), 7.33–7.28 (m, 3H), 4.53 (d, <i>J</i> = 9.2 Hz, 1H), 4.28–4.24 (m, 2H), 4.13–4.09 (m, 1H), 3.82–3.78 (m, 1H), 3.67–3.36 (m, 1H), 2.59 (d, <i>J</i> = 2.9 Hz, 1H), 1.46 (s, 3H), 1.36 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 132.9, 132.4, 129.2, 128.2, 110.3, 88.4, 78.4, 73.1, 71.7, 65.9, 28.0, 26.3 ppm. [α]<sub>D</sub><sup>20</sup>: +17.6 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>14</sub>H<sub>18</sub>O<sub>4</sub>NaS: [M + Na]<sup>+</sup> 305.0818, found 305.0818 (−0.05 ppm).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Phenyl 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-1-thio-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>19α</b>)</h4><div class="NLM_p last">To a solution of 3.85 g of <b>18α</b> (13.63 mmol) in THF (100.00 mL) at room temperature under an argon atmosphere, a solution of 1.64 g of sodium hydride (40.89 mmol) in THF (20.00 mL) was added. After 1 h, 2.00 g of IN(Bu)<sub>4</sub> (5.45 mmol) was added and the reaction mixture was stirred for 30 min. Then, a solution of 2.47 mL of <i>p</i>-fluorobenzyl chloride <b>6</b> (20.45 mmol) in THF (10.00 mL) was added. After 24 h, the reaction mixture was quenched with a saturated NH<sub>4</sub>Cl aqueous solution. The aqueous phase was extracted with ethyl acetate (3 × 40 mL), and the combined organic phases were washed with a saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:10) to obtain 5.05 g of <b>19α</b> (13.62 mmol, quantitative yield) as a yellow oil; <i>R</i><sub>f</sub> = 0.50 (EtOAc/hexane, 1:3); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.52–7.50 (m, 2H), 7.39–7.36 (m, 2H), 7.31–7.24 (m, 3H), 7.05–7.00 (m, 2H), 4.79 (d, <i>J</i> = 8.2 Hz, 1H), 4.78 (d, <i>J</i> = 11.4 Hz, 1H), 4.65 (d, <i>J</i> = 11.3 Hz, 1H), 4.31–4.28 (m, 1H), 4.23 (t, <i>J</i> = 6.1 Hz, 1H), 4.20 (dd, <i>J</i> = 3.8, 13.2 Hz, 1H), 3.77 (dd, <i>J</i> = 3.8, 13.0 Hz, 1H), 3.59 (dd, <i>J</i> = 6.1, 8.0 Hz, 1H), 1.47 (s, 3H), 1.37 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6 (d, <i>J</i><sub>CF</sub> = 245.7 Hz), 134.1, 133.7 (d, <i>J</i><sub>CF</sub> = 3.1 Hz), 132.0, 130.1 (d, <i>J</i><sub>CF</sub> = 8.1 Hz), 129.0, 127.6, 115.3, (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 110.1, 86.5, 78.4, 72.8, 72.7, 64.9, 27.9, 26.3 ppm. [α]<sub>D</sub><sup>20</sup>: −10 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>21</sub>H<sub>23</sub>O<sub>4</sub>FNaS: [M + Na]<sup>+</sup> 413.1193, found 413.1188 (−1.3 ppm).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α,β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>20</b>(α,β))</h4><div class="NLM_p last">To a solution of 4.60 g of <b>19α</b> (12.40 mmol) in acetone/water 99:1 (130.00 mL) in the darkness at −15 °C, 2.80 g of NBS (15.62 mmol) was added. After 15 min, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The aqueous phase was extracted with dichloromethane (3 × 40.00 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the reaction crude was purified by flash chromatography (EtOAc/hexane, 1:5) to obtain 2.94 g of a mixture of both anomers <b>20α:20β</b> in a 1:2 ratio (9.93 mmol, 80% yield) as a white solid; <i>R</i><sub>f</sub> = 0.49 (EtOAc/hexane, 1:1).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>20α</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.38–7.32 (m, 2H), 7.05–7.01 (m, 2H), 4.76–4.74 (m, 2H), 4.73 (d, <i>J</i> = 6.0 Hz, 1H), 4.26–4.21 (m, 2H), 4.08 (dd, <i>J</i> = 2.6 and 13.1 Hz, 1H), 3.82 (dd, <i>J</i> = 3.2 and 13.1 Hz, 1H), 3.46 (t, <i>J</i> = 5.9 Hz, 1H), 1.47 (s, 3H), 1.36 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6 (d, <i>J</i> = 245.4 Hz), 133.6 (d, <i>J</i> = 2.8 Hz), 129.9 (d, <i>J</i> = 8.1 Hz), 115.4 (d, <i>J</i> = 21.2 Hz), 109.4, 91.1, 77.4, 74.6, 72.8, 72.1, 60.0, 27.8, 25.9 ppm. HRMS: calcd for C<sub>15</sub>H<sub>19</sub>O<sub>5</sub>FNa: [M + Na]<sup>+</sup> 321.1109, found 321.1106 (−0.9 ppm).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>20β</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.38–7.32 (m, 2H), 7.05–7.01 (m, 2H), 5.17 (d, <i>J</i> = 3.4 Hz, 1H), 4.77 (d, <i>J</i> = 12.0 Hz, 1H), 4.66 (d, <i>J</i> = 11.9 Hz, 1H), 4.37 (t, <i>J</i> = 6.1 Hz, 1H), 4.26–4.21 (m, 1H), 4.15 (dd, <i>J</i> = 3.0 and 13.1 Hz, 1H), 3.87 (dd, <i>J</i> = 1.8 and 13.1 Hz, 1H), 3.58 (dd, <i>J</i> = 3.4 and 6.2 Hz, 1H), 1.45 (s, 3H), 1.36 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7 (d, <i>J</i> = 246.3 Hz,), 133.9 (d, <i>J</i> = 3.7 Hz), 130.0 (d, <i>J</i> = 8.0 Hz), 115.5 (d, <i>J</i> = 21.5 Hz), 110.1, 95.8, 79.5, 76.4, 73.0, 72.5, 62.8, 27.9, 26.1 ppm. HRMS: calcd for C<sub>15</sub>H<sub>19</sub>O<sub>5</sub>FNa: [M + Na]<sup>+</sup> 321.1109, found 321.1106 (−0.9 ppm).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-{1-[35-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-3,4-<i>O</i>-isopropylidene-α,β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside, (<b>22α</b>) and (<b>22β</b>)</h4><div id="sec4_1_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Method A</h5><div class="NLM_p last">To a solution of 1.41 g of <b>20(α,β)</b> (4.74 mmol) in 35 mL of dichloromethane at room temperature under an argon atmosphere, a catalytic amount of 98% DBU (0.70 mL, 4.74 mmol) and 2.40 mL of a 98% 2,2,2-trichloroacetonitrile solution (23.68 mmol) was added dropwise. After stirring overnight, the reaction mixture was quenched with water, and the organic phase was washed with a saturated NaCl aqueous solution and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to give 2.08 g of trichloroacetimidate 2-<i>O</i>-(<i>p</i>-fluorobenzyl)-3,4-<i>O</i>-isopropylidene-6-<i>O</i>-α,β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside, <b>21(α,β)</b> (4.70 mmol, quantitative yield), as a mixture of both anomers α:β in a 1:2 ratio, as a black syrup, which was used directly in the next reaction without further purification (<i>R</i><sub>f</sub> = compound unstable in silica gel).</div></div></div><div id="s0060" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranosyl Trichloroacetimidate (21α)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.37–7.30 (m, 2H); 7.03–6.98 (m, 2H); 5.90 (d, <i>J</i> = 6.4 Hz, 1H); 4.77 (s, 2H); 4.45–4.40 (m, 1H); 4.06 (dd, <i>J</i> = 1.5 and 13.3 Hz, 1H); 3.99–3.96 (m, 2H); 3.80 (t, <i>J</i> = 6.8 Hz, 1H); 1.45 (s, 3H); 1.37 (s, 3H) ppm.</div></div><div id="s0061" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-<i>O</i>-(<i>p</i>-Fluorobenzyl)-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside Trichloroacetimidate (21β)</h4><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.37–7.30 (m, 2H); 7.03–6.98 (m, 2H); 6.36 (d, <i>J</i> = 3.2 Hz, 1H); 4.71 (s, 2H); 4.45–4.40 (m, 1H); 4.34–4.31 (m, 1H); 4.25 (t, <i>J</i> = 6.9 Hz, 1H); 4.17 (dd, <i>J</i> = 2.9 and 13.2 Hz, 1H); 3.72 (dd, <i>J</i> = 3.2 and 7.3 Hz, 1H); 1.44 (s, 3H); 1.37 (s, 3H) ppm.</div><div class="NLM_p">To a solution of 2.80 g of the obtained tricloroacetimidate <b>21(α,β)</b> (4.70 mmol) and 1.21 g of (1<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol (4.70 mmol) with 200.00 mg of a molecular sieve (4 Å) in 95.00 mL of ether at 0 °C under an argon atmosphere, 0.11 mL of trimethylsilyl trifluoromethanesulfonate (0.01 mmol) was added dropwise. After stirring for 24 h at room temperature, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The resulting suspension was filtered through a pad of Celite. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to obtain 1.68 g (3.12 mmol, 66% yield) of a mixture of both anomers <b>22α</b>:<b>22β</b> in a 1:2 ratio, as a yellow syrup. After purification by flash chromatography (EtOAc/hexane, 1:20; and acetone/hexane, 1:50), 420.00 mg of <b>22α</b> (0.75 mmol, 16% yield) and 1.26 mg of <b>22β</b> (2.31 mmol, 50% yield) were obtained.</div><div id="sec4_1_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Method B</h5><div class="NLM_p last">To a solution of 4.85 g of thioglycoside <b>19α</b> (12.42 mmol) and 9.62 g of (1<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol (37.26 mmol) with 300.00 mg of a molecular sieve (4 Å) in 150.00 mL of dichloromethane at 0 °C under an argon atmosphere, 14.00 g of NIS (62.10 mmol) was added. After stirring for 6 h at room temperature, the reaction mixture was quenched with a saturated NaHCO<sub>3</sub> aqueous solution. The resulting suspension was filtered through a pad of Celite. The aqueous phase was extracted with dichloromethane (3 × 40 mL), and the combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure to give 4.41 g (8.20 mmol, 66% yield) of the mixture of both anomers <b>22α:22β</b> in a 1:1 ratio, as a yellow syrup. After purification by flash chromatography (EtOAc/hexane, 1:4; and acetone/hexane, 1:50), 2.21 g of <b>22α</b> (4.10 mmol, 33% yield), <i>R</i><sub>f</sub> = 0.64 (EtOAc/hexane, 1:2), and 2.21 g of <b>22β</b> (4.10 mmol, 33% yield), <i>R</i><sub>f</sub> = 0.72 (EtOAc/hexane, 1:2), were obtained.</div></div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>R</i>)-{1-[35-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-3,4-<i>O</i>-isopropylidene-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>22α</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.80 (bs, 2H), 7.78 (bs, 1H), 7.40–7.36 (m, 2H), 7.04 (tt, <i>J</i> = 3.0, 8.7 Hz, 2H), 4.94 (q, <i>J</i> = 6.5 Hz, 1H), 4.82 (d, <i>J</i> = 11.8 Hz, 1H), 4.79 (d, <i>J</i> = 11.8 Hz, 1H), 4.59 (d, <i>J</i> = 6.8 Hz, 1H), 4.25 (dt, <i>J</i> = 4.4, 6.3 Hz, 1H), 4.16 (t, <i>J</i> = 6.8 Hz, 1H), 3.87 (dd, <i>J</i> = 4.5, 12.8 Hz, 1H), 3.63 (dd, <i>J</i> = 4.3, 12.8 Hz, 1H), 3.52 (t, <i>J</i> = 7.0 Hz, 1H), 1.52 (d, <i>J</i> = 6.5 Hz, 3H), 1.41 (s, 3H), 1.35 (s, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.6, (d, <i>J</i><sub>CF</sub> = 245.7 Hz), 146.6, 134.0 (d, <i>J</i><sub>CF</sub> = 2.9 HZ), 131.7 (q, <i>J</i><sub>CF</sub> = 33.3 Hz), 129.9 (d, <i>J</i><sub>CF</sub> = 8.0 Hz), 126.4 (q, <i>J</i><sub>CF</sub> = 3.0 Hz), 123.5 (q, <i>J</i><sub>CF</sub> = 272.8 Hz), 121.4 (sept, <i>J</i><sub>CF</sub> = 3.9 Hz), 115.3 (d, <i>J</i><sub>CF</sub> = 21.3 Hz), 110.3, 100.8, 79.7, 78.0, 75.0, 72.9, 72.7, 62.5, 27.8, 26.0, 22.6 ppm. [α]<sub>D</sub><sup>20</sup>: +11 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>25</sub>H<sub>25</sub>O<sub>5</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 561.1482, found 561.1477 (−1.04 ppm).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-3,4-<i>O</i>-isopropylidene-β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>22β</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (bs, 2H), 7.82 (bs, 1H), 7.22–7.17 (m, 2H), 6.95 (t, <i>J</i> = 8.7 Hz, 2H), 4.91 (q, <i>J</i> = 6.6 Hz, 1H), 4.64–4.60 (m, 2H), 4.59 (d, <i>J</i> = 3.4 Hz, 1H), 4.43 (dd, <i>J</i> = 5.7, 7.7 Hz, 1H), 4.31–4.26 (m, 1H), 4.03 (dd, <i>J</i> = 2.8, 13.2 Hz, 1H), 4.00 (t, <i>J</i> = 13.1 Hz, 1H), 3.44 (dd, <i>J</i> = 3.4, 7.8 Hz, 1H), 1.52 (d, <i>J</i> = 6.6 Hz, 3H), 1.37 (s, 6H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.5, (d, <i>J</i><sub>CF</sub> = 245.5 Hz), 145.8, 133.8 (d, <i>J</i><sub>CF</sub> = 2.9 Hz), 132.0 (q, <i>J</i><sub>CF</sub> = 33.2 Hz), 129.7 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.8 (q, <i>J</i><sub>CF</sub> = 2.9 Hz), 123.4 (q, <i>J</i><sub>CF</sub> = 272.6 Hz), 121.8 (sept, <i>J</i><sub>CF</sub> = 3.8 Hz), 115.2 (d, <i>J</i><sub>CF</sub> = 21.6 Hz), 109.1, 95.1, 76.0, 75.7, 73.6, 72.9, 71.4, 59.3, 28.2, 26.4, 24.5 ppm. [α]<sub>D</sub><sup>20</sup>: +57 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>25</sub>H<sub>25</sub>O<sub>5</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 561.1482, found 561.1483 (−0.02 ppm).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-α-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>23α</b>)</h4><div class="NLM_p last">To a solution of 3.55 g of <b>22α</b> (6.60 mmol) in methanol (160.00 mL) at room temperature, a catalytic amount of CSA was added. After stirring overnight, the solvent was evaporated under reduced pressure. The residue obtained was purified by flash chromatography (EtOAc/hexane, 1:1) to obtain 3.36 g of <b>23α</b> (6.55 mmol, quantitative yield) as a white solid; <i>R</i><sub>f</sub> = 0.19 (EtOAc/hexane, 1:1); m.p.: 62–65 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.81 (bs, 2H), 7.79 (bs, 1H), 7.36–7.32 (m, 2H), 7.06–7.02 (m, 2H), 4.98 (q, <i>J</i> = 6.5 Hz, 1H), 4.88 (d, <i>J</i> = 11.4 Hz, 1H), 4.71 (d, <i>J</i> = 11.6 Hz, 1H), 4.58 (d, <i>J</i> = 6.3 Hz, 1H), 3.89 (dd, <i>J</i> = 3.5, 5.8 Hz, 1H), 3.77 (dd, <i>J</i> = 3.9, 12.6 Hz, 1H), 3.71 (dd, <i>J</i> = 3.5, 8.1 Hz, 1H), 3.59–3.56 (m, 1H), 3.47–3.43 (m, 2H), 2.84–2.80 (m, 1H), 1.53 (d, <i>J</i> = 6.5 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7 (d, <i>J</i><sub>CF</sub> = 246.4 Hz), 146.0, 133.9 (d, <i>J</i><sub>CF</sub> = 3.3 Hz), 131.8 (q, <i>J</i><sub>CF</sub> = 33.3 Hz), 129.8, (d, <i>J</i><sub>CF</sub> = 8.9 Hz), 126.4 (q, <i>J</i><sub>CF</sub> = 2.8 Hz), 123.4 (q, <i>J</i><sub>CF</sub> = 272.7 Hz), 121.6 (sept, <i>J</i><sub>CF</sub> = 3.7 Hz), 115.6 (d, <i>J</i><sub>CF</sub> = 21.6 Hz), 101.0, 78.6, 75.2, 73.7, 72.1, 67.4, 64.7, 22.1 ppm. [α]<sub>D</sub><sup>20</sup>: +8.1 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>22</sub>H<sub>21</sub>O<sub>5</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 521.1169, found 521.1167 (−0.6 ppm).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-{1-[3,5-Bis-(trifluoromethyl)phenyl]ethyl} 2-<i>O</i>-<i>p</i>-Fluorobenzyl-β-<span class="smallcaps smallerCapital">l</span>-arabinopyranoside (<b>23β</b>)</h4><div class="NLM_p last">To a solution of 1.47 g of <b>22β</b> (2.75 mmol) in methanol (60.00 mL) at room temperature, a catalytic amount of CSA was added. After stirring overnight, the solvent was evaporated under reduced pressure. The residue obtained was purified by flash chromatography (EtOAc) to obtain 1.35 g of <b>23β</b> (2.72 mmol, quantitative yield) as a white solid; <i>R</i><sub>f</sub> = 0.19 (EtOAc/hexane, 1:1); m.p.: 91–93 °C; <sup>1</sup> H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.89 (bs, 2H), 7.83 (bs, 1H), 7.18–7.15 (m, 2H), 6.99–6.95 (m, 2H), 4.92 (q, <i>J</i> = 6.6 Hz, 1H), 4.73 (d, <i>J</i> = 3.4 Hz, 1H), 4.53 (d, <i>J</i> = 11.9 Hz, 1H), 4.32 (d, <i>J</i> = 11.8 Hz, 1H), 4.12 (dd, <i>J</i> = 3.5, 9.7 Hz, 1H), 4.06–4.05 (m, 1H), 3.93 (dd, <i>J</i> = 1.4, 12.6 Hz, 1H), 3.79 (dd, <i>J</i> = 1.8, 12.5 Hz, 1H), 3.67 (dd, <i>J</i> = 3.4, 9.7 Hz, 1H), 1.82 (bs, 2H), 1.54 (d, <i>J</i> = 6.7 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 162.7 (d, <i>J</i><sub>CF</sub> = 246.5 Hz), 145.9, 133.4 (d, <i>J</i><sub>CF</sub> = 3.3 Hz), 132.1 (q, <i>J</i><sub>CF</sub> = 33.3 Hz), 129.8 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 126.8 (q, <i>J</i><sub>CF</sub> = 3.0 Hz), 123.4 (q, <i>J</i><sub>CF</sub> = 272.6 Hz), 121.9 (sept, <i>J</i><sub>CF</sub> = 3.8 Hz), 115.5 (d, <i>J</i><sub>CF</sub> = 21.8 Hz), 95.1, 76.1, 73.0, 72.0, 69.2, 68.7, 62.6, 24.3 ppm. [α]<sub>D</sub><sup>20</sup>: +12.02 (<i>c</i>1, chloroform). HRMS: calcd for C<sub>22</sub>H<sub>21</sub>O<sub>5</sub>F<sub>7</sub>Na: [M + Na]<sup>+</sup> 521.1169, found 521.1164 (−1.1 ppm).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Biological Evaluation</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Cell Culture and Transfection</h4><div class="NLM_p">Cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cell culture media, fetal bovine serum (FBS), and additives were provided by Invitrogen. CHO cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, at 37 °C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. Nonessential amino acids (Invitrogen) were also added to the media.</div><div class="NLM_p last">Transient transfection of the cell lines was performed using electroporation in a 300 μL volume with a total of 10 μg of DNA (pRK5 Neo-NK1 wild type) plasmid up to 500 ng plus pRK5 as carrier DNA to reach 10 μg containing 107 cells in an electroporation buffer (50 mM K<sub>2</sub>HPO<sub>4</sub>, 20 mM CH<sub>3</sub>COOK, 20 mM KOH, and 26 mM MgSO<sub>4</sub>, pH 7.4). After electroporation (280 V, 1 mF, Gene Zapper 450/2500; IBI, New Haven, CT), cells were suspended in a complete medium and seeded into 96-well culture plates at a density of 105 cells per well. First, 96-well culture plates were coated with polyornithine diluted in phosphate-buffered saline (PBS), incubated at 37 °C for 30 min, and then rinsed with PBS before seeding.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Enzyme-Linked Immunosorbent Assay (ELISA)</h4><div class="NLM_p last">To measure the expression of the transfected receptors, cells were transfected with pRK5-NK1-6His. After 24 h of electroporation, cells were fixed with 4% paraformaldehyde in PBS for 5 min and rinsed three times with PBS. A blocking step of 30 min with PBS + 1% decomplemented FBS was performed before incubation with an anti-6 His primary antibody (0.5 μg/mL) for 30 min. The cells were then rinsed four times for 5 min in PBS + 1% FBS and incubated for 30 min with an antimouse antibody conjugated with horseradish peroxidase (1/1000; Amersham, Orsay, France). The cells were rinsed three times with PBS + 1% FBS and three times with PBS. Afterward, 60 μL of PBS and 20 μL of Supersignal ELISA Femto (Perbio-Pierce, Brebières, France) were added to the wells. The luminescence was read using a Wallac Victor2 (PerkinElmer Life and Analytical Sciences, Courtaboeuf, France)</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Second Messenger (IP1) Accumulation</h4><div class="NLM_p">Activation/inhibition of the IP pathway by NK1R agonists or antagonists, respectively, was determined using the IP-One dynamic kit (Cisbio Bioassays, Bagnols-sur-Cèze, France). In brief, after transfection, 105 cells were distributed in 100 μL of complete medium into a 96-well assay plate (Greiner Bio-One, Courtaboeuf, France). Twenty-four hours later, the medium was removed and replaced with 40 μL of incubation medium containing the agonist and/or antagonist at the appropriate concentrations. The IP-One assay is based on the accumulation of IP<sub>1</sub>, a downstream metabolite of the IP pathway that is produced by phospholipase C activated by the Gq/11 protein; IP<sub>1</sub> is stable in the presence of LiCl. The homogeneous time-resolved fluorescence–fluorescence resonance energy transfer (HTRF–FRET) assay was performed as described previously. This assay involves the transfer of energy from a Lumi4TM-Terbium cryptate donor fluorophore to a d<sub>2</sub> acceptor fluorophore. The assay is an immunoassay that measures competition between native IP1 produced by the cells and IP1 labeled with the d<sub>2</sub> acceptor, as revealed by a monoclonal antibody against IP<sub>1</sub> labeled with Lumi4TM-Terbium cryptate. Fifteen microliters of antibody and 15 μL of competitor diluted in lysis buffer provided in the kits were added to the wells after a 30 min incubation at 37 °C with the agonist. As a negative control, some wells only received the donor fluorophore-labeled antibody. After 1 h of incubation at room temperature, fluorescence emissions were measured at both 620 and 665 nm on a RubyStar fluorometer (BMG Labtechnologies, Offenburg, Germany) equipped with a nitrogen laser as the excitation source (337 nm). A 400 μs reading was recorded after a 50 μs delay to eliminate the short-lived fluorescence background from the acceptor fluorophore-labeled antibody. The fluorescence intensities measured at 620 and 665 nm correspond to the total europium cryptate emission and to the FRET signal, respectively. The specific FRET signal was calculated using the following equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_m001.gif" alt="" id="_i63" /></img></span>with <i>R</i><sub>pos</sub> being the fluorescence ratio (665/620 nm) calculated in wells incubated with both donor- and acceptor-labeled antibodies and <i>R</i><sub>neg</sub> being the same ratio for the negative control incubated only with the donor fluorophore-labeled antibody. The FRET signal (Δ<i>F</i>%), which is inversely proportional to the concentration of IP<sub>1</sub> in the cells, was then transformed into IP<sub>1</sub> accumulation using a calibration curve prepared on the same plate. It is worth noting that all comparisons of agonist or antagonist effects were done on the same day, on the same culture and plate, and were made against the SP effect. The experiments were repeated at least three times on different cultures. Values corresponding to the low basal activities, determined in unstimulated cells, were first subtracted. Activation/inhibition curves were plotted to the log of agonist or antagonist concentrations and fitted to the Hill equation to extract the EC<sub>50</sub>, the Hill coefficient, and minimal/maximal values.</div><div class="NLM_p last">The inhibitory effect of the specific nonpeptidic NK1 antagonist on IP<sub>1</sub> accumulations induced by SP was studied according to Arunlakshana and Schild.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Preincubation for 10 min with the antagonist was followed by a 30 min incubation with the antagonist and SP. IP<sub>1</sub> accumulation was then measured as described above.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Cell Lines</h4><div class="NLM_p">MRC-5 (human fetal lung fibroblastic cells) and A549 (human nonsmall cell lung cancer cells) were purchased from the European Collection of Cell Cultures. HaCaT cells (human keratinocytes) were kindly provided by Dr. Motilva (originally Cell Line Service; L#300493-4212). MDA-MB-231 (human breast cancer cells) was purchased from the American Type Culture Collection (ATCC). UACC-62 (human melanoma cells) was obtained from the National Cancer Institute. VH10 (human foreskin fibroblast cells), HepG2 (human hepatocellular carcinoma cells), PC-3 (human prostate cancer cells), and HT29 (human colorectal cancer cells) were generously provided by Dr. Helleday (Karolinska Institute, Sweden). GAMG cells (human glioblastoma cells) were provided by Dr. Ayala (University of Seville, Spain). HNO97 (human tongue cancer cells), A64-CLS (human submaxillary gland adenoma cells), AN3Ca (human endometrial adenocarcinoma cells), Sk-OV-3 (human ovarian cancer cells), KATO III (gastric cancer), Sk-Br-3 (HER2-positive breast cancer), T24 (bladder cancer), and MeWo (Melanoma; BRAF WT) were purchased from Cell Lines Service (CLS). MCF7 (human breast adenocarcinoma cells) and MCF 10 (human mammary epithelial cells) cell lines were a gift from Dr. D. Ruano and Dr. P. Daza (University of Seville, Spain).</div><div class="NLM_p">To study the possible DNA damage response induced by the tested compound, VC8 (V79 Chinese hamster lung cells mutated in BRCA2, homologous recombination (HR) deficient) and VC8B2 (VC8 cells complemented with human BRCA2 (HR proficient)) were used. These DNA repair-deficient cell lines were kindly provided by Dr. Thomas Helleday.</div><div class="NLM_p last">Cells were maintained in the recommended medium and propagated according to standard protocols. MRC-5, VH10, A549, MCF7, HaCaT, MDA-MB-231, HT29, GAMG, Sk-Br-3, MeWo, HNO97, A64-CLS, SK-OV-3, HepG2, VC8B2, and VC8 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) high-glucose medium. PC-3 and T24 were grown in DMEM-F12. UACC-62 was maintained in RPMI 1640. Except for MCF 10, all media were supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. The MCF 10 cell line was maintained in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium supplemented with a 20 ng/mL epidermal growth factor, 100 ng/mL cholera toxin, 10 μg/mL insulin, and 500 ng/mL hydrocortisone (95%) and horse serum (5%). All cells were cultured in a humidified atmosphere of 95% air and 5% CO<sub>2</sub> at 37 °C. Cell culture reagents were obtained from Biowest.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Binding Assay</h4><div class="NLM_p">Binding assay was carried out by Eurofins Cerep France. The hNK1 binding affinity for compound <b>14α</b> was determined by measuring their ability to displace [<sup>125</sup>I]SP (0.05 nM) from U-373MG cells. To define the nonspecific binding, [Sar9,Met(O2)11]-SP (1 μM) was used and the incubation time was extended to 30 min.</div><div class="NLM_p">The specific ligand binding to the receptors is defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabeled ligand. All data were averaged from five independent experiments, and the results are expressed as a percent of control specific binding [(measured specific binding/control specific binding) × 100] and as a percent inhibition of control specific binding {100 – [(measured specific binding/control specific binding) × 100]} obtained in the presence of the test compounds.</div><div class="NLM_p">The IC<sub>50</sub> value (concentration causing a half-maximal inhibition of control specific binding) and the Hill coefficient (nH) were determined by nonlinear regression analysis of the competition curve generated with mean replicate values using the Hill equation curve fitting (Y = D + [(A – D)/(1 + (C/C<sub>50</sub>)<sup>nH</sup>)], where Y is the specific binding, D is the minimum specific binding, A is the maximum specific binding, C is the compound concentration, C<sub>50</sub> is IC<sub>50</sub>, and nH is the slope factor). This analysis was performed using a software developed at Cerep (Hill software) and validated by comparison with data generated by commercial software SigmaPlot 4.0 for Windows (©1997 by SPSS Inc.).</div><div class="NLM_p last">The inhibition constant (<i>K</i><sub>i</sub>) was calculated using the Cheng Prusoff equation (<i>K</i><sub>i</sub> = IC<sub>50</sub>/(1 + (<i>L</i>/<i>K</i><sub>D</sub>)), where <i>L</i> is the concentration of the radioligand in the assay and <i>K</i><sub>D</sub> is the affinity of the radioligand for the receptor). A scatchard plot is used to determine the <i>K</i><sub>D</sub>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Cell Viability Assay</h4><div class="NLM_p">Cell viability was estimated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or the resazurin assay. Both assays are redox-based colorimetric techniques based on the capability of viable cells to reduce the yellow product MTT or the blue reagent resazurin into a purple formazan dye or a pink-colored product, respectively. The number of live cells is directly proportional to the amount of the final product created. Exponentially growing cells were seeded in 96-well plates and were allowed to grow during 24 h. The cells were then treated with several concentrations of the tested compounds for 48–96 h (the incubation periods are specified in the figures and table legends) before measuring the cell viability using the MTT assay or the resazurin assay.</div><div class="NLM_p">For the MTT assay, after the incubation period, the growth medium was removed and 125 μL of MTT solution (1 mg/mL in medium) was added to each well for 3–4 h. Then, 80 μL of 20% sodium dodecyl sulfate (SDS) in 20 mM HCl was added to dissolve the insoluble purple formazan product and plates were incubated for 15 h at 37 °C. The optical density (OD) of each well was measured at 540 nm with a multiwell plate spectrophotometer reader to quantify cell survivals.</div><div class="NLM_p">For the resazurin assay, after treatment, the medium was removed and 150 μL of resazurin solution (20 μg/mL in medium) was added to each well for 3–6 h. The OD of each well was measured at 540 and 620 nm on a multiwell plate spectrophotometer reader.</div><div class="NLM_p">In both assays, results were expressed as the percentage of cell viability in relation to untreated cells (controls). All data were averaged from two to five independent experiments and were expressed as the means ± standard error of the mean (SEM). For statistical analysis, the <i>t</i>-test (paired, two-tailed) was used. A <i>p</i> value >0.05 is not considered statistically significant and is not represented by any symbol, a <i>p</i> value <0.05 is considered statistically significant and is indicated with an asterisk (*), a <i>p</i> value <0.01 is indicated with a double asterisk (**), and a <i>p</i> value <0.001 is indicated with a triple asterisk (***).</div><div class="NLM_p">Selectivity indices (SIs) are useful to evaluate the anticancer potential in vitro.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> SIs were calculated as the mean of the IC<sub>50</sub> value in the normal cell line divided by the IC<sub>50</sub> in the cancer cell line obtained in each independent experiment.</div><div class="NLM_p last">Glycolysis inhibition was assessed by measuring concentrations of glucose (initial product of glycolysis) and lactate (final product of glycolysis) in control and treated cells. Briefly, 4 × 10<sup>5</sup> cells were seeded into 24-well plates. After 10 h, the medium of cells was renewed and drugs were added. Cells were exposed to the tested compounds for 8 h, and glucose and lactate concentrations were determined in cell supernatants using the Accutrend Plus analyzer together with Accutrend glucose strips and BM-Lactate strips (Roche Diagnostics). After calibrating the instrument with glucose and lactate calibration strips, test strips were used to determine glucose and lactate levels via colorimetric-oxidase mediator reactions according to the manufacturer’s instructions.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Results are expressed as a percentage of lactate production and percentage of glucose consumption in relation to untreated cells and are shown as the means ± SEM of two independent experiments.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Molecular Modeling</h4><div class="NLM_p">To validate the docking method used with AutoDock Vina, we redocked three cocrystallized ligands existing with the NKR1 protein—CP-99,994 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLL">6HLL</a>), Aprepitant (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>), and Netupitant (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLP">6HLP</a>)—and then compared the obtained Cartesian coordinates of the docked ligand atoms with those of the native ones, using root-mean-square deviation (RMSD) values. All of the predicted docking poses presented RMSD values lower than 1.5 Å (0.893 Å for CP-99,994, 1.242 Å for Aprepitant, and 1.075 Å for Netupitant) when compared to the experimentally cocrystallized binding pose (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf" class="ext-link">Figure S1</a>). These results indicate that the used molecular docking protocol using AutoDock Vina is satisfactory for inferring the correct binding modes and the interactions of such ligands with NKR1.</div><div class="NLM_p last">Molecular structures of the ligands were optimized in the ground state at the DFT level with the B3LYP<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and the 6-31G (d,p) basis set<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> implemented in the Gaussian 09 Rev.D.O1 package programs.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Molecular docking calculations were performed by AutoDock Vina<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and AutodockTools software.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The structure of NKR1 was retrieved from the Protein Data Bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>), and all water molecules and cocrystallized ligand were removed from crystallographic structures to prepare the docking receptor. The best docking poses and interactions involved in the binding mode were visualized with Discovery Studio Visualizer (Accelrys Software Inc.).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> log <i>P</i> (octanol/water partition coefficient) values of the ligands were calculated from the Molinspiration server (<a href="http://www.molinspiration.com/" class="extLink">http://www.molinspiration.com/</a>) by providing the SMILES code of the fragments of the ligands as input.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00793" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00793?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00793</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data concerning characterization of products (NMR), docking validation figure concerning NK1 receptor antagonists, biological evaluation figures, and HPLC traces for lead compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the prepared compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Structural data for Aprepitant (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for Netupitant (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for CP99,994 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>13α</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>13β</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>14α</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>14β</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_009.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf">jm1c00793_si_001.pdf (5.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_002.csv">jm1c00793_si_002.csv (2.32 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_003.pdb">jm1c00793_si_003.pdb (380.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_004.pdb">jm1c00793_si_004.pdb (387.82 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_005.pdb">jm1c00793_si_005.pdb (395.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_006.pdb">jm1c00793_si_006.pdb (387.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_007.pdb">jm1c00793_si_007.pdb (387.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_008.pdb">jm1c00793_si_008.pdb (387.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_009.pdb">jm1c00793_si_009.pdb (387.82 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00793" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noureddine Khiar</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Investigaciones Químicas (IIQ), CSIC-Universidad de Sevilla, Avenida Américo Vespucio, 49, Isla de la
Cartuja, 41092 Sevilla, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-4211-7138" title="Orcid link">https://orcid.org/0000-0003-4211-7138</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4afacada5b684adadb5eaa7b7ada7eaa1b7"><span class="__cf_email__" data-cfemail="68030001091a28010119460b1b010b460d1b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inmaculada Fernández</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3468-387X" title="Orcid link">https://orcid.org/0000-0002-3468-387X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d1b8bfbcb0b7b791a4a2ffb4a2"><span class="__cf_email__" data-cfemail="7e1710131f18183e0b0d501b0d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rocío Recio</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Lerena</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5048-9524" title="Orcid link">https://orcid.org/0000-0002-5048-9524</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Esther Pozo</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Manuel Calderón-Montaño</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Estefanía Burgos-Morón</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miguel López-Lázaro</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Farmacología, Facultad de Farmacia, Universidad de Sevilla, C/ Profesor García González, 2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victoria Valdivia</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manuel Pernia Leal</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Orgánica y Farmacéutica, Facultad
de Farmacia, Universidad de Sevilla, C/ Profesor García González,
2, 41012 Sevilla, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8160-0574" title="Orcid link">https://orcid.org/0000-0001-8160-0574</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernard Mouillac</span> - <span class="hlFld-Affiliation affiliation">Institut
de Génomique Fonctionnelle (IGF), INSERM, Université de Montpellier, CNRS, F-34094 Montpellier, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Ángel Organero</span> - <span class="hlFld-Affiliation affiliation">Departamento
de Química Física, Facultad de Ciencias Ambientales
y Bioquímicas and INAMOL, Universidad
de Castilla-La Mancha, Avenida Carlos III, s/n, 45071 Toledo, Spain</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.R. and P.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6340-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support was provided by the Spanish Ministry of Economy and Competitiveness (MEC) (CTQ2016-78580-C2-2-R, CTQ2016-78580-C2-1-R, CTQ2017-86655-R, and PID2019-104767RB-I00) and the Spanish Ministry of Science and Innovation (PID2019-104767RB-I00), all of them cofinanced by the European Regional Development Fund (ERDF) from FEDER, the Andalusian Ministry of Economy, Science and Innovation (P06-FQM-01852), the Andalusian Ministry of Economic Transformation, Knowledge, Industry and Universities (CV20-04221), the PAIDI Program from the Andalusian Government (FQM-313 and FQM-102), and the Spanish Research Council (CSIC) (CSIC-COV19-047). The authors also thank the Centre of Research Technology and Innovation of the University of Seville (CITIUS) for NMR facilities.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">NK1R</td><td class="NLM_def"><p class="first last">neurokinin 1 receptor</p></td></tr><tr><td class="NLM_term">SP</td><td class="NLM_def"><p class="first last">substance P</p></td></tr><tr><td class="NLM_term">CarbNK1RAnt</td><td class="NLM_def"><p class="first last">carbohydrate-based NK1R antagonists</p></td></tr><tr><td class="NLM_term">GalNK1RAnt</td><td class="NLM_def"><p class="first last">galactose-derived NK1R antagonist</p></td></tr><tr><td class="NLM_term">AraNK1RAnt</td><td class="NLM_def"><p class="first last">arabinose-derived NK1R antagonist</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Severini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Improta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falconieri-Erspamer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erspamer, V.</span></span> <span> </span><span class="NLM_article-title">The tachykinin peptide family</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1124%2Fpr.54.2.285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12037144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=285-322&author=C.+Severiniauthor=G.+Improtaauthor=G.+Falconieri-Erspamerauthor=S.+Salvadoriauthor=V.+Erspamer&title=The+tachykinin+peptide+family&doi=10.1124%2Fpr.54.2.285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The tachykinin peptide family</span></div><div class="casAuthors">Severini, Cinzia; Improta, Giovanna; Falconieri-Erspamer, Giuliana; Salvadori, Severo; Erspamer, Vittorio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-322</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The tachykinin peptide family certainly represents one of the largest peptide families described in the animal organism.  So far, more than 40 tachykinins have been isolated from invertebrate (insects, worms, and molluscs), protochordate, and vertebrate (skin, gastrointestinal tract, peripheral and central nervous system) tissues.  Substance P (SP), first identified by bioassay as early as 1931 but sequenced only in 1971, several years after the elucidation of the structure of eledoisin from molluscan tissues and of physalemin from amphibian skin, may be considered as a prototype of the tachykinins.  Hitherto, as many as 19 tachykinins have been isolated from amphibian integument, and eight addnl.; peptides have been isolated from amphibian gut and brain.  Counterparts of skin tachykinins in mammalian tissues are SP, neurokinin A, and neurokinin B.  Three main receptor subtypes for the tachykinins have been identified (NK1, NK2, and NK3), but their no. is probably destined to increase.  It is obvious that the peripheral and central effects of the tachykinins may substantially vary depending on the activation of different receptor subtypes.  Matters are further complicated by the frequent capacity of the single tachykinins to bind, although with different affinity, to more receptors.  It has been recognized that tachykinins have a variety of effects in physiol. and pathol. conditions, and there is evidence suggesting intrinsic neuroprotective and neurodegenerative properties of these neuropeptides.  This review provides an update on the current body of knowledge regarding tachykinin occurrence and distribution in the animal kingdom, from the lowest invertebrates to man; and the physiol. and pharmacol. actions of tachykinins outlining the pregnant importance of this large peptide family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQNEeQFUUd6bVg90H21EOLACvtfcHk0ljGIvtwv83SoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOhsr0%253D&md5=25dd6ad49975a98b8aae7a824381aac2</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.285%26sid%3Dliteratum%253Aachs%26aulast%3DSeverini%26aufirst%3DC.%26aulast%3DImprota%26aufirst%3DG.%26aulast%3DFalconieri-Erspamer%26aufirst%3DG.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DErspamer%26aufirst%3DV.%26atitle%3DThe%2520tachykinin%2520peptide%2520family%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D285%26epage%3D322%26doi%3D10.1124%2Fpr.54.2.285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mentzer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pthoulakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buennett, N. W.</span></span> <span> </span><span class="NLM_article-title">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1152/physrev.00031.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1152%2Fphysrev.00031.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24382888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=265-301&author=M.+S.+Steinhoffauthor=B.+von+Mentzerauthor=P.+Geppettiauthor=C.+Pthoulakisauthor=N.+W.+Buennett&title=Tachykinins+and+their+receptors%3A+contributions+to+physiological+control+and+the+mechanisms+of+disease&doi=10.1152%2Fphysrev.00031.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span></div><div class="casAuthors">Steinhoff, Martin S.; von Mentzer, Bengt; Geppetti, Pierangelo; Pothoulakis, Charalabos; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-301</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The tachykinins, exemplified by substance P, are one of the most intensively studied neuropeptide families.  They comprise a series of structurally related peptides that derive from alternate processing of three Tac genes and are expressed throughout the nervous and immune systems.  Tachykinins interact with three neurokinin G protein-coupled receptors.  The signaling, trafficking, and regulation of neurokinin receptors have also been topics of intense study.  Tachykinins participate in important physiol. processes in the nervous, immune, gastrointestinal, respiratory, urogenital, and dermal systems, including inflammation, nociception, smooth muscle contractility, epithelial secretion, and proliferation.  They contribute to multiple diseases processes, including acute and chronic inflammation and pain, fibrosis, affective and addictive disorders, functional disorders of the intestine and urinary bladder, infection, and cancer.  Neurokinin receptor antagonists are selective, potent, and show efficacy in models of disease.  In clin. trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting.  New information about the involvement of tachykinins in infection, fibrosis, and pruritus justifies further trials.  A deeper understanding of disease mechanisms is required for the development of more predictive exptl. models, and for the design and interpretation of clin. trials.  Knowledge of neurokinin receptor structure, and the development of targeting strategies to disrupt disease-relevant subcellular signaling of neurokinin receptors, may refine the next generation of neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYRTZzTeU6bVg90H21EOLACvtfcHk0ljdP9Qeb-RMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D&md5=a7813685174b8b89eef8b604a78eebdf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00031.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00031.2013%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3Dvon%2BMentzer%26aufirst%3DB.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DPthoulakis%26aufirst%3DC.%26aulast%3DBuennett%26aufirst%3DN.%2BW.%26atitle%3DTachykinins%2520and%2520their%2520receptors%253A%2520contributions%2520to%2520physiological%2520control%2520and%2520the%2520mechanisms%2520of%2520disease%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D265%26epage%3D301%26doi%3D10.1152%2Fphysrev.00031.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0ljdP9Qeb-RMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hökfelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahren, J.</span></span> <span> </span><span class="NLM_article-title">Substance P: a pioneer amongst neuropeptides</span>. <i>J. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1046/j.0954-6820.2000.00773.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1046%2Fj.0954-6820.2000.00773.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11168782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlKms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2001&pages=27-40&author=T.+H%C3%B6kfeltauthor=B.+Pernowauthor=J.+Wahren&title=Substance+P%3A+a+pioneer+amongst+neuropeptides&doi=10.1046%2Fj.0954-6820.2000.00773.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P: A pioneer amongst neuropeptides</span></div><div class="casAuthors">Hokfelt, T.; Pernow, B.; Wahren, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Internal Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-40</span>CODEN:
                <span class="NLM_cas:coden">JINMEO</span>;
        ISSN:<span class="NLM_cas:issn">0954-6820</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 98 refs.  A brief overview of recent developments in the substance P field is provided, in addn. to a historical introduction.  It is emphasized that there are multiple tachykinins and tachykinin receptors and that there are examples of coexistence of several tachykinin peptides and of several tachykinin receptors in single cells, and there is evidence for tachykininergic cotransmission.  The distribution and functional significance of tachykinins in the gastrointestinal tract and in sensory neurons, and interactions with other peptides and transmitters, are reviewed.  The recent prodn. of knock-out mice for either substance P or the NK1 receptor is discussed, as well as the exciting concept of substance P receptor internalization.  Finally, the development of specific substance P antagonists is summarized, and possible clin. implications discussed, and, in particular, a recent study which reports that a substance P antagonist shows clin. efficacy in depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4e3Ua2P94G7Vg90H21EOLACvtfcHk0ljdP9Qeb-RMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlKms7c%253D&md5=5a52aeea15a91513ca021a2469079357</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1046%2Fj.0954-6820.2000.00773.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0954-6820.2000.00773.x%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25B6kfelt%26aufirst%3DT.%26aulast%3DPernow%26aufirst%3DB.%26aulast%3DWahren%26aufirst%3DJ.%26atitle%3DSubstance%2520P%253A%2520a%2520pioneer%2520amongst%2520neuropeptides%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D2001%26volume%3D249%26spage%3D27%26epage%3D40%26doi%3D10.1046%2Fj.0954-6820.2000.00773.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span> <span> </span><span class="NLM_article-title">Substance P</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/S1357-2725(01)00031-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS1357-2725%2801%2900031-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11378438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=555-576&author=S.+Harrisonauthor=P.+Geppetti&title=Substance+P&doi=10.1016%2FS1357-2725%2801%2900031-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P</span></div><div class="casAuthors">Harrison, S.; Geppetti, P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-576</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 253 refs., on the history of substance P from its discovery in the 1930s to the present day.  The development of substance P receptor agonists and antagonists, and more recently the employment of transgenic mice, provide a framework to explore the functional role of substance P.  Chronic inflammation and pain are assocd. with a no. of diseases, and it has been proposed that substance P released from primary afferent nerve endings plays a role in these conditions.  Recent developments with substance P antagonists have demonstrated the importance of substance P in several models of disease that span asthma, chronic bronchitis, cystitis, inflammatory bowel disease, migraine, emesis, depression, pain, and seizures.  Advancements in the knowledge of the role of substance P and its agonists and antagonists could provide clin. solns. for a variety of chronic inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKivF1NgJO87Vg90H21EOLACvtfcHk0lj1QyQCf9anbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2nt78%253D&md5=41c240a7ba84aef101ebe8f3f10a0216</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2801%2900031-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252801%252900031-0%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DGeppetti%26aufirst%3DP.%26atitle%3DSubstance%2520P%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2001%26volume%3D33%26spage%3D555%26epage%3D576%26doi%3D10.1016%2FS1357-2725%2801%2900031-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentzer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pothoulakis, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnett, N. W.</span></span> <span> </span><span class="NLM_article-title">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1152/physrev.00031.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1152%2Fphysrev.00031.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24382888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=265-301&author=M.+S.+Steinhoffauthor=B.+Mentzerauthor=P.+Geppettiauthor=C.+H.+Pothoulakisauthor=N.+W.+Bunnett&title=Tachykinins+and+their+receptors%3A+contributions+to+physiological+control+and+the+mechanisms+of+disease&doi=10.1152%2Fphysrev.00031.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span></div><div class="casAuthors">Steinhoff, Martin S.; von Mentzer, Bengt; Geppetti, Pierangelo; Pothoulakis, Charalabos; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-301</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The tachykinins, exemplified by substance P, are one of the most intensively studied neuropeptide families.  They comprise a series of structurally related peptides that derive from alternate processing of three Tac genes and are expressed throughout the nervous and immune systems.  Tachykinins interact with three neurokinin G protein-coupled receptors.  The signaling, trafficking, and regulation of neurokinin receptors have also been topics of intense study.  Tachykinins participate in important physiol. processes in the nervous, immune, gastrointestinal, respiratory, urogenital, and dermal systems, including inflammation, nociception, smooth muscle contractility, epithelial secretion, and proliferation.  They contribute to multiple diseases processes, including acute and chronic inflammation and pain, fibrosis, affective and addictive disorders, functional disorders of the intestine and urinary bladder, infection, and cancer.  Neurokinin receptor antagonists are selective, potent, and show efficacy in models of disease.  In clin. trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting.  New information about the involvement of tachykinins in infection, fibrosis, and pruritus justifies further trials.  A deeper understanding of disease mechanisms is required for the development of more predictive exptl. models, and for the design and interpretation of clin. trials.  Knowledge of neurokinin receptor structure, and the development of targeting strategies to disrupt disease-relevant subcellular signaling of neurokinin receptors, may refine the next generation of neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYRTZzTeU6bVg90H21EOLACvtfcHk0lj1QyQCf9anbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D&md5=a7813685174b8b89eef8b604a78eebdf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00031.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00031.2013%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3DMentzer%26aufirst%3DB.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DPothoulakis%26aufirst%3DC.%2BH.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26atitle%3DTachykinins%2520and%2520their%2520receptors%253A%2520contributions%2520to%2520physiological%2520control%2520and%2520the%2520mechanisms%2520of%2520disease%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D265%26epage%3D301%26doi%3D10.1152%2Fphysrev.00031.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycroft, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladduwahetty, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">C Swain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(96)00020-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0028-3908%2896%2900020-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9121615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=1121-1129&author=F.+D.+Tattersallauthor=W.+Rycroftauthor=B.+Francisauthor=D.+Pearceauthor=K.+Merchantauthor=A.+M.+MacLeodauthor=T.+Ladduwahettyauthor=L.+Keownauthor=C.+C+Swainauthor=R.+Bakerauthor=M.+Cascieriauthor=E.+Berauthor=J.+Metzgerauthor=D.+E.+MacIntyreauthor=R.+G.+Hillauthor=R.+J.+Hargreaves&title=Tachykinin+NK1+receptor+antagonists+act+centrally+to+inhibit+emesis+induced+by+the+chemotherapeutic+agent+cisplatin+in+ferrets&doi=10.1016%2FS0028-3908%2896%2900020-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets</span></div><div class="casAuthors">Tattersall, F. D.; Rycroft, W.; Francis, B.; Pearce, D.; Merchant, K.; Macleod, A. M.; Ladduwahetty, T.; Keown, L.; Swain, C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1121-1129</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">These studies have compared the pharmacol. profile of two non-peptide human type neurokinin1 (hNK1) receptor selective antagonists, L-741671 and a quaternized compd. L-743310.  In radioligand binding studies L-741671 and L-743310 had high affinity for ferret and cloned hNK1 receptors [Ki (nM) ferret 0.7 and 0.1; human 0.03 and 0.06, resp.] but low affinity for rodent NK1 receptors [Ki (nM) 64 and 17, resp.] suggesting that ferret receptors have hNK1-like binding pharmacol.  Studies in vivo showed that L-741,671 and L-743,310 had equiv. functional activity in the periphery (ID50S of 1.6 and 2 μg/kg i.v., resp.) as measured by inhibition of plasma protein extravasation evoked in the esophagus of guinea pigs by resiniferatoxin (7 nmol/kg i.v.).  Using an in situ brain perfusion technique in anesthetized rats, L-741671 was shown to be much more brain penetrant than the quaternary compd. L-743310 which had an entry rate similar to the poorly brain penetrant plasma marker inulin.  These compds. thus provided an opportunity to compare the anti-emetic effects of equi-active hNK1 receptor antagonists with and without brain penetration to central NK1 receptor sites.  When tested against cisplatin-induced emesis in ferrets, L-741671 (0.3, 1 and 3 mg/kg i.v.) produced marked dose-dependent inhibition of retching and vomiting but L-743310 was inactive at 3 and 10 mg/kg i.v.  In contrast, direct central injection of L-741671 and L-743310 (30 μg) into the vicinity of the nucleus tractus solitarius or L-743310 (200 μg) intracisternally was shown to inhibit retching and vomiting induced by i.v. cisplatin.  L-741671 and L-743310 had equiv. functional activity, at the same dose, against cisplatin-induced emesis when injected centrally.  These observations indicated that had L-743310 penetrated into the brain after systemic administration it would have been active in the cisplatin-induced emesis assay and so show that brain penetration is essential for the anti-emetic action of systemically administered NK1 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvhvxeZGKTFbVg90H21EOLACvtfcHk0lj1QyQCf9anbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFKrtA%253D%253D&md5=13dc878ce34da4716b288f4c3c1a817f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2896%2900020-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252896%252900020-2%26sid%3Dliteratum%253Aachs%26aulast%3DTattersall%26aufirst%3DF.%2BD.%26aulast%3DRycroft%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DB.%26aulast%3DPearce%26aufirst%3DD.%26aulast%3DMerchant%26aufirst%3DK.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DLadduwahetty%26aufirst%3DT.%26aulast%3DKeown%26aufirst%3DL.%26aulast%3DC%2BSwain%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DCascieri%26aufirst%3DM.%26aulast%3DBer%26aufirst%3DE.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BG.%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3DTachykinin%2520NK1%2520receptor%2520antagonists%2520act%2520centrally%2520to%2520inhibit%2520emesis%2520induced%2520by%2520the%2520chemotherapeutic%2520agent%2520cisplatin%2520in%2520ferrets%26jtitle%3DNeuropharmacology%26date%3D1996%26volume%3D35%26spage%3D1121%26epage%3D1129%26doi%3D10.1016%2FS0028-3908%2896%2900020-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantyh, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basbaum, A. I.</span></span> <span> </span><span class="NLM_article-title">Primary afferent tachykinins are required to experience moderate to intense pain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/32897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2F32897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9537322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=1998&pages=390-394&author=Y.+Q.+Caoauthor=P.+W.+Mantyhauthor=E.+J.+Carlsonauthor=A.+M.+Gillespieauthor=C.+J.+Epsteinauthor=A.+I.+Basbaum&title=Primary+afferent+tachykinins+are+required+to+experience+moderate+to+intense+pain&doi=10.1038%2F32897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Primary afferent tachykinins are required to experience moderate to intense pain</span></div><div class="casAuthors">Cao, Yu Qing; Mantyh, Patrick W.; Carlson, Elaine J.; Gillespie, Anne-Marie; Epstein, Charles J.; Basbaum, Allan I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">6674</span>),
    <span class="NLM_cas:pages">390-394</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The excitatory neurotransmitter glutamate coexists with the peptide known as substance P in primary afferents that respond to painful stimulation.  Because blockers of glutamate receptors reliably reduce pain behavior, it is assumed that 'pain' messages are mediated by glutamate action on dorsal horn neurons.  The contribution of substance P, however, is still unclear.  The authors have now disrupted the mouse preprotachykinin A gene (PPT-A), which encodes substance P and a related tachykinin, neurokinin A.  The authors find that although the behavioral response to mildly painful stimuli is intact in these mice, the response to moderate to intense pain is significantly reduced.  Neurogenic inflammation, which results from peripheral release of substance P and neurokinin A is almost absent in the mutant mice.  The authors conclude that the release of tachykinins from primary afferent pain-sensing receptors (nociceptors) is required to produce moderate to intense pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpConFsx38BFrVg90H21EOLACvtfcHk0li84J45zIDUYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSiu74%253D&md5=b04ba3220271c19b3ed8c08a736a9043</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F32897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F32897%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%2BQ.%26aulast%3DMantyh%26aufirst%3DP.%2BW.%26aulast%3DCarlson%26aufirst%3DE.%2BJ.%26aulast%3DGillespie%26aufirst%3DA.%2BM.%26aulast%3DEpstein%26aufirst%3DC.%2BJ.%26aulast%3DBasbaum%26aufirst%3DA.%2BI.%26atitle%3DPrimary%2520afferent%2520tachykinins%2520are%2520required%2520to%2520experience%2520moderate%2520to%2520intense%2520pain%26jtitle%3DNature%26date%3D1998%26volume%3D392%26spage%3D390%26epage%3D394%26doi%3D10.1038%2F32897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pintér, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozsgai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helyes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szolcsányi, J.</span></span> <span> </span><span class="NLM_article-title">Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1111/bcp.12097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fbcp.12097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23432438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFOk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=5-20&author=E.+Pint%C3%A9rauthor=G.+Pozsgaiauthor=Z.+Hajnaauthor=Z.+Helyesauthor=J.+Szolcs%C3%A1nyi&title=Neuropeptide+receptors+as+potential+drug+targets+in+the+treatment+of+inflammatory+conditions&doi=10.1111%2Fbcp.12097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions</span></div><div class="casAuthors">Pinter, Erika; Pozsgai, Gabor; Hajna, Zsofia; Helyes, Zsuzsanna; Szolcsanyi, Janos</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-20</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cross-talk between the nervous, endocrine and immune systems exists via regulator mols., such as neuropeptides, hormones and cytokines.  A no. of neuropeptides have been implicated in the genesis of inflammation, such as tachykinins and calcitonin gene-related peptide.  Development of their receptor antagonists could be a promising approach to anti-inflammatory pharmacotherapy.  Anti-inflammatory neuropeptides, such as vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, α-MSH, urocortin, adrenomedullin, somatostatin, cortistatin, ghrelin, galanin and opioid peptides, are also released and act on their own receptors on the neurons as well as on different inflammatory and immune cells.  The aim of the present review is to summarize the most prominent data of preclin. animal studies concerning the main pharmacol. effects of ligands acting on the neuropeptide receptors.  Promising therapeutic impacts of these compds. as potential candidates for the development of novel types of anti-inflammatory drugs are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8t57Qc8KgX7Vg90H21EOLACvtfcHk0li84J45zIDUYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFOk&md5=07b814188fba5fd3b142d47da4430c2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12097%26sid%3Dliteratum%253Aachs%26aulast%3DPint%25C3%25A9r%26aufirst%3DE.%26aulast%3DPozsgai%26aufirst%3DG.%26aulast%3DHajna%26aufirst%3DZ.%26aulast%3DHelyes%26aufirst%3DZ.%26aulast%3DSzolcs%25C3%25A1nyi%26aufirst%3DJ.%26atitle%3DNeuropeptide%2520receptors%2520as%2520potential%2520drug%2520targets%2520in%2520the%2520treatment%2520of%2520inflammatory%2520conditions%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D77%26spage%3D5%26epage%3D20%26doi%3D10.1111%2Fbcp.12097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. S.</span></span> <span> </span><span class="NLM_article-title">Distinct mechanism for antidepressant activity by blockade of central substance P receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.1126/science.281.5383.1640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1126%2Fscience.281.5383.1640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9733503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXmtVSqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=1640-1645&author=M.+S.+Kramer&title=Distinct+mechanism+for+antidepressant+activity+by+blockade+of+central+substance+P+receptors&doi=10.1126%2Fscience.281.5383.1640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct mechanism for antidepressant activity by blockade of central substance P receptors</span></div><div class="casAuthors">Kramer, Mark S.; Cutler, Neal; Feighner, John; Shrivastava, Ram; Carman, John; Sramek, John J.; Reines, Scott A.; Liu, Guanghan; Snavely, Duane; Wyatt-Knowles, Edwina; Hale, Jeffrey J.; Mills, Sander G.; MacCoss, Malcolm; Swain, Christopher J.; Harrison, Timothy; Hill, Raymond G.; Hefti, Franz; Scolnick, Edward M.; Cascieri, Margaret A.; Chicchi, Gary G.; Sadowski, Sharon; Williams, Angela R.; Hewson, Louise; Smith, David; Carlson, Emma J.; Hargreaves, Richard J.; Rupniak, Nadia M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5383</span>),
    <span class="NLM_cas:pages">1640-1645</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties.  Like clin. used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs.  In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently obsd.  In preclin. studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs.  These findings suggest that substance P may play an important role in psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPAlbpoVBCrVg90H21EOLACvtfcHk0li84J45zIDUYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtVSqtb0%253D&md5=f6ac9f6dc063d6269a80ae80726c62b6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5383.1640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5383.1640%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DM.%2BS.%26atitle%3DDistinct%2520mechanism%2520for%2520antidepressant%2520activity%2520by%2520blockade%2520of%2520central%2520substance%2520P%2520receptors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D1640%26epage%3D1645%26doi%3D10.1126%2Fscience.281.5383.1640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, M.</span></span> <span> </span><span class="NLM_article-title">The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs</span>. <i>J. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1007/s12038-015-9530-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs12038-015-9530-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25963269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=441-463&author=M.+Mu%C3%B1ozauthor=R.+Cove%C3%B1asauthor=F.+Estebanauthor=M.+Redondo&title=The+substance+P%2FNK-1+receptor+system%3A+NK-1+receptor+antagonists+as+anti-cancer+drugs&doi=10.1007%2Fs12038-015-9530-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs</span></div><div class="casAuthors">Munoz, Miguel; Covenas, Rafael; Esteban, Francisco; Redondo, Maximino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biosciences (New Delhi, India)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-463</span>CODEN:
                <span class="NLM_cas:coden">JOBSDN</span>;
        ISSN:<span class="NLM_cas:issn">0250-5991</span>.
    
            (<span class="NLM_cas:orgname">Springer (India) Private Ltd.</span>)
        </div><div class="casAbstract">A review.  The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in cancer.  SP promotes the proliferation of tumor cells, angiogenesis and the migration of tumor cells.  We review the involvement of SP, the NK-1 receptor and NK-1 receptor antagonists in cancer.  Tumor cells overexpress NK-1 receptors, which are involved in their viability.  This overexpression suggests the possibility of specific treatment against tumor cells using NK-1 receptor antagonists, thus promoting a considerable decrease in the side effects of the treatment.  This strategy opens up new approaches for cancer treatment, since these antagonists, after binding to their mol. target, induce the death of tumor cells by apoptosis, exert an antiangiogenic action and inhibit the migration of tumor cells.  The use of NK-1 receptor antagonists such as aprepitant (used in clin. practice) as antitumor agents could be a promising innovation.  The value of aprepitant as an antitumor agent could be detd. faster than for less well-known compds. because many studies addressing its safety and characterization have already been completed.  The NK-1 receptor may be a promising target in the treatment of cancer; NK-1 receptor antagonists could act as specific drugs against tumor cells; and these antagonists could be new candidate anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIkaGJREvCobVg90H21EOLACvtfcHk0lh7xQTYcMEnvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOjur0%253D&md5=c026bb778ec7331bc196af6ebf378b0c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs12038-015-9530-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12038-015-9530-8%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26aulast%3DEsteban%26aufirst%3DF.%26aulast%3DRedondo%26aufirst%3DM.%26atitle%3DThe%2520substance%2520P%252FNK-1%2520receptor%2520system%253A%2520NK-1%2520receptor%2520antagonists%2520as%2520anti-cancer%2520drugs%26jtitle%3DJ.%2520Biosci.%26date%3D2015%26volume%3D40%26spage%3D441%26epage%3D463%26doi%3D10.1007%2Fs12038-015-9530-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Frias, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas-Martin, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2010.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Flabinvest.2010.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=20458280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptl2jtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=1259-1269&author=M.+Mu%C3%B1ozauthor=M.+Rossoauthor=M.+J.+Robles-Friasauthor=M.+V.+Salinas-Martinauthor=R.+Rossoauthor=A.+Gonzalez-Ortegaauthor=R.+Cove%C3%B1as&title=The+NK-1+receptor+is+expressed+in+human+melanoma+and+is+involved+in+the+antitumor+action+of+the+NK-1+receptor+antagonist+aprepitant+on+melanoma+cell+lines&doi=10.1038%2Flabinvest.2010.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines</span></div><div class="casAuthors">Munoz, Miguel; Rosso, Marisa; Robles-Frias, Maria Jose; Salinas-Martin, Manuel Vicente; Rosso, Rosario; Gonzalez-Ortega, Ana; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1259-1269</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Melanoma, the most deadly form of skin cancer, is aggressive and resistant to current therapies.  It has been previously reported that the substance P and neurokinin-1 (NK-1) receptor antagonists induce cell proliferation and cell inhibition, resp., in human melanoma cell lines.  Aprepitant is a selective high-affinity antagonist of the human NK-1 receptor.  Until now, this drug has been used as an anxiolytic, antidepressant and antiemetic.  Moreover, the antitumor action of aprepitant has been previously reported.  However, the presence of NK-1 receptors in human melanomas and whether the antitumor action of the NK-1 receptor antagonist aprepitant is exerted on human malignant melanomas have not been previously described.  The aims of this study are to show the presence of NK-1 receptors in human malignant melanomas and the antitumoral action of aprepitant against several human melanoma cell lines.  Immunoblot anal. was used to det. the presence of NK-1 receptors in human melanoma cell lines, and immunohistochem. was used to demonstrate NK-1 receptors in human melanoma samples.  We performed an in vitro study of the cytotoxicity of the NK-1 receptor antagonist aprepitant on human melanoma cell lines.  A coulter counter was used to det. viable cell nos., followed by application of the tetrazolium compd. MTS.  The DAPI method was applied to demonstrate apoptosis.  We obsd. that NK-1 receptors were present in all the melanoma samples studied as well as in human melanoma cell lines.  We also showed that melanoma cell lines expressed mRNA for the NK-1 receptor.  Moreover, after using a knockdown method, we showed that NK-1 receptors are involved in the viability of tumor cells.  In this study, we also report that aprepitant, at 10-60 μM concns., elicits cell growth inhibition in a concn.-dependent manner in all melanoma cell lines studied, that the specific antitumor action of aprepitant occurs through the NK-1 receptor and that melanoma cell death is de to apoptosis.  These findings show for the first time that the NK-1 receptor may be a promising new target and that the NK-1 receptor antagonist aprepitant could be a candidate as a new antitumor drug in the treatment of human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqOOWBv5HJV7Vg90H21EOLACvtfcHk0lh7xQTYcMEnvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptl2jtr0%253D&md5=7a9c894ed406f4bbe50d6a5e4fdc00c6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2010.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2010.92%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DRobles-Frias%26aufirst%3DM.%2BJ.%26aulast%3DSalinas-Martin%26aufirst%3DM.%2BV.%26aulast%3DRosso%26aufirst%3DR.%26aulast%3DGonzalez-Ortega%26aufirst%3DA.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DThe%2520NK-1%2520receptor%2520is%2520expressed%2520in%2520human%2520melanoma%2520and%2520is%2520involved%2520in%2520the%2520antitumor%2520action%2520of%2520the%2520NK-1%2520receptor%2520antagonist%2520aprepitant%2520on%2520melanoma%2520cell%2520lines%26jtitle%3DLab.%2520Invest.%26date%3D2010%26volume%3D90%26spage%3D1259%26epage%3D1269%26doi%3D10.1038%2Flabinvest.2010.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannstrom, G.</span></span> <span> </span><span class="NLM_article-title">Substance P enhances forskol in stimulated cyclic AMP production in human UC11MG astrocytoma cells</span>. <i>Methods Find. Exp. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=7513037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Wqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1994&pages=21-28&author=C.+J.+Fowlerauthor=G.+Brannstrom&title=Substance+P+enhances+forskol+in+stimulated+cyclic+AMP+production+in+human+UC11MG+astrocytoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells</span></div><div class="casAuthors">Fowler, Christopher J.; Braennstroem, Gunilla</div><div class="citationInfo"><span class="NLM_cas:title">Methods and Findings in Experimental and Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-8</span>CODEN:
                <span class="NLM_cas:coden">MFEPDX</span>;
        ISSN:<span class="NLM_cas:issn">0379-0355</span>.
    </div><div class="casAbstract">The effects of substance P (SP) upon basal and forskolin-stimulated cAMP prodn. have been investigated in UC11MG cells.  The cells expressed 40,000 NK1 receptors/cell, the stimulation of which led to enhanced phosphoinositide breakdown.  Forskolin (10 and 100 μM) stimulated cAMP prodn., whereas SP (3 and 300 nM) produced no significant increase in cAMP prodn.  However, SP enhanced the response to forskolin, with an EC50 value of ∼10 nM.  The response to forskolin was also enhanced by physalemin and eledoisin, and was sensitive to inhibition by (+/-)CP 96345.  Thus, in the UC11MG cell line, SP not only stimulates phosphoinositide breakdown but also enhances the cAMP response to forskolin, possibly via stimulation of NK1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUPQJ2u5NIBLVg90H21EOLACvtfcHk0lh7xQTYcMEnvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Wqt70%253D&md5=edde6c3eb28e11eb3af6fed1645d7d1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DBrannstrom%26aufirst%3DG.%26atitle%3DSubstance%2520P%2520enhances%2520forskol%2520in%2520stimulated%2520cyclic%2520AMP%2520production%2520in%2520human%2520UC11MG%2520astrocytoma%2520cells%26jtitle%3DMethods%2520Find.%2520Exp.%2520Clin.%2520Pharmacol.%26date%3D1994%26volume%3D16%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friess, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrikhande, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchler, M. W.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1097/01.LAB.0000067499.57309.F6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1097%2F01.LAB.0000067499.57309.F6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12746482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlKjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=731-742&author=H.+Friessauthor=Z.+Zhuauthor=V.+Liardauthor=X.+Shiauthor=S.+V.+Shrikhandeauthor=L.+Wangauthor=K.+Liebauthor=M.+Korcauthor=C.+Palmaauthor=A.+Zimmermannauthor=J.+C.+Reubiauthor=M.+W.+Buchler&title=Neurokinin-1+receptor+expression+and+its+potential+effects+on+tumor+growth+in+human+pancreatic+cancer&doi=10.1097%2F01.LAB.0000067499.57309.F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer</span></div><div class="casAuthors">Friess, Helmut; Zhu, Zhaowen; Liard, Veronique; Shi, Xin; Shrikhande, Shailesh V.; Wang, Li; Lieb, Klaus; Korc, Murray; Palma, Carla; Zimmermann, Arthur; Reubi, Jean Claude; Buechler, Markus W.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-742</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The neurokinin-1 receptor (NK-1R) and its ligand substance P (SP) are involved in the pathogenesis of certain neural tumors.  Because nerves are significantly altered in pancreatic cancer, evidence for alteration of this pathway in human pancreatic cancer was sought.  Expression of NK-1R was analyzed by real-time quant. RT-PCR, in situ hybridization, immunohistochem., and Western blot anal. in normal human pancreatic and pancreatic cancer tissue samples and in pancreatic cancer cell lines.  Furthermore, the influence of SP analogs and of the NK-1R antagonist MEN 11467 on pancreatic cancer cell growth was analyzed by sulforhodamine B (SRB) assay.  By real-time quant. RT-PCR, NK-1R mRNA was increased 36.7-fold (p < 0.001) in human pancreatic cancer samples compared with normal controls.  Enhanced NK-1R expression levels were not related to tumor grade but were assocd. with advanced tumor stage and poorer prognosis.  By in situ hybridization and immunohistochem., NK-1R mRNA and immunoreactivity were only occasionally weakly present in acinar and ductal cells in the normal pancreas.  In contrast, moderate to strong NK-1R mRNA signals and immunoreactivity were present in most cancer cells.  By Western blot anal., NK-1R was increased 26-fold (p < 0.01) in pancreatic cancer samples in comparison to normal controls.  NK-1R mRNA was detected in 5 pancreatic cancer cell lines by real-time quant. RT-PCR, with the highest levels in CAPAN-1 cells and the lowest in ASPC-1 cells.  SP analogs stimulated pancreatic cancer cell growth, depending on the NK-1R expression level, and this effect could be blocked by a selective NK-1R antagonist.  These findings illustrate that the NK-1R pathway is activated in human pancreatic cancer and has the potential to contribute to cancer cell growth, thus suggesting the existence of a neuro-cancer cell interaction in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpurDo_E8owzrVg90H21EOLACvtfcHk0ljALkDflak_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlKjs7o%253D&md5=c70ea8cf40d3c8aadc9d3eeab54c723a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2F01.LAB.0000067499.57309.F6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.LAB.0000067499.57309.F6%26sid%3Dliteratum%253Aachs%26aulast%3DFriess%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLiard%26aufirst%3DV.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DShrikhande%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLieb%26aufirst%3DK.%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DPalma%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DBuchler%26aufirst%3DM.%2BW.%26atitle%3DNeurokinin-1%2520receptor%2520expression%2520and%2520its%2520potential%2520effects%2520on%2520tumor%2520growth%2520in%2520human%2520pancreatic%2520cancer%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D731%26epage%3D742%26doi%3D10.1097%2F01.LAB.0000067499.57309.F6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloof, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameshwar, P.</span></span> <span> </span><span class="NLM_article-title">Increased expression of preprotachykinin-I and neurokinin receptors cells: Implications for bone marrow metastasis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.1.388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.97.1.388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10618428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=388-393&author=D.+Singhauthor=D.+D.+Joshiauthor=M.+Hameedauthor=J.+Qianauthor=P.+Gasconauthor=P.+B.+Maloofauthor=A.+Mosenthalauthor=P.+Rameshwar&title=Increased+expression+of+preprotachykinin-I+and+neurokinin+receptors+cells%3A+Implications+for+bone+marrow+metastasis&doi=10.1073%2Fpnas.97.1.388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of preprotachykinin-1 and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis</span></div><div class="casAuthors">Singh, Deeppreet; Joshi, Deval D.; Hameed, Meera; Qian, Jing; Gascon, Pedro; Maloof, Paul B.; Mosenthal, Anne; Rameshwar, Pranela</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neuropeptides are implicated in many tumors, breast cancer (BC) included.  Preprotachykinin-1 (PPT-I) encodes multiple neuropeptides with pleiotropic functions such as neurotransmission, immune/hematopoietic modulation, angiogenesis, and mitogenesis.  PPT-I is constitutively expressed in some tumors.  In this study, we investigated a role for PPT-I and its receptors, neurokinin-1 (NK-1) and NK-2, in BC by using quant. reverse transcription-PCR, ELISA, and in situ hybridization.  Compared with normal mammary epithelial cells (n = 2) and benign breast biopsies (n = 21), BC cell lines (n = 7) and malignant breast biopsies (n = 25) showed increased expression of PPT-I and NK-1.  NK-2 levels were high in normal and malignant cells.  Specific NK-1 and NK-2 antagonists inhibited BC cell proliferation, suggesting autocrine and/or intercrine stimulation of BC cells by PPT-I peptides.  NK-2 showed no effect on the proliferation of normal cells but mediated the proliferation of BC cells.  Cytosolic exts. from malignant BC cells enhanced PPT-I translation whereas exts. from normal mammary epithelial cells caused no change.  These enhancing effects may be protein-specific because a similar increase was obsd. for IL-6 translation and no effect was obsd. for IL-1α and stem cell factor.  The data suggest that PPT-I peptides and their receptors may be important in BC development.  Considering that PPT-I peptides are hematopoietic modulators, these results could be extended to understand early integration of BC cells in the bone marrow, a preferred site of metastasis.  Mol. signaling transduced by PPT-I peptides and the mechanism that enhances translation of PPT-I mRNA could lead to innovative strategies for BC treatments and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropkyT7xbj-LVg90H21EOLACvtfcHk0ljALkDflak_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVGhtQ%253D%253D&md5=b25cd6e16a08a3ce774f5e862abbf72e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.1.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.1.388%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DD.%2BD.%26aulast%3DHameed%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGascon%26aufirst%3DP.%26aulast%3DMaloof%26aufirst%3DP.%2BB.%26aulast%3DMosenthal%26aufirst%3DA.%26aulast%3DRameshwar%26aufirst%3DP.%26atitle%3DIncreased%2520expression%2520of%2520preprotachykinin-I%2520and%2520neurokinin%2520receptors%2520cells%253A%2520Implications%2520for%2520bone%2520marrow%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D388%26epage%3D393%26doi%3D10.1073%2Fpnas.97.1.388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells</span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1042/CBI20100229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1042%2FCBI20100229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21091434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVCgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=623-629&author=F.+Fengauthor=J.+Yangauthor=L.+Tongauthor=S.+Yuanauthor=Y.+Tianauthor=L.+Hongauthor=W.+Wangauthor=H.+Zhang&title=Substance+P+immunoreactive+nerve+fibres+are+related+to+gastric+cancer+differentiation+status+and+could+promote+proliferation+and+migration+of+gastric+cancer+cells&doi=10.1042%2FCBI20100229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P immunoreactive nerve fibrers are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells</span></div><div class="casAuthors">Feng, Fan; Yang, Jian-Jun; Tong, Li-Ping; Yuan, Shi-Fa; Tian, Yang-Zi; Hong, Liu; Wang, Wei-Zhong; Zhang, Hong-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-629</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Tachykinins such as SP (substance P) may be involved in the progression of gastric adenocarcinoma through binding to NK-1 receptor.  However, the existence and relationship between SP and gastric cancer progression and differentiation remained unknown.  We have studied the NK-1 receptor in human gastric cancer tissue and MKN45 cell line and found SP-contg. nerve fibers in human gastric cancer and found that the amts. of SP-pos. nerves were related to gastric cancer differentiation.  SP could promote proliferation, adhesion, migration and invasion of MKN45 cells in vitro.  In addn., the intracellular calcium level of MKN45 cells was elevated after SP stimulation, and administration of CRACs (calcium release-activated calcium channels) inhibitor SKF-96365 could partially abolish these effects induced by SP.  These results demonstrated that NK-1 receptor and SP-contg. nerves existed in human gastric cancer; SP pos. nerves may play an important role in human gastric cancer progression, and calcium is critically significant among SP-induced biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbEhtMUEW8bVg90H21EOLACvtfcHk0ljALkDflak_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVCgtbk%253D&md5=eac20ab66021b7f5967572e49652a803</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FCBI20100229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCBI20100229%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DSubstance%2520P%2520immunoreactive%2520nerve%2520fibres%2520are%2520related%2520to%2520gastric%2520cancer%2520differentiation%2520status%2520and%2520could%2520promote%2520proliferation%2520and%2520migration%2520of%2520gastric%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2011%26volume%3D35%26spage%3D623%26epage%3D629%26doi%3D10.1042%2FCBI20100229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayyer Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naveed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad-ul-Hussan, S.</span></span> <span> </span><span class="NLM_article-title">Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach</span>. <i>Comput. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>122</i></span>, <span class="NLM_elocation-id">103848</span> <span class="refDoi"> DOI: 10.1016/j.compbiomed.2020.103848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.compbiomed.2020.103848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32658735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2020&author=H.+Iftikharauthor=H.+Nayyer+Aliauthor=S.+Farooqauthor=H.+Naveedauthor=S.+Shahzad-ul-Hussan&title=Identification+of+potential+inhibitors+of+three+key+enzymes+of+SARS-CoV2+using+computational+approach&doi=10.1016%2Fj.compbiomed.2020.103848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach</span></div><div class="casAuthors">Iftikhar, Hafsa; Ali, Hafiza Nayyer; Farooq, Sadia; Naveed, Hammad; Shahzad-ul-Hussan, Syed</div><div class="citationInfo"><span class="NLM_cas:title">Computers in Biology and Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103848</span>CODEN:
                <span class="NLM_cas:coden">CBMDAW</span>;
        ISSN:<span class="NLM_cas:issn">0010-4825</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The recent outbreak of coronavirus disease-19 (COVID-19) continues to drastically affect healthcare throughout the world.  To date, no approved treatment regimen or vaccine is available to effectively attenuate or prevent the infection.  Therefore, collective and multidisciplinary efforts are needed to identify new therapeutics or to explore effectiveness of existing drugs and drug-like small mols. against SARS-CoV-2 for lead identification and repurposing prospects.  This study addresses the identification of small mols. that specifically bind to any of the three essential proteins (RdRp, 3CL-protease and helicase) of SARS-CoV-2.  By applying computational approaches we screened a library of 4574 compds. also contg. FDA-approved drugs against these viral proteins.  Shortlisted hits from initial screening were subjected to iterative docking with the resp. proteins.  Ranking score on the basis of binding energy, clustering score, shape complementarity and functional significance of the binding pocket was applied to identify the binding compds.  Finally, to minimize chances of false positives, we performed docking of the identified mols. with 100 irrelevant proteins of diverse classes thereby ruling out the non-specific binding.  Three FDA-approved drugs showed binding to 3CL-protease either at the catalytic pocket or at an allosteric site related to functionally important dimer formation.  A drug-like mol. showed binding to RdRp in its catalytic pocket blocking the key catalytic residues.  Two other drug-like mols. showed specific interactions with helicase at a key domain involved in catalysis.  This study provides lead drugs or drug-like mols. for further in vitro and clin. investigation for drug repurposing and new drug development prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoheOjWPbTyP7Vg90H21EOLACvtfcHk0lgtrjyBkE5JcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCju7nN&md5=df84538269d193bb799eabb10b29d733</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiomed.2020.103848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiomed.2020.103848%26sid%3Dliteratum%253Aachs%26aulast%3DIftikhar%26aufirst%3DH.%26aulast%3DNayyer%2BAli%26aufirst%3DH.%26aulast%3DFarooq%26aufirst%3DS.%26aulast%3DNaveed%26aufirst%3DH.%26aulast%3DShahzad-ul-Hussan%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520potential%2520inhibitors%2520of%2520three%2520key%2520enzymes%2520of%2520SARS-CoV2%2520using%2520computational%2520approach%26jtitle%3DComput.%2520Biol.%2520Med.%26date%3D2020%26volume%3D122%26doi%3D10.1016%2Fj.compbiomed.2020.103848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehboob, R.</span>; <span class="NLM_string-name">Ahmad, F. J.</span>; <span class="NLM_string-name">Qayyum, A.</span>; <span class="NLM_string-name">Rana, M. A.</span>; <span class="NLM_string-name">Tariq, M. A.</span>; <span class="NLM_string-name">Ali, G.</span>; <span class="NLM_string-name">Akram, J.</span></span> <span> </span><span class="NLM_article-title">Aprepitant as a combinant with dexamethasone reduces the inflammation via neurokinin 1 receptor antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: a novel therapeutic approach</span>, <span class="NLM_year">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.08.01.20166678</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1101%2F2020.08.01.20166678" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Mehboob&author=F.+J.+Ahmad&author=A.+Qayyum&author=M.+A.+Rana&author=M.+A.+Tariq&author=G.+Ali&author=J.+Akram&title=Aprepitant+as+a+combinant+with+dexamethasone+reduces+the+inflammation+via+neurokinin+1+receptor+antagonism+in+severe+to+critical+Covid-19+patients+and+potentiates+respiratory+recovery%3A+a+novel+therapeutic+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1101%2F2020.08.01.20166678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1101%252F2020.08.01.20166678%26sid%3Dliteratum%253Aachs%26aulast%3DMehboob%26aufirst%3DR.%26atitle%3DAprepitant%2520as%2520a%2520combinant%2520with%2520dexamethasone%2520reduces%2520the%2520inflammation%2520via%2520neurokinin%25201%2520receptor%2520antagonism%2520in%2520severe%2520to%2520critical%2520Covid-19%2520patients%2520and%2520potentiates%2520respiratory%2520recovery%253A%2520a%2520novel%2520therapeutic%2520approach%26date%3D2020%26doi%3D10.1101%2F2020.08.01.20166678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> A search in clinical trials.gov accessed
on the 27 of August 2020 show that, currently there are three clinical
trials on the use of NK1 antagonists (2 with aprepitant and 1 with
taradipitant) in the treatment of COVID19 pandemic.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+search+in+clinical+trials.gov+accessed%0Aon+the+27+of+August+2020+show+that%2C+currently+there+are+three+clinical%0Atrials+on+the+use+of+NK1+antagonists+%282+with+aprepitant+and+1+with%0Ataradipitant%29+in+the+treatment+of+COVID19+pandemic."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korlipara, V. L.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor antagonists: a comprehensive patent survey</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1517/13543776.2010.495121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2010.495121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=20533894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1SltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1019-1045&author=S.-C.+Huangauthor=V.+L.+Korlipara&title=Neurokinin-1+receptor+antagonists%3A+a+comprehensive+patent+survey&doi=10.1517%2F13543776.2010.495121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 receptor antagonists: a comprehensive patent survey</span></div><div class="casAuthors">Huang, Shih-Chung; Korlipara, Vijaya L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1019-1045</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Substance P is involved in mediating a no. of biol. effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor.  Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions.  Areas covered in this review: More than 300 patents have been filed by nearly 20 companies and 2 academic institutions in the past 2 decades.  This review provides an overview of the patenting activity in the NK1 antagonist field over the last 20 years.  What the reader will gain: Chem. diverse non-peptide NK1 receptor antagonists have been identified since the discovery of CP-96,345 by Pfizer in 1991.  Representative examples of patented ligands and their biol. activities are presented in a company-wise approach.  Take home message: The NK1 receptor research has led to the clin. introduction of aprepitant in 2003 and its water sol. injectable form, fosaprepitant dimeglumine, in 2009 by Merck for the prevention of postoperative nausea and vomiting and for inhibiting chemotherapy-induced nausea and vomiting.  In addn., maropitant citrate received approval in 2007 for veterinary use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMh4tbEQ3PrVg90H21EOLACvtfcHk0lgtrjyBkE5JcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1SltL0%253D&md5=a773b58ac061cdc03a5d3c9bdc69e4b0</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.495121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.495121%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DKorlipara%26aufirst%3DV.%2BL.%26atitle%3DNeurokinin-1%2520receptor%2520antagonists%253A%2520a%2520comprehensive%2520patent%2520survey%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1019%26epage%3D1045%26doi%3D10.1517%2F13543776.2010.495121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Armesto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.697153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2012.697153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22697287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Mu%C3%B1oz%2C+M.%3B+Martinez-Armesto%2C+J.%3B+Cove%C3%B1as%2C+R.+Expert+Opin.+Ther.+Pat.+2012%2C+22%2C+735%E2%80%93746%2C+10.1517%2F13543776.2012.697153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span></div><div class="casAuthors">Munoz, Miguel; Martinez-Armesto, Juan; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-746</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: After binding to the neurokinin (NK-1) receptor, substance P (SP) induces tumor cell proliferation, the migration of tumor cells (invasion and metastasis) and angiogenesis.  By contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells and exert antiangiogenic properties.Areas covered: This review offers a 12-yr overview of the underlying mechanism of the action of the SP/NK-1 receptor system and NK-1 receptor antagonists in cancer, providing a new approach to the treatment of tumors.Expert opinion: Chem. diverse NK-1 receptor antagonists have been identified.  The antitumor action of these compds. is independent of their chem. structures and such action is assocd. with their affinity for the NK-1 receptor and with the dose of the antagonist administered.  The NK-1 receptor can be considered as a target in cancer treatment and NK-1 receptor antagonists could be considered as new antitumor drugs.  The NK-1 receptor antagonist aprepitant is used in clin. practice and exerts an antitumor action against tumor cells in vitro.  In the future, such antitumor action should be tested in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowJRmIy_bZ7Vg90H21EOLACvtfcHk0lgtrjyBkE5JcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D&md5=8e5b53c6b90cac0e5144cc1f448d178b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.697153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.697153%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMartinez-Armesto%26aufirst%3DJ.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D735%26epage%3D746%26doi%3D10.1517%2F13543776.2012.697153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snider, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantine, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebel, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinick, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, H.-J.</span></span> <span> </span><span class="NLM_article-title">A potent nonpeptide antagonist of the substance P (NK1) receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1126/science.1703323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1126%2Fscience.1703323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1703323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlKnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1991&pages=435-437&author=R.+M.+Sniderauthor=J.+W.+Constantineauthor=J.+A.+Loweauthor=K.+P.+Longoauthor=W.+S.+Lebelauthor=H.+A.+Woodyauthor=S.+E.+Drozdaauthor=M.+C.+Desaiauthor=F.+J.+Vinickauthor=R.+W.+Spencerauthor=H.-J.+Hess&title=A+potent+nonpeptide+antagonist+of+the+substance+P+%28NK1%29+receptor&doi=10.1126%2Fscience.1703323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A potent nonpeptide antagonist of the substance P (NK1) receptor</span></div><div class="casAuthors">Snider, R. Michael; Constantine, Jay W.; Lowe, John A., III; Longo, Kelly P.; Lebel, Wesley S.; Woody, Heidi A.; Drozda, Susan E.; Desai, Manoj C.; Vinick, Fredric J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">4992</span>),
    <span class="NLM_cas:pages">435-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]octan-3-amine (I) is a potent nonpeptide antagonist of the substance P (NK1) receptor.  I inhibited 3H-labeled substance P binding and was a classical competitive antagonist in the NK1 monoreceptor dog carotid artery prepn.  I inhibited substance P-induced salivation in the rat, a classical in vivo bioassay, but did not inhibit NK2, NK3, or numerous other receptors; it is thus a selective NK1 antagonist.  I may prove to be a powerful tool for investigation of the physiol. properties of substance P and exploration of its role in diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoy7oM7Y6V7LVg90H21EOLACvtfcHk0lhbkZDAVAVWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlKnurY%253D&md5=1b3decaacb7402d5ce8f754097233c10</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1703323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1703323%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DConstantine%26aufirst%3DJ.%2BW.%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DLongo%26aufirst%3DK.%2BP.%26aulast%3DLebel%26aufirst%3DW.%2BS.%26aulast%3DWoody%26aufirst%3DH.%2BA.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26aulast%3DVinick%26aufirst%3DF.%2BJ.%26aulast%3DSpencer%26aufirst%3DR.%2BW.%26aulast%3DHess%26aufirst%3DH.-J.%26atitle%3DA%2520potent%2520nonpeptide%2520antagonist%2520of%2520the%2520substance%2520P%2520%2528NK1%2529%2520receptor%26jtitle%3DScience%26date%3D1991%26volume%3D251%26spage%3D435%26epage%3D437%26doi%3D10.1126%2Fscience.1703323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giardina, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, M.</span></span> <span> </span><span class="NLM_article-title">Antagonists at the neurokinin receptors - recent patent literature</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12917772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVGkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=758-772&author=G.+A.+Giardinaauthor=S.+Gagliardiauthor=M.+Martinelli&title=Antagonists+at+the+neurokinin+receptors+-+recent+patent+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists at the neurokinin receptors - recent patent literature</span></div><div class="casAuthors">Giardina, Giuseppe A. M.; Gagliardi, Stefania; Martinelli, Marisa</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">758-772</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">This review describes the patent applications and relevant scientific literature published during 2002 in the field of novel neurokinin receptor antagonists, with an emphasis on the medicinal chem. of recent patent publications.  A brief update on the development status of compds. including: the neurokinin-1 receptor antagonists aprepitant (Merck & Co Inc), vofopitant, ezlopitant (Pfizer Inc), R-673 (F Hoffmann-La Roche Ltd); the neurokinin-2 receptor antagonists nepadutant (Menarini Ricerche SpA), saredutant (Sanofi-Synthelabo), SR-144190 (Sanofi-Synthelabo) and UK-290795 (Pfizer Inc); and the neurokinin-3 receptor antagonists osanetant (Sanofi-Synthelabo) and talnetant (GlaxoSmithKline plc) will be given.  The review also reports the recent published patent literature in the area of novel therapeutic uses and novel formulations and combinations claimed for neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmP-QXsiXq_7Vg90H21EOLACvtfcHk0lhbkZDAVAVWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVGkurc%253D&md5=19cb9a8aedf8341d724795b208b51606</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGagliardi%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DM.%26atitle%3DAntagonists%2520at%2520the%2520neurokinin%2520receptors%2520-%2520recent%2520patent%2520literature%26jtitle%3DIDrugs%26date%3D2003%26volume%3D6%26spage%3D758%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicchi, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eirmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupniak, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycroft, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargraves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span> <span> </span><span class="NLM_article-title">Structural optimization affording 2-(<i>R</i>)-(1-(<i>R</i>)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(<i>S</i>)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4607</span>– <span class="NLM_lpage">4614</span>, <span class="refDoi"> DOI: 10.1021/jm980299k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980299k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlansrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4607-4614&author=J.+J.+Haleauthor=S.+G.+Millsauthor=M.+MacCossauthor=P.+E.+Finkeauthor=M.+A.+Cascieriauthor=S.+Sadowskiauthor=E.+Verauthor=G.+G.+Chicchiauthor=M.+Kurtzauthor=J.+Metzgerauthor=G.+Eirmannauthor=N.+N.+Tsouauthor=F.+D.+Tettersallauthor=N.+M.+Rupniakauthor=A.+R.+Williamsauthor=W.+Rycroftauthor=R.+Hargravesauthor=D.+E.+MacIntyre&title=Structural+optimization+affording+2-%28R%29-%281-%28R%29-3%2C5-bis%28trifluoromethyl%29phenylethoxy%29-3-%28S%29-%284-fluoro%29phenyl-4-+%283-oxo-1%2C2%2C4-triazol-5-yl%29methylmorpholine%2C+a+potent%2C+orally+active%2C+long-acting+morpholine+acetal+human+NK-1+receptor+antagonist&doi=10.1021%2Fjm980299k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist</span></div><div class="casAuthors">Hale, Jeffrey J.; Mills, Sander G.; MacCoss, Malcolm; Finke, Paul E.; Cascieri, Margaret A.; Sadowski, Sharon; Ber, Elzbieta; Chicchi, Gary G.; Kurtz, Marc; Metzger, Joseph; Eiermann, George; Tsou, Nancy N.; Tattersall, F. David; Rupniak, Nadia M. J.; Williams, Angela R.; Rycroft, Wayne; Hargreaves, Richard; MacIntyre, D. Euan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4607-4614</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural modifications requiring novel synthetic chem. were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist L-742694, and this resulted in the discovery of 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methyl morpholine (I).  This modified compd. is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to displace [125I]Substance P from hNK-1 receptors stably expressed in CHO cells (IC50 = 0.09 ± 0.06 nM) and by the measurement of the rates of assocn. (k1 = 2.8 ± 1.1 × 108 M-1 min-1) and dissocn. (k-1 = 0.0054 ± 0.003 min-1) of I from hNK-1 expressed in Sf9 membranes which yields Kd = 19 ± 12 pM and a t1/2 for receptor occupancy equal to 154 ± 75 min.  Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of I (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compd. has good oral bioavailability and peripheral duration of action.  Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of I as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 ± 0.006 mg/kg; IC50 (24 h) = 0.33 ± 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge.  The activity of I at extended time points in these preclin. animal models sets it apart from earlier morpholine antagonists (such as L-742694), and the piperidine antagonists CP 122721 and GR 205171 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P.  In part on the basis of these data, I has been identified as a potential clin. candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZTzBjAJV7W7Vg90H21EOLACvtfcHk0lhLF6kmGWbjrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlansrY%253D&md5=0ca98b5fb6a2957deffee22fa62aa988</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm980299k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980299k%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DFinke%26aufirst%3DP.%2BE.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DSadowski%26aufirst%3DS.%26aulast%3DVer%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DKurtz%26aufirst%3DM.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DEirmann%26aufirst%3DG.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DTettersall%26aufirst%3DF.%2BD.%26aulast%3DRupniak%26aufirst%3DN.%2BM.%26aulast%3DWilliams%26aufirst%3DA.%2BR.%26aulast%3DRycroft%26aufirst%3DW.%26aulast%3DHargraves%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26atitle%3DStructural%2520optimization%2520affording%25202-%2528R%2529-%25281-%2528R%2529-3%252C5-bis%2528trifluoromethyl%2529phenylethoxy%2529-3-%2528S%2529-%25284-fluoro%2529phenyl-4-%2520%25283-oxo-1%252C2%252C4-triazol-5-yl%2529methylmorpholine%252C%2520a%2520potent%252C%2520orally%2520active%252C%2520long-acting%2520morpholine%2520acetal%2520human%2520NK-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4607%26epage%3D4614%26doi%3D10.1021%2Fjm980299k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.2165/00003495-200464070-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2165%2F00003495-200464070-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=15025555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVOmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=777-794&author=T.+M.+Dandoauthor=C.+M.+Perry&title=Aprepitant%3A+a+review+of+its+use+in+the+prevention+of+chemotherapy-induced+nausea+and+vomiting&doi=10.2165%2F00003495-200464070-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Dando, Toni M.; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-794</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Aprepitant (Emend) is the first com. available drug from a new class of agents, the neurokinin NK1 receptor antagonists.  Oral aprepitant, in combination with other agents, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) assocd. with highly emetogenic chemotherapy in adults.  In three randomised, double-blind, placebo-controlled trials comparing aprepitant (125mg day 1, 80mg once daily on days 2 and 3 or 2-5) plus std. therapy (i.v. ondansetron and oral dexamethasone) with std. therapy plus placebo, overall complete responses (primary endpoint, defined as no emesis and no rescue therapy) were seen in significantly more patients in the aprepitant arms (63-73% vs. 43-52%, p < 0.01 for all comparisons).  Complete responses and complete protection during the acute and delayed phase, and overall complete protection were also obsd. in significantly more patients in the aprepitant arms.  The difference between treatment groups was more marked in the overall and delayed phases than in the acute phase.  The antiemetic efficacy of aprepitant plus std. therapy in the prevention of CINV was maintained for up to six cycles of chemotherapy.  Where assessed, more patients in the aprepitant plus std. therapy arms than the std. therapy plus placebo arms reported no impact of CINV on daily life, as assessed by the Functional Living Index-Emesis.  Aprepitant is generally well tolerated.  The most common adverse events in randomised trials were asthenia or fatigue.  Other adverse events experienced by aprepitant recipients include anorexia, constipation, diarrhoea, nausea (after day 5 of the study) and hiccups.  In addn. to being a substrate for cytochrome P 450 (CYP) 3A4, aprepitant is also a moderate inhibitor and inducer of this isoenzyme as well as an inducer of CYP2C9.  Thus, aprepitant has the potential to interact with other agents metabolised by hepatic CYP isoenzymes.  In one trial, there was a higher incidence of serious infection or febrile neutropenia in the aprepitant plus std. therapy arm than the std. therapy plus placebo arm; this was attributed to a pharmacokinetic interaction between aprepitant and dexamethasone.  In subsequent trials, a modified dexamethasone regimen was used.  In conclusion, when added to std. therapy (a serotonin 5-HT3 receptor antagonist and a corticosteroid), aprepitant is effective and generally well tolerated in the prevention of CINV assocd. with highly emetogenic chemotherapy in adults.  Despite marked advances in the prevention of CINV, std. therapy does not protect all patients.  The addn. of aprepitant to std. therapy provides an advance in the prevention of both acute and delayed CINV in adults with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopge6j7AQuILVg90H21EOLACvtfcHk0lhLF6kmGWbjrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVOmtrk%253D&md5=6583a8ed8cea7ba7d8d6f8cd8d7e12af</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464070-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464070-00013%26sid%3Dliteratum%253Aachs%26aulast%3DDando%26aufirst%3DT.%2BM.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DAprepitant%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D777%26epage%3D794%26doi%3D10.2165%2F00003495-200464070-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arjona Ferreira, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S.</span></span> <span> </span><span class="NLM_article-title">Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1222</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2011.05961.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1749-6632.2011.05961.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21434941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1222&publication_year=2011&pages=40-48&author=R.+Hargreavesauthor=J.+C.+Arjona+Ferreiraauthor=D.+Hughesauthor=J.+Brandsauthor=J.+Haleauthor=B.+Mattesonauthor=S.+Mills&title=Development+of+aprepitant%2C+the+first+neurokinin-1+receptor+antagonist+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting&doi=10.1111%2Fj.1749-6632.2011.05961.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Hargreaves, Richard; Ferreira, Juan Camilo Arjona; Hughes, David; Brands, Jos; Hale, Jeff; Mattson, Britta; Mills, Sandy</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-48</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Chemotherapy can be a life-prolonging treatment for many cancer patients, but it is often assocd. with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects.  EMEND (aprepitant) is the first and only neurokinin-1 (NK-1) receptor antagonist available on the market for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).  Aprepitant acts centrally at NK-1 receptors in vomiting centers within the central nervous system to block their activation by substance P released as an unwanted consequence of chemotherapy.  By controlling nausea and vomiting, EMEND helps improve patients' daily living and their ability to complete multiple cycles of chemotherapy.  The development of aprepitant included a novel nanoparticle formulation to optimize oral absorption and innovative chem. to discover a prodrug form suitable for i.v. administration to improve compliance and convenience for healthcare professionals and cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLqa3WCNyLLVg90H21EOLACvtfcHk0lhLF6kmGWbjrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVykuro%253D&md5=124db36771a8f5445b8e389cff6c3ea8</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2011.05961.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2011.05961.x%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DArjona%2BFerreira%26aufirst%3DJ.%2BC.%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DBrands%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DMatteson%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520aprepitant%252C%2520the%2520first%2520neurokinin-1%2520receptor%2520antagonist%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D1222%26spage%3D40%26epage%3D48%26doi%3D10.1111%2Fj.1749-6632.2011.05961.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Rolapitant: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0485-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs40265-015-0485-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26467681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1941-1945&author=Y.+Y.+Syed&title=Rolapitant%3A+first+global+approval&doi=10.1007%2Fs40265-015-0485-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1941-1945</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rolapitant (Varubi) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.  Unlike other approved agents in this class, rolapitant does not interact with cytochrome P 450 (CYP) enzyme CYP3A4.  It also has a long elimination half-life which means that a single dose could prevent CINV during the entire at-risk period (0-120 h).  An i.v. formulation of rolapitant is under clin. development in the USA.  Phase II development of rolapitant in postoperative nausea and vomiting, and cough appears to have been discontinued.  This article summarizes the milestones in the development of rolapitant leading to the first approval for the prevention of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwyS3mfly17Vg90H21EOLACvtfcHk0lhLF6kmGWbjrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM&md5=053f47d986332d2442b6fc8a08066814</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0485-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0485-8%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRolapitant%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1941%26epage%3D1945%26doi%3D10.1007%2Fs40265-015-0485-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Navari, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aapro, M.</span></span> <span> </span><span class="NLM_article-title">Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1356</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1515442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1056%2FNEJMra1515442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27050207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ojtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1356-1367&author=R.+M.+Navariauthor=M.+Aapro&title=Antiemetic+prophylaxis+for+chemotherapy-induced+nausea+and+vomiting&doi=10.1056%2FNEJMra1515442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Antiemetic prophylaxis for chemotherapy- induced nausea and vomiting</span></div><div class="casAuthors">Navari, Rudolph M.; Aapro, Matti</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1356-1367</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRt3NWIY_cBLVg90H21EOLACvtfcHk0ljmjsnc_YqXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ojtb%252FN&md5=09992cf025790eeff1959b9f83d752d9</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1515442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1515442%26sid%3Dliteratum%253Aachs%26aulast%3DNavari%26aufirst%3DR.%2BM.%26aulast%3DAapro%26aufirst%3DM.%26atitle%3DAntiemetic%2520prophylaxis%2520for%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1356%26epage%3D1367%26doi%3D10.1056%2FNEJMra1515442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human NK1 tachykinin receptor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">13264</span>– <span class="NLM_lpage">13269</span>, <span class="refDoi"> DOI: 10.1073/pnas.1812717115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1812717115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=30538204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=13264-13269&author=J.+Yinauthor=K.+Chapmanauthor=L.+D.+Clarkauthor=Z.+Shaoauthor=D.+Borekauthor=Q.+Xuauthor=J.+Wangauthor=D.+M.+Rosenbaum&title=Crystal+structure+of+the+human+NK1+tachykinin+receptor&doi=10.1073%2Fpnas.1812717115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human NK1 tachykinin receptor</span></div><div class="casAuthors">Yin, Jie; Chapman, Karen; Clark, Lindsay D.; Shao, Zhenhua; Borek, Dominika; Xu, Qingping; Wang, Junmei; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">13264-13269</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The NK1 tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals.  Through activation of NK1R, substance P modulates a wide variety of physiol. and disease processes including nociception, inflammation, and depression.  Human NK1R (hNK1R) modulators have shown promise in clin. trials for migraine, depression, and emesis.  However, the only currently approved drugs targeting hNK1R are inhibitors for chemotherapy-induced nausea and vomiting (CINV).  To better understand the mol. basis of ligand recognition and selectivity, we solved the crystal structure of hNK1R bound to the inhibitor L760735, a close analog of the drug aprepitant.  Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor.  We used our structure as a template for computational docking and mol.-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant.  The structure of hNK1R is a valuable tool in the further development of tachykinin receptor modulators for multiple clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLQ8thSAml-7Vg90H21EOLACvtfcHk0ljmjsnc_YqXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rsrjM&md5=8e19c80ab2ebe7911c81df25e1232d01</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1812717115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1812717115%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DL.%2BD.%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DBorek%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520NK1%2520tachykinin%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D13264%26epage%3D13269%26doi%3D10.1073%2Fpnas.1812717115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wüthrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Human Substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">638</span> <span class="refDoi"> DOI: 10.1038/s41467-019-08568-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fs41467-019-08568-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=30733446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Crurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=S.+Chenauthor=M.+Luauthor=D.+Liuauthor=L.+Yangauthor=C.+Yiauthor=L.+Maauthor=H.+Zhangauthor=Q.+Liuauthor=T.+M.+Frimurerauthor=M.-W.+Wangauthor=T.+W.+Schwartzauthor=R.+C.+Stevensauthor=B.+Wuauthor=K.+W%C3%BCthrichauthor=Q.+Zhao&title=Human+Substance+P+receptor+binding+mode+of+the+antagonist+drug+aprepitant+by+NMR+and+crystallography&doi=10.1038%2Fs41467-019-08568-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography</span></div><div class="casAuthors">Chen, Shuanghong; Lu, Mengjie; Liu, Dongsheng; Yang, Lingyun; Yi, Cuiying; Ma, Limin; Zhang, Hui; Liu, Qing; Frimurer, Thomas M.; Wang, Ming-Wei; Schwartz, Thue W.; Stevens, Raymond C.; Wu, Beili; Wuthrich, Kurt; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">638</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting.  However, the lack of data on NK1R structure and biochem. has limited further drug development targeting this receptor.  Here, we combine NMR spectroscopy and X-ray crystallog. to provide dynamic and static characterization of the binding mode of aprepitant in complexes with human NK1R variants.  The 19F-NMR showed a slow off-rate in the binding site, where aprepitant occupies multiple substates that exchange with frequencies in the millisecond range.  The environment of the bound ligand is affected by the amino acid in position 2.50, which plays a key role in ligand binding and receptor signaling in class A GPCRs.  Crystal structures now reveal how receptor signaling relates to the conformation of the conserved NP7.50xxY motif in transmembrane helix VII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJt3rhlppsLVg90H21EOLACvtfcHk0ljmjsnc_YqXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Crurg%253D&md5=e00d2059f8f51f3ce8b20d43ea874217</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08568-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08568-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DHuman%2520Substance%2520P%2520receptor%2520binding%2520mode%2520of%2520the%2520antagonist%2520drug%2520aprepitant%2520by%2520NMR%2520and%2520crystallography%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-08568-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vengut-Climent, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orcel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological studies of a library of NK1-receptor ligands based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4<i>H</i>-pyran core: switch from antagonist to agonist effect by chemical modification</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">644</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.ejmech.2017.06.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28710964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=644-660&author=R.+Recioauthor=E.+Vengut-Climentauthor=B.+Mouillacauthor=H.+Orcelauthor=M.+L%C3%B3pez-L%C3%A1zaroauthor=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=E.+%C3%81lvarezauthor=N.+Khiarauthor=I.+Fern%C3%A1ndez&title=Design%2C+synthesis+and+biological+studies+of+a+library+of+NK1-receptor+ligands+based+on+a+5-arylthiosubstituted+2-amino-4%2C6-diaryl-3-cyano-4H-pyran+core%3A+switch+from+antagonist+to+agonist+effect+by+chemical+modification&doi=10.1016%2Fj.ejmech.2017.06.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification</span></div><div class="casAuthors">Recio, Rocio; Vengut-Climent, Empar; Mouillac, Bernard; Orcel, Helene; Lopez-Lazaro, Miguel; Calderon-Montano, Jose Manuel; Alvarez, Eleuterio; Khiar, Noureddine; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">644-660</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A library of 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyrans has been synthesized as a new family of non-peptide NK1 receptor ligands by a one-pot cascade process.  Their biol. effects via interaction with the NK1 receptor were exptl. detd. as percentage of inhibition (for antagonists) and percentage of activation (for agonists), compared to the substance P (SP) effect, in IPone assay.  A set of these amino compds. was found to inhibit the action of SP, and therefore can be considered as a new family of SP-antagonists.  Interestingly, the acylation of the 2-amino position causes a switch from antagonist to agonist activity.  The 5-phenylsulfonyl-2-amino deriv. I showed the highest antagonist activity, while the 5-p-tolylsulfenyl-2-trifluoroacetamide deriv. II showed the highest agonist effect.  As expected, in the case of the 5-sulfinyl derivs., there was an enantiomeric discrimination in favor of one of the two enantiomers, specifically those with (SS,RC) configuration.  The anticancer activity studies assessed by using human A-549 lung cancer cells and MRC-5 non-malignant lung fibroblasts, revealed a statistically significant selective cytotoxic effect of some of these 2-amino-4H-pyran derivs. toward the lung cancer cells.  These studies demonstrated that the newly synthesized 4H-pyran derivs. can be used as a starting point for the synthesis of novel SP-antagonists with higher anticancer activity in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8uRlj5H-X6rVg90H21EOLACvtfcHk0lh5rnPH_fQ2NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7jL&md5=4cc3a564a7950ef574a7a82740030368</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DRecio%26aufirst%3DR.%26aulast%3DVengut-Climent%26aufirst%3DE.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DOrcel%26aufirst%3DH.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3D%25C3%2581lvarez%26aufirst%3DE.%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520studies%2520of%2520a%2520library%2520of%2520NK1-receptor%2520ligands%2520based%2520on%2520a%25205-arylthiosubstituted%25202-amino-4%252C6-diaryl-3-cyano-4H-pyran%2520core%253A%2520switch%2520from%2520antagonist%2520to%2520agonist%2520effect%2520by%2520chemical%2520modification%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D644%26epage%3D660%26doi%3D10.1016%2Fj.ejmech.2017.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span>; <span class="NLM_string-name">Fernández, I.</span>; <span class="NLM_string-name">Recio, R.</span>; <span class="NLM_string-name">López, M.</span>; <span class="NLM_string-name">Calderón, J. M.</span></span> <span> </span><span class="NLM_article-title">Antagonistas de los receptores NK1 derivados de hidratos de carbono, método de obtención y uso médico</span>. WIPO Patent <span class="NLM_patent">WO2016189179A1</span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=N.+Khiar&author=I.+Fern%C3%A1ndez&author=R.+Recio&author=M.+L%C3%B3pez&author=J.+M.+Calder%C3%B3n&title=Antagonistas+de+los+receptores+NK1+derivados+de+hidratos+de+carbono%2C+m%C3%A9todo+de+obtenci%C3%B3n+y+uso+m%C3%A9dico"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26atitle%3DAntagonistas%2520de%2520los%2520receptores%2520NK1%2520derivados%2520de%2520hidratos%2520de%2520carbono%252C%2520m%25C3%25A9todo%2520de%2520obtenci%25C3%25B3n%2520y%2520uso%2520m%25C3%25A9dico%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordner, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-alkyl quinuclidinium substance P antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1156</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)80246-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0960-894X%2801%2980246-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVGisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=1153-1156&author=J.+A.+Loweauthor=S.+Drozdaauthor=S.+McLeanauthor=R.+Crawfordauthor=D.+Bryceauthor=J.+Bordner&title=N-alkyl+quinuclidinium+substance+P+antagonists&doi=10.1016%2FS0960-894X%2801%2980246-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">N-alkyl quinuclidinium substance P antagonists</span></div><div class="casAuthors">Lowe, John A., III; Drozda, Susan E.; McLean, Stafford; Crawford, Rosemary T.; Bryce, Dianne K.; Bordner, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1153-6</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    </div><div class="casAbstract">The synthesis and structure-activity relationship of bridgehead N-alkylated analogs of the nonpeptide substance P antagonist CP-96,345 are described.  The results indicate that the bridgehead nitrogen may provide more of an anchoring function rather than being in intimate contact with the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXbmzNwXeMTrVg90H21EOLACvtfcHk0lh5rnPH_fQ2NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVGisrw%253D&md5=dc0c355418a1652c5b3f3aa094dbda29</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980246-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980246-8%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DDrozda%26aufirst%3DS.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DR.%26aulast%3DBryce%26aufirst%3DD.%26aulast%3DBordner%26aufirst%3DJ.%26atitle%3DN-alkyl%2520quinuclidinium%2520substance%2520P%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D1153%26epage%3D1156%26doi%3D10.1016%2FS0960-894X%2801%2980246-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewart, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanNiel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2] octane human NK1 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4793</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1021/jm00024a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00024a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2MXptVGqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4793-4805&author=C.+J.+Swainauthor=E.+M.+Sewartauthor=M.+A.+Cascieriauthor=T.+M.+Fangauthor=R.+Herbertauthor=D.+E.+MacIntyreauthor=K.+J.+Merchantauthor=S.+N.+Owenauthor=A.+P.+Owensauthor=R.+Bakerauthor=V.+Sabinauthor=M.+Teallauthor=M.+B.+VanNielauthor=B.+J.+Williamsauthor=S.+Sadowskiauthor=C.+Straderauthor=R.+G.+Ballauthor=R.+Baker&title=Identification+of+a+series+of+3-%28benzyloxy%29-1-azabicyclo%5B2.2.2%5D+octane+human+NK1+antagonists&doi=10.1021%2Fjm00024a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Series of 3-(Benzyloxy)-1-azabicyclo[2.2.2]octane Human NK1 Antagonists</span></div><div class="casAuthors">Swain, Christopher J.; Sewart, Eileen M.; Cascieri, Margaret A.; Fong, Tung M.; Herbert, Richard; MacIntyre, D Euan; Merchant, Kevin J.; Owen, Simon N.; Owens, Andrew P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4793-805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and in vitro and in vivo evaluation of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists are described.  While a no. of 3,5-disubstituted benzyl ethers afford high affinity, the 3,5-bis(trifluoromethyl)benzyl was found to combine high in vitro affinity with good oral activity.  Detailed structure-activity relationship studies in conjunction with data from mol. modeling and mutagenesis work have allowed the construction of a model of the pharmacophore.  Specific interactions that have been identified include an interaction between His-197 and one of the rings of the benzhydryl, a lipophilic pocket contg. His-265 that the benzyl ether occupies, and a possible hydrogen bond between Asp-165 and the oxygen of the benzyl ether.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8b_adDk4k7Vg90H21EOLACvtfcHk0lh5rnPH_fQ2NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptVGqtrw%253D&md5=87b83ba4cc52988c19da7762c85e2891</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Fjm00024a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00024a007%26sid%3Dliteratum%253Aachs%26aulast%3DSwain%26aufirst%3DC.%2BJ.%26aulast%3DSewart%26aufirst%3DE.%2BM.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DFang%26aufirst%3DT.%2BM.%26aulast%3DHerbert%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DMerchant%26aufirst%3DK.%2BJ.%26aulast%3DOwen%26aufirst%3DS.%2BN.%26aulast%3DOwens%26aufirst%3DA.%2BP.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DTeall%26aufirst%3DM.%26aulast%3DVanNiel%26aufirst%3DM.%2BB.%26aulast%3DWilliams%26aufirst%3DB.%2BJ.%26aulast%3DSadowski%26aufirst%3DS.%26aulast%3DStrader%26aufirst%3DC.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DBaker%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520a%2520series%2520of%25203-%2528benzyloxy%2529-1-azabicyclo%255B2.2.2%255D%2520octane%2520human%2520NK1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4793%26epage%3D4805%26doi%3D10.1021%2Fjm00024a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shands, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beusen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G. R.</span></span> <span> </span><span class="NLM_article-title">Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3609</span>– <span class="NLM_lpage">3623</span>, <span class="refDoi"> DOI: 10.1021/jm9700171</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9700171" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3609-3623&author=Y.+Takeuchiauthor=E.+F.+Shandsauthor=D.+D.+Beusenauthor=G.+R.+Marshall&title=Derivation+of+a+three-dimensional+pharmacophore+model+of+substance+P+antagonists+bound+to+the+neurokinin-1+receptor&doi=10.1021%2Fjm9700171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Derivation of a 3-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor</span></div><div class="casAuthors">Takeuchi, Yasuo; Shands, E. F. Berkley; Beusen, Denise D.; Marshall, Garland R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3609-3623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constrained systematic search was used in an exhaustive conformational anal. of a structurally diverse set of substance P (SP) antagonists to identify a unique hypothesis for their bound conformation at the neurokinin-1 receptor.  In this conformation, 2 arom. groups essential for high affinity adopt a perpendicular or edge-on arrangement.  This pharmacophore hypothesis for the receptor-bound conformation was used in a comparative mol. field anal. (CoMFA) of an expanded set of SP antagonists, and the predictive ability of the resulting 3-dimensional quant. structure-activity relationship (3D-QSAR) was evaluated against a test set of SP antagonists different from those in the training set.  This CoMFA model based on the Constrained Search alignment yielded cross-validated, conventional, and predictive r2 values equal to 0.70, 0.93, and 0.82, resp.  For comparison, the SP antagonists were forced into an alternative poorer alignment in which the 2 arom. rings were parallel and then subjected to a CoMFA anal.  Both the parallel and perpendicular arrangements of the arom. rings are seen in x-ray structures of SP antagonists and were proposed as candidates for the receptor-bound conformation.  The parallel (or stacked) conformation yielded a poorer correlation.  The results indicate that although both alignments could generate a reasonable CoMFA correlation, the stacked conformation is unlikely to be the receptor-bound conformation, as the covalent structure of the antagonists precludes a common geometry in which the arom. rings are stacked.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoqyowQ9wK7Vg90H21EOLACvtfcHk0lg1Z02Ei4qCHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1Smsb8%253D&md5=26b04f7ea82804a36ab6a9017a930469</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9700171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9700171%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DY.%26aulast%3DShands%26aufirst%3DE.%2BF.%26aulast%3DBeusen%26aufirst%3DD.%2BD.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26atitle%3DDerivation%2520of%2520a%2520three-dimensional%2520pharmacophore%2520model%2520of%2520substance%2520P%2520antagonists%2520bound%2520to%2520the%2520neurokinin-1%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D3609%26epage%3D3623%26doi%3D10.1021%2Fjm9700171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin1 receptor antagonists possessing two penicillamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5491</span>– <span class="NLM_lpage">5501</span>, <span class="refDoi"> DOI: 10.1021/jm100157m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100157m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ektbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5491-5501&author=T.+Yamamotoauthor=P.+Nairauthor=N.+E.+Jacobsenauthor=V.+Kulkarniauthor=P.+Davisauthor=S.+Maauthor=E.+Navratilovaauthor=H.+I.+Yamamuraauthor=T.+W.+Vanderahauthor=F.+Porrecaauthor=J.+Laiauthor=V.+J.+Hruby&title=Biological+and+conformational+evaluation+of+bifunctional+compounds+for+opioid+receptor+agonists+and+neurokinin1+receptor+antagonists+possessing+two+penicillamines&doi=10.1021%2Fjm100157m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and Conformational Evaluation of Bifunctional Compounds for Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists Possessing Two Penicillamines</span></div><div class="casAuthors">Yamamoto, Takashi; Nair, Padma; Jacobsen, Neil E.; Kulkarni, Vinod; Davis, Peg; Ma, Shou-wu; Navratilova, Edita; Yamamura, Henry I.; Vanderah, Todd W.; Porreca, Frank; Lai, Josephine; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5491-5501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuropathic pain states and tolerance to opioids can result from system changes in the CNS, such as up-regulation of the NK1 receptor and substance P, lead to antiopioid effects in ascending or descending pain-signaling pathways.  Bifunctional compds., possessing both the NK1 antagonist pharmacophore and the opioid agonist pharmacophore with δ-selectivity, could counteract these system changes to have significant analgesic efficacy without undesirable side effects.  As a result of the introduction of cyclic and topol. constraints with penicillamines, Tyr-cyclo[D-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3',5'-(CF3)2-Bzl] (I) was found as the best bifunctional compd. with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold δ-selectivity over the μ-receptor.  The NMR structural anal. of I revealed that the relative positioning of the two connected pharmacophores as well as its cyclic and topol. constraints might be responsible for its excellent bifunctional activities as well as its significant δ-opioid selectivity.  Together with the obsd. high metabolic stability, I could be considered as a valuable research tool and possibly a promising candidate for a novel analgesic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXStfjzinIYrVg90H21EOLACvtfcHk0lg1Z02Ei4qCHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ektbs%253D&md5=786e32725d25cff7fbe2b5c2589da44d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm100157m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100157m%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DJacobsen%26aufirst%3DN.%2BE.%26aulast%3DKulkarni%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DNavratilova%26aufirst%3DE.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DBiological%2520and%2520conformational%2520evaluation%2520of%2520bifunctional%2520compounds%2520for%2520opioid%2520receptor%2520agonists%2520and%2520neurokinin1%2520receptor%2520antagonists%2520possessing%2520two%2520penicillamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5491%26epage%3D5501%26doi%3D10.1021%2Fjm100157m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junicke, H.</span></span> <span> </span><span class="NLM_article-title">Carbohydrate complexes of platinum-group metals</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4283</span>– <span class="NLM_lpage">4317</span>, <span class="refDoi"> DOI: 10.1021/cr9903050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9903050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVamtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=4283-4317&author=D.+Steinbornauthor=H.+Junicke&title=Carbohydrate+complexes+of+platinum-group+metals&doi=10.1021%2Fcr9903050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Carbohydrate Complexes of Platinum-Group Metals</span></div><div class="casAuthors">Steinborn, Dirk; Junicke, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4283-4317</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 263 refs., discusses the prepn. of carbohydrate complexes of platinum-group metals, not including complexes with ligands that contain carbohydrate moieties remote from the ligator atoms, in relation to their mode of coordination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3DeQNIvCx-LVg90H21EOLACvtfcHk0lg1Z02Ei4qCHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVamtL8%253D&md5=d8ec6423e3eef474b7da12c7364cf440</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fcr9903050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9903050%26sid%3Dliteratum%253Aachs%26aulast%3DSteinborn%26aufirst%3DD.%26aulast%3DJunicke%26aufirst%3DH.%26atitle%3DCarbohydrate%2520complexes%2520of%2520platinum-group%2520metals%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D4283%26epage%3D4317%26doi%3D10.1021%2Fcr9903050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Benessere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Litto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Roma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffo, F.</span></span> <span> </span><span class="NLM_article-title">Carbohydrates as building blocks of privileged ligands</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.ccr.2009.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2010&pages=390-401&author=V.+Benessereauthor=R.+Del+Littoauthor=A.+De+Romaauthor=F.+Ruffo&title=Carbohydrates+as+building+blocks+of+privileged+ligands&doi=10.1016%2Fj.ccr.2009.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Carbohydrates as building blocks of privileged ligands</span></div><div class="casAuthors">Benessere, Vincenzo; Del Litto, Raffaella; De Roma, Antonella; Ruffo, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Privileged ligands are chiral auxiliaries of wide applicability in asym. catalysis.  In the previous decades, their effective three-dimensional structures were often reproduced by using building blocks from a chiral pool, such as the carbohydrates.  This strategy provided unique ligand moieties which combine the performance of privileged ligands with increased flexibility and accessibility.  This review gave an overview of the research within this field, giving emphasis to the best results obtained with each ligand type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvddL-_d0Xp7Vg90H21EOLACvtfcHk0lgV_mIqhWByTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLrP&md5=aaa5303aeb7e77022d28712bd36efd21</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DBenessere%26aufirst%3DV.%26aulast%3DDel%2BLitto%26aufirst%3DR.%26aulast%3DDe%2BRoma%26aufirst%3DA.%26aulast%3DRuffo%26aufirst%3DF.%26atitle%3DCarbohydrates%2520as%2520building%2520blocks%2520of%2520privileged%2520ligands%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2010%26volume%3D254%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.ccr.2009.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suárez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Phosphinite thioglygosides as useful ligands for palladium catalyzed asymmetric substitution: synthesis of both enantiomers using natural sugars as catalyst precursors</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">2963</span>– <span class="NLM_lpage">2967</span>, <span class="refDoi"> DOI: 10.1055/s-2005-918963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1055%2Fs-2005-918963" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=2963-2967&author=N.+Khiarauthor=B.+Su%C3%A1rezauthor=V.+Valdiviaauthor=I.+Fern%C3%A1ndez&title=Phosphinite+thioglygosides+as+useful+ligands+for+palladium+catalyzed+asymmetric+substitution%3A+synthesis+of+both+enantiomers+using+natural+sugars+as+catalyst+precursors&doi=10.1055%2Fs-2005-918963"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-918963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-918963%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DB.%26aulast%3DValdivia%26aufirst%3DV.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DPhosphinite%2520thioglygosides%2520as%2520useful%2520ligands%2520for%2520palladium%2520catalyzed%2520asymmetric%2520substitution%253A%2520synthesis%2520of%2520both%2520enantiomers%2520using%2520natural%2520sugars%2520as%2520catalyst%2520precursors%26jtitle%3DSynlett%26date%3D2005%26volume%3D2005%26spage%3D2963%26epage%3D2967%26doi%3D10.1055%2Fs-2005-918963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallouk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soufiaoui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective organocatalytic oxidation of functionalized sterically hindered disulfides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1021/ol070056z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol070056z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1255-1258&author=N.+Khiarauthor=S.+Malloukauthor=V.+Valdiviaauthor=K.+Bougrinauthor=M.+Soufiaouiauthor=I.+Fern%C3%A1ndez&title=Enantioselective+organocatalytic+oxidation+of+functionalized+sterically+hindered+disulfides&doi=10.1021%2Fol070056z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Organocatalytic Oxidation of Functionalized Sterically Hindered Disulfides</span></div><div class="casAuthors">Khiar, Noureddine; Mallouk, Siham; Valdivia, Victoria; Bougrin, Khalid; Soufiaoui, Mohammed; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1255-1258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1st study on enantioselective oxidn. of functionalized sterically hindered disulfides is reported.  The Shi organocatalytic system using carbohydrate-derived ketone with oxone is superior to the Ellman-Bolm vanadium catalyst in terms of chem. yield and enantioselectivity.  Whereas the latter system afforded mostly racemic thiosulfinates in low to moderate yields, the former one afforded thiosulfinates (e.g. S-1-(acetoxymethyl)cyclohexyl 1-(acetoxymethyl)cyclohexanesulfinothioate) with up to 96% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOuYPj0UtPPLVg90H21EOLACvtfcHk0lgV_mIqhWByTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisbw%253D&md5=4572f40f6ac4864339de12266d2bf01e</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1021%2Fol070056z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070056z%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DMallouk%26aufirst%3DS.%26aulast%3DValdivia%26aufirst%3DV.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DSoufiaoui%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DEnantioselective%2520organocatalytic%2520oxidation%2520of%2520functionalized%2520sterically%2520hindered%2520disulfides%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D1255%26epage%3D1258%26doi%3D10.1021%2Fol070056z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelouan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">“Sulfolefin”: highly modular mixed S/olefin ligands for enantioselectve Rh-catalyzed 1,4-addition</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2366</span>– <span class="NLM_lpage">2368</span>, <span class="refDoi"> DOI: 10.1039/c2ob07132k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1039%2Fc2ob07132k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22277929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Ghu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2366-2368&author=N.+Khiarauthor=A.+Salvadorauthor=A.+Chelouanauthor=I.+Fern%C3%A1ndez&title=%E2%80%9CSulfolefin%E2%80%9D%3A+highly+modular+mixed+S%2Folefin+ligands+for+enantioselectve+Rh-catalyzed+1%2C4-addition&doi=10.1039%2Fc2ob07132k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29cR"><div class="casContent"><span class="casTitleNuber">29c</span><div class="casTitle"><span class="NLM_cas:atitle">"Sulfolefin": Highly modular mixed S/Olefin ligands for enantioselective Rh-catalyzed 1,4-addition</span></div><div class="casAuthors">Khiar, Noureddine; Salvador, Alvaro; Chelouan, Ahmed; Alcudia, Ana; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2366-2368</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Reported is a single high yielding step approxn. to mixed olefin/sulfinamide ligands enclosing a chiral sulfur atom as the sole chiral center.  The synthetic design is validated by a rapid optimization of the substituent at the sulfinyl sulfur, and by the synthesis of an efficient, highly enantioselective catalyst for the Rh-catalyzed 1,4-addn. of boronic acids to both, cyclic and acyclic olefins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGbjtq3m85LVg90H21EOLACvtfcHk0lgV_mIqhWByTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Ghu78%253D&md5=7e1a42ef46c58d7f15274c94e29b5cb0</span></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1039%2Fc2ob07132k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob07132k%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DSalvador%26aufirst%3DA.%26aulast%3DChelouan%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3D%25E2%2580%259CSulfolefin%25E2%2580%259D%253A%2520highly%2520modular%2520mixed%2520S%252Folefin%2520ligands%2520for%2520enantioselectve%2520Rh-catalyzed%25201%252C4-addition%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D2366%26epage%3D2368%26doi%3D10.1039%2Fc2ob07132k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Assali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span> <span> </span><span class="NLM_article-title">Supramolecular diversity through click chemistry: switching from nanomicelles to 1D nanotubes and tridimensional hydrogels</span>. <i>Chem. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4250</span>– <span class="NLM_lpage">4261</span>, <span class="refDoi"> DOI: 10.1021/cm4022613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cm4022613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGkurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=4250-4261&author=M.+Assaliauthor=J.-J.+Cidauthor=I.+Fern%C3%A1ndezauthor=N.+Khiar&title=Supramolecular+diversity+through+click+chemistry%3A+switching+from+nanomicelles+to+1D+nanotubes+and+tridimensional+hydrogels&doi=10.1021%2Fcm4022613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29dR"><div class="casContent"><span class="casTitleNuber">29d</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular Diversity through Click Chemistry: Switching from Nanomicelles to 1D-Nanotubes and Tridimensional Hydrogels</span></div><div class="casAuthors">Assali, Mohyeddin; Cid, Juan-Jose; Fernandez, Inmaculada; Khiar, Noureddine</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Materials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4250-4261</span>CODEN:
                <span class="NLM_cas:coden">CMATEX</span>;
        ISSN:<span class="NLM_cas:issn">0897-4756</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The size and shape of nanoparticles are of prominent importance for their biol. activities and for their application as smart drug delivery systems.  Thus, synthetic designs allowing divergent synthesis of nanoscale materials with controlled size, morphol., and surface chem. are currently highly desirable, but they remain a major challenge.  Herein, we report a simple method for the creation of supramol. diversity from structurally related diacetylenic-based glycolipids.  We have found that neoglycolipids with an amide function between the hydrophilic and hydrophobic part of the amphiphile afford tridimensional micelles, while those having a triazole self-organize into 1D-nanotubes.  Addnl., at higher concns., the clicked amphiphiles form hydrogels through three-dimensional networks of bundled nanotubes.  Photopolymn. of the obtained nanomaterials leads to the formation of conjugated polydiacetylene backbone of alternating enyne groups, which rigidify glyconanomaterial structures enhancing their phys. stability.  The obtained nanostructures were extensively characterized using transmission electron microscopy (TEM), SEM, and at. force microscopy (AFM) techniques, enabling the confirmation of the formation of tubular structures in water for all triazolo-substituted neoglycolipids and micellar structures for the glycolipid contg. an amide group.  This fact refutes the so-called isosteric character of 1,2,3-triazole and amide groups, at least, at the supramol. level and point out to the possibility of using the CuAAC between azides and alkynes to create supramol. diversity at the nanoscale.  The functionality of the gel was, moreover, evaluated as a nanocontainer for the incarceration and controlled release of the antitumoral topotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWE9llsGxFLVg90H21EOLACvtfcHk0ljXoE6zM4M-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGkurnL&md5=101f71dd222a4ba1a995ef8bb6755f6f</span></div><a href="/servlet/linkout?suffix=cit29d&amp;dbid=16384&amp;doi=10.1021%2Fcm4022613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcm4022613%26sid%3Dliteratum%253Aachs%26aulast%3DAssali%26aufirst%3DM.%26aulast%3DCid%26aufirst%3DJ.-J.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26aulast%3DKhiar%26aufirst%3DN.%26atitle%3DSupramolecular%2520diversity%2520through%2520click%2520chemistry%253A%2520switching%2520from%2520nanomicelles%2520to%25201D%2520nanotubes%2520and%2520tridimensional%2520hydrogels%26jtitle%3DChem.%2520Mater.%26date%3D2013%26volume%3D25%26spage%3D4250%26epage%3D4261%26doi%3D10.1021%2Fcm4022613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiviriga, I.</span></span> <span> </span><span class="NLM_article-title">Selective excitation 1D-NMR experiments for the assignement of the absolute configuration of secondary alcohols</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">3978</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1021/jo3003375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo3003375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=3978-3985&author=I.+Ghiviriga&title=Selective+excitation+1D-NMR+experiments+for+the+assignement+of+the+absolute+configuration+of+secondary+alcohols&doi=10.1021%2Fjo3003375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Excitation 1D-NMR Experiments for the Assignment of the Absolute Configuration of Secondary Alcohols</span></div><div class="casAuthors">Ghiviriga, Ion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3978-3985</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Routine selective excitation expts., easy to set up on modern NMR spectrometers, allow for the detn. of the abs. configuration of chiral secondary alcs. by double derivatization directly in the NMR tube.  As a general method, TOCSY1D with selective excitation of the α proton in the MPA esters and with a short mixing time reveals only the nearby protons in the coupling network.  Typically, the anal. takes less than 30 min.  A longer mixing time, selective excitation of other signals, or NOESY1D expts. can be used for measuring ΔδRS of other protons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPP0DPdXIL7Vg90H21EOLACvtfcHk0ljXoE6zM4M-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVWksrc%253D&md5=3fd8b819eaa16c15bc606cad90a3d86a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo3003375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo3003375%26sid%3Dliteratum%253Aachs%26aulast%3DGhiviriga%26aufirst%3DI.%26atitle%3DSelective%2520excitation%25201D-NMR%2520experiments%2520for%2520the%2520assignement%2520of%2520the%2520absolute%2520configuration%2520of%2520secondary%2520alcohols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D3978%26epage%3D3985%26doi%3D10.1021%2Fjo3003375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer ancer</span>. <i>Sci. World J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>, <span class="NLM_elocation-id">381434</span> <span class="refDoi"> DOI: 10.1100/2012/381434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1100%2F2012%2F381434" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&author=M.+Rossoauthor=M.+Mu%C3%B1ozauthor=M.+Berger&title=The+role+of+neurokinin-1+receptor+in+the+microenvironment+of+inflammation+and+cancer+ancer&doi=10.1100%2F2012%2F381434"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1100%2F2012%2F381434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1100%252F2012%252F381434%26sid%3Dliteratum%253Aachs%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520neurokinin-1%2520receptor%2520in%2520the%2520microenvironment%2520of%2520inflammation%2520and%2520cancer%2520ancer%26jtitle%3DSci.%2520World%2520J.%26date%3D2012%26volume%3D2012%26doi%3D10.1100%2F2012%2F381434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Armesto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.697153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2012.697153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22697287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=735-746&author=M.+Mu%C3%B1ozauthor=J.+Martinez-Armestoauthor=R.+Cove%C3%B1as&title=NK-1+receptor+antagonists+as+antitumor+drugs%3A+a+survey+of+the+literature+from+2000+to+2011&doi=10.1517%2F13543776.2012.697153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span></div><div class="casAuthors">Munoz, Miguel; Martinez-Armesto, Juan; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-746</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: After binding to the neurokinin (NK-1) receptor, substance P (SP) induces tumor cell proliferation, the migration of tumor cells (invasion and metastasis) and angiogenesis.  By contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells and exert antiangiogenic properties.Areas covered: This review offers a 12-yr overview of the underlying mechanism of the action of the SP/NK-1 receptor system and NK-1 receptor antagonists in cancer, providing a new approach to the treatment of tumors.Expert opinion: Chem. diverse NK-1 receptor antagonists have been identified.  The antitumor action of these compds. is independent of their chem. structures and such action is assocd. with their affinity for the NK-1 receptor and with the dose of the antagonist administered.  The NK-1 receptor can be considered as a target in cancer treatment and NK-1 receptor antagonists could be considered as new antitumor drugs.  The NK-1 receptor antagonist aprepitant is used in clin. practice and exerts an antitumor action against tumor cells in vitro.  In the future, such antitumor action should be tested in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowJRmIy_bZ7Vg90H21EOLACvtfcHk0ljXoE6zM4M-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D&md5=8e5b53c6b90cac0e5144cc1f448d178b</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.697153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.697153%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMartinez-Armesto%26aufirst%3DJ.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DNK-1%2520receptor%2520antagonists%2520as%2520antitumor%2520drugs%253A%2520a%2520survey%2520of%2520the%2520literature%2520from%25202000%2520to%25202011%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D735%26epage%3D746%26doi%3D10.1517%2F13543776.2012.697153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, P. R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting</span>. <i>J. Adv. Pharm. Technol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.4103/2231-4040.104710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.4103%2F2231-4040.104710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23378940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ylt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=202-209&author=P.+R.+Bhandari&title=Recent+advances+in+pharmacotherapy+of+chemotherapy-induced+nausea+and+vomiting&doi=10.4103%2F2231-4040.104710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31cR"><div class="casContent"><span class="casTitleNuber">31c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Bhandari, Prasan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Pharmaceutical Technology & Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JAPTDW</span>;
        ISSN:<span class="NLM_cas:issn">0976-2094</span>.
    
            (<span class="NLM_cas:orgname">Society of Pharmaceutical Education & Research</span>)
        </div><div class="casAbstract">A review.  Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients.  Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV).  During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV and resulted in more effective and better tolerated treatment of CINV.  Despite recent progress, however, a significant no. of patients still develop CINV, particularly during the 2-5-day period (delayed emesis) following chemotherapy.  There is evidence that this may be an underappreciated problem on the part of some caregivers.  Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory approval in the U.S.  Both represent useful addns. to the therapeutic armamentarium for the management of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDefAVYtNjLVg90H21EOLACvtfcHk0lgmLYHnpDxaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ylt7c%253D&md5=fd4c8ae3e3b9dec61d1a68618e91d5fd</span></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=10.4103%2F2231-4040.104710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2231-4040.104710%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DP.%2BR.%26atitle%3DRecent%2520advances%2520in%2520pharmacotherapy%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DJ.%2520Adv.%2520Pharm.%2520Technol.%2520Res.%26date%3D2012%26volume%3D3%26spage%3D202%26epage%3D209%26doi%3D10.4103%2F2231-4040.104710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Frias, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carranza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas-Martín, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2012.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.peptides.2012.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23026680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqtrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=318-325&author=M.+Mu%C3%B1ozauthor=A.+Gonz%C3%A1lez-Ortegaauthor=M.+Rossoauthor=M.+J.+Robles-Friasauthor=A.+Carranzaauthor=M.+V.+Salinas-Mart%C3%ADnauthor=R.+Cove%C3%B1as&title=The+substance+P%2Fneurokinin-1+receptor+system+in+lung+cancer%3A+focus+on+the+antitumor+action+of+neurokinin-1+receptor+antagonists&doi=10.1016%2Fj.peptides.2012.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31dR"><div class="casContent"><span class="casTitleNuber">31d</span><div class="casTitle"><span class="NLM_cas:atitle">The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists</span></div><div class="casAuthors">Munoz, Miguel; Gonzalez-Ortega, Ana; Rosso, Marisa; Robles-Frias, Maria Jose; Carranza, Andres; Salinas-Martin, Manuel Vicente; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-325</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies.  The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists resp. induce cell proliferation and inhibition in human cancer cell lines.  No study of the involvement of this system in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells has been carried out in depth.  Here, we demonstrate the involvement of the SP/NK-1R system in human H-69 (SCLC) and COR-L23 (NSCLC) cell lines: (1) they express isoforms of the NK-1R and mRNA for the NK-1R; (2) they overexpress the tachykinin 1 gene; (3) the NK-1R is involved in their viability; (4) SP induces their proliferation; (5) NK-1R antagonists (Aprepitant (Emend), L-733,060, L-732,138) inhibit the growth of both cell lines in a concn.-dependent manner; (6) the specific antitumor action of these antagonists against such cells occurs through the NK-1R; and (7) lung cancer cell death is due to apoptosis.  We also demonstrate the presence of NK-1Rs and SP in all the human SCLC and NSCLC samples studied.  Our findings indicate that the NK-1R may be a promising new target in the treatment of lung cancer and that NK-1R antagonists could be new candidate antitumor drugs in the treatment of SCLC and NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQD9pYl1S5oLVg90H21EOLACvtfcHk0lgmLYHnpDxaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqtrjJ&md5=ba76e14b8c79524a994d31c593e50bad</span></div><a href="/servlet/linkout?suffix=cit31d&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2012.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2012.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DGonz%25C3%25A1lez-Ortega%26aufirst%3DA.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DRobles-Frias%26aufirst%3DM.%2BJ.%26aulast%3DCarranza%26aufirst%3DA.%26aulast%3DSalinas-Mart%25C3%25ADn%26aufirst%3DM.%2BV.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DThe%2520substance%2520P%252Fneurokinin-1%2520receptor%2520system%2520in%2520lung%2520cancer%253A%2520focus%2520on%2520the%2520antitumor%2520action%2520of%2520neurokinin-1%2520receptor%2520antagonists%26jtitle%3DPeptides%26date%3D2012%26volume%3D38%26spage%3D318%26epage%3D325%26doi%3D10.1016%2Fj.peptides.2012.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamarriego, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, R.</span></span> <span> </span><span class="NLM_article-title">Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines</span>. <i>Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1097/01.cmr.0000129376.22141.a3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1097%2F01.cmr.0000129376.22141.a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=15179186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksF2ls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=183-188&author=M.+Mu%C3%B1ozauthor=A.+P%C3%A9rezauthor=M.+Rossoauthor=C.+Zamarriegoauthor=R.+Rosso&title=Antitumoral+action+of+the+neurokinin-1+receptor+antagonist+L-733+060+on+human+melanoma+cell+lines&doi=10.1097%2F01.cmr.0000129376.22141.a3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31eR"><div class="casContent"><span class="casTitleNuber">31e</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines</span></div><div class="casAuthors">Munoz, Miguel; Perez, Ana; Rosso, Marisa; Zamarriego, Carmen; Rosso, Rosario</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Melanoma represents 1% of all cancers and accounts for approx. 65% of skin cancer deaths.  At present, effective treatment does not exist.  Substance P (SP) is a neuropeptide expressed in invasive malignant melanomas.  We studied the in vitro growth inhibitory capacity of the potent and long-acting neurokinin-1 (NK1) receptor antagonist L-733 060 at concn. ranges of 2.5-20 μM, 10-30 μM and 20-50 μM in the melanoma cell lines COLO 858, MEL H0 and COLO 679, resp.  A Coulter counter was used to det. the no. of viable cells, and the tetrazolium compd. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) colorimetric method was used to evaluate cell proliferation.  L-733 060 inhibited the growth of all three cell lines in a dose-dependent manner.  The 50% inhibition concn. (IC50) was 8.7 μM at 48 h and 7.1 μM at 96 h for COLO 858, 27.5 μM at 24 h and 18.9 μM at 48 h for MEL H0, and 33.8 μM at 30 h and 31.5 μM at 72 h for COLO 679.  These findings indicate that the NK1 receptor antagonist L-733 060 acts as an antitumoral agent.  This action, shown here for the first time, suggests that the NK1 receptor antagonist L-733 060 could be a promising therapeutic drug in the treatment of the human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5t5MWNKifLVg90H21EOLACvtfcHk0lgmLYHnpDxaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksF2ls7o%253D&md5=d8e429a30fd3dea1cc058e5b7f697470</span></div><a href="/servlet/linkout?suffix=cit31e&amp;dbid=16384&amp;doi=10.1097%2F01.cmr.0000129376.22141.a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cmr.0000129376.22141.a3%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DA.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DZamarriego%26aufirst%3DC.%26aulast%3DRosso%26aufirst%3DR.%26atitle%3DAntitumoral%2520action%2520of%2520the%2520neurokinin-1%2520receptor%2520antagonist%2520L-733%2520060%2520on%2520human%2520melanoma%2520cell%2520lines%26jtitle%3DMelanoma%2520Res.%26date%3D2004%26volume%3D14%26spage%3D183%26epage%3D188%26doi%3D10.1097%2F01.cmr.0000129376.22141.a3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nizam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köksoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erin, N.</span></span> <span> </span><span class="NLM_article-title">NK1R Antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1007/s00262-020-02574-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs00262-020-02574-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32322911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2020&pages=1639-1650&author=E.+Nizamauthor=S.+K%C3%B6ksoyauthor=N.+Erin&title=NK1R+Antagonist+decreases+inflammation+and+metastasis+of+breast+carcinoma+cells+metastasized+to+liver+but+not+to+brain%3B+phenotype-dependent+therapeutic+and+toxic+consequences&doi=10.1007%2Fs00262-020-02574-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31fR"><div class="casContent"><span class="casTitleNuber">31f</span><div class="casTitle"><span class="NLM_cas:atitle">NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences</span></div><div class="casAuthors">Nizam, Esra; Koksoy, Sadi; Erin, Nuray</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1639-1650</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Substance P a neuro-immune mediator acts on Neurokinin-1 and -2 receptors (NK1R and NK2R).  Inhibitors of NK1R are considered to be safe and effective approaches for cancer treatment since Aprepitant, a non-peptide antagonist of NK1R is widely used for chemotherapy-induced emesis and has cytotoxic and antitumor effects in various models for cancer.  On the other hand, our previous findings demonstrated that systemic inhibition of NK1R may decrease cytotoxic anti-tumoral immune response.  Hence, actual consequences of inhibition of neurokinin receptors under in vivo conditions in a syngeneic model of carcinoma should be detd.  The effects of highly potent and selective non-peptide mouse NK1R and NK2R antagonists RP 67580 and GR 159897, resp., on metastatic breast carcinoma were evaluated.  Specifically, 4T1 breast cancer cells metastasized to brain (denoted as 4TBM) and liver (denoted as 4TLM) were used to induce tumors in Balb-c mice.  Changes in tumor growth, metastasis and immune response to cancer cells were detd.  We here obsd. differential effects of NK1R antagonist depended on the subset of metastatic cells.  Specifically, inhibition of NK1R markedly increased liver metastasis of tumors formed by 4TBM but not 4TLM cells.  On the contrary, NK1R antagonist decreased inflammatory response and liver metastasis in 4TLM-injected mice. 4TLM tumors act more aggressively inducing more inflammatory response compared to 4TBM tumors.  Hence, differential effects of NK1R antagonist are at least partly due to extend and type of the inflammatory response evoked by specific subset metastatic cells.  These findings demonstrate the necessity for understanding the immunol. consequences of tumor-microenvironment interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCJt0jZ81PLVg90H21EOLACvtfcHk0lgmLYHnpDxaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSitrY%253D&md5=0b19bf97cd7db8bcecd43722de837d25</span></div><a href="/servlet/linkout?suffix=cit31f&amp;dbid=16384&amp;doi=10.1007%2Fs00262-020-02574-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-020-02574-z%26sid%3Dliteratum%253Aachs%26aulast%3DNizam%26aufirst%3DE.%26aulast%3DK%25C3%25B6ksoy%26aufirst%3DS.%26aulast%3DErin%26aufirst%3DN.%26atitle%3DNK1R%2520Antagonist%2520decreases%2520inflammation%2520and%2520metastasis%2520of%2520breast%2520carcinoma%2520cells%2520metastasized%2520to%2520liver%2520but%2520not%2520to%2520brain%253B%2520phenotype-dependent%2520therapeutic%2520and%2520toxic%2520consequences%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2020%26volume%3D69%26spage%3D1639%26epage%3D1650%26doi%3D10.1007%2Fs00262-020-02574-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">19635</span>– <span class="NLM_lpage">19645</span>, <span class="refDoi"> DOI: 10.1073/pnas.1908998116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1908998116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31488714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGnsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=19635-19645&author=C.+Geauthor=H.+Huangauthor=F.+Huangauthor=T.+Yangauthor=T.+Zhangauthor=H.+Wuauthor=H.+Zhouauthor=Q.+Chenauthor=Y.+Shiauthor=Y.+Sunauthor=L.+Liuauthor=X.+Wangauthor=R.+B.+Pearsonauthor=Y.+Caoauthor=J.+Kangauthor=C.+Fu&title=Neurokinin-1+receptor+is+an+effective+target+for+treating+leukemia+by+inducing+oxidative+stress+through+mitochondrial+calcium+overload&doi=10.1073%2Fpnas.1908998116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31gR"><div class="casContent"><span class="casTitleNuber">31g</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload</span></div><div class="casAuthors">Ge, Chentao; Huang, Hemiao; Huang, Feiyan; Yang, Tianxin; Zhang, Tengfei; Wu, Hongzhang; Zhou, Hanwei; Chen, Qi; Shi, Yue; Sun, Yanfang; Liu, Liangjue; Wang, Xi; Pearson, Richard B.; Cao, Yihai; Kang, Jian; Fu, Caiyun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">19635-19645</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Substance P (SP) regulates multiple biol. processes through its high-affinity neurokinin-1 receptor (NK-1R).  While the SP/NK-1R signaling axis is involved in the pathogenesis of solid cancer, the role of this signaling pathway in hematol. malignancy remains unknown.  Here, we demonstrate that NK-1R expression is markedly elevated in the white blood cells from acute myeloid leukemia patients and a panel of human leukemia cell lines.  Blocking NK-1R induces apoptosis in vitro and in vivo via increase of mitochondrial reactive oxygen species.  This oxidative stress was triggered by rapid calcium flux from the endoplasmic reticulum into mitochondria and, consequently, impairment of mitochondrial function, a mechanism underlying the cytotoxicity of NK-1R antagonists.  Besides anticancer activity, blocking NK-1R produces a potent antinociceptive effect in myeloid leukemia-induced bone pain by alleviating inflammation and inducing apoptosis.  These findings thus raise the exciting possibility that the NK-1R antagonists, drugs currently used in the clinic for preventing chemotherapy-induced nausea and vomiting, may provide a therapeutic option for treating human myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1nwfHbyI_rVg90H21EOLACvtfcHk0lgLx3uU4FpBjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGnsr%252FO&md5=9dddf3fe0b2a9456ba4f1b479b334f8d</span></div><a href="/servlet/linkout?suffix=cit31g&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1908998116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1908998116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPearson%26aufirst%3DR.%2BB.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DC.%26atitle%3DNeurokinin-1%2520receptor%2520is%2520an%2520effective%2520target%2520for%2520treating%2520leukemia%2520by%2520inducing%2520oxidative%2520stress%2520through%2520mitochondrial%2520calcium%2520overload%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D19635%26epage%3D19645%26doi%3D10.1073%2Fpnas.1908998116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi Avval, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-KB signal transduction pathways</span>. <i>Mol. Biol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2253</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1007/s11033-020-05330-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs11033-020-05330-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32072401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=2253-2263&author=H.+Javidauthor=J.+Asadiauthor=F.+Zahedi+Avvalauthor=A.+R.+Afshariauthor=S.+I.+Hashemy&title=The+role+of+substance+P%2Fneurokinin+1+receptor+in+the+pathogenesis+of+esophageal+squamous+cell+carcinoma+through+constitutively+active+PI3K%2FAkt%2FNF-KB+signal+transduction+pathways&doi=10.1007%2Fs11033-020-05330-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31hR"><div class="casContent"><span class="casTitleNuber">31h</span><div class="casTitle"><span class="NLM_cas:atitle">The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways</span></div><div class="casAuthors">Javid, Hossein; Asadi, Jahanbakhsh; Zahedi Avval, Farnaz; Afshari, Amir R.; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2253-2263</span>CODEN:
                <span class="NLM_cas:coden">MLBRBU</span>;
        ISSN:<span class="NLM_cas:issn">0301-4851</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: One of the most prevalent malignancies is esophageal squamous cell carcinoma (ESCC), which is assocd. with high morbidity and mortality.  Substance P (SP), as one of the peptides released from sensory nerves, causes the enhancement of cellular excitability through the activation of the neurokinin-1 (NK1) receptor in several human tumor cells.  Aprepitant, a specific, potent, and long-acting NK1 receptor antagonist, is considered as a novel agent to inhibit proliferation and induce apoptosis in malignant cells.  Since the antitumor mechanism of aprepitant in ESCC is not completely understood, we conducted this study and found that aprepitant induced growth inhibition of KYSE-30 cells and arrested cells in the G2/M phase of the cell cycle.  Aprepitant also caused apoptotic cell death and inhibited activation of the PI3K/Akt axis and its downstream effectors, including NF-κB in KYSE-30 cells.  Besides, quant. real-time (qRT)-PCR anal. showed a significant down-regulation of NF-κB target genes in KYSE-30 cells, indicating a probable NF-κB-dependent mechanism involved in aprepitant cytotoxicity.  Thus, the present study recommends that SP/NK1R system might, therefore, be considered as an emerging and promising therapeutic strategy against ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrshOSiT5N4JLVg90H21EOLACvtfcHk0lgLx3uU4FpBjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlagtLw%253D&md5=33f1390918235c19523bbc845d3c4b45</span></div><a href="/servlet/linkout?suffix=cit31h&amp;dbid=16384&amp;doi=10.1007%2Fs11033-020-05330-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-020-05330-9%26sid%3Dliteratum%253Aachs%26aulast%3DJavid%26aufirst%3DH.%26aulast%3DAsadi%26aufirst%3DJ.%26aulast%3DZahedi%2BAvval%26aufirst%3DF.%26aulast%3DAfshari%26aufirst%3DA.%2BR.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DThe%2520role%2520of%2520substance%2520P%252Fneurokinin%25201%2520receptor%2520in%2520the%2520pathogenesis%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%2520through%2520constitutively%2520active%2520PI3K%252FAkt%252FNF-KB%2520signal%2520transduction%2520pathways%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2020%26volume%3D47%26spage%3D2253%26epage%3D2263%26doi%3D10.1007%2Fs11033-020-05330-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Faps.2016.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27374491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1013-1019&author=X.-S.+Chenauthor=L.-Y.+Liauthor=Y.+Guanauthor=J.-M.+Yangauthor=Y.+Cheng&title=Anticancer+strategies+based+on+the+metabolic+profile+of+tumor+cells%3A+therapeutic+targeting+of+the+Warburg+effect&doi=10.1038%2Faps.2016.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect</span></div><div class="casAuthors">Chen, Xi-sha; Li, Lan-ya; Guan, Yi-di; Yang, Jin-ming; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1013-1019</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor cells rely mainly on glycolysis for energy prodn. even in the presence of sufficient oxygen, a phenomenon termed the Warburg effect, which is the most outstanding characteristic of energy metab. in cancer cells.  This metabolic adaptation is believed to be crit. for tumor cell growth and proliferation, and a no. of onco-proteins and tumor suppressors, including the PI3K/Akt/mTOR signaling pathway, Myc, hypoxia-inducible factor and p53, are involved in the regulation of this metabolic adaptation.  Moreover, glycolytic cancer cells are often invasive and impervious to therapeutic intervention.  Thus, altered energy metab. is now appreciated as a hallmark of cancer and a promising target for cancer treatment.  A better understanding of the biol. and the regulatory mechanisms of aerobic glycolysis has the potential to facilitate the development of glycolysis-based therapeutic interventions for cancer.  In addn., glycolysis inhibition combined with DNA damaging drugs or chemotherapeutic agents may be effective anticancer strategies through weakening cell damage repair capacity and enhancing drug cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9rTu0uo_ITLVg90H21EOLACvtfcHk0lgLx3uU4FpBjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KlsrrF&md5=1fa5b2846aaa68ee82282ec5999f3027</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.47%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-S.%26aulast%3DLi%26aufirst%3DL.-Y.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.-M.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DAnticancer%2520strategies%2520based%2520on%2520the%2520metabolic%2520profile%2520of%2520tumor%2520cells%253A%2520therapeutic%2520targeting%2520of%2520the%2520Warburg%2520effect%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D1013%26epage%3D1019%26doi%3D10.1038%2Faps.2016.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adalsteinsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peress, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldenfels, J.</span></span> <span> </span><span class="NLM_article-title">Case report: sodium dichloroacetate (DCA) inhibition of the “Warburg effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1007/s10863-012-9496-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs10863-012-9496-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23263938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFKrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=307-315&author=S.+B.+Strumauthor=O.+Adalsteinssonauthor=R.+R.+Blackauthor=D.+Segalauthor=N.+L.+Peressauthor=J.+Waldenfels&title=Case+report%3A+sodium+dichloroacetate+%28DCA%29+inhibition+of+the+%E2%80%9CWarburg+effect%E2%80%9D+in+a+human+cancer+patient%3A+complete+response+in+non-Hodgkin%E2%80%99s+lymphoma+after+disease+progression+with+rituximab-CHOP&doi=10.1007%2Fs10863-012-9496-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Case Report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP</span></div><div class="casAuthors">Strum, Stephen B.; Adalsteinsson, Oern; Black, Richard R.; Segal, Dmitri; Peress, Nancy L.; Waldenfels, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-315</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The uptake of fluorodeoxyglucose Positron Emission Tomog. in the tumors of various cancer types demonstrates the key role of glucose in the proliferation of cancer.  Dichloroacetate is a 2-carbon mol. having crucial biol. activity in altering the metabolic breakdown of glucose to lactic acid.  Human cell line studies show that dichloroacetate switches alter the metabolomics of the cancer cell from one of glycolysis to oxidative phosphorylation, and in doing so restore mitochondrial functions that trigger apoptosis of the cancer cell.  Reports of dichloroacetate in human subjects are rare.  The authors contacted individuals from Internet forums who had reported outstanding anti-cancer responses to self-medication with dichloroacetate.  With informed consent, complete medical records were requested to document response to dichloroacetate, emphasizing the context of monotherapy with dichloroacetate.  Of ten patients agreeing to such an evaluation, only one met the criteria of having comprehensive clinic records as well as pathol., imaging and lab. reports, along with single agent therapy with dichloroacetate.  That individual is the focus of this report.  In this case report of a man with documented relapse after state-of-the-art chemotherapy for non-Hodgkin's lymphoma, a significant response to dichloroacetate is documented with a complete remission, which remains ongoing after 4 years.  Dichloroacetate appears to be a novel therapy warranting further investigation in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBHinMTOHfVLVg90H21EOLACvtfcHk0lj16ktSO6UfAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFKrurc%253D&md5=e61de6bd2a9976a3333569a5518d026a</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1007%2Fs10863-012-9496-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-012-9496-2%26sid%3Dliteratum%253Aachs%26aulast%3DStrum%26aufirst%3DS.%2BB.%26aulast%3DAdalsteinsson%26aufirst%3DO.%26aulast%3DBlack%26aufirst%3DR.%2BR.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPeress%26aufirst%3DN.%2BL.%26aulast%3DWaldenfels%26aufirst%3DJ.%26atitle%3DCase%2520report%253A%2520sodium%2520dichloroacetate%2520%2528DCA%2529%2520inhibition%2520of%2520the%2520%25E2%2580%259CWarburg%2520effect%25E2%2580%259D%2520in%2520a%2520human%2520cancer%2520patient%253A%2520complete%2520response%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520after%2520disease%2520progression%2520with%2520rituximab-CHOP%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2013%26volume%3D45%26spage%3D307%26epage%3D315%26doi%3D10.1007%2Fs10863-012-9496-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.2174/187152008783961932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F187152008783961932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=18393789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BD1c3jsFChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=305-312&author=M.+L%C3%B3pez-L%C3%A1zaro&title=The+Warburg+effect%3A+why+and+how+do+cancer+cells+activate+glycolysis+in+the+presence+of+oxygen%3F&doi=10.2174%2F187152008783961932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-12</span>
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    </div><div class="casAbstract">Cells can obtain energy through the oxygen-dependent pathway of oxidative phosphorylation (OXPHOS) and through the oxygen-independent pathway of glycolysis.  Since OXPHOS is more efficient in generating ATP than glycolysis, it is recognized that the presence of oxygen results in the activation of OXPHOS and the inhibition of glycolysis (Pasteur effect).  However, it has been known for many years that cancer cells and non-malignant proliferating cells can activate glycolysis in the presence of adequate oxygen levels (aerobic glycolysis or Warburg effect).  Accumulating evidence suggests that the persistent activation of aerobic glycolysis in tumor cells plays a crucial role in cancer development; the inhibition of the increased glycolytic capacity of malignant cells may therefore represent a key anticancer strategy.  Although some important knowledge has been gained in the last few years on this growing field of research, the basis of the Warburg effect still remains poorly understood.  This communication analyzes why cancer cells switch from OXPHOS to glycolysis in the presence of adequate oxygen levels, and how these cells manage to avoid the inhibition of glycolysis induced by oxygen.  Several strategies and drugs that may interfere with the glycolytic metabolism of cancer cells are also shown.  This information may help develop anticancer approaches that may have clinical relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHC2sBl7F214kFb3mqPUYDfW6udTcc2eaiVSGlFxpZALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3jsFChtQ%253D%253D&md5=4313e8e840d2821297ad27772876de88</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.2174%2F187152008783961932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008783961932%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DThe%2520Warburg%2520effect%253A%2520why%2520and%2520how%2520do%2520cancer%2520cells%2520activate%2520glycolysis%2520in%2520the%2520presence%2520of%2520oxygen%253F%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D305%26epage%3D312%26doi%3D10.2174%2F187152008783961932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Cordero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon-Gonzalez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon-Montano, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Moron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lazaro, M.</span></span> <span> </span><span class="NLM_article-title">Pro-oxidant natural products as anticancer agents</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.2174/138945012802009044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F138945012802009044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22594470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGmu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1006-1028&author=C.+Martin-Corderoauthor=A.+J.+Leon-Gonzalezauthor=J.+M.+Calderon-Montanoauthor=E.+Burgos-Moronauthor=M.+Lopez-Lazaro&title=Pro-oxidant+natural+products+as+anticancer+agents&doi=10.2174%2F138945012802009044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Pro-oxidant natural products as anticancer agents</span></div><div class="casAuthors">Martin-Cordero, Carmen; Leon-Gonzalez, Antonio Jose; Calderon-Montano, Jose Manuel; Burgos-Moron, Estefania; Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1006-1028</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer cells produce high levels of reactive oxygen species (ROS) that lead to a state of increased basal oxidative stress.  Since this state of oxidative stress makes cancer cells vulnerable to agents that further augment ROS levels, the use of pro-oxidant agents is emerging as an exciting strategy to selectively target tumor cells.  Natural products have provided a significant contribution to the development of several drugs currently used in cancer chemotherapy.  Although many natural products are known to affect the redox state of the cell, most studies on these compds. have focused on their antioxidant activity instead of on their pro-oxidant properties.  This article provides an overview of natural products with pro-oxidant and anticancer activities, with special focus on plant secondary metabolites, and discusses their possible use as cancer chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBjHSp5_aZ7Vg90H21EOLACvtfcHk0lj16ktSO6UfAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGmu7jO&md5=f819ac481cc8152416d5c6971d5c6594</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.2174%2F138945012802009044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945012802009044%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Cordero%26aufirst%3DC.%26aulast%3DLeon-Gonzalez%26aufirst%3DA.%2BJ.%26aulast%3DCalderon-Montano%26aufirst%3DJ.%2BM.%26aulast%3DBurgos-Moron%26aufirst%3DE.%26aulast%3DLopez-Lazaro%26aufirst%3DM.%26atitle%3DPro-oxidant%2520natural%2520products%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2012%26volume%3D13%26spage%3D1006%26epage%3D1028%26doi%3D10.2174%2F138945012802009044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galadari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallichankandy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayyullathil, F.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species and cancer paradox: to promote or to suppress?</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2017.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.freeradbiomed.2017.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28088622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ahs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2017&pages=144-164&author=S.+Galadariauthor=A.+Rahmanauthor=S.+Pallichankandyauthor=F.+Thayyullathil&title=Reactive+oxygen+species+and+cancer+paradox%3A+to+promote+or+to+suppress%3F&doi=10.1016%2Fj.freeradbiomed.2017.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species and cancer paradox: To promote or to suppress?</span></div><div class="casAuthors">Galadari, Sehamuddin; Rahman, Anees; Pallichankandy, Siraj; Thayyullathil, Faisal</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-164</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reactive oxygen species (ROS), a group of highly reactive ions and mols., are increasingly being appreciated as powerful signaling mols. involved in the regulation of a variety of biol. processes.  Indeed, their role is continuously being delineated in a variety of pathophysiol. conditions.  For instance, cancer cells are shown to have increased ROS levels in comparison to their normal counterparts.  This is partly due to an enhanced metab. and mitochondrial dysfunction in cancer cells.  The escalated ROS generation in cancer cells contributes to the biochem. and mol. changes necessary for the tumor initiation, promotion and progression, as well as, tumor resistance to chemotherapy.  Therefore, increased ROS in cancer cells may provide a unique opportunity to eliminate cancer cells via elevating ROS to highly toxic levels intracellularly, thereby, activating various ROS-induced cell death pathways, or inhibiting cancer cell resistance to chemotherapy.  Such results can be achieved by using agents that either increase ROS generation, or inhibit antioxidant defense, or even a combination of both.  In fact, a large variety of anticancer drugs, and some of those currently under clin. trials, effectively kill cancer cells and overcome drug resistance via enhancing ROS generation and/or impeding the antioxidant defense mechanism.  This review focuses on our current understanding of the tumor promoting (tumorigenesis, angiogenesis, invasion and metastasis, and chemoresistance) and the tumor suppressive (apoptosis, autophagy, and necroptosis) functions of ROS, and highlights the potential mechanism(s) involved.  It also sheds light on a very novel and an actively growing field of ROS-dependent cell death mechanism referred to as ferroptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8Jr12AOG4bVg90H21EOLACvtfcHk0lhV9J9f8Lr5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ahs78%253D&md5=9c5fac488a1a6a6370bdc0a4353ba810</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2017.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2017.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DGaladari%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DPallichankandy%26aufirst%3DS.%26aulast%3DThayyullathil%26aufirst%3DF.%26atitle%3DReactive%2520oxygen%2520species%2520and%2520cancer%2520paradox%253A%2520to%2520promote%2520or%2520to%2520suppress%253F%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2017%26volume%3D104%26spage%3D144%26epage%3D164%26doi%3D10.1016%2Fj.freeradbiomed.2017.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">The two faces of reactive oxygen species in cancer</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-041916-065808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1146%2Fannurev-cancerbio-041916-065808" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=79-98&author=C.+R.+Reczekauthor=N.+S.+Chandel&title=The+two+faces+of+reactive+oxygen+species+in+cancer&doi=10.1146%2Fannurev-cancerbio-041916-065808"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-041916-065808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-041916-065808%26sid%3Dliteratum%253Aachs%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DThe%2520two%2520faces%2520of%2520reactive%2520oxygen%2520species%2520in%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2017%26volume%3D1%26spage%3D79%26epage%3D98%26doi%3D10.1146%2Fannurev-cancerbio-041916-065808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linley, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamper, N.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E1578</span>– <span class="NLM_lpage">E1586</span>, <span class="refDoi"> DOI: 10.1073/pnas.1201544109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1201544109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22586118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E1578-E1586&author=J.+E.+Linleyauthor=L.+Ooiauthor=L.+Pettingerauthor=H.+Kirtonauthor=J.+P.+Boyleauthor=C.+Peersauthor=N.+Gamper&title=Reactive+oxygen+species+are+second+messengers+of+neurokinin+signaling+in+peripheral+sensory+neurons&doi=10.1073%2Fpnas.1201544109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons</span></div><div class="casAuthors">Linley, John E.; Ooi, Lezanne; Pettinger, Louisa; Kirton, Hannah; Boyle, John P.; Peers, Chris; Gamper, Nikita</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">E1578-E1586, SE1578/1-SE1578/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Substance P (SP) is a prominent neuromodulator, which is produced and released by peripheral damage-sensing (nociceptive) neurons; these neurons also express SP receptors.  However, the mechanisms of peripheral SP signaling are poorly understood.  We report a signaling pathway of SP in nociceptive neurons: acting predominantly through NK1 receptors and Gi/o proteins, SP stimulates increased release of reactive oxygen species from the mitochondrial electron transport chain.  Reactive oxygen species, functioning as second messengers, induce oxidative modification and augment M-type potassium channels, thereby suppressing excitability.  This signaling cascade requires activation of phospholipase C but is largely uncoupled from the inositol 1,4,5-trisphosphate sensitive Ca2+ stores.  In rats SP causes sensitization of TRPV1 and produces thermal hyperalgesia.  However, the lack of coupling between SP signaling and inositol 1,4,5-trisphosphate sensitive Ca2+ stores, together with the augmenting effect on M channels, renders the SP pathway ineffective to excite nociceptors acutely and produce spontaneous pain.  Our study describes a mechanism for neurokinin signaling in sensory neurons and provides evidence that spontaneous pain and hyperalgesia can have distinct underlying mechanisms within a single nociceptive neuron.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOW8oZPFxu7Vg90H21EOLACvtfcHk0lhV9J9f8Lr5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWisLw%253D&md5=9f2cfb434dd0fb4eaf5f16526accf689</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1201544109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1201544109%26sid%3Dliteratum%253Aachs%26aulast%3DLinley%26aufirst%3DJ.%2BE.%26aulast%3DOoi%26aufirst%3DL.%26aulast%3DPettinger%26aufirst%3DL.%26aulast%3DKirton%26aufirst%3DH.%26aulast%3DBoyle%26aufirst%3DJ.%2BP.%26aulast%3DPeers%26aufirst%3DC.%26aulast%3DGamper%26aufirst%3DN.%26atitle%3DReactive%2520oxygen%2520species%2520are%2520second%2520messengers%2520of%2520neurokinin%2520signaling%2520in%2520peripheral%2520sensory%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3DE1578%26epage%3DE1586%26doi%3D10.1073%2Fpnas.1201544109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnaudeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenorio Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenssen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells</span>. <i>Mutat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/S0921-8777(00)00052-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0921-8777%2800%2900052-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11056293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosV2ju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2000&pages=221-228&author=C.+Arnaudeauauthor=E.+Tenorio+Mirandaauthor=D.+Jenssenauthor=T.+Helleday&title=Inhibition+of+DNA+synthesis+is+a+potent+mechanism+by+which+cytostatic+drugs+induce+homologous+recombination+in+mammalian+cells&doi=10.1016%2FS0921-8777%2800%2900052-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells</span></div><div class="casAuthors">Arnaudeau, Catherine; Miranda, Erika Tenorio; Jenssen, Dag; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, DNA Repair</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-228</span>CODEN:
                <span class="NLM_cas:coden">MRDRBE</span>;
        ISSN:<span class="NLM_cas:issn">0921-8777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recombination is a process thought to be underlying genomic instability involved in carcinogenesis.  This report examines the potential of cytostatic drugs to induce intrachromosomal homologous recombination.  In order to address this question, the hprt gene of a well-characterized mammalian cell line was employed as a unique endogenous marker for homologous recombination.  Commonly used cytostatic drugs with different mode of action were investigated in this context, i.e. bifunctional alkylating agents, inhibitors of DNA synthesis, inhibitors of topoisomerases and a spindle poison.  With the exception of the spindle poison, all these drugs were found to induce homologous recombination, with clear differences in their recombination potency, which could be related to their mechanism of action.  Bifunctional alkylating agents were the least efficient, whereas inhibitors of DNA synthesis were found to be the most potent inducers of homologous recombination.  This raises the question whether these later drugs should be considered for adverse effects in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9OQcmYdG2E7Vg90H21EOLACvtfcHk0lhV9J9f8Lr5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosV2ju7Y%253D&md5=f033ba2713b2f22e503e28fd9690ac6f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0921-8777%2800%2900052-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0921-8777%252800%252900052-5%26sid%3Dliteratum%253Aachs%26aulast%3DArnaudeau%26aufirst%3DC.%26aulast%3DTenorio%2BMiranda%26aufirst%3DE.%26aulast%3DJenssen%26aufirst%3DD.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520DNA%2520synthesis%2520is%2520a%2520potent%2520mechanism%2520by%2520which%2520cytostatic%2520drugs%2520induce%2520homologous%2520recombination%2520in%2520mammalian%2520cells%26jtitle%3DMutat.%2520Res.%26date%3D2000%26volume%3D461%26spage%3D221%26epage%3D228%26doi%3D10.1016%2FS0921-8777%2800%2900052-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0lgOwxiNua5dWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Morón, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orta, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a Review</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3419</span>– <span class="NLM_lpage">3454</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140601203816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F0929867321666140601203816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24934343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCgtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3419-3454&author=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=E.+Burgos-Mor%C3%B3nauthor=M.+L.+Ortaauthor=M.+L%C3%B3pez-L%C3%A1zaro&title=Effect+of+DNA+repair+deficiencies+on+the+cytotoxicity+of+drugs+used+in+cancer+therapy+-+a+Review&doi=10.2174%2F0929867321666140601203816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review</span></div><div class="casAuthors">Calderon-Montano, Jose Manuel; Burgos-Moron, Estefania; Orta, Manuel Luis; Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3419-3454</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents.  The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy.  This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs.  It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacol. target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies).  This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBwl7-e1M4bVg90H21EOLACvtfcHk0lgOwxiNua5dWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCgtL3O&md5=88ee7907ae5c9c9706941170025e5c86</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140601203816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140601203816%26sid%3Dliteratum%253Aachs%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DBurgos-Mor%25C3%25B3n%26aufirst%3DE.%26aulast%3DOrta%26aufirst%3DM.%2BL.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DEffect%2520of%2520DNA%2520repair%2520deficiencies%2520on%2520the%2520cytotoxicity%2520of%2520drugs%2520used%2520in%2520cancer%2520therapy%2520-%2520a%2520Review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3419%26epage%3D3454%26doi%3D10.2174%2F0929867321666140601203816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Recio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascón, P.</span></span> <span> </span><span class="NLM_article-title">Biological and pharmacological aspects of the NK1-receptor</span>. <i>Biomed. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>, <span class="NLM_elocation-id">495704</span> <span class="refDoi"> DOI: 10.1155/2015/495704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1155%2F2015%2F495704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26421291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC283nsFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&author=S.+Garc%C3%ADa-Recioauthor=P.+Gasc%C3%B3n&title=Biological+and+pharmacological+aspects+of+the+NK1-receptor&doi=10.1155%2F2015%2F495704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and Pharmacological Aspects of the NK1-Receptor</span></div><div class="casAuthors">Garcia-Recio Susana; Gascon Pedro</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">495704</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neurokinin 1 receptor (NK-1R) is the main receptor for the tachykinin family of peptides.  Substance P (SP) is the major mammalian ligand and the one with the highest affinity.  SP is associated with multiple processes: hematopoiesis, wound healing, microvasculature permeability, neurogenic inflammation, leukocyte trafficking, and cell survival.  It is also considered a mitogen, and it has been associated with tumorigenesis and metastasis.  Tachykinins and their receptors are widely expressed in various human systems such as the nervous, cardiovascular, genitourinary, and immune system.  Particularly, NK-1R is found in the nervous system and in peripheral tissues and are involved in cellular responses such as pain transmission, endocrine and paracrine secretion, vasodilation, and modulation of cell proliferation.  It also acts as a neuromodulator contributing to brain homeostasis and to sensory neuronal transmission associated with depression, stress, anxiety, and emesis.  NK-1R and SP are present in brain regions involved in the vomiting reflex (the nucleus tractus solitarius and the area postrema).  This anatomical localization has led to the successful clinical development of antagonists against NK-1R in the treatment of chemotherapy-induced nausea and vomiting (CINV).  The first of these antagonists, aprepitant (oral administration) and fosaprepitant (intravenous administration), are prescribed for high and moderate emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSk9oaM_G1iCDEwO064Z95rfW6udTcc2eaYzygCIQi06bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283nsFektQ%253D%253D&md5=f9d6fd4c4e9af92be114679ab77634e1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1155%2F2015%2F495704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F495704%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Recio%26aufirst%3DS.%26aulast%3DGasc%25C3%25B3n%26aufirst%3DP.%26atitle%3DBiological%2520and%2520pharmacological%2520aspects%2520of%2520the%2520NK1-receptor%26jtitle%3DBiomed.%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26doi%3D10.1155%2F2015%2F495704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantoreggi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regolia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist netupitant</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2012.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.peptides.2012.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22732666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=86-97&author=A.+Rizziauthor=B.+Campiaauthor=V.+Camardaauthor=S.+Molinariaauthor=S.+Cantoreggiauthor=D.+Regoliaauthor=C.+Pietraauthor=G.+Calo&title=In+vitro+and+in+vivo+pharmacological+characterization+of+the+novel+NK1+receptor+selective+antagonist+netupitant&doi=10.1016%2Fj.peptides.2012.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant</span></div><div class="casAuthors">Rizzi, Anna; Campi, Barbara; Camarda, Valeria; Molinari, Stefano; Cantoreggi, Sergio; Regoli, Domenico; Pietra, Claudio; Calo', Girolamo</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-97</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The novel NK1 receptor ligand Netupitant has been characterized in vitro and in vivo.  In calcium mobilization studies CHO cells expressing the human NK receptors responded to a panel of agonists with the expected order of potency.  In CHO NK1 cells Netupitant concn.-dependently antagonized the stimulatory effects of substance P (SP) showing insurmountable antagonism (pKB 8.87).  In cells expressing NK2 or NK3 receptors Netupitant was inactive.  In the guinea pig ileum Netupitant concn.-dependently depressed the maximal response to SP (pKB 7.85) and, in functional washout expts., displayed persistent (up to 5 h) antagonist effects.  In mice the intrathecal injection of SP elicited the typical scratching, biting and licking response that was dose-dependently inhibited by Netupitant given i.p. in the 1-10 mg/kg dose range.  In gerbils, foot tapping behavior evoked by the intracerebroventricular injection of a NK1 agonist was dose-dependently counteracted by Netupitant given i.p. (ID50 1.5 mg/kg) or orally (ID50 0.5 mg/kg).  In time course expts. in gerbils Netupitant displayed long lasting effects.  In all the assays Aprepitant elicited similar effects as Netupitant.  These results suggest that Netupitant behaves as a brain penetrant, orally active, potent and selective NK1 antagonist.  Thus this mol. can be useful for investigating the NK1 receptor role in the control of central and peripheral functions.  Netupitant has clin. potential in conditions such as chemotherapy induced nausea and vomiting, in which the blockade of NK1 receptors has been demonstrated valuable for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnqeqtlg4ALVg90H21EOLACvtfcHk0lgOwxiNua5dWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGhurs%253D&md5=63bc4c31758959f00c4da2317e8747e4</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2012.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2012.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCampia%26aufirst%3DB.%26aulast%3DCamarda%26aufirst%3DV.%26aulast%3DMolinaria%26aufirst%3DS.%26aulast%3DCantoreggi%26aufirst%3DS.%26aulast%3DRegolia%26aufirst%3DD.%26aulast%3DPietra%26aufirst%3DC.%26aulast%3DCalo%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%2520the%2520novel%2520NK1%2520receptor%2520selective%2520antagonist%2520netupitant%26jtitle%3DPeptides%26date%3D2012%26volume%3D37%26spage%3D86%26epage%3D97%26doi%3D10.1016%2Fj.peptides.2012.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vykoukal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubertus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Schweinitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilmer, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.3892/ijo.2015.3016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.3892%2Fijo.2015.3016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25998227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=151-160&author=A.+Garnierauthor=J.+Vykoukalauthor=J.+Hubertusauthor=E.+Altauthor=D.+von+Schweinitzauthor=R.+Kapplerauthor=M.+Bergerauthor=M.+Ilmer&title=Targeting+the+neurokinin-1+receptor+inhibits+growth+of+human+colon+cancer+cells&doi=10.3892%2Fijo.2015.3016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells</span></div><div class="casAuthors">Garnier, Agnes; Vykoukal, Jody; Hubertus, Jochen; Alt, Eckhard; Von Schweinitz, Dietrich; Kappler, Roland; Berger, Michael; Ilmer, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-160</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The substance P (SP)/neurokinin-1 receptor (NK1R) complex and the Wnt cascade are pivotal signaling pathways in the regulation of cell growth and hence, potent targets for future anticancer therapies.  However, while the Wnt cascade has long been assocd. with colon cancer, little is known about the expression of the NK1R complex as a potential target in this tumor and its mol. basis in tumorigenesis in general.  We treated the human colon cancer cell lines LiM6 and DLD1 with the NK1R antagonist and the clin. drug aprepitant (AP) and analyzed both growth response and downstream mechanisms using MTT-assay, reverse phase protein array (RPPA), Western blot, Super TOP/FOP, confocal microscopy, and sphere formation ability (SFA) assays.  Following NK1R blockage, we found significant growth inhibition of both colon cancer cell lines.  When analyzing downstream mechanisms, we found a striking inhibition of the canonical Wnt pathway represented by decreased Super TOP/FOP and increased membrane stabilization of β-catenin.  This effect was independent from baseline Wnt activity and mutational status of β-catenin.  Further, treatment of colon cancer cells grown under cancer stem cell (CSC) conditions reduced sphere formation in both no. and size after a single treatment period.  We show that the NK1R can be a potent anticancer target in colon cancer and that NK1R antagonists could potentially serve as future anticancer drugs.  This effect was seen not only in primary cancer cells but, for the first time, also in CSC-like cells, potentially including these cells in a therapeutic effect.  Also, we describe the robust inhibition of canonical Wnt signaling through targeting the SP/NK1R signaling cascade.  These findings give important insight into the mol. mechanisms of the SP/NK1R complex as a crit. component in tumorigenesis and could help to identify future anticancer therapies for colon and other Wnt-activated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXrgQecPGexrVg90H21EOLACvtfcHk0lihWlCfVVwsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVyksQ%253D%253D&md5=b969fd06b97aae7bfdffc5451443812d</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.3892%2Fijo.2015.3016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2015.3016%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier%26aufirst%3DA.%26aulast%3DVykoukal%26aufirst%3DJ.%26aulast%3DHubertus%26aufirst%3DJ.%26aulast%3DAlt%26aufirst%3DE.%26aulast%3Dvon%2BSchweinitz%26aufirst%3DD.%26aulast%3DKappler%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DIlmer%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520neurokinin-1%2520receptor%2520inhibits%2520growth%2520of%2520human%2520colon%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D47%26spage%3D151%26epage%3D160%26doi%3D10.3892%2Fijo.2015.3016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vykoukal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Schweinitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the neurokinin-1 receptor compromises canonical Wnt signaling in hepatoblastoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2712</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1158%2F1535-7163.MCT-15-0206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26516161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2712-2721&author=M.+Ilmerauthor=A.+Garnierauthor=J.+Vykoukalauthor=E.+Altauthor=D.+von+Schweinitzauthor=R.+Kapplerauthor=M.+Berger&title=Targeting+the+neurokinin-1+receptor+compromises+canonical+Wnt+signaling+in+hepatoblastoma&doi=10.1158%2F1535-7163.MCT-15-0206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma</span></div><div class="casAuthors">Ilmer, Matthias; Garnier, Agnes; Vykoukal, Jody; Alt, Eckhard; von Schweinitz, Dietrich; Kappler, Roland; Berger, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2712-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The substance P (SP)/NK-1 receptor (NK1R) complex represents an intriguing anticancer target for a variety of tumors, including hepatoblastoma (HB).  Therefore, NK1R antagonists, such as the clin. drug aprepitant, recently have been proposed as potent anticancer agents.  However, very little is known regarding the mol. basis of NK1R inhibition in cancer.  Using reverse phase protein array, Western blot, Super TOP/FOP, confocal microscopy, and sphere formation ability (SFA) assays, we identified the AKT and Wnt signaling pathways as the key targets of aprepitant in three human HB cell lines (HepT1, HepG2, and HuH6).  Following NK1R blockage, we obsd. decreased phosphorylation of p70S6K and 4E-BP1/2 and inhibition of the canonical Wnt pathway with subsequent decrease of HB cell growth.  This effect was dependent of high baseline Wnt activity either by mutational status of β-catenin or extrinsic Wnt activation.  Wnt inhibition seemed to be strengthened by disruption of the FOXM1-β-catenin complex.  Furthermore, treatment of HB cells with aprepitant led to reduced expression of (liver) stemness markers (AFP, CD13, SOX2, NANOG, and OCT4) and SFA when grown under cancer stem cell conditions.  Taken together, we show for the first time that targeting the SP/NK1R signaling cascade inhibits canonical Wnt signaling in HB cells.  These findings reveal important insight into the mol. mechanisms of the SP/NK1R complex as a crit. component in a model of pediatric liver cancer and may support the development of novel therapeutic interventions for HB and other Wnt-activated cancers.  Mol Cancer Ther; 14(12); 2712-21. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFgozKFSTZ3rVg90H21EOLACvtfcHk0lihWlCfVVwsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zL&md5=f9ec62e8300b8fab0fdb8c1bc9b79431</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0206%26sid%3Dliteratum%253Aachs%26aulast%3DIlmer%26aufirst%3DM.%26aulast%3DGarnier%26aufirst%3DA.%26aulast%3DVykoukal%26aufirst%3DJ.%26aulast%3DAlt%26aufirst%3DE.%26aulast%3Dvon%2BSchweinitz%26aufirst%3DD.%26aulast%3DKappler%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520neurokinin-1%2520receptor%2520compromises%2520canonical%2520Wnt%2520signaling%2520in%2520hepatoblastoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2712%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-15-0206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J-X.</span></span> <span> </span><span class="NLM_article-title">The NK1 receptor antagonist NKP608 inhibits proliferation of human colorectal cancer cells via Wnt signaling pathway</span>. <i>Biol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>, <span class="NLM_elocation-id">14</span> <span class="refDoi"> DOI: 10.1186/s40659-018-0163-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1186%2Fs40659-018-0163-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=29843798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&author=X-L.+Niuauthor=J-F.+Houauthor=J-X.+Li&title=The+NK1+receptor+antagonist+NKP608+inhibits+proliferation+of+human+colorectal+cancer+cells+via+Wnt+signaling+pathway&doi=10.1186%2Fs40659-018-0163-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">The NK1 receptor antagonist NKP608 inhibits proliferation of human colorectal cancer cells via Wnt signaling pathway</span></div><div class="casAuthors">Niu, Xiao-Ling; Hou, Jian-Feng; Li, Jing-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Biological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14/1-14/8</span>CODEN:
                <span class="NLM_cas:coden">BESEEB</span>;
        ISSN:<span class="NLM_cas:issn">0717-6287</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Neurokinin1 (NK1) receptor has played a vital role in the development of tumor.  However, NKP608 as a NK1 receptor antagonist whether has the effect of the resistance of colorectal cancer is still unclear.  Thereby, in this study, we investigated the role of NKP608 on human colorectal cancer and explored the underlying mechanism.  Methods: The cell proliferation of colorectal cancer cells was detected by cell counting kit-8 (CCK8) assay, cell migra- tion and invasion were assessed by transwell assay, the apoptotic ratio of cells was assessed by Annexin V-fuorescein isothiocyanate/propidium iodide stained and fow cytometry.  The involvement of mol. mechanisms was exam- ined by western blot.  Results: In this study, we found that NKP608 inhibited the proliferation, migration/invasion of HCT116 cells.  In addi- tion, NKP608 reduced expressions of Wnt-3a, β-catenin, Cyclin D1, and (vascular endothelial growth factor) VEGF while induced expression of E-Cadherin.  Furthermore, fow cytometry analyzed that NKP608 induced apoptosis of HCT116 cells, consistently, western blotting detecting of apoptosis-related proteins revealed that NKP608 downregulated Bcl-2 while upregulated Bax and Active-Caspase-3.  Conclusions: Taken together, our results demonstrated that NKP608 inhibited colorectal cancer cell proliferation, migration and invasion via suppressing the Wnt/β-catenin signaling pathway.  Therefore, NKP608 might represent a promising therapeutic agent in the treatment of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYfNfxAlLw7Vg90H21EOLACvtfcHk0lihWlCfVVwsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWqsr%252FO&md5=6252059f8044051a36d682f0caa5d3cc</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1186%2Fs40659-018-0163-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40659-018-0163-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DX-L.%26aulast%3DHou%26aufirst%3DJ-F.%26aulast%3DLi%26aufirst%3DJ-X.%26atitle%3DThe%2520NK1%2520receptor%2520antagonist%2520NKP608%2520inhibits%2520proliferation%2520of%2520human%2520colorectal%2520cancer%2520cells%2520via%2520Wnt%2520signaling%2520pathway%26jtitle%3DBiol.%2520Res.%26date%3D2018%26volume%3D51%26doi%3D10.1186%2Fs40659-018-0163-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahiri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells</span>. <i>J. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1007/s13105-019-00697-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs13105-019-00697-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31372898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyhsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=415-421&author=H.+Javidauthor=F.+Mohammadiauthor=E.+Zahiriauthor=S.+I.+Hashemy&title=The+emerging+role+of+substance+P%2Fneurokinin-1+receptor+signaling+pathways+in+growth+and+development+of+tumor+cells&doi=10.1007%2Fs13105-019-00697-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39dR"><div class="casContent"><span class="casTitleNuber">39d</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells</span></div><div class="casAuthors">Javid, Hossein; Mohammadi, Fariba; Zahiri, Elnaz; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-421</span>CODEN:
                <span class="NLM_cas:coden">JPBIF2</span>;
        ISSN:<span class="NLM_cas:issn">1138-7548</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tachykinins (TKs) include an evolutionarily conserved group of small bio-active peptides which possess a common carboxyl-terminal sequence, Phe-X-Gly-Leu-Met-NH2.  TKs also have been shown to have implications in different steps of carcinogenesis, such as angiogenesis, mitogenesis, metastasis, and other growth-related events.  The biol. actions of substance P (SP), as the most important member of the TK family, are mainly mediated through a G protein-coupled receptor named neurokinin-1 receptor (NK1R).  More recently, it has become clear that SP/NK1R system is involved in the initiation and activation of signaling pathways involved in cancer development and progression.  Therefore, SP may contribute to triggering a variety of effector mechanisms including protein synthesis and a no. of transcription factors that modulate the expression of genes involved in these processes.  The overwhelming insights into the blockage of NK1R using specific antagonists could suggest a therapeutic approach in cancer therapy.  In this review, we focus on evidence supporting an assocn. between the signaling pathways of the SP/NK1R system and cancer cell proliferation and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_IqPU9_J_rVg90H21EOLACvtfcHk0liyghJnmPKYbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyhsLrP&md5=b297036d3d62c04ec2225c2a09660fbf</span></div><a href="/servlet/linkout?suffix=cit39d&amp;dbid=16384&amp;doi=10.1007%2Fs13105-019-00697-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13105-019-00697-1%26sid%3Dliteratum%253Aachs%26aulast%3DJavid%26aufirst%3DH.%26aulast%3DMohammadi%26aufirst%3DF.%26aulast%3DZahiri%26aufirst%3DE.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DThe%2520emerging%2520role%2520of%2520substance%2520P%252Fneurokinin-1%2520receptor%2520signaling%2520pathways%2520in%2520growth%2520and%2520development%2520of%2520tumor%2520cells%26jtitle%3DJ.%2520Physiol.%2520Biochem.%26date%3D2019%26volume%3D75%26spage%3D415%26epage%3D421%26doi%3D10.1007%2Fs13105-019-00697-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heuillet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallourd, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1993.tb03231.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1471-4159.1993.tb03231.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=7679727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVCgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=868-876&author=E.+Heuilletauthor=J.+M%C3%A9nagerauthor=V.+Fardinauthor=O.+Flamandauthor=M.+Bockauthor=C.+Garretauthor=A.+Crespoauthor=A.+M.+Fallourdauthor=A.+Doble&title=Characterization+of+a+human+NK1+tachykinin+receptor+in+the+astrocytoma+cell+line+U+373+MG&doi=10.1111%2Fj.1471-4159.1993.tb03231.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG</span></div><div class="casAuthors">Heuillet, E.; Menager, J.; Fardin, V.; Flamand, O.; Bock, M.; Garret, C.; Crespo, A.; Fallourd, A. M.; Doble, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-76</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">The human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG was characterized using selective agonists and antagonists described for this receptor in the rat.  Specific [3H]substance P binding sites were present on cell homogenates, whereas [3H]neurokinin A or [3H]senktide binding sites were absent.  The binding was saturable and reversible.  The binding of [3H]substance P was inhibited by very low concns. of [L-Pro9]substance P and [Sar9,Met(O2)11]substance P; septide was ∼1000-fold less potent.  The most potent peptide antagonist was trans-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-propyl-N-methyl-N-(phenylmethyl)-L-tyrosineamide.  The rank order of potency for the nonpeptide antagonists was (S,S)-CP 96,345 > (±)-CP 96,345 > (±)-2-chlorobenzylquinuclidinone > (R,R)-CP 96,345 > RP 67580 > RP 68651.  In [3H]inositol-labeled cells, substance P stimulated phosphatidylinositol turnover.  A good correlation was found when the abilities of NK1 receptor agonists for stimulating inositol phosphate prodn. and for inhibiting [3H]substance P binding were compared.  Similarly, the binding and functional assays were well correlated for the antagonists.  As a result of its high sensitivity and selectivity, the U 373 MG cell line thus appears an excellent tool for investigating the pharmacol. of the human NK1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplaB94lnCfcbVg90H21EOLACvtfcHk0lhAMtO_XaGl2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVCgt7o%253D&md5=1011fc8c6ebe17c37fb7d5acb337dc23</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1993.tb03231.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1993.tb03231.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeuillet%26aufirst%3DE.%26aulast%3DM%25C3%25A9nager%26aufirst%3DJ.%26aulast%3DFardin%26aufirst%3DV.%26aulast%3DFlamand%26aufirst%3DO.%26aulast%3DBock%26aufirst%3DM.%26aulast%3DGarret%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DFallourd%26aufirst%3DA.%2BM.%26aulast%3DDoble%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520human%2520NK1%2520tachykinin%2520receptor%2520in%2520the%2520astrocytoma%2520cell%2520line%2520U%2520373%2520MG%26jtitle%3DJ.%2520Neurochem.%26date%3D1993%26volume%3D60%26spage%3D868%26epage%3D876%26doi%3D10.1111%2Fj.1471-4159.1993.tb03231.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eistetter, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alouani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambosson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, E.</span></span> <span> </span><span class="NLM_article-title">Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1002/glia.440060203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fglia.440060203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1328053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADyaK3s%252FhsVSktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1992&pages=89-95&author=H.+R.+Eistetterauthor=A.+Millsauthor=R.+Brewsterauthor=S.+Alouaniauthor=C.+Rambossonauthor=E.+Kawashima&title=Functional+characterization+of+neurokinin-1+receptors+on+human+U373MG+astrocytoma+cells&doi=10.1002%2Fglia.440060203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells</span></div><div class="casAuthors">Eistetter H R; Mills A; Brewster R; Alouani S; Rambosson C; Kawashima E</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">The neurokinin-1 (NK-1, substance P) receptor belongs to the class of seven transmembrane domain (7-TM) receptors that interact with cellular effector systems via guanine nucleotide binding regulatory proteins (G-proteins).  In this study, coupling mechanisms of functional NK-1 receptors endogenously expressed in a human astrocytoma cell line (U373MG) were analyzed.  Stimulation with substance P (SP) resulted in 1) a rapid increase in inositol 1,4,5-trisphosphate (IP3) synthesis; 2) a rise in cytosolic free calcium concentration ([Ca2+]i); 3) induction of immediate early gene transcription as monitored by c-fos and c-jun expression; and 4) a significant increase in de novo DNA synthesis.  Thus, the functional responses induced by stimulation of NK-1 receptors on U373MG strongly correlate with those observed after treatment of primary astrocytes with SP and make U373MG cells a useful in vitro model system for the analysis of NK-1 receptor function on astrocytes in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx81PrkQfihpotVjB3IRIyfW6udTcc2eb9HpOG8NGZRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FhsVSktw%253D%253D&md5=d81f98adf72ba69c17867ff1f079efca</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1002%2Fglia.440060203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.440060203%26sid%3Dliteratum%253Aachs%26aulast%3DEistetter%26aufirst%3DH.%2BR.%26aulast%3DMills%26aufirst%3DA.%26aulast%3DBrewster%26aufirst%3DR.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DRambosson%26aufirst%3DC.%26aulast%3DKawashima%26aufirst%3DE.%26atitle%3DFunctional%2520characterization%2520of%2520neurokinin-1%2520receptors%2520on%2520human%2520U373MG%2520astrocytoma%2520cells%26jtitle%3DGlia%26date%3D1992%26volume%3D6%26spage%3D89%26epage%3D95%26doi%3D10.1002%2Fglia.440060203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Magalhães, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardenne, L. E.</span></span> <span> </span><span class="NLM_article-title">Receptor-ligand molecular docking</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s12551-013-0130-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs12551-013-0130-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28509958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlSqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=75-87&author=I.+A.+Guedesauthor=C.+S.+de+Magalh%C3%A3esauthor=L.+E.+Dardenne&title=Receptor-ligand+molecular+docking&doi=10.1007%2Fs12551-013-0130-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-ligand molecular docking</span></div><div class="casAuthors">Guedes, Isabella A.; Magalhaes, Camila S.; Dardenne, Laurent E.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-87</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Docking methodol. aims to predict the exptl. binding modes and affinities of small mols. within the binding site of particular receptor targets and is currently used as a std. computational tool in drug design for lead compd. optimization and in virtual screening studies to find novel biol. active mols.  The basic tools of a docking methodol. include a search algorithm and an energy scoring function for generating and evaluating ligand poses.  In this review, we present the search algorithms and scoring functions most commonly used in current mol. docking methods that focus on protein-ligand applications.  We summarize the main topics and recent computational and methodol. advances in protein-ligand docking.  Protein flexibility, multiple ligand binding modes and the free-energy landscape profile for binding affinity prediction are important and interconnected challenges to be overcome by further methodol. developments in the docking field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH7lCjEKQC4bVg90H21EOLACvtfcHk0lhAMtO_XaGl2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlSqtbc%253D&md5=dac42875205a64dd33aca13ec9f710a4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs12551-013-0130-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-013-0130-2%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DI.%2BA.%26aulast%3Dde%2BMagalh%25C3%25A3es%26aufirst%3DC.%2BS.%26aulast%3DDardenne%26aufirst%3DL.%2BE.%26atitle%3DReceptor-ligand%2520molecular%2520docking%26jtitle%3DBiophys.%2520Rev.%26date%3D2014%26volume%3D6%26spage%3D75%26epage%3D87%26doi%3D10.1007%2Fs12551-013-0130-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popielarska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabińska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, M. K.</span></span> <span> </span><span class="NLM_article-title">The Log P parameter as a molecular descriptor in the computer-aided drug design–an overview</span>. <i>Comput. Methods Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.12921/cmst.2012.18.02.81-88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.12921%2Fcmst.2012.18.02.81-88" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=81-88&author=J.+Kujawskiauthor=H.+Popielarskaauthor=A.+Mykaauthor=B.+Drabi%C5%84skaauthor=M.+K.+Bernard&title=The+Log+P+parameter+as+a+molecular+descriptor+in+the+computer-aided+drug+design%E2%80%93an+overview&doi=10.12921%2Fcmst.2012.18.02.81-88"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.12921%2Fcmst.2012.18.02.81-88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12921%252Fcmst.2012.18.02.81-88%26sid%3Dliteratum%253Aachs%26aulast%3DKujawski%26aufirst%3DJ.%26aulast%3DPopielarska%26aufirst%3DH.%26aulast%3DMyka%26aufirst%3DA.%26aulast%3DDrabi%25C5%2584ska%26aufirst%3DB.%26aulast%3DBernard%26aufirst%3DM.%2BK.%26atitle%3DThe%2520Log%2520P%2520parameter%2520as%2520a%2520molecular%2520descriptor%2520in%2520the%2520computer-aided%2520drug%2520design%25E2%2580%2593an%2520overview%26jtitle%3DComput.%2520Methods%2520Sci.%2520Technol.%26date%3D2012%26volume%3D18%26spage%3D81%26epage%3D88%26doi%3D10.12921%2Fcmst.2012.18.02.81-88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravanan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span> <span> </span><span class="NLM_article-title">DeepBindRG: a deep learning based method for estimating effective protein-ligand affinity</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e7362</span> <span class="refDoi"> DOI: 10.7717/peerj.7362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.7717%2Fpeerj.7362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31380152" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=H.+Zhangauthor=L.+Liaoauthor=K.+M.+Saravananauthor=P.+Yinauthor=Y.+Wei&title=DeepBindRG%3A+a+deep+learning+based+method+for+estimating+effective+protein-ligand+affinity&doi=10.7717%2Fpeerj.7362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.7362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.7362%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DSaravanan%26aufirst%3DK.%2BM.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DDeepBindRG%253A%2520a%2520deep%2520learning%2520based%2520method%2520for%2520estimating%2520effective%2520protein-ligand%2520affinity%26jtitle%3DPeerJ%26date%3D2019%26volume%3D7%26doi%3D10.7717%2Fpeerj.7362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit42c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rücker, C.</span></span> <span> </span><span class="NLM_article-title">Octanol–water partition coefficient measurement by a simple <sup>1</sup>H NMR method</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">6244</span>– <span class="NLM_lpage">6249</span>, <span class="refDoi"> DOI: 10.1021/acsomega.7b01102</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.7b01102" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOht7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=6244-6249&author=H.+Cummingauthor=C.+R%C3%BCcker&title=Octanol%E2%80%93water+partition+coefficient+measurement+by+a+simple+1H+NMR+method&doi=10.1021%2Facsomega.7b01102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42cR"><div class="casContent"><span class="casTitleNuber">42c</span><div class="casTitle"><span class="NLM_cas:atitle">Octanol-Water Partition Coefficient Measurement by a Simple 1H NMR Method</span></div><div class="casAuthors">Cumming, Hemi; Rucker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6244-6249</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a simple miniature shake-flask method to measure the octanol-water partition coeff. of an org. compd.  Partition between water and octanol is performed in an NMR tube; the aq. phase is analyzed by 1H NMR spectroscopy using a benchtop low-field NMR instrument.  Neither pre-equilibration of solvents nor isolation of the two phases is required.  The procedure is fast and easy enough to be used in a students' lab.  Scope and limitations as well as possible sources of error are discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9kBHuX3aA8LVg90H21EOLACvtfcHk0lhTX_dUkMiaaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOht7rM&md5=0d7fcd42f9d82f746494ec33f15c2e51</span></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=10.1021%2Facsomega.7b01102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.7b01102%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DH.%26aulast%3DR%25C3%25BCcker%26aufirst%3DC.%26atitle%3DOctanol%25E2%2580%2593water%2520partition%2520coefficient%2520measurement%2520by%2520a%2520simple%25201H%2520NMR%2520method%26jtitle%3DACS%2520Omega%26date%3D2017%26volume%3D2%26spage%3D6244%26epage%3D6249%26doi%3D10.1021%2Facsomega.7b01102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieraccini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sironi, M.</span></span> <span> </span><span class="NLM_article-title">Halogen bonding in ligand–receptor systems in the framework of classical force fields</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">19508</span>– <span class="NLM_lpage">19516</span>, <span class="refDoi"> DOI: 10.1039/c1cp22436k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1039%2Fc1cp22436k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21964576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKjurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=19508-19516&author=S.+Rendineauthor=S.+Pieracciniauthor=A.+Forniauthor=M.+Sironi&title=Halogen+bonding+in+ligand%E2%80%93receptor+systems+in+the+framework+of+classical+force+fields&doi=10.1039%2Fc1cp22436k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen bonding in ligand-receptor systems in the framework of classical force fields</span></div><div class="casAuthors">Rendine, Stefano; Pieraccini, Stefano; Forni, Alessandra; Sironi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">19508-19516</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Halogen bond is an important noncovalent interaction which is receiving a growing attention in the study of protein-ligand complexes.  Many drugs are halogenated mols. and it has been recently shown that many halogenated ligands establish halogen bonds with biomols.  As the halogen bond nature is due to an anisotropy of the electrostatic potential around halogen atoms, it is not possible to use traditional force fields based on a set of atom-centered charges to study halogen bonds in biomols.  The authors show that the introduction of pseudo-atoms on halogens permits the authors to correctly describe the anisotropy of the electrostatic potential and to perform mol. dynamics simulations on complexes of proteins with halogenated ligands that reproduce exptl. values.  The results are compared with crystallog. data and with hybrid quantum mechanics/mol. mechanics calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkRo6pzepT7Vg90H21EOLACvtfcHk0lhTX_dUkMiaaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKjurvN&md5=4f158f241315335dc3f6070d710178d6</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1039%2Fc1cp22436k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cp22436k%26sid%3Dliteratum%253Aachs%26aulast%3DRendine%26aufirst%3DS.%26aulast%3DPieraccini%26aufirst%3DS.%26aulast%3DForni%26aufirst%3DA.%26aulast%3DSironi%26aufirst%3DM.%26atitle%3DHalogen%2520bonding%2520in%2520ligand%25E2%2580%2593receptor%2520systems%2520in%2520the%2520framework%2520of%2520classical%2520force%2520fields%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2011%26volume%3D13%26spage%3D19508%26epage%3D19516%26doi%3D10.1039%2Fc1cp22436k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sirimulla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegesna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, M.</span></span> <span> </span><span class="NLM_article-title">Halogen interactions in protein–ligand complexes: implications of halogen bonding for rational drug design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1021/ci400257k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400257k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2781-2791&author=S.+Sirimullaauthor=J.+B.+Baileyauthor=R.+Vegesnaauthor=M.+Narayan&title=Halogen+interactions+in+protein%E2%80%93ligand+complexes%3A+implications+of+halogen+bonding+for+rational+drug+design&doi=10.1021%2Fci400257k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span></div><div class="casAuthors">Sirimulla, Suman; Bailey, Jake B.; Vegesna, Rahulsimham; Narayan, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2781-2791</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Halogen bonding interactions between halogenated ligands and proteins were examd. using the crystal structures deposited to date in the PDB.  The data was analyzed as a function of halogen bonding to main chain Lewis bases, viz. oxygen of backbone carbonyl and backbone amide nitrogen.  This anal. also examd. halogen bonding to side-chain Lewis bases (O, N, and S) and to the electron-rich arom. amino acids.  All interactions were restricted to van der Waals radii with resp. atoms.  The data reveals that while fluorine and chlorine have strong tendencies favoring interactions with the backbone Lewis bases at glycine, the trend is not restricted to the achiral amino acid backbone for larger halogens.  Halogen side-chain interactions are not restricted to amino acids contg. O, N, and S as Lewis bases.  Electron-rich arom. amino acids host a high frequency of halogen bonds as does Leu.  A closer examn. of the latter hydrophobic side chain reveals that the "propensity of interactions" of halogen ligands at this oily residue is an outcome of strong classical halogen bonds with Lewis bases in the vicinity.  Finally, an examn. of Θ1 (C-X···O and C-X···N) and Θ2 (X···O-Z and X···N-Z) angles reveals that very few ligands adopt classical halogen bonding angles, suggesting that steric and other factors may influence these angles.  The data is discussed in the context of ligand design for pharmaceutical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wcnZDXmkYrVg90H21EOLACvtfcHk0lhTX_dUkMiaaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O&md5=a73378681587e3ac13143452ecb78882</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1021%2Fci400257k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400257k%26sid%3Dliteratum%253Aachs%26aulast%3DSirimulla%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DJ.%2BB.%26aulast%3DVegesna%26aufirst%3DR.%26aulast%3DNarayan%26aufirst%3DM.%26atitle%3DHalogen%2520interactions%2520in%2520protein%25E2%2580%2593ligand%2520complexes%253A%2520implications%2520of%2520halogen%2520bonding%2520for%2520rational%2520drug%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2781%26epage%3D2791%26doi%3D10.1021%2Fci400257k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arunlakshana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schild, H. O.</span></span> <span> </span><span class="NLM_article-title">Some quantitative uses of drug antagonists</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1959.tb00928.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1476-5381.1959.tb00928.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=13651579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaG1MXhtFCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1959&pages=48-58&author=O.+Arunlakshanaauthor=H.+O.+Schild&title=Some+quantitative+uses+of+drug+antagonists&doi=10.1111%2Fj.1476-5381.1959.tb00928.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Some quantitative uses of drug antagonists</span></div><div class="casAuthors">Arunlakshana, O.; Schild, H. O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">C.A. 42, 281h.  Various applications of pAx measurements were discussed, based on the hypothesis that drugs and drug antagonists compete for receptors according to mass law.  Examples were given illustrating the use of pAx measurements to identify antagonists which acted on the same receptors and to compare receptors of different tissues.  Tests of competitive and noncompetitive antagonism were considered in relation to the antagonisms acetylcholine-atropine, histamine-atropine, and acetylcholine-cinchonidine.  A new measure of pAh, defined as the neg. log of the molar concn. of antagonist which reduces the attainable max. of the dose response curve to 1/2, was introduced to express the activity of unsurmountable antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIFhlFzfMrbVg90H21EOLACvtfcHk0ljcxGo5cEfqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXhtFCmu7w%253D&md5=9b9b86041b30647fb4ebe330e9ec61d9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1959.tb00928.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1959.tb00928.x%26sid%3Dliteratum%253Aachs%26aulast%3DArunlakshana%26aufirst%3DO.%26aulast%3DSchild%26aufirst%3DH.%2BO.%26atitle%3DSome%2520quantitative%2520uses%2520of%2520drug%2520antagonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1959%26volume%3D14%26spage%3D48%26epage%3D58%26doi%3D10.1111%2Fj.1476-5381.1959.tb00928.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">How many times should we screen a chemical library to discover an anticancer drug?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.drudis.2014.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25523188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC2MzotlOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=167-169&author=M.+L%C3%B3pez-L%C3%A1zaro&title=How+many+times+should+we+screen+a+chemical+library+to+discover+an+anticancer+drug%3F&doi=10.1016%2Fj.drudis.2014.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">How many times should we screen a chemical library to discover an anticancer drug?</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpvBDY_lavNiO2kE7krGOBfW6udTcc2eZ1mp-cs-WWLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzotlOhtg%253D%253D&md5=01dfaaefaaac142ef97137fd178cd028</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DHow%2520many%2520times%2520should%2520we%2520screen%2520a%2520chemical%2520library%2520to%2520discover%2520an%2520anticancer%2520drug%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D167%26epage%3D169%26doi%3D10.1016%2Fj.drudis.2014.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">A simple and reliable approach for assessing anticancer activity in vitro</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1324</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150209150639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F0929867322666150209150639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25666807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1amu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1324-1334&author=M.+L%C3%B3pez-L%C3%A1zaro&title=A+simple+and+reliable+approach+for+assessing+anticancer+activity+in+vitro&doi=10.2174%2F0929867322666150209150639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro</span></div><div class="casAuthors">Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1324-1334</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer patients need better anticancer drugs, and medicinal chem. can play a crit. role in the discovery of these drugs.  For an efficient drug discovery process, chemists working on the synthesis of potential anticancer agents need to use reliable screening methods.  These methods should not only detect the compds. with the highest therapeutic potential, but should also predict whether such potential is high enough to deserve addnl. attention.  Unfortunately, the current strategies for assessing anticancer activity in vitro are unable to do this reliably.  This review article analyzes these strategies and describes an alternative screening approach.  It is based on establishing suitable exptl. conditions to detect compds. that improve the selective cytotoxicity of the drugs used in cancer therapy.  This patient-oriented approach is easy to implement and may help medicinal chemists, and other researchers involved in cancer drug discovery, assess in vitro anticancer activity more reliably.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkwbmtgWQQLVg90H21EOLACvtfcHk0ljcxGo5cEfqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1amu7c%253D&md5=c47c9532bf4f825b9782c9476a1a1d75</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150209150639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150209150639%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DA%2520simple%2520and%2520reliable%2520approach%2520for%2520assessing%2520anticancer%2520activity%2520in%2520vitro%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1324%26epage%3D1334%26doi%3D10.2174%2F0929867322666150209150639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials</span>. <i>Oncoscience</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.18632/oncoscience.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.18632%2Foncoscience.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25859551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC2MjivVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=91-98&author=M.+L%C3%B3pez-L%C3%A1zaro&title=Two+preclinical+tests+to+evaluate+anticancer+activity+and+to+help+validate+drug+candidates+for+clinical+trials&doi=10.18632%2Foncoscience.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45cR"><div class="casContent"><span class="casTitleNuber">45c</span><div class="casTitle"><span class="NLM_cas:atitle">Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Oncoscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-8</span>
        ISSN:<span class="NLM_cas:issn">2331-4737</span>.
    </div><div class="casAbstract">Current approaches to assessing preclinical anticancer activity do not reliably predict drug efficacy in cancer patients.  Most of the compounds that show remarkable anticancer effects in preclinical models actually fail when tested in clinical trials.  We blame these failures on the complexity of the disease and on the limitations of the preclinical tools we require for our research.  This manuscript argues that this lack of clinical response may also be caused by poor in vitro and in vivo preclinical designs, in which cancer patients' needs are not fully considered.  Then, it proposes two patient-oriented tests to assess in vitro and in vivo anticancer activity and to help validate drug candidates for clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUqvJfzVVhz0EgZCMqtRBifW6udTcc2eZ1mp-cs-WWLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjivVKrsQ%253D%253D&md5=a9a9dd2f3ca9c99f36a74537c996003f</span></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.18632%2Foncoscience.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncoscience.132%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DTwo%2520preclinical%2520tests%2520to%2520evaluate%2520anticancer%2520activity%2520and%2520to%2520help%2520validate%2520drug%2520candidates%2520for%2520clinical%2520trials%26jtitle%3DOncoscience%26date%3D2015%26volume%3D2%26spage%3D91%26epage%3D98%26doi%3D10.18632%2Foncoscience.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopp, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1158%2F1078-0432.CCR-07-1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=18347186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtleisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1831-1839&author=X.+Caoauthor=M.+Bloomstonauthor=T.+Zhangauthor=W.+L.+Frankelauthor=G.+Jiaauthor=B.+Wangauthor=N.+C.+Hallauthor=R.+M.+Kochauthor=H.+Chengauthor=M.+V.+Knoppauthor=D.+Sun&title=Synergistic+antipancreatic+tumor+effect+by+simultaneously+targeting+hypoxic+cancer+cells+with+HSP90+inhibitor+and+glycolysis+inhibitor&doi=10.1158%2F1078-0432.CCR-07-1607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor</span></div><div class="casAuthors">Cao, Xianhua; Bloomston, Mark; Zhang, Tao; Frankel, Wendy L.; Jia, Guang; Wang, Bing; Hall, Nathan C.; Koch, Regina M.; Cheng, Hao; Knopp, Michael V.; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1831-1839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We sought to examine the synergistic antipancreatic cancer effect by simultaneously targeting hypoxic cancer cells with heat-shock protein 90 (HSP90) inhibitor and blockade of energy prodn.  Exptl. Design: The anticancer effects of an HSP90 inhibitor (geldanamycin) in pancreatic cells were investigated in hypoxia and normoxia.  A hexokinase II inhibitor, 3-broma-pyruvate (3BrPA), was evaluated for selective glycolysis inhibition in hypoxia as a sensitizer of HSP90 inhibitor against pancreatic cancer.  The HSP90 client protein degrdn. was monitored by Western blot.  The synergistic antitumor effect of geldanamycin and 3BrPA was evaluated in a xenograft pancreatic cancer model and monitored by a noninvasive dynamic contrast-enhanced magnetic resonance imaging.  Results: Hypoxia enhanced HIF-1α expression by 11-fold in pancreatic cancer cells, and HSP90 inhibitor exhibited a seven- to eightfold higher anticancer effect in hypoxia compared with normoxia via HSP90 client protein degrdn. 3BrPA selectively inhibited glycolysis and sensitized geldanamycin against pancreatic cancer cells by 17- to 400-fold through HSP90 client protein degrdn.  The synergistic anticancer effect of reduced doses of geldanamycin and 3-BrPA was confirmed in xenograft models in vivo by more than 75% tumor growth inhibition.  Conclusions: The combination of HSP90 inhibitors and glycolysis inhibitors provides preferential inhibition of cancer cells in hypoxia through HSP90 client protein degrdn. and selective glycolysis inhibition.  This may provide a new therapeutic regimen to battle chemotherapy-resistant pancreatic cancers, by enhancing the synergistic therapeutic efficacy and reducing dose-limiting toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3rak4ki6gprVg90H21EOLACvtfcHk0lgqk0UtObBS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtleisr8%253D&md5=dcca2fc98383448fb6bf16878b8cf8cf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1607%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DBloomston%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DFrankel%26aufirst%3DW.%2BL.%26aulast%3DJia%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DN.%2BC.%26aulast%3DKoch%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKnopp%26aufirst%3DM.%2BV.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DSynergistic%2520antipancreatic%2520tumor%2520effect%2520by%2520simultaneously%2520targeting%2520hypoxic%2520cancer%2520cells%2520with%2520HSP90%2520inhibitor%2520and%2520glycolysis%2520inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1831%26epage%3D1839%26doi%3D10.1158%2F1078-0432.CCR-07-1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry III. The role of exact exchange</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">5648</span>– <span class="NLM_lpage">5652</span>, <span class="refDoi"> DOI: 10.1063/1.464913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.464913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1993&pages=5648-5652&author=A.+D.+Becke&title=Density-functional+thermochemistry+III.+The+role+of+exact+exchange&doi=10.1063%2F1.464913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry. III. The role of exact exchange</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5648-52</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Despite the remarkable thermochem. accuracy of Kohn-Sham d.-functional theories with gradient corrections for exchange-correlation, the author believes that further improvements are unlikely unless exact-exchange information is considered.  Arguments to support this view are presented, and a semiempirical exchange-correlation functional (contg. local-spin-d., gradient, and exact-exchange terms) is tested for 56 atomization energies, 42 ionization potentials, 8 proton affinities, and 10 total at. energies of first- and second-row systems.  This functional performs better than previous functionals with gradient corrections only, and fits expt. atomization energies with an impressively small av. abs. deviation of 2.4 kcal/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3BqpycUTBwLVg90H21EOLACvtfcHk0lgqk0UtObBS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D&md5=291bbfc119095338bb1624f0c21c7ca8</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1063%2F1.464913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.464913%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry%2520III.%2520The%2520role%2520of%2520exact%2520exchange%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1993%26volume%3D98%26spage%3D5648%26epage%3D5652%26doi%3D10.1063%2F1.464913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry I. The effect of the exchange-only gradient correction</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1063/1.462066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.462066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK38XhtFeqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1992&pages=2155-2160&author=A.+D.+Becke&title=Density-functional+thermochemistry+I.+The+effect+of+the+exchange-only+gradient+correction&doi=10.1063%2F1.462066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry.  I.  The effect of the exchange-only gradient correction</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2155-60</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Results are given of an extensive survey of d.-functional atomization energies on the 55 mols. of the Gaussian-1 thermochem. data base of Pople and co-workers [J. Chem. Phys. 90, 5622 (1989); 93, 2537 (1990)].  These calcns. have been performed by the fully numerical mols. (NUMOL) program of Becke and Dickson [J. Chem. Phys. 92, 3610 (1990)] and are therefore free of basis-set uncertainties.  An av. abs. error is found in the total atomization energies of the 55 test mols. of 3.7 kcal/mol, compared to 1.6 kcal/mol for the Gaussian-1 procedure and 1.2 kcal/mol for Gaussian-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfVgdx5QFx_7Vg90H21EOLACvtfcHk0lgqk0UtObBS0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhtFeqtb8%253D&md5=09dff1fa3a088b78de16f9970f38f522</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1063%2F1.462066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.462066%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry%2520I.%2520The%2520effect%2520of%2520the%2520exchange-only%2520gradient%2520correction%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1992%26volume%3D96%26spage%3D2155%26epage%3D2160%26doi%3D10.1063%2F1.462066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of the colle-salvetti correlation-energy formula into a functional of the electron density</span>. <i>Phys. Rev. B</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>, <span class="NLM_elocation-id">785</span> <span class="refDoi"> DOI: 10.1103/PhysRevB.37.785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1103%2FPhysRevB.37.785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&author=C.+Leeauthor=W.+Yangauthor=R.+G.+Parr&title=Development+of+the+colle-salvetti+correlation-energy+formula+into+a+functional+of+the+electron+density&doi=10.1103%2FPhysRevB.37.785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47cR"><div class="casContent"><span class="casTitleNuber">47c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span></div><div class="casAuthors">Lee, Chengteh; Yang, Weitao; Parr, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review B:  Condensed Matter and Materials Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">PRBMDO</span>;
        ISSN:<span class="NLM_cas:issn">0163-1829</span>.
    </div><div class="casAbstract">A correlation-energy formula due to R. Colle and D. Salvetti (1975), in which the correlation energy d. is expressed in terms of the electron d. and a Laplacian of the 2nd-order Hartree-Fock d. matrix, is restated as a formula involving the d. and local kinetic-energy d.  On insertion of gradient expansions for the local kinetic-energy d., d.-functional formulas for the correlation energy and correlation potential are then obtained.  Through numerical calcns. on a no. of atoms, pos. ions, and mols., of both open- and closed-shell type, it is demonstrated that these formulas, like the original Colle-Salvetti formulas, give correlation energies within a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yJ1cBkpi67Vg90H21EOLACvtfcHk0lgtvm7iTvFF5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D&md5=ee7b59267a2ff72e15171a481819ccf8</span></div><a href="/servlet/linkout?suffix=cit47c&amp;dbid=16384&amp;doi=10.1103%2FPhysRevB.37.785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevB.37.785%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DParr%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520the%2520colle-salvetti%2520correlation-energy%2520formula%2520into%2520a%2520functional%2520of%2520the%2520electron%2520density%26jtitle%3DPhys.%2520Rev.%2520B%26date%3D1988%26volume%3D37%26doi%3D10.1103%2FPhysRevB.37.785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditchfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">Self—consistent molecular orbital methods XII. Further extensions of gaussian—type basis sets for use in molecular orbital studies of organic molecules</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1063/1.1677527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.1677527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaE38XptVemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1972&pages=2257-2261&author=W.+J.+Hehreauthor=R.+Ditchfieldauthor=J.+A.+Pople&title=Self%E2%80%94consistent+molecular+orbital+methods+XII.+Further+extensions+of+gaussian%E2%80%94type+basis+sets+for+use+in+molecular+orbital+studies+of+organic+molecules&doi=10.1063%2F1.1677527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">Self-consistent molecular orbital methods.  XII.  Further extensions of Gaussian-type basis sets for use in molecular orbital studies of organic molecules</span></div><div class="casAuthors">Hehre, W. J.; Ditchfield, R.; Pople, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2257-61</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Two extended basis sets (termed 5-31G and 6-31G) consisting of AO expressed as fixed linear combinations of Gaussian functions are presented for the 1st row atoms C to F.  These basis functions are similar to the 4-31G set in that each valence shell is split into inner and outer parts described by 3 and 1 Gaussian function, resp.  Inner shells are represented by a single basis function taken as a sum of 5 (5-31G) or 6 (6-31G) Guassians.  Studies with a no. of polyat. mols. indicate a substantial lowering of calcd. total energies over the 4-31G set.  Calcd. relative energies and equil. geometries do not appear to be altered significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3y4IIe93A3bVg90H21EOLACvtfcHk0lgtvm7iTvFF5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XptVemsw%253D%253D&md5=3b63ef94029197bf1b90941d5ee39956</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=10.1063%2F1.1677527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.1677527%26sid%3Dliteratum%253Aachs%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DDitchfield%26aufirst%3DR.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DSelf%25E2%2580%2594consistent%2520molecular%2520orbital%2520methods%2520XII.%2520Further%2520extensions%2520of%2520gaussian%25E2%2580%2594type%2520basis%2520sets%2520for%2520use%2520in%2520molecular%2520orbital%2520studies%2520of%2520organic%2520molecules%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1972%26volume%3D56%26spage%3D2257%26epage%3D2261%26doi%3D10.1063%2F1.1677527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Francl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietro, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkley, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFrees, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">Self-consistent molecular orbital methods XXIII. A polarization-type basis set for second-row elements</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">3654</span>– <span class="NLM_lpage">3665</span>, <span class="refDoi"> DOI: 10.1063/1.444267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.444267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaL38XlsFSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1982&pages=3654-3665&author=M.+M.+Franclauthor=W.+J.+Pietroauthor=W.+J.+Hehreauthor=J.+S.+Binkleyauthor=M.+S.+Gordonauthor=D.+J.+DeFreesauthor=J.+A.+Pople&title=Self-consistent+molecular+orbital+methods+XXIII.+A+polarization-type+basis+set+for+second-row+elements&doi=10.1063%2F1.444267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48bR"><div class="casContent"><span class="casTitleNuber">48b</span><div class="casTitle"><span class="NLM_cas:atitle">Self-consistent molecular orbital methods.  XXIII.  A polarization-type basis set for second-row elements</span></div><div class="casAuthors">Francl, Michelle M.; Pietro, William J.; Hehre, Warren J.; Binkley, J. Stephen; Gordon, Mark S.; DeFrees, Douglas J.; Pople, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3654-65</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">The 6-31G* and 6-31G** basis sets previously introduced for 1st-row atoms are extended through the 2nd-row of the periodic table.  Equil. geometries for 1-heavy-atom hydrides calcd. for the 2-basis sets and using Hartree-Fock wave functions are in good agreement both with each other and with the exptl. data.  HF/6-31G* structures, obtained for 2-heavy-atom hydrides and for a variety of hypervalent 2nd-row mols., are also in excellent accord with exptl. equil. geometries.  No large deviations between calcd. and exptl. single bond lengths exist, in contrast to previous work on analogous 1st-row compds., where limiting Hartree-Fock distances were in error by up to a 10th of an angstrom.  Equil. geometries calcd. at the HF/6-31G level are consistently in better agreement with the exptl. data than are those previously obtained using the simple split-valence 3-21G basis set for both normal- and hypervalent compds.  Normal-mode vibrational frequencies derived from 6-31G* level calcns. are consistently larger than the corresponding exptl. values, typically by 10-15%; they are of much more quality than those obtained from the 3-21G basis set.  Hydrogenation energies calcd. for normal- and hypervalent compds. are in moderate accord with exptl. data, although in some instances large errors appear.  Calcd. energies relating to the stabilities of single and multiple bonds are in much better accord with the exptl. energy differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX-ZMZokBE2LVg90H21EOLACvtfcHk0lgtvm7iTvFF5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFSqt7g%253D&md5=87dfa4667072f128ef633198ae94b388</span></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=10.1063%2F1.444267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.444267%26sid%3Dliteratum%253Aachs%26aulast%3DFrancl%26aufirst%3DM.%2BM.%26aulast%3DPietro%26aufirst%3DW.%2BJ.%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DBinkley%26aufirst%3DJ.%2BS.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DDeFrees%26aufirst%3DD.%2BJ.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DSelf-consistent%2520molecular%2520orbital%2520methods%2520XXIII.%2520A%2520polarization-type%2520basis%2520set%2520for%2520second-row%2520elements%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1982%26volume%3D77%26spage%3D3654%26epage%3D3665%26doi%3D10.1063%2F1.444267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Marenich, A.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Janesko, B. G.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Mennuci, B.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Williams-Young, D.</span>; <span class="NLM_string-name">Ding, F.</span>; <span class="NLM_string-name">Lipparini, F.</span>; <span class="NLM_string-name">Egidi, F.</span>; <span class="NLM_string-name">Goings, J.</span>; <span class="NLM_string-name">Peng, B.</span>; <span class="NLM_string-name">Petrone, A.</span>; <span class="NLM_string-name">Henderson, T.</span>; <span class="NLM_string-name">Ranasinghe, D.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Gao, J.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Liang, W.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Throssell, K.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Keith, T.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Milam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 09</i>, revision A.02; <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.17265%2F2159-5313%2F2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=G.+A.+Petersson&author=H.+Nakatsuji&author=X.+Li&author=M.+Caricato&author=A.+Marenich&author=J.+Bloino&author=B.+G.+Janesko&author=R.+Gomperts&author=B.+Mennuci&author=H.+P.+Hratchian&author=J.+V.+Ortiz&author=A.+F.+Izmaylov&author=J.+L.+Sonnenberg&author=D.+Williams-Young&author=F.+Ding&author=F.+Lipparini&author=F.+Egidi&author=J.+Goings&author=B.+Peng&author=A.+Petrone&author=T.+Henderson&author=D.+Ranasinghe&author=V.+G.+Zakrzewski&author=J.+Gao&author=N.+Rega&author=G.+Zheng&author=W.+Liang&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=K.+Throssell&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+Bearpark&author=J.+J.+Heyd&author=E.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=T.+Keith&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=J.+M.+Milam&author=M.+Klene&author=C.+Adamo&author=R.+Cammi&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=O.+Farkas&author=J.+B.+Foresman&author=D.+J.+Fox&title=Gaussian+09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.17265%2F2159-5313%2F2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26id%3Ddoi%3A10.17265%252F2159-5313%252F2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252009%26pub%3DGaussian%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+vina%3A+improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0liJ6dWqJEaVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520vina%253A%2520improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: automated docking with sSelective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+automated+docking+with+sSelective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0liJ6dWqJEaVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520sSelective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span> <i>Discovery studio
visualizer, version 4.0; software for viewing,
sharing, and analyzing protein and modeling data</i>; <span class="NLM_publisher-name">BIOVIA</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Discovery+studio%0Avisualizer%2C+version+4.0%3B+software+for+viewing%2C%0Asharing%2C+and+analyzing+protein+and+modeling+data%3B+BIOVIA%3A+San+Diego%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520studio%250Avisualizer%252C%2520version%25204.0%253B%2520software%2520for%2520viewing%252C%250Asharing%252C%2520and%2520analyzing%2520protein%2520and%2520modeling%2520data%26pub%3DBIOVIA%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29a','cit29b','cit29c','cit29d'],'ref30':['cit30'],'ref31':['cit31a','cit31b','cit31c','cit31d','cit31e','cit31f','cit31g','cit31h'],'ref32':['cit32a','cit32b','cit32c'],'ref33':['cit33a','cit33b','cit33c'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b','cit39c','cit39d'],'ref40':['cit40a','cit40b'],'ref41':['cit41'],'ref42':['cit42a','cit42b','cit42c'],'ref43':['cit43a','cit43b'],'ref44':['cit44'],'ref45':['cit45a','cit45b','cit45c'],'ref46':['cit46'],'ref47':['cit47a','cit47b','cit47c'],'ref48':['cit48a','cit48b'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Generalized nonpeptide NK1R antagonist pharmacophore consisting of two aromatic rings held together by various scaffolds, which contains at least one hydrogen-bond acceptor. Possible arrangement of the aromatic rings: parallel face-to-face (a), perpendicular “T” (b), and edge-on “L” (c). (B) Structures and color visualization of differences and similarities of some pioneering NK1R antagonists, (C) marketed NK1 antagonists, and (D) new NK1R antagonists derived from carbohydrates described in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure and retrosynthetic route of carbohydrate-based NK1R antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>p</i>-Fluorobenzyl <span class="smallcaps smallerCapital">d</span>-Galactose Derivative <b>7β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PhSH, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 90%; (b) MeONa, MeOH, 0 °C, quant; (c) 2,2-dimethoxypropane (2,2-DMP), 10-camforsulfonic acid (CSA), rt, 85%; (d) <i>tert</i>-butyldiphenylsilyl chloride (TBDPSCI), imidazole, dimethylformamide (DMF), rt, 96%; (e) NaH, TBAI, (<b>6</b>), tetrahydrofuran (THF), rt, 90%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of <b>11α</b> and <b>11β</b> by Glycosylation of <i>p</i>-Fluorobenzyl <span class="smallcaps smallerCapital">d</span>-Galactose Derivative <b>7β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, acetone (99%), darkness, −15 °C, <b>8α</b>:<b>8β</b> = 2:1, 91%; (b) CCl<sub>3</sub>CN, DBU (cat), c-hex:CH<sub>2</sub>Cl<sub>2</sub> 4:1, rt, <b>9α</b>:<b>9β</b> = 3:1, 97%; (c) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol, <b>10</b><i><b>R</b></i>, TMSOTf, diethyl ether, 4 Å MS, 0 °C to rt, column chromatography: <b>11α</b> 60% and <b>11β</b> 25%; (d) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol, <b>10</b><i><b>R</b></i>, NIS, TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å MS, 0 °C to rt, <b>11α</b>:<b>11β</b> = 1:1 (81%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Deprotection and Protection of Hydroxylic Groups at <b>3</b>, <b>4</b>, and <b>6</b> Positions of <span class="smallcaps smallerCapital">d</span>-Galactose Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBAF, THF, rt, 80% <b>12α</b>, and 75% <b>12β</b>; (b) CSA (cat), MeOH, rt, quant <b>13α</b> and <b>13β</b>; (c) benzaldehyde dimethyl acetal, CSA (cat), DMF, 40 °C, 95% <b>14α</b> and <b>14β</b>.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Fully Protected <span class="smallcaps smallerCapital">l</span>-Arabinose Derivatives <b>22α</b> and <b>22β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PhSH, BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, quant; (b) MeONa, MeOH, 0 °C to rt, quant; (c) 2,2-DMP, CSA, rt, 89%; (d) NaH, TBAI, <b>6</b>, THF, rt, quant; (e) NBS, acetone (99%), darkness, −15 °C, <b>20α</b>:<b>20β</b> = 1:2, 80%; (f) CCl<sub>3</sub>CN, DBU (cat), CH<sub>2</sub>Cl<sub>2</sub>, rt, <b>21α</b>:<b>21β</b> = 1:2, quant; (g) (<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethan-1-ol (<b>10</b><i><b>R</b></i>), Et<sub>2</sub>O, 4 Å MS, 0 °C to rt, column chromatography: <b>22α</b> 16% and <b>22β</b> 50%; (h) (<i>R</i>)-1-[3,5-bis(trifluoromethyl) phenyl]ethan-1-ol (<b>10</b><i><b>R</b></i>), NIS, CH<sub>2</sub>Cl<sub>2</sub>, 4 Å MS, 0 °C to rt, <b>22α</b>:<b>22β</b> = 1:1 (66%).</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of the Dihydroxylic <span class="smallcaps smallerCapital">l</span>-Arabinose Derivatives <b>23α</b> and <b>23β</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CSA (cat), MeOH, rt, quant.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>14α</b> induces selective cytotoxicity toward breast cancer and melanoma cells. Breast cell lines (A) and skin cell lines (B) were exposed to the NK1R antagonist <b>14α</b> for 48 h. Cell viability was estimated with the MTT assay. Values (percentage of cell viability) derived from two independent experiments performed in duplicate, mean with SEM, and <i>p</i> values (paired <i>t</i>-test) are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Concentration–response curves for the agonist and antagonist effects of SP (blue), L732,138 (olive green), α-<span class="smallcaps smallerCapital">d</span>-galactosyl derivatives (<b>13α</b> green; <b>14α</b> pink), and β-<span class="smallcaps smallerCapital">d</span>-arabinosyl derivative <b>23β</b> (black) using the IPone assay. The IP<sub>1</sub> accumulation (pmoles) was measured as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are illustrated from a representative experiment performed at least three times.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Superposition of the docked poses of Aprepitant (yellow), <b>13α</b> (red), <b>13β</b> (dark blue), <b>14α</b> (green), and <b>14β</b> (light blue) complexed with NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>). For clarity, hydrogen atoms have been removed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding site residues (dark green), hydrophobicity surface, and docked poses for Aprepitant (yellow), <b>14α</b> (green), <b>13α</b> (red), <b>13β</b> (dark blue), and <b>14β</b> (light blue), complexed with NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>). Top (A) and down (B) views are on the left and right sides, respectively. Brown color represents the most hydrophobic surface area and blue color, the least hydrophobic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/medium/jm1c00793_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Two-dimensional view of the interaction type of Aprepitant (A), <b>14α</b> (B), <b>14β</b> (C), <b>13α</b> (D), and <b>13β</b> (E) with surrounding amino acids of NK1R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO">6HLO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/acs.jmedchem.1c00793/20210716/images/large/jm1c00793_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00793&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Severini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Improta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falconieri-Erspamer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erspamer, V.</span></span> <span> </span><span class="NLM_article-title">The tachykinin peptide family</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1124%2Fpr.54.2.285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12037144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=285-322&author=C.+Severiniauthor=G.+Improtaauthor=G.+Falconieri-Erspamerauthor=S.+Salvadoriauthor=V.+Erspamer&title=The+tachykinin+peptide+family&doi=10.1124%2Fpr.54.2.285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The tachykinin peptide family</span></div><div class="casAuthors">Severini, Cinzia; Improta, Giovanna; Falconieri-Erspamer, Giuliana; Salvadori, Severo; Erspamer, Vittorio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-322</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The tachykinin peptide family certainly represents one of the largest peptide families described in the animal organism.  So far, more than 40 tachykinins have been isolated from invertebrate (insects, worms, and molluscs), protochordate, and vertebrate (skin, gastrointestinal tract, peripheral and central nervous system) tissues.  Substance P (SP), first identified by bioassay as early as 1931 but sequenced only in 1971, several years after the elucidation of the structure of eledoisin from molluscan tissues and of physalemin from amphibian skin, may be considered as a prototype of the tachykinins.  Hitherto, as many as 19 tachykinins have been isolated from amphibian integument, and eight addnl.; peptides have been isolated from amphibian gut and brain.  Counterparts of skin tachykinins in mammalian tissues are SP, neurokinin A, and neurokinin B.  Three main receptor subtypes for the tachykinins have been identified (NK1, NK2, and NK3), but their no. is probably destined to increase.  It is obvious that the peripheral and central effects of the tachykinins may substantially vary depending on the activation of different receptor subtypes.  Matters are further complicated by the frequent capacity of the single tachykinins to bind, although with different affinity, to more receptors.  It has been recognized that tachykinins have a variety of effects in physiol. and pathol. conditions, and there is evidence suggesting intrinsic neuroprotective and neurodegenerative properties of these neuropeptides.  This review provides an update on the current body of knowledge regarding tachykinin occurrence and distribution in the animal kingdom, from the lowest invertebrates to man; and the physiol. and pharmacol. actions of tachykinins outlining the pregnant importance of this large peptide family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQNEeQFUUd6bVg90H21EOLACvtfcHk0lgLyIasIQqgnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOhsr0%253D&md5=25dd6ad49975a98b8aae7a824381aac2</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.285%26sid%3Dliteratum%253Aachs%26aulast%3DSeverini%26aufirst%3DC.%26aulast%3DImprota%26aufirst%3DG.%26aulast%3DFalconieri-Erspamer%26aufirst%3DG.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DErspamer%26aufirst%3DV.%26atitle%3DThe%2520tachykinin%2520peptide%2520family%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D285%26epage%3D322%26doi%3D10.1124%2Fpr.54.2.285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mentzer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pthoulakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buennett, N. W.</span></span> <span> </span><span class="NLM_article-title">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1152/physrev.00031.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1152%2Fphysrev.00031.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24382888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=265-301&author=M.+S.+Steinhoffauthor=B.+von+Mentzerauthor=P.+Geppettiauthor=C.+Pthoulakisauthor=N.+W.+Buennett&title=Tachykinins+and+their+receptors%3A+contributions+to+physiological+control+and+the+mechanisms+of+disease&doi=10.1152%2Fphysrev.00031.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span></div><div class="casAuthors">Steinhoff, Martin S.; von Mentzer, Bengt; Geppetti, Pierangelo; Pothoulakis, Charalabos; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-301</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The tachykinins, exemplified by substance P, are one of the most intensively studied neuropeptide families.  They comprise a series of structurally related peptides that derive from alternate processing of three Tac genes and are expressed throughout the nervous and immune systems.  Tachykinins interact with three neurokinin G protein-coupled receptors.  The signaling, trafficking, and regulation of neurokinin receptors have also been topics of intense study.  Tachykinins participate in important physiol. processes in the nervous, immune, gastrointestinal, respiratory, urogenital, and dermal systems, including inflammation, nociception, smooth muscle contractility, epithelial secretion, and proliferation.  They contribute to multiple diseases processes, including acute and chronic inflammation and pain, fibrosis, affective and addictive disorders, functional disorders of the intestine and urinary bladder, infection, and cancer.  Neurokinin receptor antagonists are selective, potent, and show efficacy in models of disease.  In clin. trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting.  New information about the involvement of tachykinins in infection, fibrosis, and pruritus justifies further trials.  A deeper understanding of disease mechanisms is required for the development of more predictive exptl. models, and for the design and interpretation of clin. trials.  Knowledge of neurokinin receptor structure, and the development of targeting strategies to disrupt disease-relevant subcellular signaling of neurokinin receptors, may refine the next generation of neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYRTZzTeU6bVg90H21EOLACvtfcHk0liMArdGjI8DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D&md5=a7813685174b8b89eef8b604a78eebdf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00031.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00031.2013%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3Dvon%2BMentzer%26aufirst%3DB.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DPthoulakis%26aufirst%3DC.%26aulast%3DBuennett%26aufirst%3DN.%2BW.%26atitle%3DTachykinins%2520and%2520their%2520receptors%253A%2520contributions%2520to%2520physiological%2520control%2520and%2520the%2520mechanisms%2520of%2520disease%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D265%26epage%3D301%26doi%3D10.1152%2Fphysrev.00031.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0liMArdGjI8DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hökfelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahren, J.</span></span> <span> </span><span class="NLM_article-title">Substance P: a pioneer amongst neuropeptides</span>. <i>J. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1046/j.0954-6820.2000.00773.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1046%2Fj.0954-6820.2000.00773.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11168782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlKms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2001&pages=27-40&author=T.+H%C3%B6kfeltauthor=B.+Pernowauthor=J.+Wahren&title=Substance+P%3A+a+pioneer+amongst+neuropeptides&doi=10.1046%2Fj.0954-6820.2000.00773.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P: A pioneer amongst neuropeptides</span></div><div class="casAuthors">Hokfelt, T.; Pernow, B.; Wahren, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Internal Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-40</span>CODEN:
                <span class="NLM_cas:coden">JINMEO</span>;
        ISSN:<span class="NLM_cas:issn">0954-6820</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 98 refs.  A brief overview of recent developments in the substance P field is provided, in addn. to a historical introduction.  It is emphasized that there are multiple tachykinins and tachykinin receptors and that there are examples of coexistence of several tachykinin peptides and of several tachykinin receptors in single cells, and there is evidence for tachykininergic cotransmission.  The distribution and functional significance of tachykinins in the gastrointestinal tract and in sensory neurons, and interactions with other peptides and transmitters, are reviewed.  The recent prodn. of knock-out mice for either substance P or the NK1 receptor is discussed, as well as the exciting concept of substance P receptor internalization.  Finally, the development of specific substance P antagonists is summarized, and possible clin. implications discussed, and, in particular, a recent study which reports that a substance P antagonist shows clin. efficacy in depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4e3Ua2P94G7Vg90H21EOLACvtfcHk0liMArdGjI8DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlKms7c%253D&md5=5a52aeea15a91513ca021a2469079357</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1046%2Fj.0954-6820.2000.00773.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0954-6820.2000.00773.x%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25B6kfelt%26aufirst%3DT.%26aulast%3DPernow%26aufirst%3DB.%26aulast%3DWahren%26aufirst%3DJ.%26atitle%3DSubstance%2520P%253A%2520a%2520pioneer%2520amongst%2520neuropeptides%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D2001%26volume%3D249%26spage%3D27%26epage%3D40%26doi%3D10.1046%2Fj.0954-6820.2000.00773.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span> <span> </span><span class="NLM_article-title">Substance P</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/S1357-2725(01)00031-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS1357-2725%2801%2900031-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11378438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=555-576&author=S.+Harrisonauthor=P.+Geppetti&title=Substance+P&doi=10.1016%2FS1357-2725%2801%2900031-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P</span></div><div class="casAuthors">Harrison, S.; Geppetti, P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-576</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 253 refs., on the history of substance P from its discovery in the 1930s to the present day.  The development of substance P receptor agonists and antagonists, and more recently the employment of transgenic mice, provide a framework to explore the functional role of substance P.  Chronic inflammation and pain are assocd. with a no. of diseases, and it has been proposed that substance P released from primary afferent nerve endings plays a role in these conditions.  Recent developments with substance P antagonists have demonstrated the importance of substance P in several models of disease that span asthma, chronic bronchitis, cystitis, inflammatory bowel disease, migraine, emesis, depression, pain, and seizures.  Advancements in the knowledge of the role of substance P and its agonists and antagonists could provide clin. solns. for a variety of chronic inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKivF1NgJO87Vg90H21EOLACvtfcHk0liMArdGjI8DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2nt78%253D&md5=41c240a7ba84aef101ebe8f3f10a0216</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2801%2900031-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252801%252900031-0%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DGeppetti%26aufirst%3DP.%26atitle%3DSubstance%2520P%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2001%26volume%3D33%26spage%3D555%26epage%3D576%26doi%3D10.1016%2FS1357-2725%2801%2900031-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mentzer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geppetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pothoulakis, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnett, N. W.</span></span> <span> </span><span class="NLM_article-title">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1152/physrev.00031.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1152%2Fphysrev.00031.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24382888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=265-301&author=M.+S.+Steinhoffauthor=B.+Mentzerauthor=P.+Geppettiauthor=C.+H.+Pothoulakisauthor=N.+W.+Bunnett&title=Tachykinins+and+their+receptors%3A+contributions+to+physiological+control+and+the+mechanisms+of+disease&doi=10.1152%2Fphysrev.00031.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease</span></div><div class="casAuthors">Steinhoff, Martin S.; von Mentzer, Bengt; Geppetti, Pierangelo; Pothoulakis, Charalabos; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-301</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The tachykinins, exemplified by substance P, are one of the most intensively studied neuropeptide families.  They comprise a series of structurally related peptides that derive from alternate processing of three Tac genes and are expressed throughout the nervous and immune systems.  Tachykinins interact with three neurokinin G protein-coupled receptors.  The signaling, trafficking, and regulation of neurokinin receptors have also been topics of intense study.  Tachykinins participate in important physiol. processes in the nervous, immune, gastrointestinal, respiratory, urogenital, and dermal systems, including inflammation, nociception, smooth muscle contractility, epithelial secretion, and proliferation.  They contribute to multiple diseases processes, including acute and chronic inflammation and pain, fibrosis, affective and addictive disorders, functional disorders of the intestine and urinary bladder, infection, and cancer.  Neurokinin receptor antagonists are selective, potent, and show efficacy in models of disease.  In clin. trials there is a singular success: neurokinin 1 receptor antagonists to treat nausea and vomiting.  New information about the involvement of tachykinins in infection, fibrosis, and pruritus justifies further trials.  A deeper understanding of disease mechanisms is required for the development of more predictive exptl. models, and for the design and interpretation of clin. trials.  Knowledge of neurokinin receptor structure, and the development of targeting strategies to disrupt disease-relevant subcellular signaling of neurokinin receptors, may refine the next generation of neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYRTZzTeU6bVg90H21EOLACvtfcHk0lgD3Cqv6HCbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Ohtrg%253D&md5=a7813685174b8b89eef8b604a78eebdf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00031.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00031.2013%26sid%3Dliteratum%253Aachs%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3DMentzer%26aufirst%3DB.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DPothoulakis%26aufirst%3DC.%2BH.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26atitle%3DTachykinins%2520and%2520their%2520receptors%253A%2520contributions%2520to%2520physiological%2520control%2520and%2520the%2520mechanisms%2520of%2520disease%26jtitle%3DPhysiol.%2520Rev.%26date%3D2014%26volume%3D94%26spage%3D265%26epage%3D301%26doi%3D10.1152%2Fphysrev.00031.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycroft, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladduwahetty, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">C Swain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(96)00020-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0028-3908%2896%2900020-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9121615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=1121-1129&author=F.+D.+Tattersallauthor=W.+Rycroftauthor=B.+Francisauthor=D.+Pearceauthor=K.+Merchantauthor=A.+M.+MacLeodauthor=T.+Ladduwahettyauthor=L.+Keownauthor=C.+C+Swainauthor=R.+Bakerauthor=M.+Cascieriauthor=E.+Berauthor=J.+Metzgerauthor=D.+E.+MacIntyreauthor=R.+G.+Hillauthor=R.+J.+Hargreaves&title=Tachykinin+NK1+receptor+antagonists+act+centrally+to+inhibit+emesis+induced+by+the+chemotherapeutic+agent+cisplatin+in+ferrets&doi=10.1016%2FS0028-3908%2896%2900020-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets</span></div><div class="casAuthors">Tattersall, F. D.; Rycroft, W.; Francis, B.; Pearce, D.; Merchant, K.; Macleod, A. M.; Ladduwahetty, T.; Keown, L.; Swain, C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1121-1129</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">These studies have compared the pharmacol. profile of two non-peptide human type neurokinin1 (hNK1) receptor selective antagonists, L-741671 and a quaternized compd. L-743310.  In radioligand binding studies L-741671 and L-743310 had high affinity for ferret and cloned hNK1 receptors [Ki (nM) ferret 0.7 and 0.1; human 0.03 and 0.06, resp.] but low affinity for rodent NK1 receptors [Ki (nM) 64 and 17, resp.] suggesting that ferret receptors have hNK1-like binding pharmacol.  Studies in vivo showed that L-741,671 and L-743,310 had equiv. functional activity in the periphery (ID50S of 1.6 and 2 μg/kg i.v., resp.) as measured by inhibition of plasma protein extravasation evoked in the esophagus of guinea pigs by resiniferatoxin (7 nmol/kg i.v.).  Using an in situ brain perfusion technique in anesthetized rats, L-741671 was shown to be much more brain penetrant than the quaternary compd. L-743310 which had an entry rate similar to the poorly brain penetrant plasma marker inulin.  These compds. thus provided an opportunity to compare the anti-emetic effects of equi-active hNK1 receptor antagonists with and without brain penetration to central NK1 receptor sites.  When tested against cisplatin-induced emesis in ferrets, L-741671 (0.3, 1 and 3 mg/kg i.v.) produced marked dose-dependent inhibition of retching and vomiting but L-743310 was inactive at 3 and 10 mg/kg i.v.  In contrast, direct central injection of L-741671 and L-743310 (30 μg) into the vicinity of the nucleus tractus solitarius or L-743310 (200 μg) intracisternally was shown to inhibit retching and vomiting induced by i.v. cisplatin.  L-741671 and L-743310 had equiv. functional activity, at the same dose, against cisplatin-induced emesis when injected centrally.  These observations indicated that had L-743310 penetrated into the brain after systemic administration it would have been active in the cisplatin-induced emesis assay and so show that brain penetration is essential for the anti-emetic action of systemically administered NK1 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvhvxeZGKTFbVg90H21EOLACvtfcHk0lgD3Cqv6HCbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFKrtA%253D%253D&md5=13dc878ce34da4716b288f4c3c1a817f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2896%2900020-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252896%252900020-2%26sid%3Dliteratum%253Aachs%26aulast%3DTattersall%26aufirst%3DF.%2BD.%26aulast%3DRycroft%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DB.%26aulast%3DPearce%26aufirst%3DD.%26aulast%3DMerchant%26aufirst%3DK.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DLadduwahetty%26aufirst%3DT.%26aulast%3DKeown%26aufirst%3DL.%26aulast%3DC%2BSwain%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DCascieri%26aufirst%3DM.%26aulast%3DBer%26aufirst%3DE.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DHill%26aufirst%3DR.%2BG.%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3DTachykinin%2520NK1%2520receptor%2520antagonists%2520act%2520centrally%2520to%2520inhibit%2520emesis%2520induced%2520by%2520the%2520chemotherapeutic%2520agent%2520cisplatin%2520in%2520ferrets%26jtitle%3DNeuropharmacology%26date%3D1996%26volume%3D35%26spage%3D1121%26epage%3D1129%26doi%3D10.1016%2FS0028-3908%2896%2900020-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantyh, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basbaum, A. I.</span></span> <span> </span><span class="NLM_article-title">Primary afferent tachykinins are required to experience moderate to intense pain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/32897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2F32897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9537322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=1998&pages=390-394&author=Y.+Q.+Caoauthor=P.+W.+Mantyhauthor=E.+J.+Carlsonauthor=A.+M.+Gillespieauthor=C.+J.+Epsteinauthor=A.+I.+Basbaum&title=Primary+afferent+tachykinins+are+required+to+experience+moderate+to+intense+pain&doi=10.1038%2F32897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Primary afferent tachykinins are required to experience moderate to intense pain</span></div><div class="casAuthors">Cao, Yu Qing; Mantyh, Patrick W.; Carlson, Elaine J.; Gillespie, Anne-Marie; Epstein, Charles J.; Basbaum, Allan I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">6674</span>),
    <span class="NLM_cas:pages">390-394</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The excitatory neurotransmitter glutamate coexists with the peptide known as substance P in primary afferents that respond to painful stimulation.  Because blockers of glutamate receptors reliably reduce pain behavior, it is assumed that 'pain' messages are mediated by glutamate action on dorsal horn neurons.  The contribution of substance P, however, is still unclear.  The authors have now disrupted the mouse preprotachykinin A gene (PPT-A), which encodes substance P and a related tachykinin, neurokinin A.  The authors find that although the behavioral response to mildly painful stimuli is intact in these mice, the response to moderate to intense pain is significantly reduced.  Neurogenic inflammation, which results from peripheral release of substance P and neurokinin A is almost absent in the mutant mice.  The authors conclude that the release of tachykinins from primary afferent pain-sensing receptors (nociceptors) is required to produce moderate to intense pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpConFsx38BFrVg90H21EOLACvtfcHk0lgD3Cqv6HCbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSiu74%253D&md5=b04ba3220271c19b3ed8c08a736a9043</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F32897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F32897%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%2BQ.%26aulast%3DMantyh%26aufirst%3DP.%2BW.%26aulast%3DCarlson%26aufirst%3DE.%2BJ.%26aulast%3DGillespie%26aufirst%3DA.%2BM.%26aulast%3DEpstein%26aufirst%3DC.%2BJ.%26aulast%3DBasbaum%26aufirst%3DA.%2BI.%26atitle%3DPrimary%2520afferent%2520tachykinins%2520are%2520required%2520to%2520experience%2520moderate%2520to%2520intense%2520pain%26jtitle%3DNature%26date%3D1998%26volume%3D392%26spage%3D390%26epage%3D394%26doi%3D10.1038%2F32897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pintér, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozsgai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helyes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szolcsányi, J.</span></span> <span> </span><span class="NLM_article-title">Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1111/bcp.12097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fbcp.12097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23432438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFOk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=5-20&author=E.+Pint%C3%A9rauthor=G.+Pozsgaiauthor=Z.+Hajnaauthor=Z.+Helyesauthor=J.+Szolcs%C3%A1nyi&title=Neuropeptide+receptors+as+potential+drug+targets+in+the+treatment+of+inflammatory+conditions&doi=10.1111%2Fbcp.12097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions</span></div><div class="casAuthors">Pinter, Erika; Pozsgai, Gabor; Hajna, Zsofia; Helyes, Zsuzsanna; Szolcsanyi, Janos</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-20</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cross-talk between the nervous, endocrine and immune systems exists via regulator mols., such as neuropeptides, hormones and cytokines.  A no. of neuropeptides have been implicated in the genesis of inflammation, such as tachykinins and calcitonin gene-related peptide.  Development of their receptor antagonists could be a promising approach to anti-inflammatory pharmacotherapy.  Anti-inflammatory neuropeptides, such as vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, α-MSH, urocortin, adrenomedullin, somatostatin, cortistatin, ghrelin, galanin and opioid peptides, are also released and act on their own receptors on the neurons as well as on different inflammatory and immune cells.  The aim of the present review is to summarize the most prominent data of preclin. animal studies concerning the main pharmacol. effects of ligands acting on the neuropeptide receptors.  Promising therapeutic impacts of these compds. as potential candidates for the development of novel types of anti-inflammatory drugs are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8t57Qc8KgX7Vg90H21EOLACvtfcHk0li5dMyQkxsfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFOk&md5=07b814188fba5fd3b142d47da4430c2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12097%26sid%3Dliteratum%253Aachs%26aulast%3DPint%25C3%25A9r%26aufirst%3DE.%26aulast%3DPozsgai%26aufirst%3DG.%26aulast%3DHajna%26aufirst%3DZ.%26aulast%3DHelyes%26aufirst%3DZ.%26aulast%3DSzolcs%25C3%25A1nyi%26aufirst%3DJ.%26atitle%3DNeuropeptide%2520receptors%2520as%2520potential%2520drug%2520targets%2520in%2520the%2520treatment%2520of%2520inflammatory%2520conditions%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D77%26spage%3D5%26epage%3D20%26doi%3D10.1111%2Fbcp.12097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M. S.</span></span> <span> </span><span class="NLM_article-title">Distinct mechanism for antidepressant activity by blockade of central substance P receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.1126/science.281.5383.1640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1126%2Fscience.281.5383.1640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9733503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXmtVSqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=1640-1645&author=M.+S.+Kramer&title=Distinct+mechanism+for+antidepressant+activity+by+blockade+of+central+substance+P+receptors&doi=10.1126%2Fscience.281.5383.1640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct mechanism for antidepressant activity by blockade of central substance P receptors</span></div><div class="casAuthors">Kramer, Mark S.; Cutler, Neal; Feighner, John; Shrivastava, Ram; Carman, John; Sramek, John J.; Reines, Scott A.; Liu, Guanghan; Snavely, Duane; Wyatt-Knowles, Edwina; Hale, Jeffrey J.; Mills, Sander G.; MacCoss, Malcolm; Swain, Christopher J.; Harrison, Timothy; Hill, Raymond G.; Hefti, Franz; Scolnick, Edward M.; Cascieri, Margaret A.; Chicchi, Gary G.; Sadowski, Sharon; Williams, Angela R.; Hewson, Louise; Smith, David; Carlson, Emma J.; Hargreaves, Richard J.; Rupniak, Nadia M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5383</span>),
    <span class="NLM_cas:pages">1640-1645</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties.  Like clin. used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs.  In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently obsd.  In preclin. studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs.  These findings suggest that substance P may play an important role in psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPAlbpoVBCrVg90H21EOLACvtfcHk0li5dMyQkxsfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtVSqtb0%253D&md5=f6ac9f6dc063d6269a80ae80726c62b6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5383.1640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5383.1640%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DM.%2BS.%26atitle%3DDistinct%2520mechanism%2520for%2520antidepressant%2520activity%2520by%2520blockade%2520of%2520central%2520substance%2520P%2520receptors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D1640%26epage%3D1645%26doi%3D10.1126%2Fscience.281.5383.1640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, M.</span></span> <span> </span><span class="NLM_article-title">The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs</span>. <i>J. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1007/s12038-015-9530-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs12038-015-9530-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25963269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=441-463&author=M.+Mu%C3%B1ozauthor=R.+Cove%C3%B1asauthor=F.+Estebanauthor=M.+Redondo&title=The+substance+P%2FNK-1+receptor+system%3A+NK-1+receptor+antagonists+as+anti-cancer+drugs&doi=10.1007%2Fs12038-015-9530-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs</span></div><div class="casAuthors">Munoz, Miguel; Covenas, Rafael; Esteban, Francisco; Redondo, Maximino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biosciences (New Delhi, India)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-463</span>CODEN:
                <span class="NLM_cas:coden">JOBSDN</span>;
        ISSN:<span class="NLM_cas:issn">0250-5991</span>.
    
            (<span class="NLM_cas:orgname">Springer (India) Private Ltd.</span>)
        </div><div class="casAbstract">A review.  The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in cancer.  SP promotes the proliferation of tumor cells, angiogenesis and the migration of tumor cells.  We review the involvement of SP, the NK-1 receptor and NK-1 receptor antagonists in cancer.  Tumor cells overexpress NK-1 receptors, which are involved in their viability.  This overexpression suggests the possibility of specific treatment against tumor cells using NK-1 receptor antagonists, thus promoting a considerable decrease in the side effects of the treatment.  This strategy opens up new approaches for cancer treatment, since these antagonists, after binding to their mol. target, induce the death of tumor cells by apoptosis, exert an antiangiogenic action and inhibit the migration of tumor cells.  The use of NK-1 receptor antagonists such as aprepitant (used in clin. practice) as antitumor agents could be a promising innovation.  The value of aprepitant as an antitumor agent could be detd. faster than for less well-known compds. because many studies addressing its safety and characterization have already been completed.  The NK-1 receptor may be a promising target in the treatment of cancer; NK-1 receptor antagonists could act as specific drugs against tumor cells; and these antagonists could be new candidate anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIkaGJREvCobVg90H21EOLACvtfcHk0li5dMyQkxsfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOjur0%253D&md5=c026bb778ec7331bc196af6ebf378b0c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs12038-015-9530-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12038-015-9530-8%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26aulast%3DEsteban%26aufirst%3DF.%26aulast%3DRedondo%26aufirst%3DM.%26atitle%3DThe%2520substance%2520P%252FNK-1%2520receptor%2520system%253A%2520NK-1%2520receptor%2520antagonists%2520as%2520anti-cancer%2520drugs%26jtitle%3DJ.%2520Biosci.%26date%3D2015%26volume%3D40%26spage%3D441%26epage%3D463%26doi%3D10.1007%2Fs12038-015-9530-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Frias, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas-Martin, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2010.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Flabinvest.2010.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=20458280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptl2jtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=1259-1269&author=M.+Mu%C3%B1ozauthor=M.+Rossoauthor=M.+J.+Robles-Friasauthor=M.+V.+Salinas-Martinauthor=R.+Rossoauthor=A.+Gonzalez-Ortegaauthor=R.+Cove%C3%B1as&title=The+NK-1+receptor+is+expressed+in+human+melanoma+and+is+involved+in+the+antitumor+action+of+the+NK-1+receptor+antagonist+aprepitant+on+melanoma+cell+lines&doi=10.1038%2Flabinvest.2010.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines</span></div><div class="casAuthors">Munoz, Miguel; Rosso, Marisa; Robles-Frias, Maria Jose; Salinas-Martin, Manuel Vicente; Rosso, Rosario; Gonzalez-Ortega, Ana; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1259-1269</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Melanoma, the most deadly form of skin cancer, is aggressive and resistant to current therapies.  It has been previously reported that the substance P and neurokinin-1 (NK-1) receptor antagonists induce cell proliferation and cell inhibition, resp., in human melanoma cell lines.  Aprepitant is a selective high-affinity antagonist of the human NK-1 receptor.  Until now, this drug has been used as an anxiolytic, antidepressant and antiemetic.  Moreover, the antitumor action of aprepitant has been previously reported.  However, the presence of NK-1 receptors in human melanomas and whether the antitumor action of the NK-1 receptor antagonist aprepitant is exerted on human malignant melanomas have not been previously described.  The aims of this study are to show the presence of NK-1 receptors in human malignant melanomas and the antitumoral action of aprepitant against several human melanoma cell lines.  Immunoblot anal. was used to det. the presence of NK-1 receptors in human melanoma cell lines, and immunohistochem. was used to demonstrate NK-1 receptors in human melanoma samples.  We performed an in vitro study of the cytotoxicity of the NK-1 receptor antagonist aprepitant on human melanoma cell lines.  A coulter counter was used to det. viable cell nos., followed by application of the tetrazolium compd. MTS.  The DAPI method was applied to demonstrate apoptosis.  We obsd. that NK-1 receptors were present in all the melanoma samples studied as well as in human melanoma cell lines.  We also showed that melanoma cell lines expressed mRNA for the NK-1 receptor.  Moreover, after using a knockdown method, we showed that NK-1 receptors are involved in the viability of tumor cells.  In this study, we also report that aprepitant, at 10-60 μM concns., elicits cell growth inhibition in a concn.-dependent manner in all melanoma cell lines studied, that the specific antitumor action of aprepitant occurs through the NK-1 receptor and that melanoma cell death is de to apoptosis.  These findings show for the first time that the NK-1 receptor may be a promising new target and that the NK-1 receptor antagonist aprepitant could be a candidate as a new antitumor drug in the treatment of human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqOOWBv5HJV7Vg90H21EOLACvtfcHk0ljdA3Luafcl1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptl2jtr0%253D&md5=7a9c894ed406f4bbe50d6a5e4fdc00c6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2010.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2010.92%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DRobles-Frias%26aufirst%3DM.%2BJ.%26aulast%3DSalinas-Martin%26aufirst%3DM.%2BV.%26aulast%3DRosso%26aufirst%3DR.%26aulast%3DGonzalez-Ortega%26aufirst%3DA.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DThe%2520NK-1%2520receptor%2520is%2520expressed%2520in%2520human%2520melanoma%2520and%2520is%2520involved%2520in%2520the%2520antitumor%2520action%2520of%2520the%2520NK-1%2520receptor%2520antagonist%2520aprepitant%2520on%2520melanoma%2520cell%2520lines%26jtitle%3DLab.%2520Invest.%26date%3D2010%26volume%3D90%26spage%3D1259%26epage%3D1269%26doi%3D10.1038%2Flabinvest.2010.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannstrom, G.</span></span> <span> </span><span class="NLM_article-title">Substance P enhances forskol in stimulated cyclic AMP production in human UC11MG astrocytoma cells</span>. <i>Methods Find. Exp. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=7513037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Wqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1994&pages=21-28&author=C.+J.+Fowlerauthor=G.+Brannstrom&title=Substance+P+enhances+forskol+in+stimulated+cyclic+AMP+production+in+human+UC11MG+astrocytoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells</span></div><div class="casAuthors">Fowler, Christopher J.; Braennstroem, Gunilla</div><div class="citationInfo"><span class="NLM_cas:title">Methods and Findings in Experimental and Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-8</span>CODEN:
                <span class="NLM_cas:coden">MFEPDX</span>;
        ISSN:<span class="NLM_cas:issn">0379-0355</span>.
    </div><div class="casAbstract">The effects of substance P (SP) upon basal and forskolin-stimulated cAMP prodn. have been investigated in UC11MG cells.  The cells expressed 40,000 NK1 receptors/cell, the stimulation of which led to enhanced phosphoinositide breakdown.  Forskolin (10 and 100 μM) stimulated cAMP prodn., whereas SP (3 and 300 nM) produced no significant increase in cAMP prodn.  However, SP enhanced the response to forskolin, with an EC50 value of ∼10 nM.  The response to forskolin was also enhanced by physalemin and eledoisin, and was sensitive to inhibition by (+/-)CP 96345.  Thus, in the UC11MG cell line, SP not only stimulates phosphoinositide breakdown but also enhances the cAMP response to forskolin, possibly via stimulation of NK1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUPQJ2u5NIBLVg90H21EOLACvtfcHk0ljdA3Luafcl1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Wqt70%253D&md5=edde6c3eb28e11eb3af6fed1645d7d1e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFowler%26aufirst%3DC.%2BJ.%26aulast%3DBrannstrom%26aufirst%3DG.%26atitle%3DSubstance%2520P%2520enhances%2520forskol%2520in%2520stimulated%2520cyclic%2520AMP%2520production%2520in%2520human%2520UC11MG%2520astrocytoma%2520cells%26jtitle%3DMethods%2520Find.%2520Exp.%2520Clin.%2520Pharmacol.%26date%3D1994%26volume%3D16%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friess, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrikhande, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reubi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchler, M. W.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1097/01.LAB.0000067499.57309.F6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1097%2F01.LAB.0000067499.57309.F6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12746482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlKjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=731-742&author=H.+Friessauthor=Z.+Zhuauthor=V.+Liardauthor=X.+Shiauthor=S.+V.+Shrikhandeauthor=L.+Wangauthor=K.+Liebauthor=M.+Korcauthor=C.+Palmaauthor=A.+Zimmermannauthor=J.+C.+Reubiauthor=M.+W.+Buchler&title=Neurokinin-1+receptor+expression+and+its+potential+effects+on+tumor+growth+in+human+pancreatic+cancer&doi=10.1097%2F01.LAB.0000067499.57309.F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer</span></div><div class="casAuthors">Friess, Helmut; Zhu, Zhaowen; Liard, Veronique; Shi, Xin; Shrikhande, Shailesh V.; Wang, Li; Lieb, Klaus; Korc, Murray; Palma, Carla; Zimmermann, Arthur; Reubi, Jean Claude; Buechler, Markus W.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-742</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The neurokinin-1 receptor (NK-1R) and its ligand substance P (SP) are involved in the pathogenesis of certain neural tumors.  Because nerves are significantly altered in pancreatic cancer, evidence for alteration of this pathway in human pancreatic cancer was sought.  Expression of NK-1R was analyzed by real-time quant. RT-PCR, in situ hybridization, immunohistochem., and Western blot anal. in normal human pancreatic and pancreatic cancer tissue samples and in pancreatic cancer cell lines.  Furthermore, the influence of SP analogs and of the NK-1R antagonist MEN 11467 on pancreatic cancer cell growth was analyzed by sulforhodamine B (SRB) assay.  By real-time quant. RT-PCR, NK-1R mRNA was increased 36.7-fold (p < 0.001) in human pancreatic cancer samples compared with normal controls.  Enhanced NK-1R expression levels were not related to tumor grade but were assocd. with advanced tumor stage and poorer prognosis.  By in situ hybridization and immunohistochem., NK-1R mRNA and immunoreactivity were only occasionally weakly present in acinar and ductal cells in the normal pancreas.  In contrast, moderate to strong NK-1R mRNA signals and immunoreactivity were present in most cancer cells.  By Western blot anal., NK-1R was increased 26-fold (p < 0.01) in pancreatic cancer samples in comparison to normal controls.  NK-1R mRNA was detected in 5 pancreatic cancer cell lines by real-time quant. RT-PCR, with the highest levels in CAPAN-1 cells and the lowest in ASPC-1 cells.  SP analogs stimulated pancreatic cancer cell growth, depending on the NK-1R expression level, and this effect could be blocked by a selective NK-1R antagonist.  These findings illustrate that the NK-1R pathway is activated in human pancreatic cancer and has the potential to contribute to cancer cell growth, thus suggesting the existence of a neuro-cancer cell interaction in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpurDo_E8owzrVg90H21EOLACvtfcHk0ljdA3Luafcl1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlKjs7o%253D&md5=c70ea8cf40d3c8aadc9d3eeab54c723a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2F01.LAB.0000067499.57309.F6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.LAB.0000067499.57309.F6%26sid%3Dliteratum%253Aachs%26aulast%3DFriess%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLiard%26aufirst%3DV.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DShrikhande%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLieb%26aufirst%3DK.%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DPalma%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26aulast%3DBuchler%26aufirst%3DM.%2BW.%26atitle%3DNeurokinin-1%2520receptor%2520expression%2520and%2520its%2520potential%2520effects%2520on%2520tumor%2520growth%2520in%2520human%2520pancreatic%2520cancer%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D731%26epage%3D742%26doi%3D10.1097%2F01.LAB.0000067499.57309.F6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloof, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameshwar, P.</span></span> <span> </span><span class="NLM_article-title">Increased expression of preprotachykinin-I and neurokinin receptors cells: Implications for bone marrow metastasis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.1.388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.97.1.388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10618428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=388-393&author=D.+Singhauthor=D.+D.+Joshiauthor=M.+Hameedauthor=J.+Qianauthor=P.+Gasconauthor=P.+B.+Maloofauthor=A.+Mosenthalauthor=P.+Rameshwar&title=Increased+expression+of+preprotachykinin-I+and+neurokinin+receptors+cells%3A+Implications+for+bone+marrow+metastasis&doi=10.1073%2Fpnas.97.1.388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of preprotachykinin-1 and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis</span></div><div class="casAuthors">Singh, Deeppreet; Joshi, Deval D.; Hameed, Meera; Qian, Jing; Gascon, Pedro; Maloof, Paul B.; Mosenthal, Anne; Rameshwar, Pranela</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neuropeptides are implicated in many tumors, breast cancer (BC) included.  Preprotachykinin-1 (PPT-I) encodes multiple neuropeptides with pleiotropic functions such as neurotransmission, immune/hematopoietic modulation, angiogenesis, and mitogenesis.  PPT-I is constitutively expressed in some tumors.  In this study, we investigated a role for PPT-I and its receptors, neurokinin-1 (NK-1) and NK-2, in BC by using quant. reverse transcription-PCR, ELISA, and in situ hybridization.  Compared with normal mammary epithelial cells (n = 2) and benign breast biopsies (n = 21), BC cell lines (n = 7) and malignant breast biopsies (n = 25) showed increased expression of PPT-I and NK-1.  NK-2 levels were high in normal and malignant cells.  Specific NK-1 and NK-2 antagonists inhibited BC cell proliferation, suggesting autocrine and/or intercrine stimulation of BC cells by PPT-I peptides.  NK-2 showed no effect on the proliferation of normal cells but mediated the proliferation of BC cells.  Cytosolic exts. from malignant BC cells enhanced PPT-I translation whereas exts. from normal mammary epithelial cells caused no change.  These enhancing effects may be protein-specific because a similar increase was obsd. for IL-6 translation and no effect was obsd. for IL-1α and stem cell factor.  The data suggest that PPT-I peptides and their receptors may be important in BC development.  Considering that PPT-I peptides are hematopoietic modulators, these results could be extended to understand early integration of BC cells in the bone marrow, a preferred site of metastasis.  Mol. signaling transduced by PPT-I peptides and the mechanism that enhances translation of PPT-I mRNA could lead to innovative strategies for BC treatments and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropkyT7xbj-LVg90H21EOLACvtfcHk0ljdmvx_86z5MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVGhtQ%253D%253D&md5=b25cd6e16a08a3ce774f5e862abbf72e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.1.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.1.388%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DD.%2BD.%26aulast%3DHameed%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGascon%26aufirst%3DP.%26aulast%3DMaloof%26aufirst%3DP.%2BB.%26aulast%3DMosenthal%26aufirst%3DA.%26aulast%3DRameshwar%26aufirst%3DP.%26atitle%3DIncreased%2520expression%2520of%2520preprotachykinin-I%2520and%2520neurokinin%2520receptors%2520cells%253A%2520Implications%2520for%2520bone%2520marrow%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D388%26epage%3D393%26doi%3D10.1073%2Fpnas.97.1.388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells</span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1042/CBI20100229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1042%2FCBI20100229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21091434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVCgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=623-629&author=F.+Fengauthor=J.+Yangauthor=L.+Tongauthor=S.+Yuanauthor=Y.+Tianauthor=L.+Hongauthor=W.+Wangauthor=H.+Zhang&title=Substance+P+immunoreactive+nerve+fibres+are+related+to+gastric+cancer+differentiation+status+and+could+promote+proliferation+and+migration+of+gastric+cancer+cells&doi=10.1042%2FCBI20100229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Substance P immunoreactive nerve fibrers are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells</span></div><div class="casAuthors">Feng, Fan; Yang, Jian-Jun; Tong, Li-Ping; Yuan, Shi-Fa; Tian, Yang-Zi; Hong, Liu; Wang, Wei-Zhong; Zhang, Hong-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-629</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Tachykinins such as SP (substance P) may be involved in the progression of gastric adenocarcinoma through binding to NK-1 receptor.  However, the existence and relationship between SP and gastric cancer progression and differentiation remained unknown.  We have studied the NK-1 receptor in human gastric cancer tissue and MKN45 cell line and found SP-contg. nerve fibers in human gastric cancer and found that the amts. of SP-pos. nerves were related to gastric cancer differentiation.  SP could promote proliferation, adhesion, migration and invasion of MKN45 cells in vitro.  In addn., the intracellular calcium level of MKN45 cells was elevated after SP stimulation, and administration of CRACs (calcium release-activated calcium channels) inhibitor SKF-96365 could partially abolish these effects induced by SP.  These results demonstrated that NK-1 receptor and SP-contg. nerves existed in human gastric cancer; SP pos. nerves may play an important role in human gastric cancer progression, and calcium is critically significant among SP-induced biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbEhtMUEW8bVg90H21EOLACvtfcHk0ljdmvx_86z5MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVCgtbk%253D&md5=eac20ab66021b7f5967572e49652a803</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FCBI20100229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCBI20100229%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DSubstance%2520P%2520immunoreactive%2520nerve%2520fibres%2520are%2520related%2520to%2520gastric%2520cancer%2520differentiation%2520status%2520and%2520could%2520promote%2520proliferation%2520and%2520migration%2520of%2520gastric%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2011%26volume%3D35%26spage%3D623%26epage%3D629%26doi%3D10.1042%2FCBI20100229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayyer Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naveed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad-ul-Hussan, S.</span></span> <span> </span><span class="NLM_article-title">Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach</span>. <i>Comput. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>122</i></span>, <span class="NLM_elocation-id">103848</span> <span class="refDoi"> DOI: 10.1016/j.compbiomed.2020.103848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.compbiomed.2020.103848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32658735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2020&author=H.+Iftikharauthor=H.+Nayyer+Aliauthor=S.+Farooqauthor=H.+Naveedauthor=S.+Shahzad-ul-Hussan&title=Identification+of+potential+inhibitors+of+three+key+enzymes+of+SARS-CoV2+using+computational+approach&doi=10.1016%2Fj.compbiomed.2020.103848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach</span></div><div class="casAuthors">Iftikhar, Hafsa; Ali, Hafiza Nayyer; Farooq, Sadia; Naveed, Hammad; Shahzad-ul-Hussan, Syed</div><div class="citationInfo"><span class="NLM_cas:title">Computers in Biology and Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103848</span>CODEN:
                <span class="NLM_cas:coden">CBMDAW</span>;
        ISSN:<span class="NLM_cas:issn">0010-4825</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The recent outbreak of coronavirus disease-19 (COVID-19) continues to drastically affect healthcare throughout the world.  To date, no approved treatment regimen or vaccine is available to effectively attenuate or prevent the infection.  Therefore, collective and multidisciplinary efforts are needed to identify new therapeutics or to explore effectiveness of existing drugs and drug-like small mols. against SARS-CoV-2 for lead identification and repurposing prospects.  This study addresses the identification of small mols. that specifically bind to any of the three essential proteins (RdRp, 3CL-protease and helicase) of SARS-CoV-2.  By applying computational approaches we screened a library of 4574 compds. also contg. FDA-approved drugs against these viral proteins.  Shortlisted hits from initial screening were subjected to iterative docking with the resp. proteins.  Ranking score on the basis of binding energy, clustering score, shape complementarity and functional significance of the binding pocket was applied to identify the binding compds.  Finally, to minimize chances of false positives, we performed docking of the identified mols. with 100 irrelevant proteins of diverse classes thereby ruling out the non-specific binding.  Three FDA-approved drugs showed binding to 3CL-protease either at the catalytic pocket or at an allosteric site related to functionally important dimer formation.  A drug-like mol. showed binding to RdRp in its catalytic pocket blocking the key catalytic residues.  Two other drug-like mols. showed specific interactions with helicase at a key domain involved in catalysis.  This study provides lead drugs or drug-like mols. for further in vitro and clin. investigation for drug repurposing and new drug development prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoheOjWPbTyP7Vg90H21EOLACvtfcHk0ljdmvx_86z5MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCju7nN&md5=df84538269d193bb799eabb10b29d733</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiomed.2020.103848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiomed.2020.103848%26sid%3Dliteratum%253Aachs%26aulast%3DIftikhar%26aufirst%3DH.%26aulast%3DNayyer%2BAli%26aufirst%3DH.%26aulast%3DFarooq%26aufirst%3DS.%26aulast%3DNaveed%26aufirst%3DH.%26aulast%3DShahzad-ul-Hussan%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520potential%2520inhibitors%2520of%2520three%2520key%2520enzymes%2520of%2520SARS-CoV2%2520using%2520computational%2520approach%26jtitle%3DComput.%2520Biol.%2520Med.%26date%3D2020%26volume%3D122%26doi%3D10.1016%2Fj.compbiomed.2020.103848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehboob, R.</span>; <span class="NLM_string-name">Ahmad, F. J.</span>; <span class="NLM_string-name">Qayyum, A.</span>; <span class="NLM_string-name">Rana, M. A.</span>; <span class="NLM_string-name">Tariq, M. A.</span>; <span class="NLM_string-name">Ali, G.</span>; <span class="NLM_string-name">Akram, J.</span></span> <span> </span><span class="NLM_article-title">Aprepitant as a combinant with dexamethasone reduces the inflammation via neurokinin 1 receptor antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: a novel therapeutic approach</span>, <span class="NLM_year">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.08.01.20166678</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1101%2F2020.08.01.20166678" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Mehboob&author=F.+J.+Ahmad&author=A.+Qayyum&author=M.+A.+Rana&author=M.+A.+Tariq&author=G.+Ali&author=J.+Akram&title=Aprepitant+as+a+combinant+with+dexamethasone+reduces+the+inflammation+via+neurokinin+1+receptor+antagonism+in+severe+to+critical+Covid-19+patients+and+potentiates+respiratory+recovery%3A+a+novel+therapeutic+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1101%2F2020.08.01.20166678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1101%252F2020.08.01.20166678%26sid%3Dliteratum%253Aachs%26aulast%3DMehboob%26aufirst%3DR.%26atitle%3DAprepitant%2520as%2520a%2520combinant%2520with%2520dexamethasone%2520reduces%2520the%2520inflammation%2520via%2520neurokinin%25201%2520receptor%2520antagonism%2520in%2520severe%2520to%2520critical%2520Covid-19%2520patients%2520and%2520potentiates%2520respiratory%2520recovery%253A%2520a%2520novel%2520therapeutic%2520approach%26date%3D2020%26doi%3D10.1101%2F2020.08.01.20166678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> A search in clinical trials.gov accessed
on the 27 of August 2020 show that, currently there are three clinical
trials on the use of NK1 antagonists (2 with aprepitant and 1 with
taradipitant) in the treatment of COVID19 pandemic.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+search+in+clinical+trials.gov+accessed%0Aon+the+27+of+August+2020+show+that%2C+currently+there+are+three+clinical%0Atrials+on+the+use+of+NK1+antagonists+%282+with+aprepitant+and+1+with%0Ataradipitant%29+in+the+treatment+of+COVID19+pandemic."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korlipara, V. L.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor antagonists: a comprehensive patent survey</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1517/13543776.2010.495121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2010.495121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=20533894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1SltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1019-1045&author=S.-C.+Huangauthor=V.+L.+Korlipara&title=Neurokinin-1+receptor+antagonists%3A+a+comprehensive+patent+survey&doi=10.1517%2F13543776.2010.495121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 receptor antagonists: a comprehensive patent survey</span></div><div class="casAuthors">Huang, Shih-Chung; Korlipara, Vijaya L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1019-1045</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Substance P is involved in mediating a no. of biol. effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor.  Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions.  Areas covered in this review: More than 300 patents have been filed by nearly 20 companies and 2 academic institutions in the past 2 decades.  This review provides an overview of the patenting activity in the NK1 antagonist field over the last 20 years.  What the reader will gain: Chem. diverse non-peptide NK1 receptor antagonists have been identified since the discovery of CP-96,345 by Pfizer in 1991.  Representative examples of patented ligands and their biol. activities are presented in a company-wise approach.  Take home message: The NK1 receptor research has led to the clin. introduction of aprepitant in 2003 and its water sol. injectable form, fosaprepitant dimeglumine, in 2009 by Merck for the prevention of postoperative nausea and vomiting and for inhibiting chemotherapy-induced nausea and vomiting.  In addn., maropitant citrate received approval in 2007 for veterinary use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMh4tbEQ3PrVg90H21EOLACvtfcHk0ljiaLUYiBvzvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1SltL0%253D&md5=a773b58ac061cdc03a5d3c9bdc69e4b0</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.495121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.495121%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.-C.%26aulast%3DKorlipara%26aufirst%3DV.%2BL.%26atitle%3DNeurokinin-1%2520receptor%2520antagonists%253A%2520a%2520comprehensive%2520patent%2520survey%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1019%26epage%3D1045%26doi%3D10.1517%2F13543776.2010.495121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Armesto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.697153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2012.697153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22697287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Mu%C3%B1oz%2C+M.%3B+Martinez-Armesto%2C+J.%3B+Cove%C3%B1as%2C+R.+Expert+Opin.+Ther.+Pat.+2012%2C+22%2C+735%E2%80%93746%2C+10.1517%2F13543776.2012.697153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span></div><div class="casAuthors">Munoz, Miguel; Martinez-Armesto, Juan; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-746</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: After binding to the neurokinin (NK-1) receptor, substance P (SP) induces tumor cell proliferation, the migration of tumor cells (invasion and metastasis) and angiogenesis.  By contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells and exert antiangiogenic properties.Areas covered: This review offers a 12-yr overview of the underlying mechanism of the action of the SP/NK-1 receptor system and NK-1 receptor antagonists in cancer, providing a new approach to the treatment of tumors.Expert opinion: Chem. diverse NK-1 receptor antagonists have been identified.  The antitumor action of these compds. is independent of their chem. structures and such action is assocd. with their affinity for the NK-1 receptor and with the dose of the antagonist administered.  The NK-1 receptor can be considered as a target in cancer treatment and NK-1 receptor antagonists could be considered as new antitumor drugs.  The NK-1 receptor antagonist aprepitant is used in clin. practice and exerts an antitumor action against tumor cells in vitro.  In the future, such antitumor action should be tested in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowJRmIy_bZ7Vg90H21EOLACvtfcHk0ljiaLUYiBvzvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D&md5=8e5b53c6b90cac0e5144cc1f448d178b</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.697153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.697153%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMartinez-Armesto%26aufirst%3DJ.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D735%26epage%3D746%26doi%3D10.1517%2F13543776.2012.697153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snider, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantine, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebel, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinick, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, H.-J.</span></span> <span> </span><span class="NLM_article-title">A potent nonpeptide antagonist of the substance P (NK1) receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1126/science.1703323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1126%2Fscience.1703323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1703323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlKnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1991&pages=435-437&author=R.+M.+Sniderauthor=J.+W.+Constantineauthor=J.+A.+Loweauthor=K.+P.+Longoauthor=W.+S.+Lebelauthor=H.+A.+Woodyauthor=S.+E.+Drozdaauthor=M.+C.+Desaiauthor=F.+J.+Vinickauthor=R.+W.+Spencerauthor=H.-J.+Hess&title=A+potent+nonpeptide+antagonist+of+the+substance+P+%28NK1%29+receptor&doi=10.1126%2Fscience.1703323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A potent nonpeptide antagonist of the substance P (NK1) receptor</span></div><div class="casAuthors">Snider, R. Michael; Constantine, Jay W.; Lowe, John A., III; Longo, Kelly P.; Lebel, Wesley S.; Woody, Heidi A.; Drozda, Susan E.; Desai, Manoj C.; Vinick, Fredric J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">4992</span>),
    <span class="NLM_cas:pages">435-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]octan-3-amine (I) is a potent nonpeptide antagonist of the substance P (NK1) receptor.  I inhibited 3H-labeled substance P binding and was a classical competitive antagonist in the NK1 monoreceptor dog carotid artery prepn.  I inhibited substance P-induced salivation in the rat, a classical in vivo bioassay, but did not inhibit NK2, NK3, or numerous other receptors; it is thus a selective NK1 antagonist.  I may prove to be a powerful tool for investigation of the physiol. properties of substance P and exploration of its role in diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoy7oM7Y6V7LVg90H21EOLACvtfcHk0ljiaLUYiBvzvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlKnurY%253D&md5=1b3decaacb7402d5ce8f754097233c10</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1703323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1703323%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DConstantine%26aufirst%3DJ.%2BW.%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DLongo%26aufirst%3DK.%2BP.%26aulast%3DLebel%26aufirst%3DW.%2BS.%26aulast%3DWoody%26aufirst%3DH.%2BA.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26aulast%3DVinick%26aufirst%3DF.%2BJ.%26aulast%3DSpencer%26aufirst%3DR.%2BW.%26aulast%3DHess%26aufirst%3DH.-J.%26atitle%3DA%2520potent%2520nonpeptide%2520antagonist%2520of%2520the%2520substance%2520P%2520%2528NK1%2529%2520receptor%26jtitle%3DScience%26date%3D1991%26volume%3D251%26spage%3D435%26epage%3D437%26doi%3D10.1126%2Fscience.1703323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giardina, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, M.</span></span> <span> </span><span class="NLM_article-title">Antagonists at the neurokinin receptors - recent patent literature</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=12917772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVGkurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=758-772&author=G.+A.+Giardinaauthor=S.+Gagliardiauthor=M.+Martinelli&title=Antagonists+at+the+neurokinin+receptors+-+recent+patent+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists at the neurokinin receptors - recent patent literature</span></div><div class="casAuthors">Giardina, Giuseppe A. M.; Gagliardi, Stefania; Martinelli, Marisa</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">758-772</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">This review describes the patent applications and relevant scientific literature published during 2002 in the field of novel neurokinin receptor antagonists, with an emphasis on the medicinal chem. of recent patent publications.  A brief update on the development status of compds. including: the neurokinin-1 receptor antagonists aprepitant (Merck & Co Inc), vofopitant, ezlopitant (Pfizer Inc), R-673 (F Hoffmann-La Roche Ltd); the neurokinin-2 receptor antagonists nepadutant (Menarini Ricerche SpA), saredutant (Sanofi-Synthelabo), SR-144190 (Sanofi-Synthelabo) and UK-290795 (Pfizer Inc); and the neurokinin-3 receptor antagonists osanetant (Sanofi-Synthelabo) and talnetant (GlaxoSmithKline plc) will be given.  The review also reports the recent published patent literature in the area of novel therapeutic uses and novel formulations and combinations claimed for neurokinin receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmP-QXsiXq_7Vg90H21EOLACvtfcHk0li_Ss0BYZ4_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVGkurc%253D&md5=19cb9a8aedf8341d724795b208b51606</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGagliardi%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DM.%26atitle%3DAntagonists%2520at%2520the%2520neurokinin%2520receptors%2520-%2520recent%2520patent%2520literature%26jtitle%3DIDrugs%26date%3D2003%26volume%3D6%26spage%3D758%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicchi, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eirmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tettersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupniak, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycroft, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargraves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span> <span> </span><span class="NLM_article-title">Structural optimization affording 2-(<i>R</i>)-(1-(<i>R</i>)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(<i>S</i>)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4607</span>– <span class="NLM_lpage">4614</span>, <span class="refDoi"> DOI: 10.1021/jm980299k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980299k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlansrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4607-4614&author=J.+J.+Haleauthor=S.+G.+Millsauthor=M.+MacCossauthor=P.+E.+Finkeauthor=M.+A.+Cascieriauthor=S.+Sadowskiauthor=E.+Verauthor=G.+G.+Chicchiauthor=M.+Kurtzauthor=J.+Metzgerauthor=G.+Eirmannauthor=N.+N.+Tsouauthor=F.+D.+Tettersallauthor=N.+M.+Rupniakauthor=A.+R.+Williamsauthor=W.+Rycroftauthor=R.+Hargravesauthor=D.+E.+MacIntyre&title=Structural+optimization+affording+2-%28R%29-%281-%28R%29-3%2C5-bis%28trifluoromethyl%29phenylethoxy%29-3-%28S%29-%284-fluoro%29phenyl-4-+%283-oxo-1%2C2%2C4-triazol-5-yl%29methylmorpholine%2C+a+potent%2C+orally+active%2C+long-acting+morpholine+acetal+human+NK-1+receptor+antagonist&doi=10.1021%2Fjm980299k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist</span></div><div class="casAuthors">Hale, Jeffrey J.; Mills, Sander G.; MacCoss, Malcolm; Finke, Paul E.; Cascieri, Margaret A.; Sadowski, Sharon; Ber, Elzbieta; Chicchi, Gary G.; Kurtz, Marc; Metzger, Joseph; Eiermann, George; Tsou, Nancy N.; Tattersall, F. David; Rupniak, Nadia M. J.; Williams, Angela R.; Rycroft, Wayne; Hargreaves, Richard; MacIntyre, D. Euan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4607-4614</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural modifications requiring novel synthetic chem. were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist L-742694, and this resulted in the discovery of 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methyl morpholine (I).  This modified compd. is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to displace [125I]Substance P from hNK-1 receptors stably expressed in CHO cells (IC50 = 0.09 ± 0.06 nM) and by the measurement of the rates of assocn. (k1 = 2.8 ± 1.1 × 108 M-1 min-1) and dissocn. (k-1 = 0.0054 ± 0.003 min-1) of I from hNK-1 expressed in Sf9 membranes which yields Kd = 19 ± 12 pM and a t1/2 for receptor occupancy equal to 154 ± 75 min.  Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of I (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compd. has good oral bioavailability and peripheral duration of action.  Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of I as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 ± 0.006 mg/kg; IC50 (24 h) = 0.33 ± 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge.  The activity of I at extended time points in these preclin. animal models sets it apart from earlier morpholine antagonists (such as L-742694), and the piperidine antagonists CP 122721 and GR 205171 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P.  In part on the basis of these data, I has been identified as a potential clin. candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZTzBjAJV7W7Vg90H21EOLACvtfcHk0li_Ss0BYZ4_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlansrY%253D&md5=0ca98b5fb6a2957deffee22fa62aa988</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm980299k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980299k%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DFinke%26aufirst%3DP.%2BE.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DSadowski%26aufirst%3DS.%26aulast%3DVer%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DKurtz%26aufirst%3DM.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DEirmann%26aufirst%3DG.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DTettersall%26aufirst%3DF.%2BD.%26aulast%3DRupniak%26aufirst%3DN.%2BM.%26aulast%3DWilliams%26aufirst%3DA.%2BR.%26aulast%3DRycroft%26aufirst%3DW.%26aulast%3DHargraves%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26atitle%3DStructural%2520optimization%2520affording%25202-%2528R%2529-%25281-%2528R%2529-3%252C5-bis%2528trifluoromethyl%2529phenylethoxy%2529-3-%2528S%2529-%25284-fluoro%2529phenyl-4-%2520%25283-oxo-1%252C2%252C4-triazol-5-yl%2529methylmorpholine%252C%2520a%2520potent%252C%2520orally%2520active%252C%2520long-acting%2520morpholine%2520acetal%2520human%2520NK-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4607%26epage%3D4614%26doi%3D10.1021%2Fjm980299k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.2165/00003495-200464070-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2165%2F00003495-200464070-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=15025555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVOmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=777-794&author=T.+M.+Dandoauthor=C.+M.+Perry&title=Aprepitant%3A+a+review+of+its+use+in+the+prevention+of+chemotherapy-induced+nausea+and+vomiting&doi=10.2165%2F00003495-200464070-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Dando, Toni M.; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-794</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Aprepitant (Emend) is the first com. available drug from a new class of agents, the neurokinin NK1 receptor antagonists.  Oral aprepitant, in combination with other agents, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) assocd. with highly emetogenic chemotherapy in adults.  In three randomised, double-blind, placebo-controlled trials comparing aprepitant (125mg day 1, 80mg once daily on days 2 and 3 or 2-5) plus std. therapy (i.v. ondansetron and oral dexamethasone) with std. therapy plus placebo, overall complete responses (primary endpoint, defined as no emesis and no rescue therapy) were seen in significantly more patients in the aprepitant arms (63-73% vs. 43-52%, p < 0.01 for all comparisons).  Complete responses and complete protection during the acute and delayed phase, and overall complete protection were also obsd. in significantly more patients in the aprepitant arms.  The difference between treatment groups was more marked in the overall and delayed phases than in the acute phase.  The antiemetic efficacy of aprepitant plus std. therapy in the prevention of CINV was maintained for up to six cycles of chemotherapy.  Where assessed, more patients in the aprepitant plus std. therapy arms than the std. therapy plus placebo arms reported no impact of CINV on daily life, as assessed by the Functional Living Index-Emesis.  Aprepitant is generally well tolerated.  The most common adverse events in randomised trials were asthenia or fatigue.  Other adverse events experienced by aprepitant recipients include anorexia, constipation, diarrhoea, nausea (after day 5 of the study) and hiccups.  In addn. to being a substrate for cytochrome P 450 (CYP) 3A4, aprepitant is also a moderate inhibitor and inducer of this isoenzyme as well as an inducer of CYP2C9.  Thus, aprepitant has the potential to interact with other agents metabolised by hepatic CYP isoenzymes.  In one trial, there was a higher incidence of serious infection or febrile neutropenia in the aprepitant plus std. therapy arm than the std. therapy plus placebo arm; this was attributed to a pharmacokinetic interaction between aprepitant and dexamethasone.  In subsequent trials, a modified dexamethasone regimen was used.  In conclusion, when added to std. therapy (a serotonin 5-HT3 receptor antagonist and a corticosteroid), aprepitant is effective and generally well tolerated in the prevention of CINV assocd. with highly emetogenic chemotherapy in adults.  Despite marked advances in the prevention of CINV, std. therapy does not protect all patients.  The addn. of aprepitant to std. therapy provides an advance in the prevention of both acute and delayed CINV in adults with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopge6j7AQuILVg90H21EOLACvtfcHk0li_Ss0BYZ4_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVOmtrk%253D&md5=6583a8ed8cea7ba7d8d6f8cd8d7e12af</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464070-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464070-00013%26sid%3Dliteratum%253Aachs%26aulast%3DDando%26aufirst%3DT.%2BM.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DAprepitant%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D777%26epage%3D794%26doi%3D10.2165%2F00003495-200464070-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arjona Ferreira, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S.</span></span> <span> </span><span class="NLM_article-title">Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1222</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2011.05961.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1749-6632.2011.05961.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21434941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVykuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1222&publication_year=2011&pages=40-48&author=R.+Hargreavesauthor=J.+C.+Arjona+Ferreiraauthor=D.+Hughesauthor=J.+Brandsauthor=J.+Haleauthor=B.+Mattesonauthor=S.+Mills&title=Development+of+aprepitant%2C+the+first+neurokinin-1+receptor+antagonist+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting&doi=10.1111%2Fj.1749-6632.2011.05961.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Hargreaves, Richard; Ferreira, Juan Camilo Arjona; Hughes, David; Brands, Jos; Hale, Jeff; Mattson, Britta; Mills, Sandy</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-48</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Chemotherapy can be a life-prolonging treatment for many cancer patients, but it is often assocd. with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects.  EMEND (aprepitant) is the first and only neurokinin-1 (NK-1) receptor antagonist available on the market for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).  Aprepitant acts centrally at NK-1 receptors in vomiting centers within the central nervous system to block their activation by substance P released as an unwanted consequence of chemotherapy.  By controlling nausea and vomiting, EMEND helps improve patients' daily living and their ability to complete multiple cycles of chemotherapy.  The development of aprepitant included a novel nanoparticle formulation to optimize oral absorption and innovative chem. to discover a prodrug form suitable for i.v. administration to improve compliance and convenience for healthcare professionals and cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLqa3WCNyLLVg90H21EOLACvtfcHk0lgCnx7WKvuq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVykuro%253D&md5=124db36771a8f5445b8e389cff6c3ea8</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2011.05961.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2011.05961.x%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DArjona%2BFerreira%26aufirst%3DJ.%2BC.%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DBrands%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DMatteson%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520aprepitant%252C%2520the%2520first%2520neurokinin-1%2520receptor%2520antagonist%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D1222%26spage%3D40%26epage%3D48%26doi%3D10.1111%2Fj.1749-6632.2011.05961.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Rolapitant: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0485-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs40265-015-0485-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26467681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1941-1945&author=Y.+Y.+Syed&title=Rolapitant%3A+first+global+approval&doi=10.1007%2Fs40265-015-0485-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1941-1945</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rolapitant (Varubi) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.  Unlike other approved agents in this class, rolapitant does not interact with cytochrome P 450 (CYP) enzyme CYP3A4.  It also has a long elimination half-life which means that a single dose could prevent CINV during the entire at-risk period (0-120 h).  An i.v. formulation of rolapitant is under clin. development in the USA.  Phase II development of rolapitant in postoperative nausea and vomiting, and cough appears to have been discontinued.  This article summarizes the milestones in the development of rolapitant leading to the first approval for the prevention of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwyS3mfly17Vg90H21EOLACvtfcHk0lgCnx7WKvuq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM&md5=053f47d986332d2442b6fc8a08066814</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0485-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0485-8%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRolapitant%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1941%26epage%3D1945%26doi%3D10.1007%2Fs40265-015-0485-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Navari, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aapro, M.</span></span> <span> </span><span class="NLM_article-title">Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1356</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1515442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1056%2FNEJMra1515442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27050207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ojtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1356-1367&author=R.+M.+Navariauthor=M.+Aapro&title=Antiemetic+prophylaxis+for+chemotherapy-induced+nausea+and+vomiting&doi=10.1056%2FNEJMra1515442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Antiemetic prophylaxis for chemotherapy- induced nausea and vomiting</span></div><div class="casAuthors">Navari, Rudolph M.; Aapro, Matti</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1356-1367</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRt3NWIY_cBLVg90H21EOLACvtfcHk0lgCnx7WKvuq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ojtb%252FN&md5=09992cf025790eeff1959b9f83d752d9</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1515442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1515442%26sid%3Dliteratum%253Aachs%26aulast%3DNavari%26aufirst%3DR.%2BM.%26aulast%3DAapro%26aufirst%3DM.%26atitle%3DAntiemetic%2520prophylaxis%2520for%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1356%26epage%3D1367%26doi%3D10.1056%2FNEJMra1515442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human NK1 tachykinin receptor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">13264</span>– <span class="NLM_lpage">13269</span>, <span class="refDoi"> DOI: 10.1073/pnas.1812717115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1812717115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=30538204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=13264-13269&author=J.+Yinauthor=K.+Chapmanauthor=L.+D.+Clarkauthor=Z.+Shaoauthor=D.+Borekauthor=Q.+Xuauthor=J.+Wangauthor=D.+M.+Rosenbaum&title=Crystal+structure+of+the+human+NK1+tachykinin+receptor&doi=10.1073%2Fpnas.1812717115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human NK1 tachykinin receptor</span></div><div class="casAuthors">Yin, Jie; Chapman, Karen; Clark, Lindsay D.; Shao, Zhenhua; Borek, Dominika; Xu, Qingping; Wang, Junmei; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">13264-13269</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The NK1 tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals.  Through activation of NK1R, substance P modulates a wide variety of physiol. and disease processes including nociception, inflammation, and depression.  Human NK1R (hNK1R) modulators have shown promise in clin. trials for migraine, depression, and emesis.  However, the only currently approved drugs targeting hNK1R are inhibitors for chemotherapy-induced nausea and vomiting (CINV).  To better understand the mol. basis of ligand recognition and selectivity, we solved the crystal structure of hNK1R bound to the inhibitor L760735, a close analog of the drug aprepitant.  Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor.  We used our structure as a template for computational docking and mol.-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant.  The structure of hNK1R is a valuable tool in the further development of tachykinin receptor modulators for multiple clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLQ8thSAml-7Vg90H21EOLACvtfcHk0lgCnx7WKvuq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rsrjM&md5=8e19c80ab2ebe7911c81df25e1232d01</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1812717115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1812717115%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DL.%2BD.%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DBorek%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520NK1%2520tachykinin%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D13264%26epage%3D13269%26doi%3D10.1073%2Fpnas.1812717115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimurer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wüthrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Human Substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">638</span> <span class="refDoi"> DOI: 10.1038/s41467-019-08568-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fs41467-019-08568-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=30733446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Crurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=S.+Chenauthor=M.+Luauthor=D.+Liuauthor=L.+Yangauthor=C.+Yiauthor=L.+Maauthor=H.+Zhangauthor=Q.+Liuauthor=T.+M.+Frimurerauthor=M.-W.+Wangauthor=T.+W.+Schwartzauthor=R.+C.+Stevensauthor=B.+Wuauthor=K.+W%C3%BCthrichauthor=Q.+Zhao&title=Human+Substance+P+receptor+binding+mode+of+the+antagonist+drug+aprepitant+by+NMR+and+crystallography&doi=10.1038%2Fs41467-019-08568-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography</span></div><div class="casAuthors">Chen, Shuanghong; Lu, Mengjie; Liu, Dongsheng; Yang, Lingyun; Yi, Cuiying; Ma, Limin; Zhang, Hui; Liu, Qing; Frimurer, Thomas M.; Wang, Ming-Wei; Schwartz, Thue W.; Stevens, Raymond C.; Wu, Beili; Wuthrich, Kurt; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">638</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting.  However, the lack of data on NK1R structure and biochem. has limited further drug development targeting this receptor.  Here, we combine NMR spectroscopy and X-ray crystallog. to provide dynamic and static characterization of the binding mode of aprepitant in complexes with human NK1R variants.  The 19F-NMR showed a slow off-rate in the binding site, where aprepitant occupies multiple substates that exchange with frequencies in the millisecond range.  The environment of the bound ligand is affected by the amino acid in position 2.50, which plays a key role in ligand binding and receptor signaling in class A GPCRs.  Crystal structures now reveal how receptor signaling relates to the conformation of the conserved NP7.50xxY motif in transmembrane helix VII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJt3rhlppsLVg90H21EOLACvtfcHk0lgAJXjot8KS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Crurg%253D&md5=e00d2059f8f51f3ce8b20d43ea874217</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08568-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08568-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DHuman%2520Substance%2520P%2520receptor%2520binding%2520mode%2520of%2520the%2520antagonist%2520drug%2520aprepitant%2520by%2520NMR%2520and%2520crystallography%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-08568-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vengut-Climent, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orcel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological studies of a library of NK1-receptor ligands based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4<i>H</i>-pyran core: switch from antagonist to agonist effect by chemical modification</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">644</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.ejmech.2017.06.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28710964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=644-660&author=R.+Recioauthor=E.+Vengut-Climentauthor=B.+Mouillacauthor=H.+Orcelauthor=M.+L%C3%B3pez-L%C3%A1zaroauthor=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=E.+%C3%81lvarezauthor=N.+Khiarauthor=I.+Fern%C3%A1ndez&title=Design%2C+synthesis+and+biological+studies+of+a+library+of+NK1-receptor+ligands+based+on+a+5-arylthiosubstituted+2-amino-4%2C6-diaryl-3-cyano-4H-pyran+core%3A+switch+from+antagonist+to+agonist+effect+by+chemical+modification&doi=10.1016%2Fj.ejmech.2017.06.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification</span></div><div class="casAuthors">Recio, Rocio; Vengut-Climent, Empar; Mouillac, Bernard; Orcel, Helene; Lopez-Lazaro, Miguel; Calderon-Montano, Jose Manuel; Alvarez, Eleuterio; Khiar, Noureddine; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">644-660</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A library of 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyrans has been synthesized as a new family of non-peptide NK1 receptor ligands by a one-pot cascade process.  Their biol. effects via interaction with the NK1 receptor were exptl. detd. as percentage of inhibition (for antagonists) and percentage of activation (for agonists), compared to the substance P (SP) effect, in IPone assay.  A set of these amino compds. was found to inhibit the action of SP, and therefore can be considered as a new family of SP-antagonists.  Interestingly, the acylation of the 2-amino position causes a switch from antagonist to agonist activity.  The 5-phenylsulfonyl-2-amino deriv. I showed the highest antagonist activity, while the 5-p-tolylsulfenyl-2-trifluoroacetamide deriv. II showed the highest agonist effect.  As expected, in the case of the 5-sulfinyl derivs., there was an enantiomeric discrimination in favor of one of the two enantiomers, specifically those with (SS,RC) configuration.  The anticancer activity studies assessed by using human A-549 lung cancer cells and MRC-5 non-malignant lung fibroblasts, revealed a statistically significant selective cytotoxic effect of some of these 2-amino-4H-pyran derivs. toward the lung cancer cells.  These studies demonstrated that the newly synthesized 4H-pyran derivs. can be used as a starting point for the synthesis of novel SP-antagonists with higher anticancer activity in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8uRlj5H-X6rVg90H21EOLACvtfcHk0lgAJXjot8KS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7jL&md5=4cc3a564a7950ef574a7a82740030368</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DRecio%26aufirst%3DR.%26aulast%3DVengut-Climent%26aufirst%3DE.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DOrcel%26aufirst%3DH.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3D%25C3%2581lvarez%26aufirst%3DE.%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520studies%2520of%2520a%2520library%2520of%2520NK1-receptor%2520ligands%2520based%2520on%2520a%25205-arylthiosubstituted%25202-amino-4%252C6-diaryl-3-cyano-4H-pyran%2520core%253A%2520switch%2520from%2520antagonist%2520to%2520agonist%2520effect%2520by%2520chemical%2520modification%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D644%26epage%3D660%26doi%3D10.1016%2Fj.ejmech.2017.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span>; <span class="NLM_string-name">Fernández, I.</span>; <span class="NLM_string-name">Recio, R.</span>; <span class="NLM_string-name">López, M.</span>; <span class="NLM_string-name">Calderón, J. M.</span></span> <span> </span><span class="NLM_article-title">Antagonistas de los receptores NK1 derivados de hidratos de carbono, método de obtención y uso médico</span>. WIPO Patent <span class="NLM_patent">WO2016189179A1</span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=N.+Khiar&author=I.+Fern%C3%A1ndez&author=R.+Recio&author=M.+L%C3%B3pez&author=J.+M.+Calder%C3%B3n&title=Antagonistas+de+los+receptores+NK1+derivados+de+hidratos+de+carbono%2C+m%C3%A9todo+de+obtenci%C3%B3n+y+uso+m%C3%A9dico"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26atitle%3DAntagonistas%2520de%2520los%2520receptores%2520NK1%2520derivados%2520de%2520hidratos%2520de%2520carbono%252C%2520m%25C3%25A9todo%2520de%2520obtenci%25C3%25B3n%2520y%2520uso%2520m%25C3%25A9dico%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordner, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-alkyl quinuclidinium substance P antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1156</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)80246-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0960-894X%2801%2980246-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVGisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=1153-1156&author=J.+A.+Loweauthor=S.+Drozdaauthor=S.+McLeanauthor=R.+Crawfordauthor=D.+Bryceauthor=J.+Bordner&title=N-alkyl+quinuclidinium+substance+P+antagonists&doi=10.1016%2FS0960-894X%2801%2980246-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">N-alkyl quinuclidinium substance P antagonists</span></div><div class="casAuthors">Lowe, John A., III; Drozda, Susan E.; McLean, Stafford; Crawford, Rosemary T.; Bryce, Dianne K.; Bordner, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1153-6</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    </div><div class="casAbstract">The synthesis and structure-activity relationship of bridgehead N-alkylated analogs of the nonpeptide substance P antagonist CP-96,345 are described.  The results indicate that the bridgehead nitrogen may provide more of an anchoring function rather than being in intimate contact with the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXbmzNwXeMTrVg90H21EOLACvtfcHk0lis1dGtxzZs2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVGisrw%253D&md5=dc0c355418a1652c5b3f3aa094dbda29</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980246-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980246-8%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DDrozda%26aufirst%3DS.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DR.%26aulast%3DBryce%26aufirst%3DD.%26aulast%3DBordner%26aufirst%3DJ.%26atitle%3DN-alkyl%2520quinuclidinium%2520substance%2520P%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D1153%26epage%3D1156%26doi%3D10.1016%2FS0960-894X%2801%2980246-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewart, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascieri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanNiel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2] octane human NK1 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4793</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1021/jm00024a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00024a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK2MXptVGqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4793-4805&author=C.+J.+Swainauthor=E.+M.+Sewartauthor=M.+A.+Cascieriauthor=T.+M.+Fangauthor=R.+Herbertauthor=D.+E.+MacIntyreauthor=K.+J.+Merchantauthor=S.+N.+Owenauthor=A.+P.+Owensauthor=R.+Bakerauthor=V.+Sabinauthor=M.+Teallauthor=M.+B.+VanNielauthor=B.+J.+Williamsauthor=S.+Sadowskiauthor=C.+Straderauthor=R.+G.+Ballauthor=R.+Baker&title=Identification+of+a+series+of+3-%28benzyloxy%29-1-azabicyclo%5B2.2.2%5D+octane+human+NK1+antagonists&doi=10.1021%2Fjm00024a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Series of 3-(Benzyloxy)-1-azabicyclo[2.2.2]octane Human NK1 Antagonists</span></div><div class="casAuthors">Swain, Christopher J.; Sewart, Eileen M.; Cascieri, Margaret A.; Fong, Tung M.; Herbert, Richard; MacIntyre, D Euan; Merchant, Kevin J.; Owen, Simon N.; Owens, Andrew P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4793-805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and in vitro and in vivo evaluation of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists are described.  While a no. of 3,5-disubstituted benzyl ethers afford high affinity, the 3,5-bis(trifluoromethyl)benzyl was found to combine high in vitro affinity with good oral activity.  Detailed structure-activity relationship studies in conjunction with data from mol. modeling and mutagenesis work have allowed the construction of a model of the pharmacophore.  Specific interactions that have been identified include an interaction between His-197 and one of the rings of the benzhydryl, a lipophilic pocket contg. His-265 that the benzyl ether occupies, and a possible hydrogen bond between Asp-165 and the oxygen of the benzyl ether.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8b_adDk4k7Vg90H21EOLACvtfcHk0lis1dGtxzZs2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptVGqtrw%253D&md5=87b83ba4cc52988c19da7762c85e2891</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Fjm00024a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00024a007%26sid%3Dliteratum%253Aachs%26aulast%3DSwain%26aufirst%3DC.%2BJ.%26aulast%3DSewart%26aufirst%3DE.%2BM.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DFang%26aufirst%3DT.%2BM.%26aulast%3DHerbert%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DMerchant%26aufirst%3DK.%2BJ.%26aulast%3DOwen%26aufirst%3DS.%2BN.%26aulast%3DOwens%26aufirst%3DA.%2BP.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DSabin%26aufirst%3DV.%26aulast%3DTeall%26aufirst%3DM.%26aulast%3DVanNiel%26aufirst%3DM.%2BB.%26aulast%3DWilliams%26aufirst%3DB.%2BJ.%26aulast%3DSadowski%26aufirst%3DS.%26aulast%3DStrader%26aufirst%3DC.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DBaker%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520a%2520series%2520of%25203-%2528benzyloxy%2529-1-azabicyclo%255B2.2.2%255D%2520octane%2520human%2520NK1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4793%26epage%3D4805%26doi%3D10.1021%2Fjm00024a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shands, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beusen, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G. R.</span></span> <span> </span><span class="NLM_article-title">Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3609</span>– <span class="NLM_lpage">3623</span>, <span class="refDoi"> DOI: 10.1021/jm9700171</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9700171" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3609-3623&author=Y.+Takeuchiauthor=E.+F.+Shandsauthor=D.+D.+Beusenauthor=G.+R.+Marshall&title=Derivation+of+a+three-dimensional+pharmacophore+model+of+substance+P+antagonists+bound+to+the+neurokinin-1+receptor&doi=10.1021%2Fjm9700171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Derivation of a 3-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor</span></div><div class="casAuthors">Takeuchi, Yasuo; Shands, E. F. Berkley; Beusen, Denise D.; Marshall, Garland R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3609-3623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constrained systematic search was used in an exhaustive conformational anal. of a structurally diverse set of substance P (SP) antagonists to identify a unique hypothesis for their bound conformation at the neurokinin-1 receptor.  In this conformation, 2 arom. groups essential for high affinity adopt a perpendicular or edge-on arrangement.  This pharmacophore hypothesis for the receptor-bound conformation was used in a comparative mol. field anal. (CoMFA) of an expanded set of SP antagonists, and the predictive ability of the resulting 3-dimensional quant. structure-activity relationship (3D-QSAR) was evaluated against a test set of SP antagonists different from those in the training set.  This CoMFA model based on the Constrained Search alignment yielded cross-validated, conventional, and predictive r2 values equal to 0.70, 0.93, and 0.82, resp.  For comparison, the SP antagonists were forced into an alternative poorer alignment in which the 2 arom. rings were parallel and then subjected to a CoMFA anal.  Both the parallel and perpendicular arrangements of the arom. rings are seen in x-ray structures of SP antagonists and were proposed as candidates for the receptor-bound conformation.  The parallel (or stacked) conformation yielded a poorer correlation.  The results indicate that although both alignments could generate a reasonable CoMFA correlation, the stacked conformation is unlikely to be the receptor-bound conformation, as the covalent structure of the antagonists precludes a common geometry in which the arom. rings are stacked.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoqyowQ9wK7Vg90H21EOLACvtfcHk0lis1dGtxzZs2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1Smsb8%253D&md5=26b04f7ea82804a36ab6a9017a930469</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9700171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9700171%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DY.%26aulast%3DShands%26aufirst%3DE.%2BF.%26aulast%3DBeusen%26aufirst%3DD.%2BD.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26atitle%3DDerivation%2520of%2520a%2520three-dimensional%2520pharmacophore%2520model%2520of%2520substance%2520P%2520antagonists%2520bound%2520to%2520the%2520neurokinin-1%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D3609%26epage%3D3623%26doi%3D10.1021%2Fjm9700171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navratilova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin1 receptor antagonists possessing two penicillamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5491</span>– <span class="NLM_lpage">5501</span>, <span class="refDoi"> DOI: 10.1021/jm100157m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100157m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ektbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5491-5501&author=T.+Yamamotoauthor=P.+Nairauthor=N.+E.+Jacobsenauthor=V.+Kulkarniauthor=P.+Davisauthor=S.+Maauthor=E.+Navratilovaauthor=H.+I.+Yamamuraauthor=T.+W.+Vanderahauthor=F.+Porrecaauthor=J.+Laiauthor=V.+J.+Hruby&title=Biological+and+conformational+evaluation+of+bifunctional+compounds+for+opioid+receptor+agonists+and+neurokinin1+receptor+antagonists+possessing+two+penicillamines&doi=10.1021%2Fjm100157m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and Conformational Evaluation of Bifunctional Compounds for Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists Possessing Two Penicillamines</span></div><div class="casAuthors">Yamamoto, Takashi; Nair, Padma; Jacobsen, Neil E.; Kulkarni, Vinod; Davis, Peg; Ma, Shou-wu; Navratilova, Edita; Yamamura, Henry I.; Vanderah, Todd W.; Porreca, Frank; Lai, Josephine; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5491-5501</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuropathic pain states and tolerance to opioids can result from system changes in the CNS, such as up-regulation of the NK1 receptor and substance P, lead to antiopioid effects in ascending or descending pain-signaling pathways.  Bifunctional compds., possessing both the NK1 antagonist pharmacophore and the opioid agonist pharmacophore with δ-selectivity, could counteract these system changes to have significant analgesic efficacy without undesirable side effects.  As a result of the introduction of cyclic and topol. constraints with penicillamines, Tyr-cyclo[D-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3',5'-(CF3)2-Bzl] (I) was found as the best bifunctional compd. with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold δ-selectivity over the μ-receptor.  The NMR structural anal. of I revealed that the relative positioning of the two connected pharmacophores as well as its cyclic and topol. constraints might be responsible for its excellent bifunctional activities as well as its significant δ-opioid selectivity.  Together with the obsd. high metabolic stability, I could be considered as a valuable research tool and possibly a promising candidate for a novel analgesic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXStfjzinIYrVg90H21EOLACvtfcHk0lhT9vOYfFq2ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ektbs%253D&md5=786e32725d25cff7fbe2b5c2589da44d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm100157m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100157m%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DJacobsen%26aufirst%3DN.%2BE.%26aulast%3DKulkarni%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DNavratilova%26aufirst%3DE.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DBiological%2520and%2520conformational%2520evaluation%2520of%2520bifunctional%2520compounds%2520for%2520opioid%2520receptor%2520agonists%2520and%2520neurokinin1%2520receptor%2520antagonists%2520possessing%2520two%2520penicillamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5491%26epage%3D5501%26doi%3D10.1021%2Fjm100157m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junicke, H.</span></span> <span> </span><span class="NLM_article-title">Carbohydrate complexes of platinum-group metals</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4283</span>– <span class="NLM_lpage">4317</span>, <span class="refDoi"> DOI: 10.1021/cr9903050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9903050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVamtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=4283-4317&author=D.+Steinbornauthor=H.+Junicke&title=Carbohydrate+complexes+of+platinum-group+metals&doi=10.1021%2Fcr9903050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Carbohydrate Complexes of Platinum-Group Metals</span></div><div class="casAuthors">Steinborn, Dirk; Junicke, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4283-4317</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 263 refs., discusses the prepn. of carbohydrate complexes of platinum-group metals, not including complexes with ligands that contain carbohydrate moieties remote from the ligator atoms, in relation to their mode of coordination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3DeQNIvCx-LVg90H21EOLACvtfcHk0lhT9vOYfFq2ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVamtL8%253D&md5=d8ec6423e3eef474b7da12c7364cf440</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fcr9903050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9903050%26sid%3Dliteratum%253Aachs%26aulast%3DSteinborn%26aufirst%3DD.%26aulast%3DJunicke%26aufirst%3DH.%26atitle%3DCarbohydrate%2520complexes%2520of%2520platinum-group%2520metals%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D4283%26epage%3D4317%26doi%3D10.1021%2Fcr9903050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Benessere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Litto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Roma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruffo, F.</span></span> <span> </span><span class="NLM_article-title">Carbohydrates as building blocks of privileged ligands</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.ccr.2009.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2010&pages=390-401&author=V.+Benessereauthor=R.+Del+Littoauthor=A.+De+Romaauthor=F.+Ruffo&title=Carbohydrates+as+building+blocks+of+privileged+ligands&doi=10.1016%2Fj.ccr.2009.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Carbohydrates as building blocks of privileged ligands</span></div><div class="casAuthors">Benessere, Vincenzo; Del Litto, Raffaella; De Roma, Antonella; Ruffo, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Privileged ligands are chiral auxiliaries of wide applicability in asym. catalysis.  In the previous decades, their effective three-dimensional structures were often reproduced by using building blocks from a chiral pool, such as the carbohydrates.  This strategy provided unique ligand moieties which combine the performance of privileged ligands with increased flexibility and accessibility.  This review gave an overview of the research within this field, giving emphasis to the best results obtained with each ligand type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvddL-_d0Xp7Vg90H21EOLACvtfcHk0lhT9vOYfFq2ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLrP&md5=aaa5303aeb7e77022d28712bd36efd21</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DBenessere%26aufirst%3DV.%26aulast%3DDel%2BLitto%26aufirst%3DR.%26aulast%3DDe%2BRoma%26aufirst%3DA.%26aulast%3DRuffo%26aufirst%3DF.%26atitle%3DCarbohydrates%2520as%2520building%2520blocks%2520of%2520privileged%2520ligands%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2010%26volume%3D254%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.ccr.2009.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suárez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Phosphinite thioglygosides as useful ligands for palladium catalyzed asymmetric substitution: synthesis of both enantiomers using natural sugars as catalyst precursors</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">2963</span>– <span class="NLM_lpage">2967</span>, <span class="refDoi"> DOI: 10.1055/s-2005-918963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1055%2Fs-2005-918963" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=2963-2967&author=N.+Khiarauthor=B.+Su%C3%A1rezauthor=V.+Valdiviaauthor=I.+Fern%C3%A1ndez&title=Phosphinite+thioglygosides+as+useful+ligands+for+palladium+catalyzed+asymmetric+substitution%3A+synthesis+of+both+enantiomers+using+natural+sugars+as+catalyst+precursors&doi=10.1055%2Fs-2005-918963"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-918963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-918963%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DB.%26aulast%3DValdivia%26aufirst%3DV.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DPhosphinite%2520thioglygosides%2520as%2520useful%2520ligands%2520for%2520palladium%2520catalyzed%2520asymmetric%2520substitution%253A%2520synthesis%2520of%2520both%2520enantiomers%2520using%2520natural%2520sugars%2520as%2520catalyst%2520precursors%26jtitle%3DSynlett%26date%3D2005%26volume%3D2005%26spage%3D2963%26epage%3D2967%26doi%3D10.1055%2Fs-2005-918963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallouk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soufiaoui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective organocatalytic oxidation of functionalized sterically hindered disulfides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1021/ol070056z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol070056z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1255-1258&author=N.+Khiarauthor=S.+Malloukauthor=V.+Valdiviaauthor=K.+Bougrinauthor=M.+Soufiaouiauthor=I.+Fern%C3%A1ndez&title=Enantioselective+organocatalytic+oxidation+of+functionalized+sterically+hindered+disulfides&doi=10.1021%2Fol070056z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Organocatalytic Oxidation of Functionalized Sterically Hindered Disulfides</span></div><div class="casAuthors">Khiar, Noureddine; Mallouk, Siham; Valdivia, Victoria; Bougrin, Khalid; Soufiaoui, Mohammed; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1255-1258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1st study on enantioselective oxidn. of functionalized sterically hindered disulfides is reported.  The Shi organocatalytic system using carbohydrate-derived ketone with oxone is superior to the Ellman-Bolm vanadium catalyst in terms of chem. yield and enantioselectivity.  Whereas the latter system afforded mostly racemic thiosulfinates in low to moderate yields, the former one afforded thiosulfinates (e.g. S-1-(acetoxymethyl)cyclohexyl 1-(acetoxymethyl)cyclohexanesulfinothioate) with up to 96% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOuYPj0UtPPLVg90H21EOLACvtfcHk0ljqwCEDwJVHjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisbw%253D&md5=4572f40f6ac4864339de12266d2bf01e</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1021%2Fol070056z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070056z%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DMallouk%26aufirst%3DS.%26aulast%3DValdivia%26aufirst%3DV.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DSoufiaoui%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3DEnantioselective%2520organocatalytic%2520oxidation%2520of%2520functionalized%2520sterically%2520hindered%2520disulfides%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D1255%26epage%3D1258%26doi%3D10.1021%2Fol070056z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelouan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">“Sulfolefin”: highly modular mixed S/olefin ligands for enantioselectve Rh-catalyzed 1,4-addition</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2366</span>– <span class="NLM_lpage">2368</span>, <span class="refDoi"> DOI: 10.1039/c2ob07132k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1039%2Fc2ob07132k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22277929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Ghu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2366-2368&author=N.+Khiarauthor=A.+Salvadorauthor=A.+Chelouanauthor=I.+Fern%C3%A1ndez&title=%E2%80%9CSulfolefin%E2%80%9D%3A+highly+modular+mixed+S%2Folefin+ligands+for+enantioselectve+Rh-catalyzed+1%2C4-addition&doi=10.1039%2Fc2ob07132k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29cR"><div class="casContent"><span class="casTitleNuber">29c</span><div class="casTitle"><span class="NLM_cas:atitle">"Sulfolefin": Highly modular mixed S/Olefin ligands for enantioselective Rh-catalyzed 1,4-addition</span></div><div class="casAuthors">Khiar, Noureddine; Salvador, Alvaro; Chelouan, Ahmed; Alcudia, Ana; Fernandez, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2366-2368</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Reported is a single high yielding step approxn. to mixed olefin/sulfinamide ligands enclosing a chiral sulfur atom as the sole chiral center.  The synthetic design is validated by a rapid optimization of the substituent at the sulfinyl sulfur, and by the synthesis of an efficient, highly enantioselective catalyst for the Rh-catalyzed 1,4-addn. of boronic acids to both, cyclic and acyclic olefins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGbjtq3m85LVg90H21EOLACvtfcHk0ljqwCEDwJVHjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Ghu78%253D&md5=7e1a42ef46c58d7f15274c94e29b5cb0</span></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1039%2Fc2ob07132k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob07132k%26sid%3Dliteratum%253Aachs%26aulast%3DKhiar%26aufirst%3DN.%26aulast%3DSalvador%26aufirst%3DA.%26aulast%3DChelouan%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26atitle%3D%25E2%2580%259CSulfolefin%25E2%2580%259D%253A%2520highly%2520modular%2520mixed%2520S%252Folefin%2520ligands%2520for%2520enantioselectve%2520Rh-catalyzed%25201%252C4-addition%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D2366%26epage%3D2368%26doi%3D10.1039%2Fc2ob07132k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Assali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiar, N.</span></span> <span> </span><span class="NLM_article-title">Supramolecular diversity through click chemistry: switching from nanomicelles to 1D nanotubes and tridimensional hydrogels</span>. <i>Chem. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4250</span>– <span class="NLM_lpage">4261</span>, <span class="refDoi"> DOI: 10.1021/cm4022613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cm4022613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGkurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=4250-4261&author=M.+Assaliauthor=J.-J.+Cidauthor=I.+Fern%C3%A1ndezauthor=N.+Khiar&title=Supramolecular+diversity+through+click+chemistry%3A+switching+from+nanomicelles+to+1D+nanotubes+and+tridimensional+hydrogels&doi=10.1021%2Fcm4022613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29dR"><div class="casContent"><span class="casTitleNuber">29d</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular Diversity through Click Chemistry: Switching from Nanomicelles to 1D-Nanotubes and Tridimensional Hydrogels</span></div><div class="casAuthors">Assali, Mohyeddin; Cid, Juan-Jose; Fernandez, Inmaculada; Khiar, Noureddine</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Materials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4250-4261</span>CODEN:
                <span class="NLM_cas:coden">CMATEX</span>;
        ISSN:<span class="NLM_cas:issn">0897-4756</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The size and shape of nanoparticles are of prominent importance for their biol. activities and for their application as smart drug delivery systems.  Thus, synthetic designs allowing divergent synthesis of nanoscale materials with controlled size, morphol., and surface chem. are currently highly desirable, but they remain a major challenge.  Herein, we report a simple method for the creation of supramol. diversity from structurally related diacetylenic-based glycolipids.  We have found that neoglycolipids with an amide function between the hydrophilic and hydrophobic part of the amphiphile afford tridimensional micelles, while those having a triazole self-organize into 1D-nanotubes.  Addnl., at higher concns., the clicked amphiphiles form hydrogels through three-dimensional networks of bundled nanotubes.  Photopolymn. of the obtained nanomaterials leads to the formation of conjugated polydiacetylene backbone of alternating enyne groups, which rigidify glyconanomaterial structures enhancing their phys. stability.  The obtained nanostructures were extensively characterized using transmission electron microscopy (TEM), SEM, and at. force microscopy (AFM) techniques, enabling the confirmation of the formation of tubular structures in water for all triazolo-substituted neoglycolipids and micellar structures for the glycolipid contg. an amide group.  This fact refutes the so-called isosteric character of 1,2,3-triazole and amide groups, at least, at the supramol. level and point out to the possibility of using the CuAAC between azides and alkynes to create supramol. diversity at the nanoscale.  The functionality of the gel was, moreover, evaluated as a nanocontainer for the incarceration and controlled release of the antitumoral topotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWE9llsGxFLVg90H21EOLACvtfcHk0ljqwCEDwJVHjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGkurnL&md5=101f71dd222a4ba1a995ef8bb6755f6f</span></div><a href="/servlet/linkout?suffix=cit29d&amp;dbid=16384&amp;doi=10.1021%2Fcm4022613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcm4022613%26sid%3Dliteratum%253Aachs%26aulast%3DAssali%26aufirst%3DM.%26aulast%3DCid%26aufirst%3DJ.-J.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DI.%26aulast%3DKhiar%26aufirst%3DN.%26atitle%3DSupramolecular%2520diversity%2520through%2520click%2520chemistry%253A%2520switching%2520from%2520nanomicelles%2520to%25201D%2520nanotubes%2520and%2520tridimensional%2520hydrogels%26jtitle%3DChem.%2520Mater.%26date%3D2013%26volume%3D25%26spage%3D4250%26epage%3D4261%26doi%3D10.1021%2Fcm4022613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiviriga, I.</span></span> <span> </span><span class="NLM_article-title">Selective excitation 1D-NMR experiments for the assignement of the absolute configuration of secondary alcohols</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">3978</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1021/jo3003375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo3003375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=3978-3985&author=I.+Ghiviriga&title=Selective+excitation+1D-NMR+experiments+for+the+assignement+of+the+absolute+configuration+of+secondary+alcohols&doi=10.1021%2Fjo3003375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Excitation 1D-NMR Experiments for the Assignment of the Absolute Configuration of Secondary Alcohols</span></div><div class="casAuthors">Ghiviriga, Ion</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3978-3985</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Routine selective excitation expts., easy to set up on modern NMR spectrometers, allow for the detn. of the abs. configuration of chiral secondary alcs. by double derivatization directly in the NMR tube.  As a general method, TOCSY1D with selective excitation of the α proton in the MPA esters and with a short mixing time reveals only the nearby protons in the coupling network.  Typically, the anal. takes less than 30 min.  A longer mixing time, selective excitation of other signals, or NOESY1D expts. can be used for measuring ΔδRS of other protons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPP0DPdXIL7Vg90H21EOLACvtfcHk0lhU5dVUrG-cMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVWksrc%253D&md5=3fd8b819eaa16c15bc606cad90a3d86a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo3003375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo3003375%26sid%3Dliteratum%253Aachs%26aulast%3DGhiviriga%26aufirst%3DI.%26atitle%3DSelective%2520excitation%25201D-NMR%2520experiments%2520for%2520the%2520assignement%2520of%2520the%2520absolute%2520configuration%2520of%2520secondary%2520alcohols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D3978%26epage%3D3985%26doi%3D10.1021%2Fjo3003375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer ancer</span>. <i>Sci. World J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>, <span class="NLM_elocation-id">381434</span> <span class="refDoi"> DOI: 10.1100/2012/381434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1100%2F2012%2F381434" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&author=M.+Rossoauthor=M.+Mu%C3%B1ozauthor=M.+Berger&title=The+role+of+neurokinin-1+receptor+in+the+microenvironment+of+inflammation+and+cancer+ancer&doi=10.1100%2F2012%2F381434"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1100%2F2012%2F381434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1100%252F2012%252F381434%26sid%3Dliteratum%253Aachs%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520neurokinin-1%2520receptor%2520in%2520the%2520microenvironment%2520of%2520inflammation%2520and%2520cancer%2520ancer%26jtitle%3DSci.%2520World%2520J.%26date%3D2012%26volume%3D2012%26doi%3D10.1100%2F2012%2F381434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Armesto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.697153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1517%2F13543776.2012.697153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22697287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=735-746&author=M.+Mu%C3%B1ozauthor=J.+Martinez-Armestoauthor=R.+Cove%C3%B1as&title=NK-1+receptor+antagonists+as+antitumor+drugs%3A+a+survey+of+the+literature+from+2000+to+2011&doi=10.1517%2F13543776.2012.697153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011</span></div><div class="casAuthors">Munoz, Miguel; Martinez-Armesto, Juan; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-746</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: After binding to the neurokinin (NK-1) receptor, substance P (SP) induces tumor cell proliferation, the migration of tumor cells (invasion and metastasis) and angiogenesis.  By contrast, NK-1 receptor antagonists inhibit tumor cell proliferation (tumor cells die by apoptosis), block the migratory activity of tumor cells and exert antiangiogenic properties.Areas covered: This review offers a 12-yr overview of the underlying mechanism of the action of the SP/NK-1 receptor system and NK-1 receptor antagonists in cancer, providing a new approach to the treatment of tumors.Expert opinion: Chem. diverse NK-1 receptor antagonists have been identified.  The antitumor action of these compds. is independent of their chem. structures and such action is assocd. with their affinity for the NK-1 receptor and with the dose of the antagonist administered.  The NK-1 receptor can be considered as a target in cancer treatment and NK-1 receptor antagonists could be considered as new antitumor drugs.  The NK-1 receptor antagonist aprepitant is used in clin. practice and exerts an antitumor action against tumor cells in vitro.  In the future, such antitumor action should be tested in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowJRmIy_bZ7Vg90H21EOLACvtfcHk0lhU5dVUrG-cMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGrtbg%253D&md5=8e5b53c6b90cac0e5144cc1f448d178b</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.697153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.697153%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMartinez-Armesto%26aufirst%3DJ.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DNK-1%2520receptor%2520antagonists%2520as%2520antitumor%2520drugs%253A%2520a%2520survey%2520of%2520the%2520literature%2520from%25202000%2520to%25202011%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D735%26epage%3D746%26doi%3D10.1517%2F13543776.2012.697153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, P. R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting</span>. <i>J. Adv. Pharm. Technol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.4103/2231-4040.104710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.4103%2F2231-4040.104710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23378940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ylt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=202-209&author=P.+R.+Bhandari&title=Recent+advances+in+pharmacotherapy+of+chemotherapy-induced+nausea+and+vomiting&doi=10.4103%2F2231-4040.104710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31cR"><div class="casContent"><span class="casTitleNuber">31c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Bhandari, Prasan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Pharmaceutical Technology & Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JAPTDW</span>;
        ISSN:<span class="NLM_cas:issn">0976-2094</span>.
    
            (<span class="NLM_cas:orgname">Society of Pharmaceutical Education & Research</span>)
        </div><div class="casAbstract">A review.  Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients.  Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV).  During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV and resulted in more effective and better tolerated treatment of CINV.  Despite recent progress, however, a significant no. of patients still develop CINV, particularly during the 2-5-day period (delayed emesis) following chemotherapy.  There is evidence that this may be an underappreciated problem on the part of some caregivers.  Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory approval in the U.S.  Both represent useful addns. to the therapeutic armamentarium for the management of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDefAVYtNjLVg90H21EOLACvtfcHk0lhU5dVUrG-cMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ylt7c%253D&md5=fd4c8ae3e3b9dec61d1a68618e91d5fd</span></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=10.4103%2F2231-4040.104710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2231-4040.104710%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DP.%2BR.%26atitle%3DRecent%2520advances%2520in%2520pharmacotherapy%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DJ.%2520Adv.%2520Pharm.%2520Technol.%2520Res.%26date%3D2012%26volume%3D3%26spage%3D202%26epage%3D209%26doi%3D10.4103%2F2231-4040.104710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Frias, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carranza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas-Martín, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveñas, R.</span></span> <span> </span><span class="NLM_article-title">The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2012.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.peptides.2012.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23026680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqtrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=318-325&author=M.+Mu%C3%B1ozauthor=A.+Gonz%C3%A1lez-Ortegaauthor=M.+Rossoauthor=M.+J.+Robles-Friasauthor=A.+Carranzaauthor=M.+V.+Salinas-Mart%C3%ADnauthor=R.+Cove%C3%B1as&title=The+substance+P%2Fneurokinin-1+receptor+system+in+lung+cancer%3A+focus+on+the+antitumor+action+of+neurokinin-1+receptor+antagonists&doi=10.1016%2Fj.peptides.2012.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31dR"><div class="casContent"><span class="casTitleNuber">31d</span><div class="casTitle"><span class="NLM_cas:atitle">The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists</span></div><div class="casAuthors">Munoz, Miguel; Gonzalez-Ortega, Ana; Rosso, Marisa; Robles-Frias, Maria Jose; Carranza, Andres; Salinas-Martin, Manuel Vicente; Covenas, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-325</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies.  The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists resp. induce cell proliferation and inhibition in human cancer cell lines.  No study of the involvement of this system in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells has been carried out in depth.  Here, we demonstrate the involvement of the SP/NK-1R system in human H-69 (SCLC) and COR-L23 (NSCLC) cell lines: (1) they express isoforms of the NK-1R and mRNA for the NK-1R; (2) they overexpress the tachykinin 1 gene; (3) the NK-1R is involved in their viability; (4) SP induces their proliferation; (5) NK-1R antagonists (Aprepitant (Emend), L-733,060, L-732,138) inhibit the growth of both cell lines in a concn.-dependent manner; (6) the specific antitumor action of these antagonists against such cells occurs through the NK-1R; and (7) lung cancer cell death is due to apoptosis.  We also demonstrate the presence of NK-1Rs and SP in all the human SCLC and NSCLC samples studied.  Our findings indicate that the NK-1R may be a promising new target in the treatment of lung cancer and that NK-1R antagonists could be new candidate antitumor drugs in the treatment of SCLC and NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQD9pYl1S5oLVg90H21EOLACvtfcHk0lgZoIlTp3MhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqtrjJ&md5=ba76e14b8c79524a994d31c593e50bad</span></div><a href="/servlet/linkout?suffix=cit31d&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2012.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2012.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DGonz%25C3%25A1lez-Ortega%26aufirst%3DA.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DRobles-Frias%26aufirst%3DM.%2BJ.%26aulast%3DCarranza%26aufirst%3DA.%26aulast%3DSalinas-Mart%25C3%25ADn%26aufirst%3DM.%2BV.%26aulast%3DCove%25C3%25B1as%26aufirst%3DR.%26atitle%3DThe%2520substance%2520P%252Fneurokinin-1%2520receptor%2520system%2520in%2520lung%2520cancer%253A%2520focus%2520on%2520the%2520antitumor%2520action%2520of%2520neurokinin-1%2520receptor%2520antagonists%26jtitle%3DPeptides%26date%3D2012%26volume%3D38%26spage%3D318%26epage%3D325%26doi%3D10.1016%2Fj.peptides.2012.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamarriego, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosso, R.</span></span> <span> </span><span class="NLM_article-title">Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines</span>. <i>Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1097/01.cmr.0000129376.22141.a3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1097%2F01.cmr.0000129376.22141.a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=15179186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksF2ls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=183-188&author=M.+Mu%C3%B1ozauthor=A.+P%C3%A9rezauthor=M.+Rossoauthor=C.+Zamarriegoauthor=R.+Rosso&title=Antitumoral+action+of+the+neurokinin-1+receptor+antagonist+L-733+060+on+human+melanoma+cell+lines&doi=10.1097%2F01.cmr.0000129376.22141.a3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31eR"><div class="casContent"><span class="casTitleNuber">31e</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines</span></div><div class="casAuthors">Munoz, Miguel; Perez, Ana; Rosso, Marisa; Zamarriego, Carmen; Rosso, Rosario</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Melanoma represents 1% of all cancers and accounts for approx. 65% of skin cancer deaths.  At present, effective treatment does not exist.  Substance P (SP) is a neuropeptide expressed in invasive malignant melanomas.  We studied the in vitro growth inhibitory capacity of the potent and long-acting neurokinin-1 (NK1) receptor antagonist L-733 060 at concn. ranges of 2.5-20 μM, 10-30 μM and 20-50 μM in the melanoma cell lines COLO 858, MEL H0 and COLO 679, resp.  A Coulter counter was used to det. the no. of viable cells, and the tetrazolium compd. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) colorimetric method was used to evaluate cell proliferation.  L-733 060 inhibited the growth of all three cell lines in a dose-dependent manner.  The 50% inhibition concn. (IC50) was 8.7 μM at 48 h and 7.1 μM at 96 h for COLO 858, 27.5 μM at 24 h and 18.9 μM at 48 h for MEL H0, and 33.8 μM at 30 h and 31.5 μM at 72 h for COLO 679.  These findings indicate that the NK1 receptor antagonist L-733 060 acts as an antitumoral agent.  This action, shown here for the first time, suggests that the NK1 receptor antagonist L-733 060 could be a promising therapeutic drug in the treatment of the human melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5t5MWNKifLVg90H21EOLACvtfcHk0lgZoIlTp3MhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksF2ls7o%253D&md5=d8e429a30fd3dea1cc058e5b7f697470</span></div><a href="/servlet/linkout?suffix=cit31e&amp;dbid=16384&amp;doi=10.1097%2F01.cmr.0000129376.22141.a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cmr.0000129376.22141.a3%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DA.%26aulast%3DRosso%26aufirst%3DM.%26aulast%3DZamarriego%26aufirst%3DC.%26aulast%3DRosso%26aufirst%3DR.%26atitle%3DAntitumoral%2520action%2520of%2520the%2520neurokinin-1%2520receptor%2520antagonist%2520L-733%2520060%2520on%2520human%2520melanoma%2520cell%2520lines%26jtitle%3DMelanoma%2520Res.%26date%3D2004%26volume%3D14%26spage%3D183%26epage%3D188%26doi%3D10.1097%2F01.cmr.0000129376.22141.a3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nizam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köksoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erin, N.</span></span> <span> </span><span class="NLM_article-title">NK1R Antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1007/s00262-020-02574-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs00262-020-02574-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32322911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2020&pages=1639-1650&author=E.+Nizamauthor=S.+K%C3%B6ksoyauthor=N.+Erin&title=NK1R+Antagonist+decreases+inflammation+and+metastasis+of+breast+carcinoma+cells+metastasized+to+liver+but+not+to+brain%3B+phenotype-dependent+therapeutic+and+toxic+consequences&doi=10.1007%2Fs00262-020-02574-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31fR"><div class="casContent"><span class="casTitleNuber">31f</span><div class="casTitle"><span class="NLM_cas:atitle">NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences</span></div><div class="casAuthors">Nizam, Esra; Koksoy, Sadi; Erin, Nuray</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1639-1650</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Substance P a neuro-immune mediator acts on Neurokinin-1 and -2 receptors (NK1R and NK2R).  Inhibitors of NK1R are considered to be safe and effective approaches for cancer treatment since Aprepitant, a non-peptide antagonist of NK1R is widely used for chemotherapy-induced emesis and has cytotoxic and antitumor effects in various models for cancer.  On the other hand, our previous findings demonstrated that systemic inhibition of NK1R may decrease cytotoxic anti-tumoral immune response.  Hence, actual consequences of inhibition of neurokinin receptors under in vivo conditions in a syngeneic model of carcinoma should be detd.  The effects of highly potent and selective non-peptide mouse NK1R and NK2R antagonists RP 67580 and GR 159897, resp., on metastatic breast carcinoma were evaluated.  Specifically, 4T1 breast cancer cells metastasized to brain (denoted as 4TBM) and liver (denoted as 4TLM) were used to induce tumors in Balb-c mice.  Changes in tumor growth, metastasis and immune response to cancer cells were detd.  We here obsd. differential effects of NK1R antagonist depended on the subset of metastatic cells.  Specifically, inhibition of NK1R markedly increased liver metastasis of tumors formed by 4TBM but not 4TLM cells.  On the contrary, NK1R antagonist decreased inflammatory response and liver metastasis in 4TLM-injected mice. 4TLM tumors act more aggressively inducing more inflammatory response compared to 4TBM tumors.  Hence, differential effects of NK1R antagonist are at least partly due to extend and type of the inflammatory response evoked by specific subset metastatic cells.  These findings demonstrate the necessity for understanding the immunol. consequences of tumor-microenvironment interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCJt0jZ81PLVg90H21EOLACvtfcHk0lgZoIlTp3MhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSitrY%253D&md5=0b19bf97cd7db8bcecd43722de837d25</span></div><a href="/servlet/linkout?suffix=cit31f&amp;dbid=16384&amp;doi=10.1007%2Fs00262-020-02574-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-020-02574-z%26sid%3Dliteratum%253Aachs%26aulast%3DNizam%26aufirst%3DE.%26aulast%3DK%25C3%25B6ksoy%26aufirst%3DS.%26aulast%3DErin%26aufirst%3DN.%26atitle%3DNK1R%2520Antagonist%2520decreases%2520inflammation%2520and%2520metastasis%2520of%2520breast%2520carcinoma%2520cells%2520metastasized%2520to%2520liver%2520but%2520not%2520to%2520brain%253B%2520phenotype-dependent%2520therapeutic%2520and%2520toxic%2520consequences%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2020%26volume%3D69%26spage%3D1639%26epage%3D1650%26doi%3D10.1007%2Fs00262-020-02574-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C.</span></span> <span> </span><span class="NLM_article-title">Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">19635</span>– <span class="NLM_lpage">19645</span>, <span class="refDoi"> DOI: 10.1073/pnas.1908998116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1908998116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31488714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGnsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=19635-19645&author=C.+Geauthor=H.+Huangauthor=F.+Huangauthor=T.+Yangauthor=T.+Zhangauthor=H.+Wuauthor=H.+Zhouauthor=Q.+Chenauthor=Y.+Shiauthor=Y.+Sunauthor=L.+Liuauthor=X.+Wangauthor=R.+B.+Pearsonauthor=Y.+Caoauthor=J.+Kangauthor=C.+Fu&title=Neurokinin-1+receptor+is+an+effective+target+for+treating+leukemia+by+inducing+oxidative+stress+through+mitochondrial+calcium+overload&doi=10.1073%2Fpnas.1908998116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31gR"><div class="casContent"><span class="casTitleNuber">31g</span><div class="casTitle"><span class="NLM_cas:atitle">Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload</span></div><div class="casAuthors">Ge, Chentao; Huang, Hemiao; Huang, Feiyan; Yang, Tianxin; Zhang, Tengfei; Wu, Hongzhang; Zhou, Hanwei; Chen, Qi; Shi, Yue; Sun, Yanfang; Liu, Liangjue; Wang, Xi; Pearson, Richard B.; Cao, Yihai; Kang, Jian; Fu, Caiyun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">19635-19645</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Substance P (SP) regulates multiple biol. processes through its high-affinity neurokinin-1 receptor (NK-1R).  While the SP/NK-1R signaling axis is involved in the pathogenesis of solid cancer, the role of this signaling pathway in hematol. malignancy remains unknown.  Here, we demonstrate that NK-1R expression is markedly elevated in the white blood cells from acute myeloid leukemia patients and a panel of human leukemia cell lines.  Blocking NK-1R induces apoptosis in vitro and in vivo via increase of mitochondrial reactive oxygen species.  This oxidative stress was triggered by rapid calcium flux from the endoplasmic reticulum into mitochondria and, consequently, impairment of mitochondrial function, a mechanism underlying the cytotoxicity of NK-1R antagonists.  Besides anticancer activity, blocking NK-1R produces a potent antinociceptive effect in myeloid leukemia-induced bone pain by alleviating inflammation and inducing apoptosis.  These findings thus raise the exciting possibility that the NK-1R antagonists, drugs currently used in the clinic for preventing chemotherapy-induced nausea and vomiting, may provide a therapeutic option for treating human myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1nwfHbyI_rVg90H21EOLACvtfcHk0lh2dUDoSvrg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGnsr%252FO&md5=9dddf3fe0b2a9456ba4f1b479b334f8d</span></div><a href="/servlet/linkout?suffix=cit31g&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1908998116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1908998116%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPearson%26aufirst%3DR.%2BB.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DC.%26atitle%3DNeurokinin-1%2520receptor%2520is%2520an%2520effective%2520target%2520for%2520treating%2520leukemia%2520by%2520inducing%2520oxidative%2520stress%2520through%2520mitochondrial%2520calcium%2520overload%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D19635%26epage%3D19645%26doi%3D10.1073%2Fpnas.1908998116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi Avval, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-KB signal transduction pathways</span>. <i>Mol. Biol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2253</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1007/s11033-020-05330-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs11033-020-05330-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=32072401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=2253-2263&author=H.+Javidauthor=J.+Asadiauthor=F.+Zahedi+Avvalauthor=A.+R.+Afshariauthor=S.+I.+Hashemy&title=The+role+of+substance+P%2Fneurokinin+1+receptor+in+the+pathogenesis+of+esophageal+squamous+cell+carcinoma+through+constitutively+active+PI3K%2FAkt%2FNF-KB+signal+transduction+pathways&doi=10.1007%2Fs11033-020-05330-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31hR"><div class="casContent"><span class="casTitleNuber">31h</span><div class="casTitle"><span class="NLM_cas:atitle">The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways</span></div><div class="casAuthors">Javid, Hossein; Asadi, Jahanbakhsh; Zahedi Avval, Farnaz; Afshari, Amir R.; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2253-2263</span>CODEN:
                <span class="NLM_cas:coden">MLBRBU</span>;
        ISSN:<span class="NLM_cas:issn">0301-4851</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: One of the most prevalent malignancies is esophageal squamous cell carcinoma (ESCC), which is assocd. with high morbidity and mortality.  Substance P (SP), as one of the peptides released from sensory nerves, causes the enhancement of cellular excitability through the activation of the neurokinin-1 (NK1) receptor in several human tumor cells.  Aprepitant, a specific, potent, and long-acting NK1 receptor antagonist, is considered as a novel agent to inhibit proliferation and induce apoptosis in malignant cells.  Since the antitumor mechanism of aprepitant in ESCC is not completely understood, we conducted this study and found that aprepitant induced growth inhibition of KYSE-30 cells and arrested cells in the G2/M phase of the cell cycle.  Aprepitant also caused apoptotic cell death and inhibited activation of the PI3K/Akt axis and its downstream effectors, including NF-κB in KYSE-30 cells.  Besides, quant. real-time (qRT)-PCR anal. showed a significant down-regulation of NF-κB target genes in KYSE-30 cells, indicating a probable NF-κB-dependent mechanism involved in aprepitant cytotoxicity.  Thus, the present study recommends that SP/NK1R system might, therefore, be considered as an emerging and promising therapeutic strategy against ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrshOSiT5N4JLVg90H21EOLACvtfcHk0lh2dUDoSvrg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlagtLw%253D&md5=33f1390918235c19523bbc845d3c4b45</span></div><a href="/servlet/linkout?suffix=cit31h&amp;dbid=16384&amp;doi=10.1007%2Fs11033-020-05330-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-020-05330-9%26sid%3Dliteratum%253Aachs%26aulast%3DJavid%26aufirst%3DH.%26aulast%3DAsadi%26aufirst%3DJ.%26aulast%3DZahedi%2BAvval%26aufirst%3DF.%26aulast%3DAfshari%26aufirst%3DA.%2BR.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DThe%2520role%2520of%2520substance%2520P%252Fneurokinin%25201%2520receptor%2520in%2520the%2520pathogenesis%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%2520through%2520constitutively%2520active%2520PI3K%252FAkt%252FNF-KB%2520signal%2520transduction%2520pathways%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2020%26volume%3D47%26spage%3D2253%26epage%3D2263%26doi%3D10.1007%2Fs11033-020-05330-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span> <span> </span><span class="NLM_article-title">Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Faps.2016.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=27374491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1013-1019&author=X.-S.+Chenauthor=L.-Y.+Liauthor=Y.+Guanauthor=J.-M.+Yangauthor=Y.+Cheng&title=Anticancer+strategies+based+on+the+metabolic+profile+of+tumor+cells%3A+therapeutic+targeting+of+the+Warburg+effect&doi=10.1038%2Faps.2016.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect</span></div><div class="casAuthors">Chen, Xi-sha; Li, Lan-ya; Guan, Yi-di; Yang, Jin-ming; Cheng, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1013-1019</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor cells rely mainly on glycolysis for energy prodn. even in the presence of sufficient oxygen, a phenomenon termed the Warburg effect, which is the most outstanding characteristic of energy metab. in cancer cells.  This metabolic adaptation is believed to be crit. for tumor cell growth and proliferation, and a no. of onco-proteins and tumor suppressors, including the PI3K/Akt/mTOR signaling pathway, Myc, hypoxia-inducible factor and p53, are involved in the regulation of this metabolic adaptation.  Moreover, glycolytic cancer cells are often invasive and impervious to therapeutic intervention.  Thus, altered energy metab. is now appreciated as a hallmark of cancer and a promising target for cancer treatment.  A better understanding of the biol. and the regulatory mechanisms of aerobic glycolysis has the potential to facilitate the development of glycolysis-based therapeutic interventions for cancer.  In addn., glycolysis inhibition combined with DNA damaging drugs or chemotherapeutic agents may be effective anticancer strategies through weakening cell damage repair capacity and enhancing drug cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9rTu0uo_ITLVg90H21EOLACvtfcHk0lh2dUDoSvrg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KlsrrF&md5=1fa5b2846aaa68ee82282ec5999f3027</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.47%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-S.%26aulast%3DLi%26aufirst%3DL.-Y.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.-M.%26aulast%3DCheng%26aufirst%3DY.%26atitle%3DAnticancer%2520strategies%2520based%2520on%2520the%2520metabolic%2520profile%2520of%2520tumor%2520cells%253A%2520therapeutic%2520targeting%2520of%2520the%2520Warburg%2520effect%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D1013%26epage%3D1019%26doi%3D10.1038%2Faps.2016.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adalsteinsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peress, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldenfels, J.</span></span> <span> </span><span class="NLM_article-title">Case report: sodium dichloroacetate (DCA) inhibition of the “Warburg effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP</span>. <i>J. Bioenerg. Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1007/s10863-012-9496-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs10863-012-9496-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=23263938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFKrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=307-315&author=S.+B.+Strumauthor=O.+Adalsteinssonauthor=R.+R.+Blackauthor=D.+Segalauthor=N.+L.+Peressauthor=J.+Waldenfels&title=Case+report%3A+sodium+dichloroacetate+%28DCA%29+inhibition+of+the+%E2%80%9CWarburg+effect%E2%80%9D+in+a+human+cancer+patient%3A+complete+response+in+non-Hodgkin%E2%80%99s+lymphoma+after+disease+progression+with+rituximab-CHOP&doi=10.1007%2Fs10863-012-9496-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Case Report: Sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP</span></div><div class="casAuthors">Strum, Stephen B.; Adalsteinsson, Oern; Black, Richard R.; Segal, Dmitri; Peress, Nancy L.; Waldenfels, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bioenergetics and Biomembranes</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-315</span>CODEN:
                <span class="NLM_cas:coden">JBBID4</span>;
        ISSN:<span class="NLM_cas:issn">0145-479X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The uptake of fluorodeoxyglucose Positron Emission Tomog. in the tumors of various cancer types demonstrates the key role of glucose in the proliferation of cancer.  Dichloroacetate is a 2-carbon mol. having crucial biol. activity in altering the metabolic breakdown of glucose to lactic acid.  Human cell line studies show that dichloroacetate switches alter the metabolomics of the cancer cell from one of glycolysis to oxidative phosphorylation, and in doing so restore mitochondrial functions that trigger apoptosis of the cancer cell.  Reports of dichloroacetate in human subjects are rare.  The authors contacted individuals from Internet forums who had reported outstanding anti-cancer responses to self-medication with dichloroacetate.  With informed consent, complete medical records were requested to document response to dichloroacetate, emphasizing the context of monotherapy with dichloroacetate.  Of ten patients agreeing to such an evaluation, only one met the criteria of having comprehensive clinic records as well as pathol., imaging and lab. reports, along with single agent therapy with dichloroacetate.  That individual is the focus of this report.  In this case report of a man with documented relapse after state-of-the-art chemotherapy for non-Hodgkin's lymphoma, a significant response to dichloroacetate is documented with a complete remission, which remains ongoing after 4 years.  Dichloroacetate appears to be a novel therapy warranting further investigation in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBHinMTOHfVLVg90H21EOLACvtfcHk0lh2dUDoSvrg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFKrurc%253D&md5=e61de6bd2a9976a3333569a5518d026a</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1007%2Fs10863-012-9496-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10863-012-9496-2%26sid%3Dliteratum%253Aachs%26aulast%3DStrum%26aufirst%3DS.%2BB.%26aulast%3DAdalsteinsson%26aufirst%3DO.%26aulast%3DBlack%26aufirst%3DR.%2BR.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPeress%26aufirst%3DN.%2BL.%26aulast%3DWaldenfels%26aufirst%3DJ.%26atitle%3DCase%2520report%253A%2520sodium%2520dichloroacetate%2520%2528DCA%2529%2520inhibition%2520of%2520the%2520%25E2%2580%259CWarburg%2520effect%25E2%2580%259D%2520in%2520a%2520human%2520cancer%2520patient%253A%2520complete%2520response%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520after%2520disease%2520progression%2520with%2520rituximab-CHOP%26jtitle%3DJ.%2520Bioenerg.%2520Biomembr.%26date%3D2013%26volume%3D45%26spage%3D307%26epage%3D315%26doi%3D10.1007%2Fs10863-012-9496-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?</span>. <i>Anticancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.2174/187152008783961932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F187152008783961932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=18393789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BD1c3jsFChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=305-312&author=M.+L%C3%B3pez-L%C3%A1zaro&title=The+Warburg+effect%3A+why+and+how+do+cancer+cells+activate+glycolysis+in+the+presence+of+oxygen%3F&doi=10.2174%2F187152008783961932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer agents in medicinal chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-12</span>
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    </div><div class="casAbstract">Cells can obtain energy through the oxygen-dependent pathway of oxidative phosphorylation (OXPHOS) and through the oxygen-independent pathway of glycolysis.  Since OXPHOS is more efficient in generating ATP than glycolysis, it is recognized that the presence of oxygen results in the activation of OXPHOS and the inhibition of glycolysis (Pasteur effect).  However, it has been known for many years that cancer cells and non-malignant proliferating cells can activate glycolysis in the presence of adequate oxygen levels (aerobic glycolysis or Warburg effect).  Accumulating evidence suggests that the persistent activation of aerobic glycolysis in tumor cells plays a crucial role in cancer development; the inhibition of the increased glycolytic capacity of malignant cells may therefore represent a key anticancer strategy.  Although some important knowledge has been gained in the last few years on this growing field of research, the basis of the Warburg effect still remains poorly understood.  This communication analyzes why cancer cells switch from OXPHOS to glycolysis in the presence of adequate oxygen levels, and how these cells manage to avoid the inhibition of glycolysis induced by oxygen.  Several strategies and drugs that may interfere with the glycolytic metabolism of cancer cells are also shown.  This information may help develop anticancer approaches that may have clinical relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHC2sBl7F214kFb3mqPUYDfW6udTcc2eYXt6E2wX1YNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3jsFChtQ%253D%253D&md5=4313e8e840d2821297ad27772876de88</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.2174%2F187152008783961932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008783961932%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DThe%2520Warburg%2520effect%253A%2520why%2520and%2520how%2520do%2520cancer%2520cells%2520activate%2520glycolysis%2520in%2520the%2520presence%2520of%2520oxygen%253F%26jtitle%3DAnticancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D305%26epage%3D312%26doi%3D10.2174%2F187152008783961932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Cordero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon-Gonzalez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon-Montano, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Moron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lazaro, M.</span></span> <span> </span><span class="NLM_article-title">Pro-oxidant natural products as anticancer agents</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.2174/138945012802009044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F138945012802009044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22594470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGmu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1006-1028&author=C.+Martin-Corderoauthor=A.+J.+Leon-Gonzalezauthor=J.+M.+Calderon-Montanoauthor=E.+Burgos-Moronauthor=M.+Lopez-Lazaro&title=Pro-oxidant+natural+products+as+anticancer+agents&doi=10.2174%2F138945012802009044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Pro-oxidant natural products as anticancer agents</span></div><div class="casAuthors">Martin-Cordero, Carmen; Leon-Gonzalez, Antonio Jose; Calderon-Montano, Jose Manuel; Burgos-Moron, Estefania; Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1006-1028</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer cells produce high levels of reactive oxygen species (ROS) that lead to a state of increased basal oxidative stress.  Since this state of oxidative stress makes cancer cells vulnerable to agents that further augment ROS levels, the use of pro-oxidant agents is emerging as an exciting strategy to selectively target tumor cells.  Natural products have provided a significant contribution to the development of several drugs currently used in cancer chemotherapy.  Although many natural products are known to affect the redox state of the cell, most studies on these compds. have focused on their antioxidant activity instead of on their pro-oxidant properties.  This article provides an overview of natural products with pro-oxidant and anticancer activities, with special focus on plant secondary metabolites, and discusses their possible use as cancer chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBjHSp5_aZ7Vg90H21EOLACvtfcHk0lgI1MMZFKNchw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGmu7jO&md5=f819ac481cc8152416d5c6971d5c6594</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.2174%2F138945012802009044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945012802009044%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Cordero%26aufirst%3DC.%26aulast%3DLeon-Gonzalez%26aufirst%3DA.%2BJ.%26aulast%3DCalderon-Montano%26aufirst%3DJ.%2BM.%26aulast%3DBurgos-Moron%26aufirst%3DE.%26aulast%3DLopez-Lazaro%26aufirst%3DM.%26atitle%3DPro-oxidant%2520natural%2520products%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2012%26volume%3D13%26spage%3D1006%26epage%3D1028%26doi%3D10.2174%2F138945012802009044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galadari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallichankandy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayyullathil, F.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species and cancer paradox: to promote or to suppress?</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2017.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.freeradbiomed.2017.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28088622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ahs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2017&pages=144-164&author=S.+Galadariauthor=A.+Rahmanauthor=S.+Pallichankandyauthor=F.+Thayyullathil&title=Reactive+oxygen+species+and+cancer+paradox%3A+to+promote+or+to+suppress%3F&doi=10.1016%2Fj.freeradbiomed.2017.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species and cancer paradox: To promote or to suppress?</span></div><div class="casAuthors">Galadari, Sehamuddin; Rahman, Anees; Pallichankandy, Siraj; Thayyullathil, Faisal</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-164</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reactive oxygen species (ROS), a group of highly reactive ions and mols., are increasingly being appreciated as powerful signaling mols. involved in the regulation of a variety of biol. processes.  Indeed, their role is continuously being delineated in a variety of pathophysiol. conditions.  For instance, cancer cells are shown to have increased ROS levels in comparison to their normal counterparts.  This is partly due to an enhanced metab. and mitochondrial dysfunction in cancer cells.  The escalated ROS generation in cancer cells contributes to the biochem. and mol. changes necessary for the tumor initiation, promotion and progression, as well as, tumor resistance to chemotherapy.  Therefore, increased ROS in cancer cells may provide a unique opportunity to eliminate cancer cells via elevating ROS to highly toxic levels intracellularly, thereby, activating various ROS-induced cell death pathways, or inhibiting cancer cell resistance to chemotherapy.  Such results can be achieved by using agents that either increase ROS generation, or inhibit antioxidant defense, or even a combination of both.  In fact, a large variety of anticancer drugs, and some of those currently under clin. trials, effectively kill cancer cells and overcome drug resistance via enhancing ROS generation and/or impeding the antioxidant defense mechanism.  This review focuses on our current understanding of the tumor promoting (tumorigenesis, angiogenesis, invasion and metastasis, and chemoresistance) and the tumor suppressive (apoptosis, autophagy, and necroptosis) functions of ROS, and highlights the potential mechanism(s) involved.  It also sheds light on a very novel and an actively growing field of ROS-dependent cell death mechanism referred to as ferroptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8Jr12AOG4bVg90H21EOLACvtfcHk0lgI1MMZFKNchw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ahs78%253D&md5=9c5fac488a1a6a6370bdc0a4353ba810</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2017.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2017.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DGaladari%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DPallichankandy%26aufirst%3DS.%26aulast%3DThayyullathil%26aufirst%3DF.%26atitle%3DReactive%2520oxygen%2520species%2520and%2520cancer%2520paradox%253A%2520to%2520promote%2520or%2520to%2520suppress%253F%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2017%26volume%3D104%26spage%3D144%26epage%3D164%26doi%3D10.1016%2Fj.freeradbiomed.2017.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reczek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandel, N. S.</span></span> <span> </span><span class="NLM_article-title">The two faces of reactive oxygen species in cancer</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-041916-065808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1146%2Fannurev-cancerbio-041916-065808" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=79-98&author=C.+R.+Reczekauthor=N.+S.+Chandel&title=The+two+faces+of+reactive+oxygen+species+in+cancer&doi=10.1146%2Fannurev-cancerbio-041916-065808"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-041916-065808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-041916-065808%26sid%3Dliteratum%253Aachs%26aulast%3DReczek%26aufirst%3DC.%2BR.%26aulast%3DChandel%26aufirst%3DN.%2BS.%26atitle%3DThe%2520two%2520faces%2520of%2520reactive%2520oxygen%2520species%2520in%2520cancer%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2017%26volume%3D1%26spage%3D79%26epage%3D98%26doi%3D10.1146%2Fannurev-cancerbio-041916-065808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linley, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamper, N.</span></span> <span> </span><span class="NLM_article-title">Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E1578</span>– <span class="NLM_lpage">E1586</span>, <span class="refDoi"> DOI: 10.1073/pnas.1201544109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1073%2Fpnas.1201544109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22586118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E1578-E1586&author=J.+E.+Linleyauthor=L.+Ooiauthor=L.+Pettingerauthor=H.+Kirtonauthor=J.+P.+Boyleauthor=C.+Peersauthor=N.+Gamper&title=Reactive+oxygen+species+are+second+messengers+of+neurokinin+signaling+in+peripheral+sensory+neurons&doi=10.1073%2Fpnas.1201544109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons</span></div><div class="casAuthors">Linley, John E.; Ooi, Lezanne; Pettinger, Louisa; Kirton, Hannah; Boyle, John P.; Peers, Chris; Gamper, Nikita</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">E1578-E1586, SE1578/1-SE1578/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Substance P (SP) is a prominent neuromodulator, which is produced and released by peripheral damage-sensing (nociceptive) neurons; these neurons also express SP receptors.  However, the mechanisms of peripheral SP signaling are poorly understood.  We report a signaling pathway of SP in nociceptive neurons: acting predominantly through NK1 receptors and Gi/o proteins, SP stimulates increased release of reactive oxygen species from the mitochondrial electron transport chain.  Reactive oxygen species, functioning as second messengers, induce oxidative modification and augment M-type potassium channels, thereby suppressing excitability.  This signaling cascade requires activation of phospholipase C but is largely uncoupled from the inositol 1,4,5-trisphosphate sensitive Ca2+ stores.  In rats SP causes sensitization of TRPV1 and produces thermal hyperalgesia.  However, the lack of coupling between SP signaling and inositol 1,4,5-trisphosphate sensitive Ca2+ stores, together with the augmenting effect on M channels, renders the SP pathway ineffective to excite nociceptors acutely and produce spontaneous pain.  Our study describes a mechanism for neurokinin signaling in sensory neurons and provides evidence that spontaneous pain and hyperalgesia can have distinct underlying mechanisms within a single nociceptive neuron.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOW8oZPFxu7Vg90H21EOLACvtfcHk0li8dklLQbb0dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWisLw%253D&md5=9f2cfb434dd0fb4eaf5f16526accf689</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1201544109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1201544109%26sid%3Dliteratum%253Aachs%26aulast%3DLinley%26aufirst%3DJ.%2BE.%26aulast%3DOoi%26aufirst%3DL.%26aulast%3DPettinger%26aufirst%3DL.%26aulast%3DKirton%26aufirst%3DH.%26aulast%3DBoyle%26aufirst%3DJ.%2BP.%26aulast%3DPeers%26aufirst%3DC.%26aulast%3DGamper%26aufirst%3DN.%26atitle%3DReactive%2520oxygen%2520species%2520are%2520second%2520messengers%2520of%2520neurokinin%2520signaling%2520in%2520peripheral%2520sensory%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3DE1578%26epage%3DE1586%26doi%3D10.1073%2Fpnas.1201544109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnaudeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenorio Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenssen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells</span>. <i>Mutat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/S0921-8777(00)00052-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2FS0921-8777%2800%2900052-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=11056293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosV2ju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2000&pages=221-228&author=C.+Arnaudeauauthor=E.+Tenorio+Mirandaauthor=D.+Jenssenauthor=T.+Helleday&title=Inhibition+of+DNA+synthesis+is+a+potent+mechanism+by+which+cytostatic+drugs+induce+homologous+recombination+in+mammalian+cells&doi=10.1016%2FS0921-8777%2800%2900052-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells</span></div><div class="casAuthors">Arnaudeau, Catherine; Miranda, Erika Tenorio; Jenssen, Dag; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, DNA Repair</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-228</span>CODEN:
                <span class="NLM_cas:coden">MRDRBE</span>;
        ISSN:<span class="NLM_cas:issn">0921-8777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recombination is a process thought to be underlying genomic instability involved in carcinogenesis.  This report examines the potential of cytostatic drugs to induce intrachromosomal homologous recombination.  In order to address this question, the hprt gene of a well-characterized mammalian cell line was employed as a unique endogenous marker for homologous recombination.  Commonly used cytostatic drugs with different mode of action were investigated in this context, i.e. bifunctional alkylating agents, inhibitors of DNA synthesis, inhibitors of topoisomerases and a spindle poison.  With the exception of the spindle poison, all these drugs were found to induce homologous recombination, with clear differences in their recombination potency, which could be related to their mechanism of action.  Bifunctional alkylating agents were the least efficient, whereas inhibitors of DNA synthesis were found to be the most potent inducers of homologous recombination.  This raises the question whether these later drugs should be considered for adverse effects in cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9OQcmYdG2E7Vg90H21EOLACvtfcHk0li8dklLQbb0dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosV2ju7Y%253D&md5=f033ba2713b2f22e503e28fd9690ac6f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0921-8777%2800%2900052-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0921-8777%252800%252900052-5%26sid%3Dliteratum%253Aachs%26aulast%3DArnaudeau%26aufirst%3DC.%26aulast%3DTenorio%2BMiranda%26aufirst%3DE.%26aulast%3DJenssen%26aufirst%3DD.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520DNA%2520synthesis%2520is%2520a%2520potent%2520mechanism%2520by%2520which%2520cytostatic%2520drugs%2520induce%2520homologous%2520recombination%2520in%2520mammalian%2520cells%26jtitle%3DMutat.%2520Res.%26date%3D2000%26volume%3D461%26spage%3D221%26epage%3D228%26doi%3D10.1016%2FS0921-8777%2800%2900052-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0lhDcUNG5SmhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón-Montaño, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Morón, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orta, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a Review</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3419</span>– <span class="NLM_lpage">3454</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140601203816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F0929867321666140601203816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=24934343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCgtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3419-3454&author=J.+M.+Calder%C3%B3n-Monta%C3%B1oauthor=E.+Burgos-Mor%C3%B3nauthor=M.+L.+Ortaauthor=M.+L%C3%B3pez-L%C3%A1zaro&title=Effect+of+DNA+repair+deficiencies+on+the+cytotoxicity+of+drugs+used+in+cancer+therapy+-+a+Review&doi=10.2174%2F0929867321666140601203816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review</span></div><div class="casAuthors">Calderon-Montano, Jose Manuel; Burgos-Moron, Estefania; Orta, Manuel Luis; Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3419-3454</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents.  The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy.  This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs.  It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacol. target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies).  This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBwl7-e1M4bVg90H21EOLACvtfcHk0lhDcUNG5SmhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCgtL3O&md5=88ee7907ae5c9c9706941170025e5c86</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140601203816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140601203816%26sid%3Dliteratum%253Aachs%26aulast%3DCalder%25C3%25B3n-Monta%25C3%25B1o%26aufirst%3DJ.%2BM.%26aulast%3DBurgos-Mor%25C3%25B3n%26aufirst%3DE.%26aulast%3DOrta%26aufirst%3DM.%2BL.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DEffect%2520of%2520DNA%2520repair%2520deficiencies%2520on%2520the%2520cytotoxicity%2520of%2520drugs%2520used%2520in%2520cancer%2520therapy%2520-%2520a%2520Review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3419%26epage%3D3454%26doi%3D10.2174%2F0929867321666140601203816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Recio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascón, P.</span></span> <span> </span><span class="NLM_article-title">Biological and pharmacological aspects of the NK1-receptor</span>. <i>Biomed. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>, <span class="NLM_elocation-id">495704</span> <span class="refDoi"> DOI: 10.1155/2015/495704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1155%2F2015%2F495704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26421291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC283nsFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&author=S.+Garc%C3%ADa-Recioauthor=P.+Gasc%C3%B3n&title=Biological+and+pharmacological+aspects+of+the+NK1-receptor&doi=10.1155%2F2015%2F495704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and Pharmacological Aspects of the NK1-Receptor</span></div><div class="casAuthors">Garcia-Recio Susana; Gascon Pedro</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">495704</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neurokinin 1 receptor (NK-1R) is the main receptor for the tachykinin family of peptides.  Substance P (SP) is the major mammalian ligand and the one with the highest affinity.  SP is associated with multiple processes: hematopoiesis, wound healing, microvasculature permeability, neurogenic inflammation, leukocyte trafficking, and cell survival.  It is also considered a mitogen, and it has been associated with tumorigenesis and metastasis.  Tachykinins and their receptors are widely expressed in various human systems such as the nervous, cardiovascular, genitourinary, and immune system.  Particularly, NK-1R is found in the nervous system and in peripheral tissues and are involved in cellular responses such as pain transmission, endocrine and paracrine secretion, vasodilation, and modulation of cell proliferation.  It also acts as a neuromodulator contributing to brain homeostasis and to sensory neuronal transmission associated with depression, stress, anxiety, and emesis.  NK-1R and SP are present in brain regions involved in the vomiting reflex (the nucleus tractus solitarius and the area postrema).  This anatomical localization has led to the successful clinical development of antagonists against NK-1R in the treatment of chemotherapy-induced nausea and vomiting (CINV).  The first of these antagonists, aprepitant (oral administration) and fosaprepitant (intravenous administration), are prescribed for high and moderate emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSk9oaM_G1iCDEwO064Z95rfW6udTcc2eZCI10oZh5WEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283nsFektQ%253D%253D&md5=f9d6fd4c4e9af92be114679ab77634e1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1155%2F2015%2F495704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F495704%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Recio%26aufirst%3DS.%26aulast%3DGasc%25C3%25B3n%26aufirst%3DP.%26atitle%3DBiological%2520and%2520pharmacological%2520aspects%2520of%2520the%2520NK1-receptor%26jtitle%3DBiomed.%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26doi%3D10.1155%2F2015%2F495704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantoreggi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regolia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist netupitant</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2012.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.peptides.2012.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=22732666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=86-97&author=A.+Rizziauthor=B.+Campiaauthor=V.+Camardaauthor=S.+Molinariaauthor=S.+Cantoreggiauthor=D.+Regoliaauthor=C.+Pietraauthor=G.+Calo&title=In+vitro+and+in+vivo+pharmacological+characterization+of+the+novel+NK1+receptor+selective+antagonist+netupitant&doi=10.1016%2Fj.peptides.2012.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant</span></div><div class="casAuthors">Rizzi, Anna; Campi, Barbara; Camarda, Valeria; Molinari, Stefano; Cantoreggi, Sergio; Regoli, Domenico; Pietra, Claudio; Calo', Girolamo</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-97</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The novel NK1 receptor ligand Netupitant has been characterized in vitro and in vivo.  In calcium mobilization studies CHO cells expressing the human NK receptors responded to a panel of agonists with the expected order of potency.  In CHO NK1 cells Netupitant concn.-dependently antagonized the stimulatory effects of substance P (SP) showing insurmountable antagonism (pKB 8.87).  In cells expressing NK2 or NK3 receptors Netupitant was inactive.  In the guinea pig ileum Netupitant concn.-dependently depressed the maximal response to SP (pKB 7.85) and, in functional washout expts., displayed persistent (up to 5 h) antagonist effects.  In mice the intrathecal injection of SP elicited the typical scratching, biting and licking response that was dose-dependently inhibited by Netupitant given i.p. in the 1-10 mg/kg dose range.  In gerbils, foot tapping behavior evoked by the intracerebroventricular injection of a NK1 agonist was dose-dependently counteracted by Netupitant given i.p. (ID50 1.5 mg/kg) or orally (ID50 0.5 mg/kg).  In time course expts. in gerbils Netupitant displayed long lasting effects.  In all the assays Aprepitant elicited similar effects as Netupitant.  These results suggest that Netupitant behaves as a brain penetrant, orally active, potent and selective NK1 antagonist.  Thus this mol. can be useful for investigating the NK1 receptor role in the control of central and peripheral functions.  Netupitant has clin. potential in conditions such as chemotherapy induced nausea and vomiting, in which the blockade of NK1 receptors has been demonstrated valuable for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnqeqtlg4ALVg90H21EOLACvtfcHk0lhDcUNG5SmhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGhurs%253D&md5=63bc4c31758959f00c4da2317e8747e4</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2012.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2012.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCampia%26aufirst%3DB.%26aulast%3DCamarda%26aufirst%3DV.%26aulast%3DMolinaria%26aufirst%3DS.%26aulast%3DCantoreggi%26aufirst%3DS.%26aulast%3DRegolia%26aufirst%3DD.%26aulast%3DPietra%26aufirst%3DC.%26aulast%3DCalo%26aufirst%3DG.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%2520the%2520novel%2520NK1%2520receptor%2520selective%2520antagonist%2520netupitant%26jtitle%3DPeptides%26date%3D2012%26volume%3D37%26spage%3D86%26epage%3D97%26doi%3D10.1016%2Fj.peptides.2012.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vykoukal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubertus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Schweinitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilmer, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.3892/ijo.2015.3016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.3892%2Fijo.2015.3016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25998227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=151-160&author=A.+Garnierauthor=J.+Vykoukalauthor=J.+Hubertusauthor=E.+Altauthor=D.+von+Schweinitzauthor=R.+Kapplerauthor=M.+Bergerauthor=M.+Ilmer&title=Targeting+the+neurokinin-1+receptor+inhibits+growth+of+human+colon+cancer+cells&doi=10.3892%2Fijo.2015.3016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells</span></div><div class="casAuthors">Garnier, Agnes; Vykoukal, Jody; Hubertus, Jochen; Alt, Eckhard; Von Schweinitz, Dietrich; Kappler, Roland; Berger, Michael; Ilmer, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-160</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The substance P (SP)/neurokinin-1 receptor (NK1R) complex and the Wnt cascade are pivotal signaling pathways in the regulation of cell growth and hence, potent targets for future anticancer therapies.  However, while the Wnt cascade has long been assocd. with colon cancer, little is known about the expression of the NK1R complex as a potential target in this tumor and its mol. basis in tumorigenesis in general.  We treated the human colon cancer cell lines LiM6 and DLD1 with the NK1R antagonist and the clin. drug aprepitant (AP) and analyzed both growth response and downstream mechanisms using MTT-assay, reverse phase protein array (RPPA), Western blot, Super TOP/FOP, confocal microscopy, and sphere formation ability (SFA) assays.  Following NK1R blockage, we found significant growth inhibition of both colon cancer cell lines.  When analyzing downstream mechanisms, we found a striking inhibition of the canonical Wnt pathway represented by decreased Super TOP/FOP and increased membrane stabilization of β-catenin.  This effect was independent from baseline Wnt activity and mutational status of β-catenin.  Further, treatment of colon cancer cells grown under cancer stem cell (CSC) conditions reduced sphere formation in both no. and size after a single treatment period.  We show that the NK1R can be a potent anticancer target in colon cancer and that NK1R antagonists could potentially serve as future anticancer drugs.  This effect was seen not only in primary cancer cells but, for the first time, also in CSC-like cells, potentially including these cells in a therapeutic effect.  Also, we describe the robust inhibition of canonical Wnt signaling through targeting the SP/NK1R signaling cascade.  These findings give important insight into the mol. mechanisms of the SP/NK1R complex as a crit. component in tumorigenesis and could help to identify future anticancer therapies for colon and other Wnt-activated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXrgQecPGexrVg90H21EOLACvtfcHk0liw6iLBUx6slQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVyksQ%253D%253D&md5=b969fd06b97aae7bfdffc5451443812d</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.3892%2Fijo.2015.3016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2015.3016%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier%26aufirst%3DA.%26aulast%3DVykoukal%26aufirst%3DJ.%26aulast%3DHubertus%26aufirst%3DJ.%26aulast%3DAlt%26aufirst%3DE.%26aulast%3Dvon%2BSchweinitz%26aufirst%3DD.%26aulast%3DKappler%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DIlmer%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520neurokinin-1%2520receptor%2520inhibits%2520growth%2520of%2520human%2520colon%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D47%26spage%3D151%26epage%3D160%26doi%3D10.3892%2Fijo.2015.3016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vykoukal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Schweinitz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the neurokinin-1 receptor compromises canonical Wnt signaling in hepatoblastoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2712</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1158%2F1535-7163.MCT-15-0206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=26516161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2712-2721&author=M.+Ilmerauthor=A.+Garnierauthor=J.+Vykoukalauthor=E.+Altauthor=D.+von+Schweinitzauthor=R.+Kapplerauthor=M.+Berger&title=Targeting+the+neurokinin-1+receptor+compromises+canonical+Wnt+signaling+in+hepatoblastoma&doi=10.1158%2F1535-7163.MCT-15-0206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma</span></div><div class="casAuthors">Ilmer, Matthias; Garnier, Agnes; Vykoukal, Jody; Alt, Eckhard; von Schweinitz, Dietrich; Kappler, Roland; Berger, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2712-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The substance P (SP)/NK-1 receptor (NK1R) complex represents an intriguing anticancer target for a variety of tumors, including hepatoblastoma (HB).  Therefore, NK1R antagonists, such as the clin. drug aprepitant, recently have been proposed as potent anticancer agents.  However, very little is known regarding the mol. basis of NK1R inhibition in cancer.  Using reverse phase protein array, Western blot, Super TOP/FOP, confocal microscopy, and sphere formation ability (SFA) assays, we identified the AKT and Wnt signaling pathways as the key targets of aprepitant in three human HB cell lines (HepT1, HepG2, and HuH6).  Following NK1R blockage, we obsd. decreased phosphorylation of p70S6K and 4E-BP1/2 and inhibition of the canonical Wnt pathway with subsequent decrease of HB cell growth.  This effect was dependent of high baseline Wnt activity either by mutational status of β-catenin or extrinsic Wnt activation.  Wnt inhibition seemed to be strengthened by disruption of the FOXM1-β-catenin complex.  Furthermore, treatment of HB cells with aprepitant led to reduced expression of (liver) stemness markers (AFP, CD13, SOX2, NANOG, and OCT4) and SFA when grown under cancer stem cell conditions.  Taken together, we show for the first time that targeting the SP/NK1R signaling cascade inhibits canonical Wnt signaling in HB cells.  These findings reveal important insight into the mol. mechanisms of the SP/NK1R complex as a crit. component in a model of pediatric liver cancer and may support the development of novel therapeutic interventions for HB and other Wnt-activated cancers.  Mol Cancer Ther; 14(12); 2712-21. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFgozKFSTZ3rVg90H21EOLACvtfcHk0liw6iLBUx6slQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zL&md5=f9ec62e8300b8fab0fdb8c1bc9b79431</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0206%26sid%3Dliteratum%253Aachs%26aulast%3DIlmer%26aufirst%3DM.%26aulast%3DGarnier%26aufirst%3DA.%26aulast%3DVykoukal%26aufirst%3DJ.%26aulast%3DAlt%26aufirst%3DE.%26aulast%3Dvon%2BSchweinitz%26aufirst%3DD.%26aulast%3DKappler%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520neurokinin-1%2520receptor%2520compromises%2520canonical%2520Wnt%2520signaling%2520in%2520hepatoblastoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2712%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-15-0206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J-X.</span></span> <span> </span><span class="NLM_article-title">The NK1 receptor antagonist NKP608 inhibits proliferation of human colorectal cancer cells via Wnt signaling pathway</span>. <i>Biol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>, <span class="NLM_elocation-id">14</span> <span class="refDoi"> DOI: 10.1186/s40659-018-0163-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1186%2Fs40659-018-0163-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=29843798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWqsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&author=X-L.+Niuauthor=J-F.+Houauthor=J-X.+Li&title=The+NK1+receptor+antagonist+NKP608+inhibits+proliferation+of+human+colorectal+cancer+cells+via+Wnt+signaling+pathway&doi=10.1186%2Fs40659-018-0163-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">The NK1 receptor antagonist NKP608 inhibits proliferation of human colorectal cancer cells via Wnt signaling pathway</span></div><div class="casAuthors">Niu, Xiao-Ling; Hou, Jian-Feng; Li, Jing-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Biological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14/1-14/8</span>CODEN:
                <span class="NLM_cas:coden">BESEEB</span>;
        ISSN:<span class="NLM_cas:issn">0717-6287</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Neurokinin1 (NK1) receptor has played a vital role in the development of tumor.  However, NKP608 as a NK1 receptor antagonist whether has the effect of the resistance of colorectal cancer is still unclear.  Thereby, in this study, we investigated the role of NKP608 on human colorectal cancer and explored the underlying mechanism.  Methods: The cell proliferation of colorectal cancer cells was detected by cell counting kit-8 (CCK8) assay, cell migra- tion and invasion were assessed by transwell assay, the apoptotic ratio of cells was assessed by Annexin V-fuorescein isothiocyanate/propidium iodide stained and fow cytometry.  The involvement of mol. mechanisms was exam- ined by western blot.  Results: In this study, we found that NKP608 inhibited the proliferation, migration/invasion of HCT116 cells.  In addi- tion, NKP608 reduced expressions of Wnt-3a, β-catenin, Cyclin D1, and (vascular endothelial growth factor) VEGF while induced expression of E-Cadherin.  Furthermore, fow cytometry analyzed that NKP608 induced apoptosis of HCT116 cells, consistently, western blotting detecting of apoptosis-related proteins revealed that NKP608 downregulated Bcl-2 while upregulated Bax and Active-Caspase-3.  Conclusions: Taken together, our results demonstrated that NKP608 inhibited colorectal cancer cell proliferation, migration and invasion via suppressing the Wnt/β-catenin signaling pathway.  Therefore, NKP608 might represent a promising therapeutic agent in the treatment of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYfNfxAlLw7Vg90H21EOLACvtfcHk0liw6iLBUx6slQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWqsr%252FO&md5=6252059f8044051a36d682f0caa5d3cc</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1186%2Fs40659-018-0163-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40659-018-0163-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DX-L.%26aulast%3DHou%26aufirst%3DJ-F.%26aulast%3DLi%26aufirst%3DJ-X.%26atitle%3DThe%2520NK1%2520receptor%2520antagonist%2520NKP608%2520inhibits%2520proliferation%2520of%2520human%2520colorectal%2520cancer%2520cells%2520via%2520Wnt%2520signaling%2520pathway%26jtitle%3DBiol.%2520Res.%26date%3D2018%26volume%3D51%26doi%3D10.1186%2Fs40659-018-0163-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahiri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells</span>. <i>J. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1007/s13105-019-00697-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs13105-019-00697-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31372898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyhsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=415-421&author=H.+Javidauthor=F.+Mohammadiauthor=E.+Zahiriauthor=S.+I.+Hashemy&title=The+emerging+role+of+substance+P%2Fneurokinin-1+receptor+signaling+pathways+in+growth+and+development+of+tumor+cells&doi=10.1007%2Fs13105-019-00697-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39dR"><div class="casContent"><span class="casTitleNuber">39d</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells</span></div><div class="casAuthors">Javid, Hossein; Mohammadi, Fariba; Zahiri, Elnaz; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-421</span>CODEN:
                <span class="NLM_cas:coden">JPBIF2</span>;
        ISSN:<span class="NLM_cas:issn">1138-7548</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tachykinins (TKs) include an evolutionarily conserved group of small bio-active peptides which possess a common carboxyl-terminal sequence, Phe-X-Gly-Leu-Met-NH2.  TKs also have been shown to have implications in different steps of carcinogenesis, such as angiogenesis, mitogenesis, metastasis, and other growth-related events.  The biol. actions of substance P (SP), as the most important member of the TK family, are mainly mediated through a G protein-coupled receptor named neurokinin-1 receptor (NK1R).  More recently, it has become clear that SP/NK1R system is involved in the initiation and activation of signaling pathways involved in cancer development and progression.  Therefore, SP may contribute to triggering a variety of effector mechanisms including protein synthesis and a no. of transcription factors that modulate the expression of genes involved in these processes.  The overwhelming insights into the blockage of NK1R using specific antagonists could suggest a therapeutic approach in cancer therapy.  In this review, we focus on evidence supporting an assocn. between the signaling pathways of the SP/NK1R system and cancer cell proliferation and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_IqPU9_J_rVg90H21EOLACvtfcHk0likxuIRHIMOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyhsLrP&md5=b297036d3d62c04ec2225c2a09660fbf</span></div><a href="/servlet/linkout?suffix=cit39d&amp;dbid=16384&amp;doi=10.1007%2Fs13105-019-00697-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13105-019-00697-1%26sid%3Dliteratum%253Aachs%26aulast%3DJavid%26aufirst%3DH.%26aulast%3DMohammadi%26aufirst%3DF.%26aulast%3DZahiri%26aufirst%3DE.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DThe%2520emerging%2520role%2520of%2520substance%2520P%252Fneurokinin-1%2520receptor%2520signaling%2520pathways%2520in%2520growth%2520and%2520development%2520of%2520tumor%2520cells%26jtitle%3DJ.%2520Physiol.%2520Biochem.%26date%3D2019%26volume%3D75%26spage%3D415%26epage%3D421%26doi%3D10.1007%2Fs13105-019-00697-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heuillet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménager, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallourd, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doble, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1993.tb03231.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1471-4159.1993.tb03231.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=7679727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVCgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=868-876&author=E.+Heuilletauthor=J.+M%C3%A9nagerauthor=V.+Fardinauthor=O.+Flamandauthor=M.+Bockauthor=C.+Garretauthor=A.+Crespoauthor=A.+M.+Fallourdauthor=A.+Doble&title=Characterization+of+a+human+NK1+tachykinin+receptor+in+the+astrocytoma+cell+line+U+373+MG&doi=10.1111%2Fj.1471-4159.1993.tb03231.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG</span></div><div class="casAuthors">Heuillet, E.; Menager, J.; Fardin, V.; Flamand, O.; Bock, M.; Garret, C.; Crespo, A.; Fallourd, A. M.; Doble, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-76</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">The human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG was characterized using selective agonists and antagonists described for this receptor in the rat.  Specific [3H]substance P binding sites were present on cell homogenates, whereas [3H]neurokinin A or [3H]senktide binding sites were absent.  The binding was saturable and reversible.  The binding of [3H]substance P was inhibited by very low concns. of [L-Pro9]substance P and [Sar9,Met(O2)11]substance P; septide was ∼1000-fold less potent.  The most potent peptide antagonist was trans-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-propyl-N-methyl-N-(phenylmethyl)-L-tyrosineamide.  The rank order of potency for the nonpeptide antagonists was (S,S)-CP 96,345 > (±)-CP 96,345 > (±)-2-chlorobenzylquinuclidinone > (R,R)-CP 96,345 > RP 67580 > RP 68651.  In [3H]inositol-labeled cells, substance P stimulated phosphatidylinositol turnover.  A good correlation was found when the abilities of NK1 receptor agonists for stimulating inositol phosphate prodn. and for inhibiting [3H]substance P binding were compared.  Similarly, the binding and functional assays were well correlated for the antagonists.  As a result of its high sensitivity and selectivity, the U 373 MG cell line thus appears an excellent tool for investigating the pharmacol. of the human NK1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplaB94lnCfcbVg90H21EOLACvtfcHk0likxuIRHIMOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVCgt7o%253D&md5=1011fc8c6ebe17c37fb7d5acb337dc23</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1993.tb03231.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1993.tb03231.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeuillet%26aufirst%3DE.%26aulast%3DM%25C3%25A9nager%26aufirst%3DJ.%26aulast%3DFardin%26aufirst%3DV.%26aulast%3DFlamand%26aufirst%3DO.%26aulast%3DBock%26aufirst%3DM.%26aulast%3DGarret%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DFallourd%26aufirst%3DA.%2BM.%26aulast%3DDoble%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520human%2520NK1%2520tachykinin%2520receptor%2520in%2520the%2520astrocytoma%2520cell%2520line%2520U%2520373%2520MG%26jtitle%3DJ.%2520Neurochem.%26date%3D1993%26volume%3D60%26spage%3D868%26epage%3D876%26doi%3D10.1111%2Fj.1471-4159.1993.tb03231.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eistetter, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alouani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambosson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, E.</span></span> <span> </span><span class="NLM_article-title">Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1002/glia.440060203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fglia.440060203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1328053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADyaK3s%252FhsVSktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1992&pages=89-95&author=H.+R.+Eistetterauthor=A.+Millsauthor=R.+Brewsterauthor=S.+Alouaniauthor=C.+Rambossonauthor=E.+Kawashima&title=Functional+characterization+of+neurokinin-1+receptors+on+human+U373MG+astrocytoma+cells&doi=10.1002%2Fglia.440060203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells</span></div><div class="casAuthors">Eistetter H R; Mills A; Brewster R; Alouani S; Rambosson C; Kawashima E</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">The neurokinin-1 (NK-1, substance P) receptor belongs to the class of seven transmembrane domain (7-TM) receptors that interact with cellular effector systems via guanine nucleotide binding regulatory proteins (G-proteins).  In this study, coupling mechanisms of functional NK-1 receptors endogenously expressed in a human astrocytoma cell line (U373MG) were analyzed.  Stimulation with substance P (SP) resulted in 1) a rapid increase in inositol 1,4,5-trisphosphate (IP3) synthesis; 2) a rise in cytosolic free calcium concentration ([Ca2+]i); 3) induction of immediate early gene transcription as monitored by c-fos and c-jun expression; and 4) a significant increase in de novo DNA synthesis.  Thus, the functional responses induced by stimulation of NK-1 receptors on U373MG strongly correlate with those observed after treatment of primary astrocytes with SP and make U373MG cells a useful in vitro model system for the analysis of NK-1 receptor function on astrocytes in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx81PrkQfihpotVjB3IRIyfW6udTcc2eb28vUCut1u7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FhsVSktw%253D%253D&md5=d81f98adf72ba69c17867ff1f079efca</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1002%2Fglia.440060203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.440060203%26sid%3Dliteratum%253Aachs%26aulast%3DEistetter%26aufirst%3DH.%2BR.%26aulast%3DMills%26aufirst%3DA.%26aulast%3DBrewster%26aufirst%3DR.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DRambosson%26aufirst%3DC.%26aulast%3DKawashima%26aufirst%3DE.%26atitle%3DFunctional%2520characterization%2520of%2520neurokinin-1%2520receptors%2520on%2520human%2520U373MG%2520astrocytoma%2520cells%26jtitle%3DGlia%26date%3D1992%26volume%3D6%26spage%3D89%26epage%3D95%26doi%3D10.1002%2Fglia.440060203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Magalhães, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dardenne, L. E.</span></span> <span> </span><span class="NLM_article-title">Receptor-ligand molecular docking</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1007/s12551-013-0130-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1007%2Fs12551-013-0130-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=28509958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlSqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=75-87&author=I.+A.+Guedesauthor=C.+S.+de+Magalh%C3%A3esauthor=L.+E.+Dardenne&title=Receptor-ligand+molecular+docking&doi=10.1007%2Fs12551-013-0130-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-ligand molecular docking</span></div><div class="casAuthors">Guedes, Isabella A.; Magalhaes, Camila S.; Dardenne, Laurent E.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-87</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Docking methodol. aims to predict the exptl. binding modes and affinities of small mols. within the binding site of particular receptor targets and is currently used as a std. computational tool in drug design for lead compd. optimization and in virtual screening studies to find novel biol. active mols.  The basic tools of a docking methodol. include a search algorithm and an energy scoring function for generating and evaluating ligand poses.  In this review, we present the search algorithms and scoring functions most commonly used in current mol. docking methods that focus on protein-ligand applications.  We summarize the main topics and recent computational and methodol. advances in protein-ligand docking.  Protein flexibility, multiple ligand binding modes and the free-energy landscape profile for binding affinity prediction are important and interconnected challenges to be overcome by further methodol. developments in the docking field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH7lCjEKQC4bVg90H21EOLACvtfcHk0lhYRoTLrzqT6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlSqtbc%253D&md5=dac42875205a64dd33aca13ec9f710a4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs12551-013-0130-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-013-0130-2%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DI.%2BA.%26aulast%3Dde%2BMagalh%25C3%25A3es%26aufirst%3DC.%2BS.%26aulast%3DDardenne%26aufirst%3DL.%2BE.%26atitle%3DReceptor-ligand%2520molecular%2520docking%26jtitle%3DBiophys.%2520Rev.%26date%3D2014%26volume%3D6%26spage%3D75%26epage%3D87%26doi%3D10.1007%2Fs12551-013-0130-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popielarska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabińska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, M. K.</span></span> <span> </span><span class="NLM_article-title">The Log P parameter as a molecular descriptor in the computer-aided drug design–an overview</span>. <i>Comput. Methods Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.12921/cmst.2012.18.02.81-88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.12921%2Fcmst.2012.18.02.81-88" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=81-88&author=J.+Kujawskiauthor=H.+Popielarskaauthor=A.+Mykaauthor=B.+Drabi%C5%84skaauthor=M.+K.+Bernard&title=The+Log+P+parameter+as+a+molecular+descriptor+in+the+computer-aided+drug+design%E2%80%93an+overview&doi=10.12921%2Fcmst.2012.18.02.81-88"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.12921%2Fcmst.2012.18.02.81-88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12921%252Fcmst.2012.18.02.81-88%26sid%3Dliteratum%253Aachs%26aulast%3DKujawski%26aufirst%3DJ.%26aulast%3DPopielarska%26aufirst%3DH.%26aulast%3DMyka%26aufirst%3DA.%26aulast%3DDrabi%25C5%2584ska%26aufirst%3DB.%26aulast%3DBernard%26aufirst%3DM.%2BK.%26atitle%3DThe%2520Log%2520P%2520parameter%2520as%2520a%2520molecular%2520descriptor%2520in%2520the%2520computer-aided%2520drug%2520design%25E2%2580%2593an%2520overview%26jtitle%3DComput.%2520Methods%2520Sci.%2520Technol.%26date%3D2012%26volume%3D18%26spage%3D81%26epage%3D88%26doi%3D10.12921%2Fcmst.2012.18.02.81-88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravanan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span> <span> </span><span class="NLM_article-title">DeepBindRG: a deep learning based method for estimating effective protein-ligand affinity</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e7362</span> <span class="refDoi"> DOI: 10.7717/peerj.7362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.7717%2Fpeerj.7362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=31380152" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=H.+Zhangauthor=L.+Liaoauthor=K.+M.+Saravananauthor=P.+Yinauthor=Y.+Wei&title=DeepBindRG%3A+a+deep+learning+based+method+for+estimating+effective+protein-ligand+affinity&doi=10.7717%2Fpeerj.7362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.7362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.7362%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DSaravanan%26aufirst%3DK.%2BM.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DDeepBindRG%253A%2520a%2520deep%2520learning%2520based%2520method%2520for%2520estimating%2520effective%2520protein-ligand%2520affinity%26jtitle%3DPeerJ%26date%3D2019%26volume%3D7%26doi%3D10.7717%2Fpeerj.7362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit42c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rücker, C.</span></span> <span> </span><span class="NLM_article-title">Octanol–water partition coefficient measurement by a simple <sup>1</sup>H NMR method</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">6244</span>– <span class="NLM_lpage">6249</span>, <span class="refDoi"> DOI: 10.1021/acsomega.7b01102</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.7b01102" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOht7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=6244-6249&author=H.+Cummingauthor=C.+R%C3%BCcker&title=Octanol%E2%80%93water+partition+coefficient+measurement+by+a+simple+1H+NMR+method&doi=10.1021%2Facsomega.7b01102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42cR"><div class="casContent"><span class="casTitleNuber">42c</span><div class="casTitle"><span class="NLM_cas:atitle">Octanol-Water Partition Coefficient Measurement by a Simple 1H NMR Method</span></div><div class="casAuthors">Cumming, Hemi; Rucker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6244-6249</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a simple miniature shake-flask method to measure the octanol-water partition coeff. of an org. compd.  Partition between water and octanol is performed in an NMR tube; the aq. phase is analyzed by 1H NMR spectroscopy using a benchtop low-field NMR instrument.  Neither pre-equilibration of solvents nor isolation of the two phases is required.  The procedure is fast and easy enough to be used in a students' lab.  Scope and limitations as well as possible sources of error are discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9kBHuX3aA8LVg90H21EOLACvtfcHk0lhYRoTLrzqT6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOht7rM&md5=0d7fcd42f9d82f746494ec33f15c2e51</span></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=10.1021%2Facsomega.7b01102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.7b01102%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DH.%26aulast%3DR%25C3%25BCcker%26aufirst%3DC.%26atitle%3DOctanol%25E2%2580%2593water%2520partition%2520coefficient%2520measurement%2520by%2520a%2520simple%25201H%2520NMR%2520method%26jtitle%3DACS%2520Omega%26date%3D2017%26volume%3D2%26spage%3D6244%26epage%3D6249%26doi%3D10.1021%2Facsomega.7b01102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieraccini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sironi, M.</span></span> <span> </span><span class="NLM_article-title">Halogen bonding in ligand–receptor systems in the framework of classical force fields</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">19508</span>– <span class="NLM_lpage">19516</span>, <span class="refDoi"> DOI: 10.1039/c1cp22436k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1039%2Fc1cp22436k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=21964576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKjurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=19508-19516&author=S.+Rendineauthor=S.+Pieracciniauthor=A.+Forniauthor=M.+Sironi&title=Halogen+bonding+in+ligand%E2%80%93receptor+systems+in+the+framework+of+classical+force+fields&doi=10.1039%2Fc1cp22436k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen bonding in ligand-receptor systems in the framework of classical force fields</span></div><div class="casAuthors">Rendine, Stefano; Pieraccini, Stefano; Forni, Alessandra; Sironi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">19508-19516</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Halogen bond is an important noncovalent interaction which is receiving a growing attention in the study of protein-ligand complexes.  Many drugs are halogenated mols. and it has been recently shown that many halogenated ligands establish halogen bonds with biomols.  As the halogen bond nature is due to an anisotropy of the electrostatic potential around halogen atoms, it is not possible to use traditional force fields based on a set of atom-centered charges to study halogen bonds in biomols.  The authors show that the introduction of pseudo-atoms on halogens permits the authors to correctly describe the anisotropy of the electrostatic potential and to perform mol. dynamics simulations on complexes of proteins with halogenated ligands that reproduce exptl. values.  The results are compared with crystallog. data and with hybrid quantum mechanics/mol. mechanics calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkRo6pzepT7Vg90H21EOLACvtfcHk0lhYRoTLrzqT6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKjurvN&md5=4f158f241315335dc3f6070d710178d6</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1039%2Fc1cp22436k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cp22436k%26sid%3Dliteratum%253Aachs%26aulast%3DRendine%26aufirst%3DS.%26aulast%3DPieraccini%26aufirst%3DS.%26aulast%3DForni%26aufirst%3DA.%26aulast%3DSironi%26aufirst%3DM.%26atitle%3DHalogen%2520bonding%2520in%2520ligand%25E2%2580%2593receptor%2520systems%2520in%2520the%2520framework%2520of%2520classical%2520force%2520fields%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2011%26volume%3D13%26spage%3D19508%26epage%3D19516%26doi%3D10.1039%2Fc1cp22436k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sirimulla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegesna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, M.</span></span> <span> </span><span class="NLM_article-title">Halogen interactions in protein–ligand complexes: implications of halogen bonding for rational drug design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1021/ci400257k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400257k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=2781-2791&author=S.+Sirimullaauthor=J.+B.+Baileyauthor=R.+Vegesnaauthor=M.+Narayan&title=Halogen+interactions+in+protein%E2%80%93ligand+complexes%3A+implications+of+halogen+bonding+for+rational+drug+design&doi=10.1021%2Fci400257k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen Interactions in Protein-Ligand Complexes: Implications of Halogen Bonding for Rational Drug Design</span></div><div class="casAuthors">Sirimulla, Suman; Bailey, Jake B.; Vegesna, Rahulsimham; Narayan, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2781-2791</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Halogen bonding interactions between halogenated ligands and proteins were examd. using the crystal structures deposited to date in the PDB.  The data was analyzed as a function of halogen bonding to main chain Lewis bases, viz. oxygen of backbone carbonyl and backbone amide nitrogen.  This anal. also examd. halogen bonding to side-chain Lewis bases (O, N, and S) and to the electron-rich arom. amino acids.  All interactions were restricted to van der Waals radii with resp. atoms.  The data reveals that while fluorine and chlorine have strong tendencies favoring interactions with the backbone Lewis bases at glycine, the trend is not restricted to the achiral amino acid backbone for larger halogens.  Halogen side-chain interactions are not restricted to amino acids contg. O, N, and S as Lewis bases.  Electron-rich arom. amino acids host a high frequency of halogen bonds as does Leu.  A closer examn. of the latter hydrophobic side chain reveals that the "propensity of interactions" of halogen ligands at this oily residue is an outcome of strong classical halogen bonds with Lewis bases in the vicinity.  Finally, an examn. of Θ1 (C-X···O and C-X···N) and Θ2 (X···O-Z and X···N-Z) angles reveals that very few ligands adopt classical halogen bonding angles, suggesting that steric and other factors may influence these angles.  The data is discussed in the context of ligand design for pharmaceutical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wcnZDXmkYrVg90H21EOLACvtfcHk0ljiCqrzRUuleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cisr3O&md5=a73378681587e3ac13143452ecb78882</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1021%2Fci400257k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400257k%26sid%3Dliteratum%253Aachs%26aulast%3DSirimulla%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DJ.%2BB.%26aulast%3DVegesna%26aufirst%3DR.%26aulast%3DNarayan%26aufirst%3DM.%26atitle%3DHalogen%2520interactions%2520in%2520protein%25E2%2580%2593ligand%2520complexes%253A%2520implications%2520of%2520halogen%2520bonding%2520for%2520rational%2520drug%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D2781%26epage%3D2791%26doi%3D10.1021%2Fci400257k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arunlakshana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schild, H. O.</span></span> <span> </span><span class="NLM_article-title">Some quantitative uses of drug antagonists</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1959.tb00928.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1111%2Fj.1476-5381.1959.tb00928.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=13651579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaG1MXhtFCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1959&pages=48-58&author=O.+Arunlakshanaauthor=H.+O.+Schild&title=Some+quantitative+uses+of+drug+antagonists&doi=10.1111%2Fj.1476-5381.1959.tb00928.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Some quantitative uses of drug antagonists</span></div><div class="casAuthors">Arunlakshana, O.; Schild, H. O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">C.A. 42, 281h.  Various applications of pAx measurements were discussed, based on the hypothesis that drugs and drug antagonists compete for receptors according to mass law.  Examples were given illustrating the use of pAx measurements to identify antagonists which acted on the same receptors and to compare receptors of different tissues.  Tests of competitive and noncompetitive antagonism were considered in relation to the antagonisms acetylcholine-atropine, histamine-atropine, and acetylcholine-cinchonidine.  A new measure of pAh, defined as the neg. log of the molar concn. of antagonist which reduces the attainable max. of the dose response curve to 1/2, was introduced to express the activity of unsurmountable antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIFhlFzfMrbVg90H21EOLACvtfcHk0ljiCqrzRUuleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXhtFCmu7w%253D&md5=9b9b86041b30647fb4ebe330e9ec61d9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1959.tb00928.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1959.tb00928.x%26sid%3Dliteratum%253Aachs%26aulast%3DArunlakshana%26aufirst%3DO.%26aulast%3DSchild%26aufirst%3DH.%2BO.%26atitle%3DSome%2520quantitative%2520uses%2520of%2520drug%2520antagonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1959%26volume%3D14%26spage%3D48%26epage%3D58%26doi%3D10.1111%2Fj.1476-5381.1959.tb00928.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">How many times should we screen a chemical library to discover an anticancer drug?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1016%2Fj.drudis.2014.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25523188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC2MzotlOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=167-169&author=M.+L%C3%B3pez-L%C3%A1zaro&title=How+many+times+should+we+screen+a+chemical+library+to+discover+an+anticancer+drug%3F&doi=10.1016%2Fj.drudis.2014.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">How many times should we screen a chemical library to discover an anticancer drug?</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpvBDY_lavNiO2kE7krGOBfW6udTcc2eY_9iYuebiIE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzotlOhtg%253D%253D&md5=01dfaaefaaac142ef97137fd178cd028</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DHow%2520many%2520times%2520should%2520we%2520screen%2520a%2520chemical%2520library%2520to%2520discover%2520an%2520anticancer%2520drug%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D167%26epage%3D169%26doi%3D10.1016%2Fj.drudis.2014.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">A simple and reliable approach for assessing anticancer activity in vitro</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1324</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150209150639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.2174%2F0929867322666150209150639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25666807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1amu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1324-1334&author=M.+L%C3%B3pez-L%C3%A1zaro&title=A+simple+and+reliable+approach+for+assessing+anticancer+activity+in+vitro&doi=10.2174%2F0929867322666150209150639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro</span></div><div class="casAuthors">Lopez-Lazaro, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1324-1334</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer patients need better anticancer drugs, and medicinal chem. can play a crit. role in the discovery of these drugs.  For an efficient drug discovery process, chemists working on the synthesis of potential anticancer agents need to use reliable screening methods.  These methods should not only detect the compds. with the highest therapeutic potential, but should also predict whether such potential is high enough to deserve addnl. attention.  Unfortunately, the current strategies for assessing anticancer activity in vitro are unable to do this reliably.  This review article analyzes these strategies and describes an alternative screening approach.  It is based on establishing suitable exptl. conditions to detect compds. that improve the selective cytotoxicity of the drugs used in cancer therapy.  This patient-oriented approach is easy to implement and may help medicinal chemists, and other researchers involved in cancer drug discovery, assess in vitro anticancer activity more reliably.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkwbmtgWQQLVg90H21EOLACvtfcHk0ljiCqrzRUuleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1amu7c%253D&md5=c47c9532bf4f825b9782c9476a1a1d75</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150209150639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150209150639%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DA%2520simple%2520and%2520reliable%2520approach%2520for%2520assessing%2520anticancer%2520activity%2520in%2520vitro%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1324%26epage%3D1334%26doi%3D10.2174%2F0929867322666150209150639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials</span>. <i>Oncoscience</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.18632/oncoscience.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.18632%2Foncoscience.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=25859551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A280%3ADC%252BC2MjivVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=91-98&author=M.+L%C3%B3pez-L%C3%A1zaro&title=Two+preclinical+tests+to+evaluate+anticancer+activity+and+to+help+validate+drug+candidates+for+clinical+trials&doi=10.18632%2Foncoscience.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45cR"><div class="casContent"><span class="casTitleNuber">45c</span><div class="casTitle"><span class="NLM_cas:atitle">Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Oncoscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-8</span>
        ISSN:<span class="NLM_cas:issn">2331-4737</span>.
    </div><div class="casAbstract">Current approaches to assessing preclinical anticancer activity do not reliably predict drug efficacy in cancer patients.  Most of the compounds that show remarkable anticancer effects in preclinical models actually fail when tested in clinical trials.  We blame these failures on the complexity of the disease and on the limitations of the preclinical tools we require for our research.  This manuscript argues that this lack of clinical response may also be caused by poor in vitro and in vivo preclinical designs, in which cancer patients' needs are not fully considered.  Then, it proposes two patient-oriented tests to assess in vitro and in vivo anticancer activity and to help validate drug candidates for clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUqvJfzVVhz0EgZCMqtRBifW6udTcc2eZ6D4BtNVbMhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjivVKrsQ%253D%253D&md5=a9a9dd2f3ca9c99f36a74537c996003f</span></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.18632%2Foncoscience.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncoscience.132%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DTwo%2520preclinical%2520tests%2520to%2520evaluate%2520anticancer%2520activity%2520and%2520to%2520help%2520validate%2520drug%2520candidates%2520for%2520clinical%2520trials%26jtitle%3DOncoscience%26date%3D2015%26volume%3D2%26spage%3D91%26epage%3D98%26doi%3D10.18632%2Foncoscience.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopp, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1158%2F1078-0432.CCR-07-1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=18347186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtleisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1831-1839&author=X.+Caoauthor=M.+Bloomstonauthor=T.+Zhangauthor=W.+L.+Frankelauthor=G.+Jiaauthor=B.+Wangauthor=N.+C.+Hallauthor=R.+M.+Kochauthor=H.+Chengauthor=M.+V.+Knoppauthor=D.+Sun&title=Synergistic+antipancreatic+tumor+effect+by+simultaneously+targeting+hypoxic+cancer+cells+with+HSP90+inhibitor+and+glycolysis+inhibitor&doi=10.1158%2F1078-0432.CCR-07-1607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor</span></div><div class="casAuthors">Cao, Xianhua; Bloomston, Mark; Zhang, Tao; Frankel, Wendy L.; Jia, Guang; Wang, Bing; Hall, Nathan C.; Koch, Regina M.; Cheng, Hao; Knopp, Michael V.; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1831-1839</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We sought to examine the synergistic antipancreatic cancer effect by simultaneously targeting hypoxic cancer cells with heat-shock protein 90 (HSP90) inhibitor and blockade of energy prodn.  Exptl. Design: The anticancer effects of an HSP90 inhibitor (geldanamycin) in pancreatic cells were investigated in hypoxia and normoxia.  A hexokinase II inhibitor, 3-broma-pyruvate (3BrPA), was evaluated for selective glycolysis inhibition in hypoxia as a sensitizer of HSP90 inhibitor against pancreatic cancer.  The HSP90 client protein degrdn. was monitored by Western blot.  The synergistic antitumor effect of geldanamycin and 3BrPA was evaluated in a xenograft pancreatic cancer model and monitored by a noninvasive dynamic contrast-enhanced magnetic resonance imaging.  Results: Hypoxia enhanced HIF-1α expression by 11-fold in pancreatic cancer cells, and HSP90 inhibitor exhibited a seven- to eightfold higher anticancer effect in hypoxia compared with normoxia via HSP90 client protein degrdn. 3BrPA selectively inhibited glycolysis and sensitized geldanamycin against pancreatic cancer cells by 17- to 400-fold through HSP90 client protein degrdn.  The synergistic anticancer effect of reduced doses of geldanamycin and 3-BrPA was confirmed in xenograft models in vivo by more than 75% tumor growth inhibition.  Conclusions: The combination of HSP90 inhibitors and glycolysis inhibitors provides preferential inhibition of cancer cells in hypoxia through HSP90 client protein degrdn. and selective glycolysis inhibition.  This may provide a new therapeutic regimen to battle chemotherapy-resistant pancreatic cancers, by enhancing the synergistic therapeutic efficacy and reducing dose-limiting toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3rak4ki6gprVg90H21EOLACvtfcHk0lhwOgyeFgZlBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtleisr8%253D&md5=dcca2fc98383448fb6bf16878b8cf8cf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1607%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DBloomston%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DFrankel%26aufirst%3DW.%2BL.%26aulast%3DJia%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DN.%2BC.%26aulast%3DKoch%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKnopp%26aufirst%3DM.%2BV.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DSynergistic%2520antipancreatic%2520tumor%2520effect%2520by%2520simultaneously%2520targeting%2520hypoxic%2520cancer%2520cells%2520with%2520HSP90%2520inhibitor%2520and%2520glycolysis%2520inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1831%26epage%3D1839%26doi%3D10.1158%2F1078-0432.CCR-07-1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry III. The role of exact exchange</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">5648</span>– <span class="NLM_lpage">5652</span>, <span class="refDoi"> DOI: 10.1063/1.464913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.464913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1993&pages=5648-5652&author=A.+D.+Becke&title=Density-functional+thermochemistry+III.+The+role+of+exact+exchange&doi=10.1063%2F1.464913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry. III. The role of exact exchange</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5648-52</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Despite the remarkable thermochem. accuracy of Kohn-Sham d.-functional theories with gradient corrections for exchange-correlation, the author believes that further improvements are unlikely unless exact-exchange information is considered.  Arguments to support this view are presented, and a semiempirical exchange-correlation functional (contg. local-spin-d., gradient, and exact-exchange terms) is tested for 56 atomization energies, 42 ionization potentials, 8 proton affinities, and 10 total at. energies of first- and second-row systems.  This functional performs better than previous functionals with gradient corrections only, and fits expt. atomization energies with an impressively small av. abs. deviation of 2.4 kcal/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3BqpycUTBwLVg90H21EOLACvtfcHk0lhwOgyeFgZlBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVWgtrw%253D&md5=291bbfc119095338bb1624f0c21c7ca8</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1063%2F1.464913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.464913%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry%2520III.%2520The%2520role%2520of%2520exact%2520exchange%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1993%26volume%3D98%26spage%3D5648%26epage%3D5652%26doi%3D10.1063%2F1.464913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becke, A. D.</span></span> <span> </span><span class="NLM_article-title">Density-functional thermochemistry I. The effect of the exchange-only gradient correction</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1063/1.462066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.462066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaK38XhtFeqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1992&pages=2155-2160&author=A.+D.+Becke&title=Density-functional+thermochemistry+I.+The+effect+of+the+exchange-only+gradient+correction&doi=10.1063%2F1.462066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Density-functional thermochemistry.  I.  The effect of the exchange-only gradient correction</span></div><div class="casAuthors">Becke, Axel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2155-60</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Results are given of an extensive survey of d.-functional atomization energies on the 55 mols. of the Gaussian-1 thermochem. data base of Pople and co-workers [J. Chem. Phys. 90, 5622 (1989); 93, 2537 (1990)].  These calcns. have been performed by the fully numerical mols. (NUMOL) program of Becke and Dickson [J. Chem. Phys. 92, 3610 (1990)] and are therefore free of basis-set uncertainties.  An av. abs. error is found in the total atomization energies of the 55 test mols. of 3.7 kcal/mol, compared to 1.6 kcal/mol for the Gaussian-1 procedure and 1.2 kcal/mol for Gaussian-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfVgdx5QFx_7Vg90H21EOLACvtfcHk0ljzEZmLVRqMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhtFeqtb8%253D&md5=09dff1fa3a088b78de16f9970f38f522</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1063%2F1.462066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.462066%26sid%3Dliteratum%253Aachs%26aulast%3DBecke%26aufirst%3DA.%2BD.%26atitle%3DDensity-functional%2520thermochemistry%2520I.%2520The%2520effect%2520of%2520the%2520exchange-only%2520gradient%2520correction%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1992%26volume%3D96%26spage%3D2155%26epage%3D2160%26doi%3D10.1063%2F1.462066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of the colle-salvetti correlation-energy formula into a functional of the electron density</span>. <i>Phys. Rev. B</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>, <span class="NLM_elocation-id">785</span> <span class="refDoi"> DOI: 10.1103/PhysRevB.37.785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1103%2FPhysRevB.37.785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=9944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&author=C.+Leeauthor=W.+Yangauthor=R.+G.+Parr&title=Development+of+the+colle-salvetti+correlation-energy+formula+into+a+functional+of+the+electron+density&doi=10.1103%2FPhysRevB.37.785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47cR"><div class="casContent"><span class="casTitleNuber">47c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density</span></div><div class="casAuthors">Lee, Chengteh; Yang, Weitao; Parr, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Review B:  Condensed Matter and Materials Physics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">PRBMDO</span>;
        ISSN:<span class="NLM_cas:issn">0163-1829</span>.
    </div><div class="casAbstract">A correlation-energy formula due to R. Colle and D. Salvetti (1975), in which the correlation energy d. is expressed in terms of the electron d. and a Laplacian of the 2nd-order Hartree-Fock d. matrix, is restated as a formula involving the d. and local kinetic-energy d.  On insertion of gradient expansions for the local kinetic-energy d., d.-functional formulas for the correlation energy and correlation potential are then obtained.  Through numerical calcns. on a no. of atoms, pos. ions, and mols., of both open- and closed-shell type, it is demonstrated that these formulas, like the original Colle-Salvetti formulas, give correlation energies within a few percent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8yJ1cBkpi67Vg90H21EOLACvtfcHk0ljzEZmLVRqMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFWrtbw%253D&md5=ee7b59267a2ff72e15171a481819ccf8</span></div><a href="/servlet/linkout?suffix=cit47c&amp;dbid=16384&amp;doi=10.1103%2FPhysRevB.37.785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevB.37.785%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DParr%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520the%2520colle-salvetti%2520correlation-energy%2520formula%2520into%2520a%2520functional%2520of%2520the%2520electron%2520density%26jtitle%3DPhys.%2520Rev.%2520B%26date%3D1988%26volume%3D37%26doi%3D10.1103%2FPhysRevB.37.785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditchfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">Self—consistent molecular orbital methods XII. Further extensions of gaussian—type basis sets for use in molecular orbital studies of organic molecules</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1063/1.1677527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.1677527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaE38XptVemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1972&pages=2257-2261&author=W.+J.+Hehreauthor=R.+Ditchfieldauthor=J.+A.+Pople&title=Self%E2%80%94consistent+molecular+orbital+methods+XII.+Further+extensions+of+gaussian%E2%80%94type+basis+sets+for+use+in+molecular+orbital+studies+of+organic+molecules&doi=10.1063%2F1.1677527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48aR"><div class="casContent"><span class="casTitleNuber">48a</span><div class="casTitle"><span class="NLM_cas:atitle">Self-consistent molecular orbital methods.  XII.  Further extensions of Gaussian-type basis sets for use in molecular orbital studies of organic molecules</span></div><div class="casAuthors">Hehre, W. J.; Ditchfield, R.; Pople, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2257-61</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Two extended basis sets (termed 5-31G and 6-31G) consisting of AO expressed as fixed linear combinations of Gaussian functions are presented for the 1st row atoms C to F.  These basis functions are similar to the 4-31G set in that each valence shell is split into inner and outer parts described by 3 and 1 Gaussian function, resp.  Inner shells are represented by a single basis function taken as a sum of 5 (5-31G) or 6 (6-31G) Guassians.  Studies with a no. of polyat. mols. indicate a substantial lowering of calcd. total energies over the 4-31G set.  Calcd. relative energies and equil. geometries do not appear to be altered significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3y4IIe93A3bVg90H21EOLACvtfcHk0ljzEZmLVRqMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XptVemsw%253D%253D&md5=3b63ef94029197bf1b90941d5ee39956</span></div><a href="/servlet/linkout?suffix=cit48a&amp;dbid=16384&amp;doi=10.1063%2F1.1677527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.1677527%26sid%3Dliteratum%253Aachs%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DDitchfield%26aufirst%3DR.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DSelf%25E2%2580%2594consistent%2520molecular%2520orbital%2520methods%2520XII.%2520Further%2520extensions%2520of%2520gaussian%25E2%2580%2594type%2520basis%2520sets%2520for%2520use%2520in%2520molecular%2520orbital%2520studies%2520of%2520organic%2520molecules%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1972%26volume%3D56%26spage%3D2257%26epage%3D2261%26doi%3D10.1063%2F1.1677527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit48b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Francl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietro, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hehre, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkley, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFrees, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pople, J. A.</span></span> <span> </span><span class="NLM_article-title">Self-consistent molecular orbital methods XXIII. A polarization-type basis set for second-row elements</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">3654</span>– <span class="NLM_lpage">3665</span>, <span class="refDoi"> DOI: 10.1063/1.444267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1063%2F1.444267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADyaL38XlsFSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1982&pages=3654-3665&author=M.+M.+Franclauthor=W.+J.+Pietroauthor=W.+J.+Hehreauthor=J.+S.+Binkleyauthor=M.+S.+Gordonauthor=D.+J.+DeFreesauthor=J.+A.+Pople&title=Self-consistent+molecular+orbital+methods+XXIII.+A+polarization-type+basis+set+for+second-row+elements&doi=10.1063%2F1.444267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48bR"><div class="casContent"><span class="casTitleNuber">48b</span><div class="casTitle"><span class="NLM_cas:atitle">Self-consistent molecular orbital methods.  XXIII.  A polarization-type basis set for second-row elements</span></div><div class="casAuthors">Francl, Michelle M.; Pietro, William J.; Hehre, Warren J.; Binkley, J. Stephen; Gordon, Mark S.; DeFrees, Douglas J.; Pople, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3654-65</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">The 6-31G* and 6-31G** basis sets previously introduced for 1st-row atoms are extended through the 2nd-row of the periodic table.  Equil. geometries for 1-heavy-atom hydrides calcd. for the 2-basis sets and using Hartree-Fock wave functions are in good agreement both with each other and with the exptl. data.  HF/6-31G* structures, obtained for 2-heavy-atom hydrides and for a variety of hypervalent 2nd-row mols., are also in excellent accord with exptl. equil. geometries.  No large deviations between calcd. and exptl. single bond lengths exist, in contrast to previous work on analogous 1st-row compds., where limiting Hartree-Fock distances were in error by up to a 10th of an angstrom.  Equil. geometries calcd. at the HF/6-31G level are consistently in better agreement with the exptl. data than are those previously obtained using the simple split-valence 3-21G basis set for both normal- and hypervalent compds.  Normal-mode vibrational frequencies derived from 6-31G* level calcns. are consistently larger than the corresponding exptl. values, typically by 10-15%; they are of much more quality than those obtained from the 3-21G basis set.  Hydrogenation energies calcd. for normal- and hypervalent compds. are in moderate accord with exptl. data, although in some instances large errors appear.  Calcd. energies relating to the stabilities of single and multiple bonds are in much better accord with the exptl. energy differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX-ZMZokBE2LVg90H21EOLACvtfcHk0lj8A_XZSqqNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFSqt7g%253D&md5=87dfa4667072f128ef633198ae94b388</span></div><a href="/servlet/linkout?suffix=cit48b&amp;dbid=16384&amp;doi=10.1063%2F1.444267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.444267%26sid%3Dliteratum%253Aachs%26aulast%3DFrancl%26aufirst%3DM.%2BM.%26aulast%3DPietro%26aufirst%3DW.%2BJ.%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DBinkley%26aufirst%3DJ.%2BS.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DDeFrees%26aufirst%3DD.%2BJ.%26aulast%3DPople%26aufirst%3DJ.%2BA.%26atitle%3DSelf-consistent%2520molecular%2520orbital%2520methods%2520XXIII.%2520A%2520polarization-type%2520basis%2520set%2520for%2520second-row%2520elements%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1982%26volume%3D77%26spage%3D3654%26epage%3D3665%26doi%3D10.1063%2F1.444267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Marenich, A.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Janesko, B. G.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Mennuci, B.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Williams-Young, D.</span>; <span class="NLM_string-name">Ding, F.</span>; <span class="NLM_string-name">Lipparini, F.</span>; <span class="NLM_string-name">Egidi, F.</span>; <span class="NLM_string-name">Goings, J.</span>; <span class="NLM_string-name">Peng, B.</span>; <span class="NLM_string-name">Petrone, A.</span>; <span class="NLM_string-name">Henderson, T.</span>; <span class="NLM_string-name">Ranasinghe, D.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Gao, J.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Liang, W.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Throssell, K.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Keith, T.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Milam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 09</i>, revision A.02; <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.17265%2F2159-5313%2F2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=G.+A.+Petersson&author=H.+Nakatsuji&author=X.+Li&author=M.+Caricato&author=A.+Marenich&author=J.+Bloino&author=B.+G.+Janesko&author=R.+Gomperts&author=B.+Mennuci&author=H.+P.+Hratchian&author=J.+V.+Ortiz&author=A.+F.+Izmaylov&author=J.+L.+Sonnenberg&author=D.+Williams-Young&author=F.+Ding&author=F.+Lipparini&author=F.+Egidi&author=J.+Goings&author=B.+Peng&author=A.+Petrone&author=T.+Henderson&author=D.+Ranasinghe&author=V.+G.+Zakrzewski&author=J.+Gao&author=N.+Rega&author=G.+Zheng&author=W.+Liang&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=K.+Throssell&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+Bearpark&author=J.+J.+Heyd&author=E.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=T.+Keith&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=J.+M.+Milam&author=M.+Klene&author=C.+Adamo&author=R.+Cammi&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=O.+Farkas&author=J.+B.+Foresman&author=D.+J.+Fox&title=Gaussian+09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.17265%2F2159-5313%2F2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26id%3Ddoi%3A10.17265%252F2159-5313%252F2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252009%26pub%3DGaussian%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+vina%3A+improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lj8A_XZSqqNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520vina%253A%2520improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: automated docking with sSelective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+automated+docking+with+sSelective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lj8A_XZSqqNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520automated%2520docking%2520with%2520sSelective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span> <i>Discovery studio
visualizer, version 4.0; software for viewing,
sharing, and analyzing protein and modeling data</i>; <span class="NLM_publisher-name">BIOVIA</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Discovery+studio%0Avisualizer%2C+version+4.0%3B+software+for+viewing%2C%0Asharing%2C+and+analyzing+protein+and+modeling+data%3B+BIOVIA%3A+San+Diego%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520studio%250Avisualizer%252C%2520version%25204.0%253B%2520software%2520for%2520viewing%252C%250Asharing%252C%2520and%2520analyzing%2520protein%2520and%2520modeling%2520data%26pub%3DBIOVIA%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLO','PDB','6HLO'); return false;">PDB: 6HLO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLL','PDB','6HLL'); return false;">PDB: 6HLL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HLP','PDB','6HLP'); return false;">PDB: 6HLP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_58342"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00793?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00793</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data concerning characterization of products (NMR), docking validation figure concerning NK1 receptor antagonists, biological evaluation figures, and HPLC traces for lead compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_002.csv">CSV</a>)</p></li><li><p class="inline">Structural data for Aprepitant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_008.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for Netupitant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for CP99,994 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>13α</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>13β</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>14α</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Structural data for compound <b>14β</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_009.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_001.pdf">jm1c00793_si_001.pdf (5.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_002.csv">jm1c00793_si_002.csv (2.32 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_003.pdb">jm1c00793_si_003.pdb (380.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_004.pdb">jm1c00793_si_004.pdb (387.82 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_005.pdb">jm1c00793_si_005.pdb (395.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_006.pdb">jm1c00793_si_006.pdb (387.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_007.pdb">jm1c00793_si_007.pdb (387.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_008.pdb">jm1c00793_si_008.pdb (387.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00793/suppl_file/jm1c00793_si_009.pdb">jm1c00793_si_009.pdb (387.82 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00793&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00793%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-14" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00793" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993f22eedd2332","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
